publicli
fund
repositori
covid
databas
right
unrestrict
research
reus
analys
form
mean
acknowledg
origin
sourc
permiss
grant
free
elsevi
long
resourc
centr
remain
activ
evolutionari
tree
microbiolog
b
hall
bellingham
us
phylogenet
tree
tool
repres
relationship
among
organ
focu
present
interpret
phylogenet
tree
rather
construct
tree
element
consid
branch
node
mean
tree
typic
drawn
appear
depict
order
descent
common
ancestor
ie
direct
evolut
appear
often
mislead
direct
evolut
order
descent
shown
root
tree
wherea
phylogenet
method
produc
unroot
tree
inform
requir
root
tree
tree
microbi
isol
often
includ
zerolength
branch
zerolength
branch
realli
mean
tree
estim
histor
relationship
fact
determin
reliabl
estim
tree
recombin
dramat
affect
valid
phylogenet
tree
much
recombin
construct
valid
phylogenet
tree
represent
strain
similar
molecular
microbi
type
p
vauterin
ghent
talk
cover
varieti
group
techniqu
use
repres
relat
strain
use
molecular
type
data
techniqu
strong
weak
point
discuss
guidelin
given
come
reliabl
interpret
result
emphasi
tradit
hierarch
cluster
analysi
tool
elabor
limit
applic
particular
loss
inform
introduc
cluster
analysi
discuss
well
problem
degener
solut
particular
challeng
associ
analysi
interpret
modern
larg
data
set
potenti
includ
thousand
organ
also
cover
also
discuss
novel
group
techniqu
minimum
span
tree
selforgan
map
show
tool
use
complementari
tradit
cluster
analysi
gain
insight
structur
data
antibiot
suscept
test
clinic
relev
anaerob
differ
clinic
microbiolog
laboratori
europ
less
less
frequent
carri
due
fact
clinician
treat
mani
presum
anaerob
infect
empir
even
less
data
avail
antibiot
resist
level
among
anaerob
normal
flora
isol
develop
due
use
antibiot
infect
caus
aerob
facult
anaerob
pathogen
new
antibiot
antianaerob
activ
may
test
old
isol
instead
use
recent
clinic
isol
may
creat
fals
suscept
data
incorrect
recommend
treatment
anaerob
infect
system
data
europ
avail
genera
speci
anaerob
bacteria
bacteroid
fragili
relat
speci
fusobacterium
spp
propionibacterium
acn
clostridium
perfringen
clostridium
difficil
two
europewid
resist
studi
carri
past
year
involv
almost
european
countri
evalu
develop
resist
among
b
fragili
relat
speci
similar
studi
done
clinic
isol
propionibacterium
acn
peptostreptococci
express
differ
found
resist
level
differ
bacteroid
speci
differ
area
europ
clindamycin
erythromycin
ampicillin
moxifloxacin
true
propionibacterium
acn
resist
gene
respons
carbapenem
nitroimidazol
resist
found
frequent
among
clinic
normal
flora
isol
express
resist
despit
fact
antianaerob
drug
show
good
activ
anaerob
clinic
isol
number
resist
isol
increas
parallel
time
accumul
resist
marker
observ
among
bacteroid
strain
report
case
discuss
clinic
failur
due
presenc
multiresist
anaerob
pathogen
infect
associ
intravascular
devic
notwithstand
progress
understand
pathogenesi
foreign
bodi
infect
catheterrel
infect
cri
continu
part
daili
life
icu
oncolog
haematolog
unit
consequenti
morbid
longer
hospit
stay
bring
consider
cost
howev
sever
intervent
reduc
incid
cri
year
ago
cathet
coat
impregn
antisept
antibiot
becam
part
armament
cri
howev
indiscrimin
prophylact
use
antibiot
increas
risk
antimicrobi
resist
furthermor
minocyclinrifampin
impregn
cathet
antibiot
impregn
cathet
well
document
efficaci
avail
europ
cathet
impregn
chlorhexidinesilv
sulfadiazin
cs
outer
surfac
avail
europ
shown
incid
cri
two
recent
clinic
studi
show
improv
version
cathet
cs
inner
outer
surfac
reduc
cathet
colon
vitro
evid
use
antisept
agent
substitut
antibiot
lock
prevent
endolumin
cri
avail
howev
evid
prospect
random
control
clinic
trial
use
antisept
lock
still
scarc
sever
clinic
studi
metaanalysi
support
use
chlorhexidin
prefer
disinfect
prior
cathet
insert
recent
evid
support
use
chlorhexidin
impregn
spong
place
around
insert
site
cathet
prevent
recolon
insert
site
therefor
also
exolumin
cri
shortterm
central
venou
well
arteri
cathet
gener
correct
state
microorgan
outer
surfac
cathet
exolumin
sourc
infect
cri
shortterm
cathet
microorgan
inner
surfac
endolumin
becom
import
longer
durat
cathet
use
differ
howev
gradual
therefor
set
intervent
direct
exolumin
well
endolumin
cri
combin
despit
abovement
new
develop
implement
structur
teach
program
cri
special
emphasi
adher
fullsteril
barrier
precaut
chlorhexidin
base
skin
disinfect
remov
cathet
soon
possibl
remain
cornerston
cri
prevent
evolutionari
tree
microbiolog
b
hall
bellingham
us
phylogenet
tree
tool
repres
relationship
among
organ
focu
present
interpret
phylogenet
tree
rather
construct
tree
element
consid
branch
node
mean
tree
typic
drawn
appear
depict
order
descent
common
ancestor
ie
direct
evolut
appear
often
mislead
direct
evolut
order
descent
shown
root
tree
wherea
phylogenet
method
produc
unroot
tree
inform
requir
root
tree
tree
microbi
isol
often
includ
zerolength
branch
zerolength
branch
realli
mean
tree
estim
histor
relationship
fact
determin
reliabl
estim
tree
recombin
dramat
affect
valid
phylogenet
tree
much
recombin
construct
valid
phylogenet
tree
represent
strain
similar
molecular
microbi
type
p
vauterin
ghent
talk
cover
varieti
group
techniqu
use
repres
relat
strain
use
molecular
type
data
techniqu
strong
weak
point
discuss
guidelin
given
come
reliabl
interpret
result
emphasi
tradit
hierarch
cluster
analysi
tool
elabor
limit
applic
particular
loss
inform
introduc
cluster
analysi
discuss
well
problem
degener
solut
particular
challeng
associ
analysi
interpret
modern
larg
data
set
potenti
includ
thousand
organ
also
cover
also
discuss
novel
group
techniqu
minimum
span
tree
selforgan
map
show
tool
use
complementari
tradit
cluster
analysi
gain
insight
structur
data
antimicrobi
resist
anaerob
bacteria
experi
europ
north
america
symposium
arrang
esgarab
antimicrobi
suscept
pattern
differ
european
countri
e
nagi
szege
hu
antibiot
suscept
test
clinic
relev
anaerob
differ
clinic
microbiolog
laboratori
europ
less
less
frequent
carri
due
fact
clinician
treat
mani
presum
anaerob
infect
empir
even
less
data
avail
antibiot
resist
level
among
anaerob
normal
flora
isol
develop
due
use
antibiot
infect
caus
aerob
facult
anaerob
pathogen
new
antibiot
antianaerob
activ
may
test
old
isol
instead
use
recent
clinic
isol
may
creat
fals
suscept
data
incorrect
recommend
treatment
anaerob
infect
system
data
europ
avail
genera
speci
anaerob
bacteria
bacteroid
fragili
relat
speci
fusobacterium
spp
propionibacterium
acn
clostridium
perfringen
clostridium
difficil
two
europewid
resist
studi
carri
past
year
involv
almost
european
countri
evalu
develop
resist
among
b
fragili
relat
speci
similar
studi
done
clinic
isol
propionibacterium
acn
peptostreptococci
express
differ
found
resist
level
differ
bacteroid
speci
differ
area
europ
clindamycin
erythromycin
ampicillin
moxifloxacin
true
propionibacterium
acn
resist
gene
respons
carbapenem
nitroimidazol
resist
found
frequent
among
clinic
normal
flora
isol
express
resist
despit
fact
antianaerob
drug
show
good
activ
anaerob
clinic
isol
number
resist
isol
increas
parallel
time
accumul
resist
marker
observ
among
bacteroid
strain
report
case
discuss
clinic
failur
due
presenc
multiresist
anaerob
pathogen
pathogenesi
prevent
nosocomi
infectionsnew
aspect
symposium
arrang
esgni
infect
associ
intravascular
devic
b
rijnder
rotterdam
nl
notwithstand
progress
understand
pathogenesi
foreign
bodi
infect
catheterrel
infect
cri
continu
part
daili
life
icu
oncolog
haematolog
unit
consequenti
morbid
longer
hospit
stay
bring
consider
cost
howev
sever
intervent
reduc
incid
cri
year
ago
cathet
coat
impregn
antisept
antibiot
becam
part
armament
cri
howev
indiscrimin
prophylact
use
antibiot
increas
risk
antimicrobi
resist
furthermor
minocyclinrifampin
impregn
cathet
antibiot
impregn
cathet
well
document
efficaci
avail
europ
cathet
impregn
chlorhexidinesilv
sulfadiazin
cs
outer
surfac
avail
europ
shown
incid
cri
two
recent
clinic
studi
show
improv
version
cathet
cs
inner
outer
surfac
reduc
cathet
colon
vitro
evid
use
antisept
agent
substitut
antibiot
lock
prevent
endolumin
cri
avail
howev
evid
prospect
random
control
clinic
trial
use
antisept
lock
still
scarc
sever
clinic
studi
metaanalysi
support
use
chlorhexidin
prefer
disinfect
prior
cathet
insert
recent
evid
support
use
chlorhexidin
impregn
spong
place
around
insert
site
cathet
prevent
recolon
insert
site
therefor
also
exolumin
cri
shortterm
central
venou
well
arteri
cathet
gener
correct
state
microorgan
outer
surfac
cathet
exolumin
sourc
infect
cri
shortterm
cathet
microorgan
inner
surfac
endolumin
becom
import
longer
durat
cathet
use
differ
howev
gradual
therefor
set
intervent
direct
exolumin
well
endolumin
cri
combin
despit
abovement
new
develop
implement
structur
teach
program
cri
special
emphasi
adher
fullsteril
barrier
precaut
chlorhexidin
base
skin
disinfect
remov
cathet
soon
possibl
remain
cornerston
cri
prevent
ventilatorassoci
pneumonia
w
ger
tubingen
de
sever
factor
contribut
pathogenesi
vap
therefor
sever
approach
follow
order
prevent
pathogen
invad
lung
aspir
contamin
oral
secret
consid
main
mechan
also
true
incub
patient
microaspir
occur
besid
within
fold
inflat
cuff
endotrach
tube
moreov
oral
caviti
sever
ill
patient
typic
colon
gramneg
rod
usual
case
healthi
subject
consequ
mani
vap
prevent
measur
aim
reduct
aspir
contamin
oral
secret
deepli
sedat
patient
may
abl
swallow
oral
secret
oral
hygien
suction
import
part
nurs
care
also
contribut
reduct
aspir
howev
subglott
space
usual
empti
secret
oral
suction
one
approach
suction
subglott
secret
use
special
endotrach
tube
addit
dorsal
lumen
right
cuff
wherea
sever
research
could
find
benefit
least
two
studi
show
subglott
suction
effect
reduc
incid
vap
howev
definit
indic
replac
regular
endotrach
tube
subglott
suction
tube
patient
alreadi
intub
clearli
shown
reintub
risk
factor
develop
pneumonia
like
due
aspir
occur
deflat
endotrach
tube
process
intub
also
mean
thorough
precaut
taken
endotrach
tube
chang
medic
reason
enter
feed
stop
sever
hour
advanc
patient
place
semirecumb
posit
stomach
oral
caviti
suction
well
subglott
space
visual
suction
laryngoscopi
cuff
endotrach
tube
deflat
reduct
microbi
colon
oral
caviti
causal
approach
prevent
vap
shown
patient
undergo
cardiac
surgeri
oral
chlorhexidin
solut
reduc
incid
postop
pneumonia
still
unclear
whether
gener
recommend
surgic
patient
recent
investig
point
import
bacteri
colon
teeth
pathogenesi
vap
howev
antisept
gel
appli
gingiva
teeth
far
effect
prevent
vap
likewis
iseganan
antimicrobi
peptid
appli
oral
caviti
also
effect
shown
recent
multi
centr
placebocontrol
doubleblind
trial
topic
applic
antibiot
oropharynx
part
sever
trial
use
select
digest
decontamin
sdd
exclus
administr
oral
caviti
sod
select
oral
decontamin
effect
reduc
vap
icu
patient
meanwhil
independ
clinic
trial
shown
surviv
benefit
critic
ill
patient
treat
sdd
fear
increas
select
pressur
hamper
widespread
use
sdd
critic
ill
patient
news
field
toxoplasmosi
symposium
arrang
esgt
past
present
futur
drug
treatment
toxoplasma
gondii
ideal
antitoxoplasma
drug
would
preferenti
parasiticid
differ
parasit
stage
prevent
stage
differenti
tachyzoit
bradyzoit
would
penetr
cyst
well
distribut
main
site
infect
base
vitro
vivo
data
record
last
year
appear
drug
exist
today
market
new
compound
expect
sever
year
despit
recent
identif
new
potenti
drug
target
apicoplast
parasit
penetr
among
drug
use
safe
treatment
congenit
cerebr
toxoplasmosi
drug
drug
regimen
effect
combin
pyrimethamin
sulfadiazin
among
new
macrolid
azithromycin
seem
effici
vivo
synerg
pyrimethamin
new
fluoroquinolon
activ
vivo
vitro
potenti
toxic
concern
treatment
congenit
toxoplasmosi
atovaquon
remain
interest
reduct
parasit
burden
longterm
treatment
strategi
second
line
treatment
case
intoler
sulfonamid
pyrimethamin
cotrimoxazol
effect
vitro
vivo
tachyzoit
remain
first
line
drug
combin
primari
prophylaxi
toxoplasmosi
immunocompromis
patient
interestingli
antihiv
proteas
inhibitor
inhibitori
gondii
vitro
concentr
achiev
human
note
drug
experiment
data
dramat
lack
treatment
ocular
toxoplasmosi
efficaci
longterm
treatment
chronic
infect
brain
cyst
burden
inde
signific
progress
note
vitro
vivo
method
investig
drug
includ
use
transform
parasit
express
enzym
activ
bioluminesc
develop
qsar
method
high
throughput
screen
activ
small
molecul
parasit
enzym
gondii
penetr
cell
one
expect
result
identif
new
drug
strategi
futur
review
also
point
major
lack
inform
suscept
gondii
strain
accord
genotyp
mark
differ
suscept
occasion
report
need
confirm
basi
new
knowledg
strain
genotyp
similarli
possibl
exist
natur
drug
select
resist
need
also
investig
detect
genotyp
toxoplasma
gondii
realtim
pcr
pyrosequenc
b
edvinsson
lappalainen
b
european
studi
group
toxoplasmosi
esgt
object
toxoplasma
gondii
protozoan
parasit
worldwid
distribut
primari
infect
human
usual
asymptomat
character
nonspecif
symptom
infect
howev
sever
fatal
patient
suppress
immun
system
often
caus
chronic
infect
becom
reactiv
rapid
sensit
diagnosi
pcr
may
import
surviv
patient
pcr
techniqu
use
detect
parasit
patient
sampl
yet
standard
compar
perform
two
realtim
pcr
assay
target
two
differ
repetit
dna
element
gondii
also
aim
develop
pyrosequenc
assay
discrimin
three
main
genotyp
gondii
ie
type
ii
iii
method
sensit
detect
gondii
realtim
pcr
target
repeat
gene
fold
repeat
bp
element
compar
impact
diagnost
sensit
use
two
differ
type
intern
amplif
control
either
amplifi
primer
use
detect
gondii
differ
set
primer
test
genotyp
realtim
pcr
pyrosequenc
use
analys
fragment
gene
gondii
isol
result
sensit
higher
fold
repeat
bp
element
use
diagnost
perform
realtim
pcr
target
bp
element
affect
inclus
intern
amplif
control
pyrosequenc
assay
discrimin
type
ii
iii
gondii
clinic
microbiolog
infect
volum
supplement
conclus
realtim
pcr
includ
intern
amplif
control
use
detect
low
amount
gondii
sampl
amplif
part
bp
element
may
import
aim
sensit
rapid
diagnosi
toxoplasmosi
immunocompromis
patient
pyrosequenc
use
rapid
high
throughput
genotyp
parasit
clinic
find
help
elucid
differ
clinic
manifest
toxoplasmosi
caus
type
ii
iii
gondii
prevent
microbi
biofilm
format
medic
devic
symposium
arrang
esgb
drug
releas
polyurethan
abl
inhibit
microbi
biofilm
growth
medic
devic
g
donelli
rome
recent
year
number
differ
strategi
develop
prevent
medic
deviceassoci
infect
includ
devic
coat
antimicrobi
agent
abl
inhibit
bacteri
colon
biofilm
format
howev
possibl
emerg
multidrugresist
microorgan
consequ
subinhibitori
antibiot
concentr
releas
implant
devic
regard
signific
risk
hand
larg
increas
antibiot
resist
well
establish
featur
microbi
speci
grow
sessil
mode
form
biofilm
staphylococcu
pseudomona
candida
spp
frequent
implic
bug
devic
colon
order
inhibit
microbi
colon
medic
devic
minim
multidrug
resist
design
experiment
model
base
adsorpt
function
polyurethan
waterinsolubl
antibiot
use
system
therapi
ii
two
watersolubl
antibiot
belong
differ
class
commonli
use
system
therapi
iii
ion
transit
metal
known
broad
spectrum
antimicrobi
activ
possibl
adjuv
antibiot
iv
antifung
drug
highli
effect
treatment
candida
infect
v
poreform
molecul
abl
improv
antibiot
load
control
releas
particular
develop
new
drugreleas
polym
load
usnic
acid
waterinsolubl
antibiot
molecul
abl
exert
activ
devic
level
ii
rifampin
cefamandol
nafat
associ
two
watersolubl
antibiot
exhibit
two
differ
mode
action
iii
silver
ion
ciprofloxacin
exhibit
synergist
role
iv
fluconazol
widespectrum
antifung
drug
v
albumin
polyethylenglycol
pore
former
promot
releas
rifampin
cefamandol
nafat
fluconazol
polyurethan
result
vitro
studi
suggest
combin
entrap
antibiot
antifung
drug
poreform
function
polyurethan
seem
promis
prevent
bacteri
colonis
biofilm
format
control
emerg
microbi
resist
antimicrobi
utilis
europ
futur
direct
symposium
arrang
esgap
map
antibiot
consumpt
resist
commun
surveil
critic
understand
antibiot
resist
abil
control
spread
facilit
monitor
trend
inform
clinic
practic
guid
intervent
allow
assess
effect
chang
detect
new
untoward
event
time
feedback
consumpt
resist
data
stakehold
creat
ownership
aim
improv
prudent
prescrib
howev
impact
surveil
inform
greatli
influenc
present
geograph
inform
system
gi
map
analysi
technolog
allow
larg
quantiti
inform
visual
analys
within
geograph
context
gi
map
provid
power
medium
dissemin
surveil
data
variou
surveil
group
use
gi
technolog
map
resist
data
countri
region
level
eg
european
antimicrobi
resist
surveil
system
nph
wale
use
gi
technolog
map
resist
consumpt
depriv
practic
demographi
data
local
health
board
gener
practic
level
european
surveil
data
map
countri
region
review
welsh
surveil
data
map
lhb
gener
practic
present
factor
determin
antibiot
consumpt
resist
discuss
merit
use
gi
surveil
purpos
open
debat
pointpreval
survey
antiinfect
use
survey
antiinfect
use
carri
twice
year
last
six
year
hammersmith
hospit
nh
trust
use
point
preval
methodolog
team
clinic
pharmacist
collect
data
inpati
schedul
receiv
one
system
antiinfect
day
studi
well
total
number
patient
seen
data
collect
take
place
fourday
period
one
quarter
ward
survey
day
system
antifung
antivir
drug
includ
inform
obtain
includ
number
patient
schedul
receiv
one
antiinfect
day
studi
number
antiinfect
per
patient
percentag
antiinfect
given
intraven
well
detail
combin
durat
prescrib
use
antiinfect
trust
reserv
list
examin
detail
trust
antibiot
steer
group
use
result
obtain
highlight
area
intervent
includ
target
area
intraven
oral
switch
agre
local
polici
standard
practic
identifi
clinic
area
inappropri
combin
use
result
fed
back
clinic
director
part
perform
manag
inform
recent
ten
local
hospit
collect
equival
data
part
benchmark
exercis
present
illustr
inform
obtain
discuss
advantag
disadvantag
approach
studi
antiinfect
use
nosocomi
mould
infect
symposium
arrang
efsig
sourc
mould
hospit
set
jp
gangneux
renn
fr
mould
ubiquit
natur
reproduc
make
spore
abl
travel
air
caus
ill
particular
thermotoler
aspergillu
speci
produc
numer
conidia
diamet
invas
aspergillosi
ia
major
opportunist
infect
among
patient
sever
prolong
neutropenia
spore
inhal
usual
rout
infect
rout
may
exist
nosocomi
origin
aspergillosi
demonstr
epidem
situat
airborn
spore
transmiss
via
unfilt
air
massiv
environment
contamin
construct
renov
work
insid
outsid
hospit
air
control
measur
current
effect
way
significantli
reduc
incid
nosocomi
aspergillosi
patient
room
adequ
capac
minim
accumul
fungal
spore
use
higheffici
particul
air
filtrat
laminar
air
flow
system
high
rate
roomair
chang
posit
pressur
wellseal
room
innov
system
produc
purifi
air
may
repres
interest
altern
air
filtrat
monitor
environment
fungal
contamin
strongli
recommend
detect
increas
conidia
densiti
assess
air
filtrat
effici
followup
air
surfac
fungal
load
highli
recommend
hospit
unit
benefit
air
control
measur
addit
specif
investig
case
aspergillu
infect
requir
effici
biocollector
adequ
surfac
sampl
method
suitabl
cultur
condit
must
evalu
progress
term
air
filtrat
lead
decreas
ia
neutropen
patient
first
week
bone
marrow
transplant
delay
ia
still
occur
sourc
rout
spore
transmiss
remain
unclear
altern
sourc
contamin
investig
control
opportunist
fungal
pathogen
recov
sever
hospit
water
distribut
system
usa
author
suggest
aspergillosi
waterborn
howev
environment
risk
ia
link
water
interpret
accord
local
situat
differ
water
collect
treatment
exist
besid
sever
food
colon
mould
lead
spore
absorpt
aerosol
subsequ
system
infect
previous
recommend
immunocompromis
patient
avoid
contamin
food
one
altern
disinfect
potenti
contamin
food
especi
regard
fumigatu
lastli
cloth
visitor
medic
staff
carriag
person
medic
materi
potenti
vector
spore
prevent
measur
might
appropri
postop
aspergillosi
pasqualotto
manchest
uk
aspergillu
spp
ubiquit
aerob
fungi
occur
soil
water
decay
veget
organ
also
surviv
well
air
dust
moistur
present
healthcar
facil
similar
filament
fungi
aspergillu
speci
usual
acquir
inanim
reservoir
commonli
inhal
small
airborn
spore
invas
aspergillosi
typic
affect
sever
immunocompromis
patient
case
surgic
site
infect
report
immunocompet
individu
aim
present
summar
world
literatur
regard
topic
illustr
present
three
case
origin
person
knowledg
author
part
outbreak
first
case
man
underw
elect
aortic
valv
replac
die
aspergillu
endocard
second
teenag
underw
elect
neurosurgeri
chiari
malform
receiv
week
postop
dexamethason
die
despit
amphotericin
b
therapi
third
woman
develop
cerebr
abscess
due
aspergillu
fumigatu
neurosurgeri
augment
dexamethason
recov
follow
voriconazol
treatment
medlin
lilac
embas
databas
search
refer
relev
articl
review
confer
abstract
review
well
frank
alton
firstli
publish
studi
postop
aspergillosi
case
report
cardiac
ophthalmolog
surgeri
surgic
dental
procedur
provid
commonli
report
case
postop
case
endocard
aortiti
affect
mostli
immunocompet
male
patient
submit
aortic
valv
replac
median
time
surgeri
diagnosi
month
antemortem
diagnosi
occur
blood
cultur
rare
posit
mortal
condit
vascular
graft
aspergillosi
occur
median
time
month
surgeri
aspergillu
graft
infect
usual
occur
sutur
line
previou
aortotomi
definit
diagnost
procedur
patient
gener
cultur
excis
aortic
graft
peripher
embolu
biopsi
contigu
affect
vertebr
disk
space
patient
postop
aspergillosi
follow
neurosurgeri
receiv
treatment
corticosteroid
mortal
condit
surprisingli
low
consid
mortal
rate
immunosuppress
patient
dissemin
aspergillosi
involv
central
nervou
system
aspergillu
wound
infect
occur
median
time
day
surgeri
mani
patient
immunosuppress
aspergillu
flavu
aetiolog
infect
success
treatment
postop
aspergillosi
requir
rapid
diagnosi
surgic
debrid
antifung
therapi
probabl
voriconazol
order
improv
outcom
better
diagnost
method
need
particularli
case
endocard
aortiti
patient
sourc
presum
airborn
infect
surgic
procedur
prevent
infect
requir
special
care
ventil
system
oper
room
proper
disinfect
techniqu
appropri
storag
surgic
materi
singl
proven
postop
case
aspergillosi
suffici
initi
epidemiolog
investig
nosocomi
infect
due
emerg
mould
cuencaestrella
madrid
es
opportunist
mold
emerg
past
decad
import
caus
morbid
mortal
group
patient
present
aspergillu
spp
one
common
caus
infect
bone
marrowstem
cell
transplant
recipi
mucoral
increasingli
report
caus
lethal
infect
despit
aggress
medic
surgic
intervent
addit
rare
emerg
mold
becom
common
caus
deep
invas
fungal
infect
hyalin
hyphomycet
black
fungu
speci
increasingli
report
caus
nosocomi
mycos
pneumonia
cn
infect
dissemin
infect
refractori
convent
therapi
fusarium
spp
implic
nosocomi
outbreak
respiratori
dissemin
mycosi
scedosporium
spp
caus
dissemin
local
infect
hospit
patient
paecilomyc
lilacinu
scopulariopsi
brevicauli
rare
emerg
hyphomycet
caus
nosocomi
invas
infect
immunocompromis
patient
alternaria
spp
describ
case
deep
infect
solid
organ
transplant
recipi
sever
factor
signal
caus
emerg
rare
mould
hospit
environment
chang
antimicrobi
pressur
expand
popul
immunocompromis
host
increas
capabl
identifi
rare
fungi
commonli
argu
note
emerg
fungal
infect
would
continu
increas
set
effort
made
identifi
nosocomi
emerg
mold
speci
level
know
suscept
profil
organ
correct
character
speci
signific
therapeut
level
view
distinct
antifung
suscept
profil
dna
amplificationbas
method
could
use
character
emerg
pathogen
earli
diagnosi
procedur
new
therapeut
approach
also
need
guidelin
helicobact
pylori
infect
revisit
consensu
report
symposium
arrang
ehsg
indic
h
pylori
erad
revisit
nobel
prize
medicin
award
discoveri
h
pylori
import
human
pathogen
past
year
sinc
initi
discoveri
much
research
perform
find
optim
therapi
bacteri
infect
determin
benefit
h
pylori
erad
patient
variou
upper
gastrointestin
condit
past
decad
repeat
intern
consensu
meet
basi
literatur
gradual
develop
adapt
guidelin
manag
h
pylori
infect
maastricht
guidelin
develop
author
european
h
pylori
studi
group
year
particular
impact
clinic
approach
h
pyloriposit
patient
maastricht
guidelin
recent
revis
focu
indic
therapi
diagnost
approach
treatment
issu
condit
accept
previou
maastricht
guidelin
strong
definit
indic
h
pylori
treatment
accept
includ
particular
peptic
ulcer
diseas
gastric
bcell
maltlymphoma
also
atroph
gastriti
degre
rel
gastric
cancer
patient
furthermor
h
pylori
erad
accept
appropri
option
h
pyloriposit
patient
investig
nonulc
dyspepsia
wherea
h
pylori
test
treat
accept
appropri
option
patient
uninvestig
dyspepsia
routin
test
helicobact
pylori
recommend
gerd
consensu
committe
advis
consid
h
pylori
test
patient
longterm
mainten
therapi
ppi
h
pylori
erad
consid
valu
chronic
nsaid
user
insuffici
complet
prevent
nsaidrel
ulcer
diseas
h
pylori
infect
sought
treat
patient
either
unexplain
iron
defici
anaemia
itp
indic
background
discuss
meet
manag
h
pylori
infect
well
establish
last
year
recommend
made
maastricht
confer
updat
use
consensu
confer
worldwid
nevertheless
point
emerg
past
year
led
question
discuss
confer
diagnosi
pre
treatment
regard
diagnost
test
discuss
focus
valu
noninvas
test
urea
breath
test
ubt
first
statement
conclud
serolog
could
consid
diagnost
test
situat
eg
bleed
ulcer
gastric
atrophi
malt
lymphoma
current
use
ppi
antibiot
inde
ppi
sourc
fals
neg
result
diagnost
test
except
serolog
stop
least
week
perform
test
contrast
state
neither
doctor
test
nearpati
test
detect
h
pylori
antibodi
urin
saliva
current
role
manag
h
pylori
infect
situat
differ
stool
test
consid
accept
ground
ubt
h
pylori
diagnosi
especi
case
implement
test
treat
strategi
import
perform
cultur
clarithromycin
suscept
test
use
clarithromycinbas
treatment
first
line
treatment
hardli
debat
cultur
recommend
primari
resist
antibiot
higher
respect
geograph
area
popul
well
treatment
failur
import
monitor
primari
antibiot
resist
refer
laboratori
differ
area
also
stress
event
clarithromycin
suscept
test
circumst
imposs
antibiot
use
contrast
agre
test
metronidazol
suscept
routin
necessari
manag
h
pylori
infect
metronidazol
suscept
test
need
standard
recommend
first
line
treatment
treat
recommend
first
line
therapi
therefor
remain
ppiclarithromycinamoxicillin
metronidazol
primari
resist
clarithromycin
area
lower
small
advantag
use
metronidazol
instead
amoxicillin
therefor
combin
found
prefer
area
preval
metronidazol
resist
lower
consensu
also
rather
treatment
durat
slight
advantag
term
treatment
success
howev
treatment
cost
effect
countri
anoth
addit
consensu
bismuthbas
quadrupl
therapi
avail
accept
altern
first
line
therapi
regard
second
line
therapi
bismuthbas
quadrupl
therapi
remain
best
option
unavail
ppiamoxicillin
tetracyclin
metronidazol
recommend
previous
propos
rescu
therapi
failur
cours
differ
therapi
base
antimicrobi
suscept
test
followup
h
pylori
erad
ubt
remain
prefer
test
unavail
laboratorybas
stool
test
prefer
use
monoclon
antibodi
could
use
time
followup
least
week
end
erad
treatment
prevent
gastric
cancer
h
pylori
erad
p
malferthein
magdeburg
de
light
recent
clinic
develop
manag
h
pylori
infect
european
helicobact
studi
group
ehsg
organ
maastricht
iii
consensu
report
involv
particip
countri
around
world
abstract
provid
brief
summari
novel
major
aspect
relev
clinician
routin
new
edit
maastricht
guidelin
three
area
address
indicationscontraind
h
pylori
erad
special
focu
dyspepsia
patient
expos
nsaid
aspirin
relationship
gerd
b
diagnost
proceduresstandard
rescu
therapi
h
pylori
infect
c
prevent
gastric
cancer
complic
relat
h
pylori
select
recommend
statement
list
follow
indicationscontraind
h
pylori
erad
relev
statement
uninvestig
dyspepsia
h
pylori
test
treat
appropri
option
patient
uninvestig
dyspepsia
nsaid
patient
nsaid
user
h
pylori
erad
may
partial
prevent
peptic
ulcer
andor
bleed
ii
patient
long
term
nsaid
peptic
ulcer
andor
ulcer
bleed
ppi
mainten
therapi
superior
h
pylori
erad
prevent
ulcer
recurr
andor
bleed
aspirin
patient
longterm
aspirin
ulcer
diseas
signific
clinic
bleed
test
h
pylori
posit
receiv
erad
therapi
gerd
h
pylori
erad
caus
gerd
atroph
gastriti
h
pylori
erad
halt
extens
atroph
gastriti
may
lead
regress
atrophi
effect
intestin
metaplasia
uncertain
iron
defici
anaemia
h
pylori
infect
sought
treat
patient
unexplain
iron
defici
anaemia
b
diagnosi
h
pylori
infect
noninvas
test
use
test
treat
strategi
ubt
stool
antigen
test
certain
kit
serolog
high
accuraci
also
appli
ii
ppi
sourc
fals
neg
diagnost
test
except
serolog
ppi
stop
least
week
perform
diagnost
test
iii
recommend
follow
patient
h
pylori
erad
ubt
avail
diagnost
procedur
avail
laboratorybas
stool
test
prefer
use
monoclon
antibodi
could
use
c
prevent
gastric
cancer
h
pylori
erad
prevent
develop
preneoplast
chang
intestin
metaplasia
atroph
gastriti
gastric
mucosa
ii
erad
h
pylori
potenti
reduc
risk
gastric
cancer
develop
iii
optim
time
erad
h
pylori
preneoplast
condit
atrophi
intestin
metaplasia
present
treatment
strategi
first
line
therapi
h
pylori
erad
ppiclarithromycin
amoxicillin
metronidazol
therapi
remain
recommend
first
line
therapi
popul
less
clarithromycin
resist
preval
popul
less
metronidazol
resist
preval
ppiclarithromycin
metronidazol
prefer
quadrupl
therapi
altern
first
line
therapi
case
failur
second
line
therapi
bismuthbas
quadrupl
therapi
remain
best
second
line
therapi
avail
ppiamoxicillin
tetracyclin
metronidazol
recommend
subsequ
failur
rescu
therapi
rescu
therapi
base
antimicrobi
suscept
test
new
diagnost
techniqu
microbiolog
laboratori
gener
practition
breakthrough
bacteri
detect
identif
type
struelen
brussel
number
novel
method
applic
clinic
microbiolog
laboratori
report
detect
identif
speci
level
subtyp
bacteri
pathogen
breakthrough
made
rapid
detect
bloodstream
infect
neonat
adult
patient
sepsi
use
broad
rang
bacteri
dna
detect
identif
success
method
includ
univers
gene
analysi
realtim
pcr
pcrdna
microarray
hybrid
pcrpyrosequenc
test
blood
specimen
also
sever
highli
accur
sequencebas
method
develop
valid
identif
clinic
cultur
staphylococci
mycobacteria
nocardia
burkholderia
speci
progress
also
achiev
rapid
detect
carrier
multiresist
bacteria
especi
methicillinresist
aureu
mrsa
superfici
swab
sever
chromogen
select
cultur
media
shown
sensit
excel
specif
mrsa
detect
within
hour
incub
realtim
pcr
base
orfxsccmec
junction
shown
similar
accuraci
mrsa
detect
within
hour
specimen
collect
tuberculosi
advanc
made
rapid
detect
identif
speci
level
detect
rifampin
isoniazid
resist
directli
clinic
specimen
molecular
method
includ
pcrpyrosequenc
epidemiolog
type
benefit
greatli
extens
valid
sequencebas
system
databas
includ
novel
mlst
scheme
acinetobact
b
cepacia
complex
singl
nucleotid
polymorph
analys
rapid
method
like
realtim
pcr
melt
curv
analysi
allelespecif
pcr
develop
ecoli
campylobact
vntrmlva
scheme
also
valid
rapid
type
sever
human
pathogen
gener
public
focu
proof
concept
rapid
highli
inform
molecular
assay
level
clinic
accuraci
howev
evalu
clinic
utilitysuperior
assay
routin
applic
term
costeffect
medicalpubl
health
intervent
base
test
result
thu
need
fund
kind
intervent
research
urgent
address
health
technolog
assess
author
progress
detect
bacteria
respons
infect
challeng
clinic
situat
antimicrobi
resist
r
leclercq
caen
fr
identif
convent
techniqu
bacteria
respons
infect
remain
challeng
situat
bacteria
rare
clinic
sampl
difficult
grow
antibiot
treatment
administ
earli
bone
joint
infect
endocard
mening
exampl
type
situat
anoth
challeng
issu
rapid
detect
bacteria
case
sever
infect
prevent
neonat
infect
group
b
streptococci
sever
molecular
homemad
commerci
avail
techniqu
use
provid
reliabl
result
detect
antimicrobi
resist
might
use
resist
poorli
express
convent
test
epidemiolog
purpos
particular
detect
methicillin
resist
staphylococci
subject
extens
work
sever
method
avail
allow
detect
express
meca
gene
sever
commerci
kit
avail
detect
meca
gene
gener
base
dna
amplif
follow
hybrid
kit
gener
allow
speci
identif
experi
similarli
identif
vancomycin
resist
gene
enterococci
perform
use
either
homemad
multiplex
pcr
commerci
kit
cost
techniqu
decreas
remain
balanc
benefit
expect
use
advantag
molecular
diagnost
virolog
becom
clear
grow
number
clinic
import
question
left
research
state
becom
integr
routin
diagnost
set
repertoir
assay
avail
mostli
focuss
detect
bloodborn
virus
hbv
due
avail
new
easytous
technolog
mostli
realtim
amplif
base
detect
everi
target
possibl
target
like
herpesvirus
larg
panel
virus
infect
respiratori
tract
alreadi
routin
detect
larger
univers
hospit
also
push
urgent
need
prepar
detect
new
emerg
virus
like
sar
influenza
viru
whether
also
due
possibl
develop
assay
within
rel
short
period
time
newli
detect
virus
like
coronavirus
hku
boca
viru
increas
insight
clinic
implic
virus
respiratori
tract
infect
knowledg
easytous
real
time
technolog
improv
isol
detect
platform
avail
better
control
profici
panel
increas
number
target
introduct
univers
intern
control
result
better
standard
assay
perform
result
discrep
number
commerci
avail
assay
use
virolog
target
compar
inhous
develop
assay
also
accept
molecular
diagnost
simpli
clinic
decis
better
made
due
inform
provid
last
two
hurdl
cost
timetoresult
close
solv
develop
molecular
technolog
assay
last
year
well
detect
new
pathogen
case
detect
technolog
like
viru
cultur
serolog
improv
qualiti
control
possibl
gener
virolog
dynam
disciplin
impact
good
clinic
practic
although
improv
alway
possibl
like
multiplex
small
volum
fast
turnaroundtim
dna
chip
technolog
finish
around
corner
invas
fungal
infect
ifi
becom
major
caus
increas
morbid
mortal
immunocompromis
patient
number
new
antifung
late
introduc
fight
opportunist
fungi
patient
gener
devast
diseas
dismal
prognosi
partli
due
late
diagnosi
ifi
histor
microscop
examin
bodi
fluid
tissu
biopsi
well
cultur
materi
appropri
cultur
media
princip
modal
diagnosi
ifi
high
resolut
ct
scan
serial
perform
proven
sensit
tool
diagnosi
fungal
pneumonia
haematolog
patient
lung
densiti
halo
sign
central
cavit
small
nodul
air
crescent
format
found
adult
patient
use
sign
invas
aspergillosi
ia
recent
novel
diagnost
method
serolog
molecular
develop
evalu
well
improv
cultur
techniqu
identif
perform
accur
speci
level
use
autom
method
genet
sequenc
evalu
suscept
clinic
fungal
isol
antifung
drug
also
widespread
standard
correl
vitro
vivo
effect
achiev
least
case
candida
infect
among
serolog
method
galactomannan
assay
becom
help
earli
diagnosi
ia
sequenti
perform
highrisk
patient
shown
help
use
still
problemat
young
pediatr
patient
assay
given
low
specif
high
number
fals
posit
result
well
low
sensit
certain
case
chronic
granulomat
diseas
evalu
galactomannan
bodi
fluid
blood
also
feasibl
provid
import
inform
need
howev
standard
bglucan
anoth
metabolit
increas
serum
patient
fungal
infect
specif
invas
candidiasi
intens
studi
detect
nucleic
acid
fungi
use
polymeras
chain
reaction
pcr
power
method
rapid
identif
fungi
method
howev
need
develop
standard
wide
appli
clinic
microbiolog
lab
techniqu
coupl
enhanc
radiolog
expect
enabl
physician
diagnos
seriou
fungal
infect
earlier
cours
increas
chanc
improv
outcom
almost
year
first
descript
gustav
landri
syndrom
gb
lead
caus
acut
autoimmun
neuromuscular
paralysi
worldwid
major
advanc
made
recent
year
unravel
pathophysiolog
mechan
gb
overal
approx
case
preced
infect
mostli
flulik
infect
gastroenter
caus
campylobact
jejuni
discoveri
gangliosid
mimic
microbi
glycan
quintessenti
human
well
anim
studi
support
import
role
molecular
mimicri
pathogenesi
gb
evid
accumul
genet
polymorph
c
jejuni
determin
antigangliosid
antibodi
reactiv
clinic
present
gb
gene
involv
synthesi
transfer
sialic
acid
appear
play
crucial
role
mice
inject
wild
type
gb
strain
induc
antigangliosid
antibodi
wherea
cstii
knockout
mutant
acut
motor
axon
neuropathi
aman
fisher
syndrom
particular
associ
antibodi
respect
bcell
toler
may
explain
fact
cjejuni
infect
follow
gb
although
mechan
still
poorli
understood
carbohydr
human
gangliosid
elicit
tcellindepend
humor
respons
howev
reason
specifi
tcell
also
like
play
import
role
pathogenesi
gb
role
clear
yet
recent
attempt
identifi
human
immunosuscept
factor
unsuccess
research
clearli
need
order
discov
new
treatment
modal
recent
develop
biosynthesi
surfacebound
gangliosid
deriv
may
open
new
avenu
novel
specif
diagnost
therapeut
approach
involv
chlamydia
pneumonia
multipl
sclerosi
e
fainardi
ferrara
multipl
sclerosi
ms
presum
autoimmun
chronic
inflammatori
demyelin
diseas
central
nervou
system
cn
unknown
aetiolog
epidemiolog
observ
indic
exposur
environment
factor
viru
combin
genet
predisposit
could
implic
ms
pathogenesi
howev
direct
evid
infecti
aetiolog
ms
still
lack
recent
potenti
role
caus
agent
ms
suggest
chlamydia
pneumonia
gramneg
oblig
intracellular
bacterium
induc
chronic
infect
present
high
seropreval
adult
initi
high
rate
report
molecular
cultur
demonstr
c
pneumonia
cerebrospin
fluid
csf
ms
patient
associ
c
pneumonia
ms
intens
investig
epidemiolog
studi
report
seroposit
c
pneumonia
strongli
relat
risk
clinic
exacerb
progress
diseas
moder
link
risk
develop
ms
conflict
result
obtain
use
differ
techniqu
polymeras
chain
reaction
pcr
isol
studi
csf
evid
c
pneumonia
ms
either
less
frequent
previous
describ
equival
amount
ms
neurolog
diseas
absent
evid
c
pneumonia
infect
observ
ms
brain
lesion
intrathec
product
antic
pneumonia
antibodi
within
cn
found
variabl
proport
patient
ms
neurolog
disord
undetect
c
pneumonia
abl
induc
experiment
autoimmun
encephalomyel
eae
anim
model
ms
rat
presenc
c
pneumonia
brain
tissu
csf
recent
demonstr
subgroup
ms
patient
immunohistochem
molecular
ultrastructur
level
grow
bodi
data
argu
central
role
c
pneumonia
candid
ms
pathogenesi
suggest
associ
c
pneumonia
ms
select
restrict
ms
share
neurolog
condit
find
also
rais
possibl
c
pneumonia
present
subset
patient
ms
c
pneumonia
could
caus
brain
chronic
persist
infect
act
cofactor
develop
diseas
nevertheless
actual
involv
c
pneumonia
ms
still
remain
matter
debat
varicella
zoster
viru
vzv
infect
central
nervou
system
cn
constitut
major
part
burden
diseas
viru
clinic
scope
includ
enceph
brain
stem
enceph
myeliti
cerebel
cerebr
vascul
ventricul
facial
palsi
radicul
mening
recent
improv
diagnost
reveal
vzv
major
cn
viru
sever
european
countri
present
clinic
laboratori
data
case
collect
teborg
area
vzv
dna
detect
pcr
cerebrospin
fluid
csf
last
threeyear
period
yearli
incid
vzv
cn
infect
rose
sharpli
becom
frequent
detect
viru
csf
laboratori
shift
coincid
introduct
novel
taqman
pcr
system
base
gene
code
glycoprotein
b
agerel
incid
surprisingli
evenli
distribut
except
peak
year
line
studi
other
larg
proport
case
skin
lesion
ie
neither
shingl
zoster
two
find
compat
vzv
might
recur
often
life
previous
thought
manifest
cn
might
clinic
import
part
vzv
diseas
spectrum
viral
dna
quantiti
csf
found
high
compar
similar
data
cn
infect
caus
herp
simplex
viru
suggest
vzv
sought
case
cn
infect
suspect
viral
origin
recommend
regard
dose
durat
antivir
therapi
vzv
infect
thoroughli
discuss
longterm
followup
studi
neurolog
outcom
perform
possibl
viral
aetiolog
multipl
sclerosi
pge
kennedi
glasgow
uk
demyelin
diseas
multipl
sclerosi
ms
import
caus
neurolog
disabl
young
adult
northern
temper
region
diseas
probabl
multifactori
aetiolog
sever
line
evid
indic
strong
environment
element
causat
possibl
viral
compon
ms
pathogenesi
consid
possibl
mani
year
long
list
virus
report
present
ms
brain
tissu
use
variou
techniqu
previou
report
viru
isol
gener
confirm
whole
subject
therefor
remain
highli
controversi
recent
mani
group
use
sophist
molecular
virolog
techniqu
attempt
address
issu
also
possibl
viru
may
involv
initi
stage
msthe
socal
hit
run
scenarioin
case
evid
activ
viral
infect
ms
brain
tissu
would
expect
also
ms
truli
heterogen
diseas
viru
inde
aetiolog
compon
may
involv
case
other
talk
give
broad
overview
past
current
attempt
identifi
virus
viral
nucleic
acid
viral
antigen
ms
tissu
also
focu
recent
work
implic
possibl
role
human
herp
ms
primarili
studi
suggest
viral
dna
rna
increas
ms
lesion
compar
normal
tissu
although
data
area
remain
controversi
possibl
role
human
endogen
retrovirus
herv
ms
also
mention
also
recent
interest
abnorm
immun
respons
ebv
ms
patient
latter
indic
viral
infect
alter
immun
ms
necessarili
inconsist
ctxm
extendedspectrum
relat
blactamas
first
detect
human
clinic
isol
nearli
simultan
germani
argentina
sinc
dramat
increas
preval
observ
world
nosocomi
commun
set
factor
fuell
situat
includ
genet
aspect
relat
effici
blactxm
gene
dissemin
enzymat
express
bacteri
hostspecif
featur
frequent
coresist
antimicrobi
blactxm
gene
link
appar
simpl
genet
structur
includ
sequenc
insert
sequenc
integron
integron
lesser
extent
phagerel
construct
genet
support
insert
higherord
genet
complex
structur
us
transpos
element
transposon
plasmid
undoubtedli
facilit
mobil
blactxm
gene
allodem
popul
structur
commonli
associ
ctxm
produc
isol
illustr
situat
nevertheless
success
epidem
ctxm
produc
clone
also
identifi
nosocomi
set
also
commun
blactxm
gene
environ
surround
structur
might
also
facilit
acquisit
resist
cassett
integr
structur
previous
harbour
resist
cassett
coresist
includ
aminoglycosid
fluoroquinolon
trimethoprim
sulfonamid
facilit
success
mainten
ctxm
produc
isol
coselect
within
bacteri
commun
intestin
colon
ctxm
produc
e
coli
isol
increasingli
recogn
suggest
potenti
sourc
clinic
isol
nevertheless
ctxm
produc
isol
associ
phylogenet
group
commonli
associ
extra
intestin
pathogen
isol
also
fluoroquinolon
resist
isol
hand
enzymat
express
earli
ctxm
esbl
yield
higher
resist
cefotaxim
ceftazidim
howev
ctxm
produc
isol
compens
partial
resist
phenotyp
amino
acid
substitut
expand
hydrolyt
properti
ctxm
enzym
ceftazidim
andor
acquisit
esbl
mainli
shv
tem
famili
gener
affect
expand
spectrum
cephalosporin
continu
evolut
ctxm
enzym
success
persist
mobil
blactxm
gene
allow
mainten
increas
isol
ctxm
produc
isol
clinic
set
role
integron
spread
blactamas
gm
rossolini
siena
object
mobil
blactamas
gene
carri
broad
repertoir
genet
element
includ
transposon
composit
transposon
integronborn
gene
cassett
integronassoci
structur
object
present
review
discuss
role
integron
system
dissemin
clinicallyrelev
blactamas
gene
method
comprehens
review
scientif
literatur
sequenc
databas
experiment
result
deriv
molecular
character
blactam
resist
clinic
isol
carri
gener
updat
compil
blactamas
encod
integronassoci
gene
compar
analysi
integron
structur
contain
blactamas
gene
use
deduc
inform
phylogeni
result
gene
encod
blactamas
known
molecular
class
found
integronassoci
number
class
class
b
class
blactamas
gene
carri
mobil
gene
cassett
insert
integron
addit
class
class
c
blactamas
gene
found
integronassoci
structur
clinic
standpoint
import
blactamas
gene
carri
gene
cassett
encod
metalloblactamas
imp
vim
gimand
simtyp
encod
extendedspectrum
serin
blactamas
esbl
molecular
class
eg
veband
gestyp
enzym
eg
member
lineag
integronassoci
blactamas
gene
clinic
import
encod
class
esbl
ctxmtype
lineag
encod
ampclik
enzym
dha
cmymox
lineag
carri
structur
conclus
integron
play
import
role
dissemin
express
sever
emerg
clinic
relev
blactamas
gene
among
major
gramneg
pathogen
includ
member
famili
enterobacteriacea
pseudomona
aeruginosa
acinetobact
spp
consider
structur
divers
integron
carri
blactamaseencod
cassett
underscor
role
cassett
mobil
dissemin
resist
determin
presenc
addit
integronassoci
recombin
mechan
enhanc
potenti
element
dissemin
blactamas
gene
clinic
set
quinolon
resist
efflux
type
ii
topoisomeras
mutat
enterobact
cloaca
clinic
isol
harbour
qnr
implic
quinolon
resist
e
cambau
c
lascol
j
robert
v
cattoir
v
jarlier
cj
soussi
creteil
pari
fr
object
qnr
new
mechan
resist
quinolon
due
protect
dna
gyras
qnr
protein
first
describ
escherichia
coli
klebsiella
pneumonia
recent
studi
show
franc
dissemin
mainli
enterobact
cloaca
although
qnr
known
confer
low
level
resist
quinolon
clinic
e
cloaca
qnrposit
strain
harbour
high
level
fluoroquinolon
resist
suggest
associ
mechan
quinolon
resist
method
detect
mutat
quinolon
resistancedetermin
region
qrdr
dna
gyras
gyra
gyrb
topoisomeras
iv
parc
pare
gene
perform
qnrposit
strain
e
cloaca
isol
hospit
pari
mic
nine
quinolon
determin
etest
method
result
two
mutat
one
gyra
associ
one
parc
observ
qnrposit
strain
one
mutat
gyra
observ
qnrposit
strain
remain
strain
show
wildtyp
sequenc
qrdr
gyra
gyrb
parc
pare
qnrposit
strain
intermedi
resist
nalidix
acid
pefloxacin
norfloxacin
ofloxacin
moxifloxacin
strain
suscept
ciprofloxacin
cip
levofloxacin
lvx
base
eucastcasfm
breakpoint
geometr
mean
cip
mic
mgl
rang
mgl
qnrposit
strain
topoisomeras
mutat
mgl
rang
mgl
qnrposit
strain
topoisomeras
mutat
mgl
strain
devoid
topoisomeras
mutat
rang
mgl
transfer
conjug
e
cloaca
e
coli
qnr
shown
confer
low
level
quinolon
resist
cip
mic
mgl
lvx
mic
mgl
increas
mic
quinolon
conclus
e
cloaca
clinic
strain
harbour
qnr
also
harbour
topoisomeras
mutat
explain
high
level
quinolon
resist
none
quinolon
test
easili
detect
presenc
qnr
except
e
cloaca
strain
devoid
topoisomeras
mutat
low
level
quinolon
resist
may
indic
presenc
qnr
emerg
plasmidmedi
quinolon
resist
qnr
determin
enterobacteri
isol
europ
l
poirel
c
leviandi
p
nordmann
le
kremlin
bicetr
fr
object
plasmidmedi
quinoloneresist
determin
qnra
identifi
previous
enterobacteriacea
usa
asia
europ
qnr
found
shigella
flexneri
isol
japan
goal
look
qnra
qnr
determin
collect
nalidixicacid
resist
enterobacteri
isol
recov
hospit
franc
sixmonth
period
extendedspectrum
blactamas
esbl
posit
enterobacteri
isol
recov
threeyear
period
june
june
previou
studi
perform
hospit
collect
nalidix
acid
resist
escherichia
coli
isol
recov
identifi
qnra
singl
isol
wherea
presenc
qnr
gene
test
studi
studi
far
method
pcr
perform
use
specif
primer
qnra
qnr
gene
clone
pcr
experi
perform
identifi
upstreamand
downstreamloc
region
gene
pulsedfield
gel
electrophoresi
pfge
perform
compar
genotyp
strain
identifi
qnr
posit
result
among
nalidix
acidresist
esbl
neg
isol
recov
one
qnraposit
klebsiella
pneumonia
isol
one
qnrsposit
serratia
marcescen
isol
four
qnrsposit
enterobact
cloaca
isol
correspond
two
differ
clone
pfge
identifi
determin
found
transfer
conjug
transform
e
coli
among
esblposit
isol
qnrposit
isol
identifi
singl
qnraposit
escherichia
coli
isol
posit
singl
qnraposit
e
cloaca
isol
posit
identifi
respect
six
month
one
qnraposit
enterobact
aerogen
isol
three
qnrsposit
isol
one
e
coli
one
e
cloaca
one
e
cloaca
identifi
qnrposit
isol
resist
nalidix
acid
conclus
work
demonstr
qnr
determin
emerg
europ
qnr
determin
might
preval
qnra
second
identif
qnr
japan
noteworthi
qnrsposit
isol
alway
esbl
produc
quinolon
andor
resist
aminoglycosid
isol
screen
doubl
pcr
assay
use
specif
primer
multiplex
pcr
qnra
anoth
pcr
qnr
qnrposit
result
confirm
dna
sequenc
analysi
reppcr
type
perform
qnr
contain
isol
qnrposit
isol
intermedi
suscept
cip
autom
system
mic
ciprofloxacin
cip
nalidix
acid
na
addit
determin
etest
result
qnr
detect
e
cloaca
among
isol
speci
santand
blast
analysi
nucleotid
sequenc
reveal
ident
previous
publish
qnr
sequenc
neither
qnra
qnr
gene
detect
e
cloca
sevil
e
aerogen
locat
five
differ
reppcr
profil
obtain
qnrsposit
e
cloaca
contain
isol
respect
qnrsposit
isol
resist
cip
mic
mgl
except
clonal
relat
isol
suscept
cip
mic
mgl
na
mic
mgl
strain
cipintermedi
mic
mgl
naresist
mic
mgl
although
isol
e
cloaca
carri
none
studi
organ
contain
qnra
contrast
qnr
found
clonal
relat
isol
bear
conclus
e
cloaca
contain
qnr
gene
detect
northern
spain
isol
intermedi
suscept
ciprofloxacin
determin
qnrdna
gyras
interact
site
genet
approach
cesaro
v
cattoir
c
lascol
cj
soussi
e
cambau
creteil
fr
object
qnr
new
mechan
quinolon
resist
due
protect
gyras
qnr
protein
sinc
quinolon
inhibit
gyras
hamper
qnr
hypothes
qnrgyras
interact
occur
site
close
interact
quinolon
ie
quinolon
resistancedetermin
region
qrdr
gyra
gyrb
subunit
method
first
vitro
select
quinolon
resist
mutant
perform
compar
wildtyp
wt
refer
escherichia
coli
strain
e
coli
transconjug
harbour
qnra
gene
select
carri
use
nalidix
acid
nal
ciprofloxacin
cip
moxifloxacin
mox
mutant
chosen
basi
quinolon
mic
mutat
gyra
gyrb
qrdr
determin
second
qnra
introduc
conjug
e
coli
strain
referenc
gyra
mutat
gyrb
mutat
gyra
parc
gyra
pare
result
wt
e
coli
gyra
mutat
observ
mutant
select
nal
mutant
select
cip
mutant
select
mox
e
coli
qnr
gyra
mutat
observ
mutant
select
nal
mutant
select
cip
mutant
select
mox
analysi
gyra
mutat
show
wherea
mutat
occur
codon
mutant
select
wt
e
coli
harbour
mutat
mutant
select
e
coli
qnr
convers
mutat
observ
mutant
select
e
coli
qnr
occur
codon
wt
e
coli
mutant
one
stepmut
mutant
select
mox
e
coli
qnr
mutat
observ
either
qrdr
gyra
gyrb
parc
pare
entir
gyra
gyrb
gene
wherea
select
mox
e
coli
wildtyp
result
gyra
mutant
n
n
introduct
qnr
strain
referenc
topoisomeras
mutat
mic
cip
mox
increas
nal
mic
increas
whatev
topoisomeras
mutat
harbour
recipi
strain
conclus
result
two
approach
seem
one
amino
acid
involv
qnrgyras
interact
seem
preferenti
interact
nal
cip
presenc
qnr
mox
put
implic
ycee
transport
protein
ompn
porin
resist
quinolon
escherichia
coli
fabrega
j
sanchezcesped
mm
tavio
ruiz
j
vila
barcelona
la
palma
es
object
interplay
decreas
permeabl
increas
efflux
may
play
import
role
acquisit
quinoloneresist
escherichia
coli
main
object
studi
investig
express
outer
membran
protein
efflux
pump
mechan
resist
quinolon
two
isogen
quinolonesuscept
resist
e
coli
strain
follow
genom
proteom
approach
method
quinoloneresist
mutant
select
norfloxacin
e
coli
clinic
isol
norfloxacin
accumul
wildtyp
mutant
strain
determin
fluoresc
assay
dna
microarray
contain
whole
genom
ecoli
use
analys
differenti
express
gene
rtpcr
use
confirm
dna
microarray
result
electrophoresi
use
perform
protein
analysi
strain
result
accumul
assay
demonstr
quinoloneresist
ecoli
mutant
strain
present
lower
intracellular
norfloxacin
accumul
wildtyp
strain
dna
microarray
show
gene
express
mutant
among
acra
acrb
ycee
ompn
found
wherea
gene
downregul
among
ompf
found
rtpcr
analysi
confirm
increas
express
acra
acrb
ycee
ompn
decreas
express
ompf
electrophoresi
confirm
lower
express
ompf
show
overexpress
tolc
mutant
strain
conclus
known
acrabtolc
play
import
role
quinoloneresist
acquisit
ecoli
howev
overexpress
ycee
ompn
may
also
play
role
quinolon
resist
acquisit
microorgan
potenti
fluoroquinolon
induc
express
acrab
efflux
pump
global
regul
mara
salmonella
hadar
schmidt
p
heisig
hamburg
de
object
fluoroquinolon
fq
often
antibiot
choic
combat
gastrointestin
respiratori
urinari
tract
infect
well
infect
skin
soft
tissu
sst
howev
bacteri
resist
becom
increas
problem
resist
fq
acquir
alter
target
mutat
type
ii
topoisomeras
gene
gyrab
parc
well
decreas
uptak
increas
efflux
one
import
multidrug
resist
mdr
efflux
pump
salmonella
acrabtolc
consist
rndtype
transport
acrb
membran
fusion
protein
acra
outer
membran
channel
tolc
enhanc
express
efflux
system
due
eg
mutat
gene
acrr
local
regul
acrr
alter
express
global
regul
system
marrab
question
address
present
studi
addit
fq
capabl
induc
express
acrab
efflux
pump
andor
global
regul
system
like
marrab
method
salmonella
hadar
cultiv
presenc
respect
fq
mic
correspond
approxim
concentr
achiev
tissu
therapi
well
mic
ciprofloxacin
harvest
nm
isol
total
rna
qiagen
rneasi
mini
kit
revers
transcript
use
gene
specif
primer
express
chang
acra
mara
gene
determin
realtim
pcr
use
sybr
green
result
induct
norfloxacin
upregul
acra
gene
express
determin
whilst
mara
gene
express
upregul
presenc
moxifloxacin
cultiv
led
upregul
acra
gene
express
howev
express
chang
mara
observ
exposit
neither
ciprofloxacin
mic
levofloxacin
ofloxacin
marbofloxacin
pradofloxacin
garenoxacin
mic
result
express
chang
acra
mara
respect
conclus
assort
structur
divers
fq
norfloxacin
lesser
extend
moxifloxacin
abl
effect
increas
acra
mara
express
regard
resist
develop
reassur
observ
induct
mdr
efflux
fq
clinic
relev
salmonella
horizont
gene
transfer
contribut
fluoroquinolon
resist
streptococcu
pyogen
object
date
report
pyogen
resist
fluoroquinolon
rare
recent
belgian
surveil
studi
found
preval
among
nearli
patient
tonsillopharyng
due
pyogen
malhotrakumar
et
al
clonal
spread
fluoroquinolon
nonsuscept
streptococcu
pyogen
j
antimicrob
chemoth
fluoroquinolon
resist
pyogen
aris
due
mutat
topoisomeras
type
ii
enzym
mutat
aris
spontan
acquir
horizont
gene
transfer
acquisit
fluoroquinolon
resist
interspeci
recombin
alreadi
describ
pneumococci
pyogen
aim
present
investig
elucid
contribut
horizont
gene
transfer
acquisit
fluoroquinolon
resist
pyogen
method
fluoroquinoloneresist
pyogen
previous
character
resist
mechan
surveil
studi
cite
studi
presenc
substitut
parc
featur
wild
type
pyogen
use
marker
select
isol
isol
studi
nonsuscept
ciprofloxacin
mic
mgl
suscept
fluoroquinolon
sequenc
fluoroquinolon
resist
determin
region
parc
use
perform
blast
search
first
hit
chosen
analysi
align
conduct
clustalx
phylogeni
construct
bayesian
method
recombin
statist
confirm
use
maximum
chisquar
test
result
phylogenet
analysi
reveal
evid
horizont
gene
transfer
isol
belong
differ
emmtyp
puls
field
gel
electrophoresi
cluster
isol
recombin
bovin
pathogen
streptococcu
dysgalactia
subsp
dysgalactia
confirm
maximum
chisquar
test
statist
signific
p
highli
signific
level
p
conclus
result
prove
horizont
gene
transfer
streptococc
speci
contribut
fluoroquinolon
resist
pyogen
pyogen
exhibit
evid
horizont
transfer
like
fluoroquinoloneresist
thu
fluoroquinolon
use
agricultur
might
also
indirectli
impact
resist
human
pathogen
pyogen
new
mutat
posit
gyra
clinic
strain
mycobacterium
tuberculosi
resist
quinolon
report
two
clinic
case
function
analysi
dna
gyras
mutant
enzym
matrat
n
veziri
v
jarlier
e
cambau
c
truffotpernot
j
camuset
e
bouvet
aubri
pari
argenteuil
fr
object
fluoroquinolon
resist
emerg
tuberculosi
mtb
increas
drug
use
dna
gyras
sole
target
quinolon
mtb
lack
topoisomeras
iv
mutat
heterotetram
associ
resist
quinolon
report
two
case
infect
multidrug
resist
tuberculosi
mdrtb
strain
carri
new
mutat
gyra
also
investig
role
amino
acid
posit
resist
quinolon
mtb
method
two
mutant
gene
produc
sitedirect
mutagenesi
wild
type
gyra
gene
mtb
strain
gyra
found
clinic
strain
see
result
gyra
found
takiff
vitro
mutant
select
aac
gyra
gyrb
subunit
wt
mutant
gyra
gyra
overexpress
escherichia
coli
purifi
use
reconstitut
highli
activ
gyras
complex
mic
enzym
inhibit
concentr
drug
requir
inhibit
supercoil
activ
enzym
determin
moxifloxacin
gatifloxacin
ofloxacin
levofloxacin
enoxacin
result
two
men
age
year
old
previou
stori
tb
born
algeria
congo
respect
mdr
tb
caus
mtb
strain
carri
mutat
gyra
one
cavitari
pulmonari
tb
afb
posit
hiv
neg
one
pulmonari
extrapulmonari
tb
afb
posit
hiv
posit
treat
fluoroquinolon
within
month
diagnosi
mdrtb
mic
quinolon
fold
fold
higher
wt
gyra
mutant
gyra
mutant
respect
conclus
demonstr
unequivoc
modifi
amino
acid
posit
whatev
gyra
subunit
dna
gyras
lead
quinolon
resist
mtb
point
contribut
clarifi
natur
drugenzym
bind
pocket
mtb
like
includ
aminoacid
virus
viral
diagnost
although
one
clinic
pictur
human
cytomegaloviru
hcmv
infect
adren
involv
report
especi
aid
patient
associ
herpesviru
adren
gland
diseas
never
clear
moreov
recent
investig
shown
higher
frequenc
hcmv
malign
tumour
tissu
role
pathogenesi
adren
tumour
explor
far
therefor
studi
investig
presenc
hcmv
larg
seri
normal
tumour
adren
sampl
effect
hcmv
infect
adrenocort
carcinoma
acc
cell
vitro
total
adren
tissu
adrenocort
adenoma
acc
pheochromocytoma
myelolipoma
primari
adren
nonhodgkin
lymphoma
normal
adren
tissu
examin
use
quantit
pcr
hcmv
dna
detect
adrenocort
adenoma
pheochromocytoma
normal
adren
tissu
malign
tumour
posit
sampl
confirm
immunohistochem
evalu
hcmv
immediateearli
gene
express
verifi
abil
hcmv
infect
adrenocort
cell
line
vitro
acc
cell
line
primari
acc
cell
cultur
infect
clinic
isol
hcmv
hcmv
strain
hcmv
strain
employ
result
product
replic
acc
cell
demonstr
express
earli
late
viral
antigen
analysi
kinet
viral
replic
acc
cell
show
effici
product
infecti
viral
particl
even
lower
level
cell
viral
cellular
gene
express
profil
infect
acc
cell
line
assess
quantit
rtpcr
dna
microarray
analysi
respect
timecours
experi
evalu
total
human
gene
microarray
analysi
demonstr
infect
induc
gene
promot
cell
prolifer
repress
gene
prevent
cell
migrat
invas
result
demonstr
human
adren
gland
target
hcmv
infect
hcmv
modul
sever
cellular
pathway
vitro
includ
cell
growth
stress
respons
data
repres
basi
investig
effect
hcmv
adren
function
diseas
simultan
detect
human
cytomegaloviru
dna
rna
target
gene
region
use
multiplex
realtim
polymeras
chain
reaction
assay
object
reactiv
cytomegaloviru
cmv
among
immunocompromis
patient
may
result
sever
complic
time
accur
diagnost
method
cmv
infect
crucial
polymeras
chain
reaction
pcr
base
method
report
complic
potenti
contamin
latent
cmv
infect
strain
variat
quantit
realtim
pcr
method
detect
cmv
dna
rna
may
one
solut
method
cdna
clone
obtain
clone
encompass
cmv
region
encod
splice
mrna
use
standard
region
contain
conserv
variabl
sequenc
design
primer
analys
clinic
viral
isol
cover
four
major
cmv
ul
genotyp
junction
region
mrna
restrict
map
sequenc
design
primer
junction
taqman
probe
detect
clinic
buffi
coat
sampl
realtim
revers
transcriptas
pcr
system
rrtpcr
perform
rrtpcr
compar
establish
inhous
realtim
pcr
irpcr
use
control
standard
final
develop
multiplex
realtim
pcr
rtpcr
assay
mrpcrrtpcr
simultan
detect
exist
cmv
dna
rna
clinic
sampl
suspect
cmv
infect
result
clinic
cmv
isol
genotyp
reveal
four
known
genotyp
ratio
one
possibl
mix
infect
two
junction
sequenc
rrtpcr
success
detect
splice
mrna
differ
genotyp
sensit
rrtpcr
copi
plasmid
standard
compar
previou
develop
irpcr
good
linear
observ
copi
clinic
sampl
sampl
posit
rrtpcr
irpcr
mean
copiesml
sampl
test
posit
irpcr
mean
copiesml
neg
rrtpcr
case
rrtpcr
result
posit
irpcr
result
neg
sampl
test
neg
method
mrpcrrtpcr
simultan
detect
dna
mean
copiesml
rna
mean
copiesml
clinic
sampl
rrtpcr
sensit
irpcr
detect
cmv
splice
rna
multiplex
realtim
pcr
rtpcr
feasibl
region
detect
cmv
clinic
sampl
might
help
monitor
clinic
cmv
activ
new
realtim
system
prospect
comparison
realtim
quantit
pcr
blood
rapid
cultur
urin
throat
sampl
monitor
cytomegaloviru
infect
haematopoiet
stem
cell
transplant
recipi
thoelen
w
laffut
k
van
vaerenbergh
develt
k
theunissen
j
maerten
j
van
elder
leuven
object
human
cytomegaloviru
cmv
remain
signific
caus
morbid
mortal
immunocompromis
patient
effect
preemptiv
antivir
treatment
depend
earli
detect
cmv
infect
onset
symptom
studi
prospect
evalu
use
realtim
quantit
pcr
rtpcr
whole
blood
versu
viru
isol
urin
upper
respiratori
tract
urt
sampl
monitor
cmv
infect
haematopoiet
stem
cell
transplant
hsct
patient
method
hsct
patient
includ
studi
time
point
blood
urin
urt
sampl
simultan
taken
inhous
cmvspecif
rtpcr
whole
blood
viru
cultur
urin
urt
specimen
use
rapid
shell
vial
techniqu
perform
result
link
sampl
pcr
viru
isol
neg
link
sampl
posit
rtpcr
posit
viru
cultur
isol
site
urin
urt
neg
cultur
result
urin
throat
sampl
copi
number
rtpcr
posit
urin
throat
cultur
neg
case
rang
copiesml
wherea
discord
case
low
rtpcr
copi
number
might
due
low
sensit
cultur
method
discord
case
high
copi
number
could
due
concurr
antivir
therapi
link
sampl
high
copi
number
neg
cultur
link
sampl
taken
antivir
treatment
treatment
ivperor
ganciclovir
case
iv
foscavir
case
iv
cidofovir
case
posit
rtpcr
posit
cultur
result
one
sampl
observ
case
urin
posit
isol
neg
rtpcr
combin
one
two
posit
isol
observ
link
sampl
sampl
posit
urin
cultur
neg
rtpcr
neg
throat
cultur
sampl
patient
intermitt
posit
urin
cultur
conclus
data
suggest
viru
isol
shell
vial
techniqu
use
monitor
cmv
infect
hsct
patient
high
number
fals
neg
result
due
low
sensit
cultur
techniqu
concurr
antivir
therapi
rtpcr
whole
blood
seem
sensit
tool
guid
preemptiv
therapi
object
human
herp
viru
member
bherpesvirina
subfamili
herpesvirida
famili
yet
incomplet
defin
cell
tropism
clinic
spectrum
current
clarifi
immunocompet
immunocompromis
host
introduc
use
tool
molecular
diagnosi
activ
replic
routin
clinic
practic
institut
late
summar
preliminari
result
experi
term
diagnost
effici
method
sampl
prepar
dna
isol
commerci
avail
kit
use
accord
manufactur
instruct
dna
extract
larg
clinic
sampl
plasma
serum
cerebrospin
fluid
urin
sputum
broncoalveolar
lavag
fluid
mainli
perform
use
qiaamp
dna
mini
kit
qiagen
gmbh
hilden
germani
detect
posit
sampl
clinic
specimen
score
posit
test
posit
herpesvirusconsensu
pcr
argen
biosoft
amplif
product
posit
amplif
product
neg
hsv
type
hsv
type
varicellazost
viru
epsteinbarr
viru
cytomegaloviru
amplif
quantis
dna
quantis
dna
perform
use
standard
curv
gener
taqman
probe
primer
abi
machin
real
time
system
amplimed
biolin
result
januari
octob
sampl
process
institut
collect
haematolog
unit
thirtytwo
sampl
patient
turn
posit
immunocompet
patient
patient
remain
immunocompromis
patient
patient
hiv
posit
among
immunocompet
patient
persist
fever
rash
one
persist
fever
remain
recurr
persist
stomat
among
immunocompromis
patient
diagnosi
haematolog
malign
conclus
molecular
diagnosi
activ
replic
seem
interest
tool
diagnos
wide
rang
persist
recur
clinic
condit
seem
particularli
promis
use
screen
previous
unrecogn
condit
immunocompet
host
case
recurr
stomat
persist
fever
rash
echoviru
promin
enteroviru
caus
cn
diseas
kuwait
dalwai
ahmad
pacsa
w
alnakib
kuwait
kw
object
enterovirus
gener
recogn
major
caus
asept
mening
particularli
children
howev
appear
vari
neurotrop
neurovirul
type
may
overrepres
etiolog
agent
cn
diseas
other
aim
studi
genotyp
preval
enterovirus
caus
cn
diseas
kuwait
studi
associ
particular
enteroviru
sever
diseas
method
detect
enterovir
rna
base
seminest
rtpcr
amplif
portion
enterovir
genom
follow
southern
hybrid
enteroviru
specif
probe
confirm
result
enteroviru
genotyp
sequenc
encod
region
sequenc
analys
blast
analysi
clustalw
align
phylip
phylogenet
analysi
packag
result
enterovir
rna
detect
csf
cn
diseas
case
major
enteroviru
posit
case
children
less
year
age
differ
enterovirus
identifi
echoviru
common
genotyp
follow
echoviru
coxsackieviru
coxsackieviru
sever
cn
diseas
case
enceph
case
present
febril
convulsionsseizur
occurr
echoviru
significantli
higher
genotyp
observ
less
sever
cn
diseas
case
present
asept
mening
genotyp
echoviru
coxsackieviru
hand
frequent
less
sever
cn
diseas
sever
cn
diseas
case
conclus
echoviru
found
predomin
enteroviru
associ
cn
diseas
kuwait
data
obtain
studi
suggest
infect
echoviru
may
lead
sever
cn
diseas
outcom
result
sampl
adult
children
includ
studi
adult
respiratori
virus
detect
viru
cultur
patient
realtim
pcr
patient
frequent
pathogen
detect
rhinoviru
n
influenzaviru
n
rsv
n
posit
patient
one
viru
detect
realtim
pcr
children
respiratori
virus
detect
viru
cultur
patient
difassay
patient
realtim
pcr
patient
frequent
pathogen
detect
rsv
n
rhinoviru
n
coronavirus
n
influenzaviru
n
posit
patient
one
viru
detect
realtim
pcr
realtim
pcr
rsv
adenoviru
reveal
signific
differ
ctvalu
dif
posit
dif
neg
sampl
conclus
sensit
realtim
pcr
significantli
higher
compar
viru
cultur
difassay
moreov
mix
infect
detect
use
realtim
pcr
found
viru
cultur
andor
dif
assay
thu
rapid
detect
respiratori
virus
mean
realtim
pcr
increas
number
detect
pathogen
consider
result
studi
use
develop
diagnost
algorithm
select
detect
specif
respiratori
pathogen
differ
patient
group
nucleic
acid
sequenc
base
amplif
molecular
beacon
detect
realtim
identif
human
metapneumoviru
paediatr
respiratori
specimen
r
manji
f
zhang
c
ginocchio
lake
success
us
background
human
metapneumoviru
hmpv
may
account
pediatr
upper
andor
lower
respiratori
tract
diseas
respiratori
viru
rsv
influenza
parainfluenza
could
detect
studi
also
suggest
hmpv
may
contribut
increas
sever
diseas
present
viral
pathogen
laboratori
routin
diagnos
hmpv
infect
sinc
viru
slow
grow
limit
reagent
confirm
rapid
diagnosi
hmpv
infect
central
import
patient
manag
ration
use
antibiot
antivir
agent
hospit
infect
control
understand
epidemiolog
diseas
pattern
hmpv
studi
includ
technic
valid
retrospect
clinic
evalu
real
time
nasba
assay
detect
hmpv
pediatr
respiratori
sampl
method
sampl
test
includ
dilut
panel
hmpv
viral
isol
isol
common
respiratori
pathogen
frozen
respiratori
specimen
nasopharyng
aspir
wash
swab
children
age
rang
day
year
present
respiratori
diseas
nucleic
acid
na
isol
amplif
detect
perform
use
nuclisen
easyq
basic
kit
nuclisen
easyq
hmpv
reagent
specimen
nucleic
acid
hmpv
specif
intern
rna
control
ic
coextract
use
nuclisen
magnet
extract
reagent
nuclisen
minimag
instrument
coamplifi
use
singl
hmpv
specif
primer
pair
includ
reaction
hmpv
specif
molecular
beacon
ic
specif
molecular
beacon
target
amplif
continu
monitor
emit
fluoresc
perform
use
nuclisen
easyq
analys
result
limit
detect
hmpv
per
reaction
detect
rate
per
reaction
assay
specif
hmpv
cross
reactiv
detect
panel
viral
bacteri
respiratori
pathogen
overal
hmpv
preval
rate
rate
sampl
viral
pathogen
detect
one
sampl
also
posit
rsv
conclus
nuclisen
easyq
hmpv
assay
demonstr
excel
sensit
specif
assay
easi
use
requir
minim
hand
time
hour
easili
provid
day
result
addit
year
round
studi
provid
import
epidemiolog
data
develop
realtim
nasba
human
metapneumoviru
e
bufflier
h
savelli
f
jacob
c
moor
p
van
de
wiel
grenobl
fr
boxtel
nl
cardiff
uk
object
aim
develop
evalu
human
metapneumoviru
hmpv
reagent
base
nasba
amplif
realtim
detect
molecular
beacon
method
hmpv
rna
isol
use
semi
autom
magnet
extract
method
minimag
intern
control
ad
sampl
prior
nucleic
acid
extract
primer
direct
mgene
region
hmpv
genom
subtyp
intern
control
molecul
famlabel
molecular
beacon
probe
use
detect
hmpv
amplicon
roxlabel
molecular
beacon
design
detect
intern
control
amplicon
amplifi
reaction
amplif
realtim
detect
reaction
perform
easyq
analys
extract
amplificationdetect
reaction
detect
hmpv
nasal
swab
sampl
perform
within
approxim
hour
result
analyt
sensit
nasba
reaction
determin
close
copi
per
input
hit
rate
use
serial
dilut
vitro
hmpv
rna
direct
amplif
combin
extract
sensit
found
copi
per
input
hit
rate
cross
reactiv
observ
piv
piv
piv
piv
rsv
rsv
b
sar
cov
influenza
influenza
b
nasba
real
time
reagent
detect
hmpv
rsv
investig
clinic
studi
perform
cardiff
amongst
clinic
respiratori
sampl
test
nasopharyng
swab
nasal
swab
throat
swab
nasopharyng
aspir
nasba
allow
detect
hmpv
posit
sampl
ca
final
effici
method
detect
four
subtyp
hmpv
demonstr
viral
stock
data
show
realtim
hmpv
reagent
allow
rapid
sensit
qualit
detect
hmpv
use
standard
reagent
offer
consider
benefit
routin
set
clinic
manag
patient
hmpv
infect
viral
induc
asthma
exacerb
associ
delay
viral
clearanc
increas
viral
load
introduct
viral
respiratori
tract
infect
rti
common
caus
asthma
exacerb
especi
human
rhino
virus
hrv
infect
lead
sever
longer
durat
lower
respiratori
tract
lrt
symptom
asthmat
nonasthmat
upregul
rhinoviru
specif
intracellular
adhes
molecul
receptor
asthmat
might
respons
increas
suscept
hrv
well
differ
immunolog
respons
result
delay
viral
clearanc
aim
assess
magnitud
durat
viral
replic
sever
symptom
relat
variou
cytokin
nasal
wash
asthmat
control
natur
occur
viral
rti
method
prospect
studi
asthmat
age
year
recruit
accord
dutch
asthma
guidelin
gener
practic
togeth
healthi
control
group
daili
record
sign
symptom
upper
respiratori
tract
urt
lrt
rate
mild
sever
asthmat
record
peak
expiratori
flow
pef
twice
daili
particip
contact
investig
urt
symptom
total
andor
lrt
symptom
next
particip
visit
within
hour
followup
visit
day
day
week
baselin
visit
nasal
wash
collect
nostril
viral
cultur
rtpcr
assay
cytokin
result
asthmat
control
enrol
studi
person
report
episod
rti
episod
viru
found
pcr
viral
cultur
addit
diagnost
valu
signific
differ
observ
number
ulrti
caus
virus
asthmat
control
major
urti
n
caus
hrv
first
symptom
ulrt
symptom
group
simultan
clearanc
virus
urt
observ
differ
proinflammatori
cytokin
determin
urt
group
lrt
symptom
asthmat
persist
week
clearanc
virus
actual
urti
preced
pef
reduct
well
lrt
symptom
conclus
viral
induc
asthma
exacerb
associ
delay
clearanc
increas
viral
load
increment
effect
mainten
therapi
intranas
antivir
antiinflammatori
medic
need
studi
period
feb
feb
collect
hsv
qpcr
retrospect
perform
specimen
result
compar
patient
characterist
outcom
differenti
perform
pcr
addit
presenc
varicellazost
viru
vzv
cytomegaloviru
cmv
human
herpesviru
epsteinbarr
viru
ebv
determin
qpcr
result
use
assist
clinic
manag
result
total
bal
specimen
includ
obtain
immunocompromis
patient
hsv
dna
detect
specimen
mean
viral
load
log
genom
equivalentsml
rang
log
specimen
contain
contain
contain
undetermin
hsv
none
contain
type
hsv
dna
level
equal
higher
log
n
significantli
associ
day
mortal
patient
hsv
level
equal
higher
log
sever
respiratori
failur
hsv
pneumonia
histolog
proven
one
patient
log
hsv
dna
bal
fluid
autopsi
patient
hsv
dna
level
log
n
high
level
cmv
n
ebv
n
vzv
n
n
die
within
day
hospit
admiss
conclus
detect
high
level
hsv
dna
bal
fluid
associ
sever
respiratori
failur
fatal
outcom
among
mainli
immunocompromis
patient
result
suggest
quantif
hsv
dna
potenti
diagnost
tool
bal
fluid
highrisk
patient
object
helic
project
europeanwid
surveil
programm
healthcareassoci
infect
network
network
contribut
nation
surveil
system
use
minim
common
dataset
http
previou
year
test
report
compar
data
routin
surveil
start
method
data
surgic
procedur
routin
collect
european
network
analys
procedur
includ
cabg
cholecystectomi
colon
surgeri
caesarean
section
hip
prosthesi
laminectomi
infect
rate
express
proport
surgic
procedur
lead
surgic
site
infect
ssi
within
day
incid
also
express
incid
densiti
number
inhospit
ssi
per
patientday
incid
calcul
surgic
procedur
stratifi
nni
risk
index
group
time
depend
ssi
rate
calcul
use
surviv
time
analysi
enhanc
interpret
intercountri
differ
result
overal
thirtyday
cumul
incid
ssi
rang
ci
cholecystectomi
colon
surgeri
figur
use
incid
densiti
rel
import
ssi
increas
procedur
associ
short
durat
stay
cholecystectomi
caesarean
section
import
intercountri
differ
observ
although
statist
signific
incid
increas
increas
nni
risk
index
level
procedur
rate
increas
first
day
surgeri
reach
peak
day
decreas
thereaft
import
differ
length
stay
countri
comparison
time
depend
infect
rate
first
week
show
signific
differ
remain
adjust
report
incid
similar
magnitud
report
previou
year
intercountri
comparison
import
identifi
opportun
improv
observ
differ
ssi
rate
simpli
assum
due
qualiti
care
differ
durat
hospit
stay
differ
procedur
postdischarg
surveil
lead
artifici
differ
moreov
rate
constant
vari
time
sinc
oper
import
recognis
limit
singl
metric
describ
ssi
risk
especi
presenc
differ
length
stay
differ
postdischarg
surveil
object
assess
risk
factor
deep
sternal
wound
infect
dswi
follow
coronari
arteri
bypass
graft
cabg
account
periop
glucos
oxygen
temperatur
control
method
prospect
cohort
studi
conduct
rabin
medic
center
israel
includ
consecut
patient
undergo
cabg
dataset
compris
periop
variabl
data
collect
daili
chart
review
ward
use
case
report
form
merg
hospit
electron
record
continu
measur
oxygen
temperatur
throughout
surgeri
includ
analysi
followup
dswi
perform
day
follow
surgeri
dswi
defin
cdc
criteria
dichotom
variabl
compar
use
chisquar
test
continu
variabl
compar
use
nonparametr
test
multivari
stepwis
logist
regress
model
construct
use
variabl
found
signific
univari
analysi
p
odd
ratio
confid
interv
report
result
patient
male
undergo
cabg
includ
cabg
elect
addit
oper
mostli
valv
replac
perform
offpump
cabg
perform
median
patient
age
year
diabet
chronic
obstruct
pulmonari
diseas
copd
necessit
chronic
therapi
present
patient
respect
dswi
occur
patient
variabl
independ
associ
dswi
includ
intraop
glucos
mean
glucos
mgdl
copd
oper
addit
cabg
haemoglobin
level
hypothermia
postop
hypoxemia
significantli
associ
dswi
euroscor
associ
dswi
univari
multivari
analysi
postop
hospit
stay
longer
among
patient
dswi
compar
without
dswi
median
vs
day
respect
p
thirtyday
mortal
significantli
differ
without
dswi
vs
respect
month
mortal
significantli
higher
dswi
vs
p
conclus
dswi
follow
cabg
grave
implic
modifi
risk
factor
includ
intraop
glucos
control
potenti
copd
studi
assess
whether
better
prepar
copd
patient
lower
dswi
rate
object
criteria
diagnosi
prosthet
shoulder
infect
psi
establish
evalu
characterist
prosthet
shoulder
infect
analys
accuraci
variou
diagnost
criteria
method
patient
undergo
shoulder
arthroplasti
revis
resect
mayo
clinic
rochest
mn
august
octob
studi
psi
diagnos
least
one
follow
present
intraop
purul
histopatholog
acut
inflamm
sinu
tract
posit
synovi
fluid
cultur
least
two
periprosthet
tissu
cultur
posit
organ
medic
record
abstract
age
gender
time
prosthesi
failur
synovi
fluid
leukocyt
count
differenti
aspir
month
surgeri
synovi
fluid
periprosthet
tissu
cultur
result
addit
explant
shoulder
implant
vortex
sonic
ml
ringer
solut
herein
defin
sonic
fluid
follow
concentr
indirect
immunofluoresc
monoclon
antibodi
staphylococci
propionibacterium
acn
result
patient
studi
asept
failur
psi
median
age
year
rang
year
femal
median
time
clinic
failur
prosthesi
month
rang
year
caus
organ
identifi
infect
patient
includ
p
acn
n
staphylococcu
aureu
n
coagulas
neg
staphylococcu
sp
n
pseudomona
aeruginosa
n
four
infect
patient
p
acn
histopatholog
acut
inflamm
intraop
purul
sinu
tract
synovi
fluid
leukocyt
count
differenti
predict
infect
sensit
infect
immunofluoresc
concentr
sonic
fluid
specif
conclus
inflammatori
respons
marker
histopatholog
synovi
fluid
leukocyt
count
purul
good
predictor
prosthet
hip
knee
infect
sensit
diagnos
psi
ie
infect
would
miss
use
criteria
like
relat
low
virul
predomin
pathogen
p
acn
accur
diagnosi
infect
synovi
fluid
periprosthet
tissu
cultur
need
indirect
immunofluoresc
microscopi
concentr
sonic
fluid
promis
diagnost
test
deserv
investig
associ
ventilatorassoci
pneumonia
icumort
approxim
attribut
mortal
background
estim
attribut
mortal
due
ventilatorassoci
pneumonia
vap
base
upon
risk
factor
matchedcohort
analys
rang
use
associ
rel
risk
reduct
rrr
vap
incid
due
prevent
icumort
determin
would
rrr
vap
yield
rrr
icumort
object
therefor
estim
crude
rel
vap
upon
outcom
random
studi
vap
prevent
method
systemat
search
medlin
cochran
librari
refer
list
relev
studi
identifi
random
vap
prevent
trial
publish
provid
data
vap
incid
icumort
studi
methodolog
studi
qualiti
mq
assess
rang
point
base
alloc
conceal
blind
intervent
patient
select
characterist
definit
pneumonia
rrr
vap
icumort
calcul
main
outcom
measur
crude
rel
attribut
icumort
vap
estim
ratio
rrr
mortal
vap
well
crude
patient
data
pool
trial
popul
result
sixti
trial
identifi
patient
vap
event
six
trial
compar
two
intervent
group
control
patient
therefor
group
comparison
includ
signific
rrr
vap
report
trial
wherea
trial
report
signific
rrr
icumort
due
prevent
measur
overal
trial
qualiti
rrr
vap
highest
antibiot
contain
strategi
ci
sdd
ci
type
antibiot
prophylaxi
wherea
lowest
found
among
stress
ulcu
prophylaxi
intervent
rrrvap
ci
signific
vap
reduct
found
ventil
circuit
chang
enter
feed
modul
signific
rrr
mortal
found
pool
sdd
studi
ci
signific
associ
mq
rrr
vap
icumort
rel
attribut
mortal
found
pool
crude
rel
attribut
mortal
vap
cam
base
upon
individu
trial
wide
variat
individu
studi
conclus
crude
rel
attribut
mortal
vap
estim
pattern
dynam
airway
colonis
mechan
ventil
patient
je
berdal
j
blomfeldt
g
bukholm
n
smitherichsen
nordbyhagen
object
investig
pattern
dynam
microbi
colon
upper
lower
airway
ventil
patient
method
seventyfour
mechan
ventil
patient
consecut
recruit
oropharyng
tracheal
bronchoalveolar
fluid
specimen
collect
hour
intub
thereaft
everi
hour
total
sampl
set
collect
patient
extub
sampl
quantit
analys
domin
isol
genotyp
result
percentag
sampl
show
growth
accept
threshold
ventil
associ
pneumonia
cfuml
median
day
initi
mechan
ventil
correl
analysi
show
high
degre
correl
domin
isol
three
sampl
site
sampl
occas
isol
found
high
degre
correl
two
subsequ
sampl
occas
ie
sampl
hour
apart
howev
correl
found
compar
isol
individu
patient
sampl
hour
apart
conclus
sampl
occas
high
percentag
ventil
patient
show
growth
accept
threshold
valu
ventil
associ
pneumonia
question
specif
diagnost
criterion
diagnosi
vap
microbi
flora
airway
ventil
stabl
period
hour
howev
sampl
collect
hour
apart
result
thu
choic
antibiot
treatment
predict
base
result
previou
sampl
genotyp
level
high
correl
domin
isol
found
oropharyng
tracheal
bronchoalveolar
fluid
studi
warrant
investig
whether
less
invas
sampl
ie
oropharyng
suffici
determin
like
involv
pathogen
ventilatorassoci
pneumonia
object
conduct
retrospect
studi
compar
outcom
patient
pneumococc
pneumonia
bacteraemia
period
method
identifi
consecut
patient
clinic
criteria
pneumonia
posit
blood
cultur
femal
male
major
patient
elderli
mean
age
year
year
addit
patient
histori
smoke
underli
medic
condit
common
chronic
lung
diseas
six
patient
treat
outpati
result
overal
patient
fail
initi
therapi
death
occur
failur
rate
among
bacteraem
patient
cardiovascular
diseas
time
higher
failur
rate
among
patient
underli
medic
condit
vs
p
patient
underli
condit
lowest
failur
rate
rate
streptococcu
pneumonia
resist
penicillin
macrolid
multipl
logist
regress
analysi
demonstr
cure
rate
group
treat
divers
antibiot
significantli
differ
levofloxacin
group
n
ceftriaxon
plu
azithromycin
iv
follow
oral
azithromycin
group
n
azithromycin
alon
group
n
overal
failur
rate
patient
resist
pathogen
similar
patient
pathogen
suscept
initi
agent
vs
major
patient
fail
therapi
coexist
ill
high
sever
risk
psi
score
patient
fail
outpati
therapi
result
studi
demonstr
antimicrobi
resist
factor
associ
treatment
failur
underli
diseas
import
predictor
outcom
mortal
communityacquir
pneumonia
due
pneumonia
complic
bacteraemia
efficaci
use
throughcathet
leukocyt
cytospin
blood
cultur
monitor
haemodialysi
cathet
colon
prospect
studi
design
prevent
bloodstreamrel
infect
object
perman
tunnel
central
venou
cathet
commonli
use
provid
vascular
access
patient
mainten
haemodialysi
infect
one
lead
complic
accord
sever
author
cathet
colon
preced
bloodstream
infect
aim
studi
detect
cathet
colon
establish
preemptiv
therapi
base
cathet
antibiot
lock
order
prevent
develop
catheterrel
bloodstream
infect
crbi
besid
evalu
impact
monitor
system
life
spam
cathet
method
period
juli
juli
haemodialysi
patient
tunnel
cathet
prospect
follow
studi
carri
univers
hospit
patient
maintain
chronic
intermitt
haemodialysi
patient
evalu
extract
throughcathet
leukocyt
cytospin
blood
cultur
everi
day
cultur
posit
pair
quantit
blood
cultur
obtain
two
lumen
cathet
peripher
vein
order
assess
absenc
relat
bacteraemia
preemptiv
therapi
consist
day
antibiot
lock
regimen
start
coagulas
neg
staphylococci
cn
isol
isol
cn
decis
conserv
treatment
individu
taken
result
total
haemodialysi
cathet
insert
patient
evalu
episod
cathet
colon
occur
patient
time
colon
cathet
place
mean
day
rang
day
coagulas
neg
staphylococci
common
microorgan
isol
isol
microorgan
preemptiv
therapi
teicoplanin
mgml
lock
abl
erad
cathet
colon
case
relaps
colon
occur
case
patient
requir
cathet
remov
due
infecti
complic
crbi
cathet
remov
two
patient
due
noninfecti
complic
mean
durat
cathet
use
day
rang
day
treatment
colon
episod
conclus
studi
show
util
intracathet
leukocyt
cytospin
blood
cultur
earli
detect
haemodialysi
cathet
colon
show
erad
biofilmrel
microorgan
possibl
without
remov
cathet
object
clinic
signific
bloodstream
infect
bsi
due
pseudomona
aeruginosa
pa
receiv
larg
attent
contrast
clinic
impact
bsi
caus
esblposit
isol
investig
esbl
common
enzym
confer
highlevel
resist
antipseudomon
cephalosporin
studi
initi
evalu
risk
factor
treatment
outcom
bsi
episod
caus
pa
strain
method
januari
septemb
bsi
case
due
ceftazidimeresist
pa
strain
observ
ospedal
di
circolo
vares
itali
mic
valu
antipseudomon
drug
determin
etest
method
ab
biodisk
solna
sweden
doubledisk
synergi
test
use
detect
esbl
product
molecular
method
pcr
amplif
dna
sequenc
use
character
esbl
type
clinic
record
bsipati
examin
retrospect
demograph
data
underli
diseas
accord
mccabejackson
classif
charlson
weight
index
risk
factor
antimicrobi
therapi
treatment
outcom
investig
compar
case
due
esblposit
due
esblneg
pa
isol
unpair
student
ttest
mannwhitney
utest
chisquar
use
statist
analysi
result
nine
pa
isol
found
express
esbl
wherea
remain
sever
sepsi
p
bladder
intravascular
cathet
p
immunosuppress
therapi
p
mechan
ventil
p
significantli
associ
bsi
due
empir
treatment
p
treatment
idast
p
less
adequ
case
hospit
admiss
longer
mean
length
hospit
stay
bsi
onset
p
p
respect
possibl
relat
express
enzym
overal
bsi
case
due
vs
case
due
isol
fail
respond
p
notabl
case
due
treat
carbapenem
fail
respond
contrast
case
due
given
carbapenem
respond
conclus
therapeut
failur
poor
outcom
associ
bsi
episod
caus
strain
thu
recognit
prompt
report
esblproduct
appear
critic
factor
manag
patient
seriou
p
aeruginosa
infect
transmiss
mrsa
frequent
patient
share
hospit
room
ds
blanc
c
balmelli
c
petignat
g
zanetti
p
francioli
lausann
ch
object
evalu
transmiss
mrsa
patient
hospit
room
method
analysi
result
screen
mrsa
roommat
patient
found
mrsa
posit
pfge
type
mrsa
isol
index
case
roommat
set
tertiari
care
hospit
bed
proport
aureu
resist
methicillin
mrsa
result
year
occas
patient
found
mrsa
posit
index
case
hospit
patient
room
total
roommat
screen
mrsa
found
posit
comparison
isol
index
case
mrsa
posit
roommat
reveal
pfge
pattern
indistinguish
instanc
suggest
transmiss
howev
instanc
isol
indistinguish
suggest
roommat
contamin
anoth
sourc
index
case
thu
mrsa
probabl
acquir
patient
share
room
index
case
conclus
set
transmiss
mrsa
patient
hospit
room
seem
frequent
howev
studi
also
reveal
half
mrsa
posit
roommat
isol
differ
index
patient
thu
interpret
screen
result
term
transmiss
cautiou
outbreak
burkolderia
cenocepacia
bacteraemia
associ
disinfect
napkin
contamin
haemodialysi
method
blood
cultur
perform
patient
intraand
postdialyt
chill
fever
investig
identifi
sourc
infect
includ
echocardiographi
perform
soon
burkholderia
cepacia
complex
isol
first
two
blood
sampl
investig
cultur
carri
deionis
tap
water
dialys
fluid
dialys
blood
compart
dialys
concentr
disinfect
solut
afterward
sampl
taken
disinfect
napkin
contain
commerci
steril
dress
kit
use
handl
central
venou
cathet
cvc
phenotyp
molecular
identif
b
cepacia
perform
standard
biochem
procedur
restrict
fragment
length
polymorphismpcr
rflppcr
analysi
respect
strain
clonal
analys
pulsedfield
gel
electrophoresi
pfge
result
seventynin
episod
bacteraemia
occur
patient
undergo
haemodialysi
cvc
one
case
endocard
diagnos
cvc
remov
patient
b
cepacia
complex
isol
blood
cultur
disinfect
napkin
one
batch
rflppcr
analysi
confirm
find
blood
napkin
cultur
b
cenocepacia
genomovar
iii
b
identifi
demonstr
clonal
ident
strictli
relat
use
pfge
follow
cvc
substitut
combin
antibiot
therapi
patient
improv
relaps
mean
week
need
week
treatment
cure
death
attribut
infect
observ
conclus
chronic
haemodialysi
patient
high
risk
infect
frequent
caus
typic
nosocomi
bacteria
hepat
virus
commonli
transmit
contamin
haemodialysi
system
andor
vascular
cathet
environment
surfac
hand
personnel
case
infect
due
b
cenocepacia
haemodialysi
patient
report
literatur
investig
show
commerci
napkin
soak
disinfect
sourc
infect
contamin
occur
time
manufactur
despit
antibiot
suscept
vitro
detect
infect
difficult
erad
probabl
due
bacteria
persist
biofilm
cvc
biofilm
highli
organis
commun
object
studi
investig
possibl
correl
biofilm
product
accessori
regulatori
gene
agr
sampl
saureu
isol
catheterassoci
infect
method
analys
abil
produc
biofilm
static
system
specthrophotometr
quantit
assay
ii
agrgenotyp
iii
express
icaoperon
correl
agr
function
activ
two
transcript
regul
sara
rsbu
rtpcr
result
result
appli
new
scairflp
method
agrtyp
show
strong
biofilm
produc
strain
belong
predominantli
agrtyp
ii
found
methicillinresist
strain
found
two
agrvari
sequenc
analysi
reveal
isol
contain
copi
within
agrlocu
two
strain
indic
iavari
element
locat
intergen
region
agrd
agrc
transcript
direct
agroperon
contrari
one
strain
ibvari
insert
sequenc
integr
agrc
caus
interrupt
gene
nucleotid
posit
agr
publish
sequenc
genebank
opposit
transcript
direct
respect
agr
gene
studi
ica
express
agrtyp
includ
three
agrvari
perform
correl
agr
function
two
transcript
regul
sara
rsbu
result
suggest
agr
polymorph
ii
ibvari
strain
produc
larg
amount
biofilm
possess
defect
agr
system
sara
may
activ
icaoperon
express
repress
icar
transcript
time
defect
haemolysin
activ
lack
transcript
b
activ
rsbu
conclus
possibl
hypothes
agr
polymorph
ii
strain
diffus
nosocomi
set
biofilm
repres
select
advantag
catheterassoci
chronicinfect
microrgan
abl
thrive
host
contribut
significantli
pathogenesi
object
due
abil
form
multilay
biofilm
aureu
epidermidi
well
coagulaseneg
staphylococci
preval
pathogen
foreign
bodi
relat
infect
howev
biofilm
format
differ
staphylococc
speci
seem
mediat
differ
mechan
method
biofilm
structur
well
singl
cell
embed
within
biofilm
analys
use
confoc
laser
scan
microscopi
clinic
relev
isol
aureu
epidermidi
lugdunensi
sciuri
homini
haemolyticu
simulan
investig
cell
stain
syto
nacetylglucosamin
marker
polysaccharid
intercellular
adhesin
pia
detect
stain
tritc
label
wheat
germ
agglutinin
wga
piasynthesi
individu
strain
confirm
dot
blot
analysi
use
piaspecif
antiserum
result
strain
investig
display
highli
structur
lm
thick
biofilm
howev
signific
amount
pia
detect
biofilm
epidermidi
aureu
larg
mass
pia
distribut
irregularli
within
epidermidi
biofilm
wherea
aureu
biofilm
cell
homogen
surround
thin
pia
layer
piadepend
biofilm
cell
rigidli
coupl
biofilm
sciuri
compact
structur
motionless
cell
observ
howev
pia
detect
speci
contrast
biofilm
rigid
celltocel
contact
biofilm
simulan
display
spongelik
structur
individu
cell
smaller
cell
cluster
fix
togeth
elast
celltocel
contact
within
biofilm
structur
stain
wga
pia
could
detect
piaantibodi
indic
pia
independ
polysaccharid
could
involv
biofilm
format
speci
biofilm
form
haemolyticu
homini
lugdunensi
larg
rigid
cell
cluster
could
detect
singl
cell
smaller
cell
cluster
fix
elast
celltocel
contact
therebi
ratio
motionless
elast
fix
cell
vari
variou
speci
conclus
least
three
differ
type
celltocel
contact
within
staphylococc
biofilm
detect
among
speci
investig
therebi
pia
independ
rigid
elast
celltocel
contact
could
observ
parallel
two
speci
object
nosocomi
staphylococc
foreignbodi
infect
major
problem
modern
medicin
demand
new
therapeut
prevent
strategi
use
known
virul
factor
vaccin
candid
critic
restrict
preval
natur
staphylococc
popul
biofilm
format
essenti
pathogenesi
staphylococcu
epidermidi
staphylococcu
aureu
foreignbodi
infect
studi
examin
distribut
gene
involv
biofilm
format
biofilm
phenotyp
product
polysaccharid
intercellular
adhesin
pia
clonal
independ
aureu
epidermidi
strain
isol
persist
prosthet
joint
infect
total
hip
arthroplasti
tha
total
knee
arthroplasti
tka
result
biofilmposit
phenotyp
detect
aureu
epidermidi
strain
major
differ
distribut
factor
mediat
primari
attach
aureu
epidermidi
strain
tka
tha
icaadbc
encod
synthesi
apparatu
pia
detect
aureu
strain
epidermidi
strain
icaadbcneg
produc
trypsin
sensit
biofilm
indic
strain
protein
factor
like
highli
preval
accumul
associ
protein
aap
suffici
intercellular
adhes
proteasesensit
biofilm
exclus
found
epidermidi
strain
tha
repres
biofilm
popul
contrast
trypsin
piacleav
dispersin
b
disintegr
aureu
biofilm
indic
speci
pia
protein
act
cooper
biofilm
format
regardless
infect
site
conclus
find
suggest
pia
protein
factor
differenti
import
pathogenesi
epidermidi
pji
tha
tka
implic
icaadbc
serv
gener
virul
marker
speci
aureu
biofilm
format
protein
overal
import
futur
work
focu
identif
function
activ
molecul
role
quorumsens
target
rnaiii
activ
protein
rnaiiiinhibit
peptid
staphylococc
biofilm
format
control
vitro
object
staphylococci
lead
caus
devicerel
infect
form
biofilm
involv
bacteria
increas
toler
antibiot
host
immun
recent
rnaiiiinhibit
peptid
rip
found
reduc
staphylococc
surfac
attach
biofilmrel
infect
mode
action
remain
unclear
rip
inhibit
phosphoryl
target
rnaiii
activ
protein
trap
thu
express
agr
agr
knockout
strain
hand
associ
increas
surfac
adhes
biofilm
format
discrep
suggest
rip
trap
might
directli
involv
biofilm
control
evalu
role
biofilm
growth
static
flow
condit
method
compar
aureu
wild
type
wt
wt
exogen
rip
trapmut
also
test
effect
rip
hour
biofilm
cathet
infect
model
surfac
area
coverag
sac
biofilm
thick
rough
biomass
quantifi
digit
time
laps
confoc
microscopi
well
bacteri
count
result
neither
trap
inactiv
addit
rip
affect
plankton
growth
static
flowcel
biofilm
model
trap
inactiv
lesser
extent
addit
rip
significantli
increas
surfac
attach
biofilm
biomass
hour
later
timepoint
hour
howev
signific
differ
sac
biofilm
thick
biomass
could
found
interestingli
wt
strain
alway
grew
rougher
ie
less
homogen
biofilm
measur
exclus
static
growth
bacteri
count
wt
biofilm
significantli
higher
hour
hour
p
addit
rip
vancomycin
improv
bacteri
clearanc
matur
cathet
biofilm
report
effect
rip
infect
anim
model
due
abolish
biofilm
format
per
se
like
relat
reduct
initi
surfac
attach
downregul
protect
aggress
virul
factor
well
alter
biofilm
architectur
clear
point
switch
rough
flat
architectur
may
reduc
virul
increas
antibiot
suscept
use
effici
antibiofilm
procedur
improv
safeti
pacifi
e
comina
k
marion
f
renaud
e
bergeron
j
freney
lyon
fr
object
mani
parent
refus
use
pacifi
consid
nonhygien
suppli
howev
recent
public
highlight
role
pacifi
prevent
sudden
infant
death
aim
studi
first
assess
bacteri
contamin
surfac
pacifi
develop
clean
method
avoid
biofilm
growth
improv
safeti
pacifi
method
use
latex
silicon
pacifi
nippl
provid
variou
day
care
center
biofilm
search
surfac
use
first
direct
stain
crystal
violet
microscopi
imag
analysi
bacteri
enumer
scrap
biofilm
reactor
system
setup
fill
contamin
media
made
artifici
saliva
supplement
lb
broth
inocul
differ
strain
reactor
use
test
differ
clean
procedur
stasi
brush
spray
steam
steril
three
first
treatment
includ
new
antibiofilm
product
result
pacifi
studi
present
biofilm
live
cell
surfac
surfac
coverag
upto
two
main
bacteri
genu
isol
staphylococcu
candida
latex
contamin
silicon
latex
nippl
contain
cfu
cm
biofilm
reactor
system
fill
artifici
saliva
lb
broth
enabl
massiv
biofilm
growth
within
day
latex
nippl
cover
surfac
almost
contain
cfucm
effici
treatment
bacteri
kill
water
steam
steril
led
lowest
biofilm
detach
brush
best
efficaci
biofilm
detach
residu
live
cell
treatment
reproduc
differ
sampl
realist
condit
lb
broth
reduc
thick
biofilm
form
control
significantli
reduc
coverag
cfucm
analysi
reveal
biofilm
treat
surfac
isol
live
cell
remain
averag
standard
deviat
calcul
paramet
n
low
standard
deviat
show
good
reproduc
clean
method
conclus
daili
clean
quick
easi
system
made
simpl
dental
brush
combin
effici
antibiofilm
agent
give
boost
use
pacifi
whose
advantag
seam
underestim
object
recent
describ
discoveri
novel
group
coronaviru
coronaviru
patient
pneumonia
studi
examin
clinic
featur
molecular
epidemiolog
communityacquir
pneumonia
method
prospect
collect
nasopharyng
aspir
npa
patient
communityacquir
pneumonia
period
fragment
rnadepend
rna
polymeras
pol
gene
amplifi
extract
rna
rtpcr
use
specif
primer
epidemiolog
clinic
laboratori
radiolog
featur
patient
pneumonia
associ
analys
specif
antibodi
detect
use
recombin
nucleocapsid
protein
base
elisa
complet
pol
spike
nucleocapsid
gene
amplifi
sequenc
rna
extract
nasopharyng
swab
faecal
sampl
wild
domest
anim
hong
kong
southern
china
subject
rtpcr
pol
gene
use
specif
primer
result
rna
extract
npa
patient
communityacquir
pneumonia
posit
epidemiolog
linkag
identifi
among
case
case
occur
spring
winter
januarymay
four
patient
underli
diseas
respiratori
tract
without
diagnost
test
ill
distinguish
communityacquir
pneumonia
clinic
two
symptom
upper
respiratori
tract
one
extrapulmonari
symptom
six
patient
serum
sampl
avail
show
fourfold
chang
igg
titr
andor
presenc
igm
respiratori
pathogen
detect
patient
two
patient
die
lower
haemoglobin
concentr
p
monocyt
count
p
serum
albumin
p
oxygen
satur
admiss
p
bilater
involv
p
number
zone
involv
p
chest
radiograph
sequenc
analysi
complet
pol
spike
nucleocapsid
gene
reveal
presenc
two
genotyp
none
anim
sampl
posit
rna
conclus
account
communityacquir
pneumonia
two
genotyp
studi
popul
without
diagnost
test
ill
clinic
indistinguish
communityacquir
pneumonia
stabil
sar
coronaviru
high
temperatur
high
rel
humid
stabil
novel
sar
coronaviru
sar
cov
viru
differ
temperatur
rel
humid
evalu
ten
microlitr
per
ml
viru
incub
differ
temperatur
differ
rel
humid
hr
hr
hr
hr
hr
residu
viral
infect
titrat
high
rel
humid
compar
low
temperatur
nt
affect
viru
stabil
significantli
higher
temperatur
rel
humid
affect
viru
infect
log
loss
titr
hr
howev
rel
humid
maintain
viru
stabil
advers
affect
log
loss
titr
time
point
hr
log
conclud
high
temperatur
high
rel
humid
synergist
effect
inactiv
sar
cov
viabil
may
help
explain
low
transmissibilil
sar
tropic
area
like
malaysia
indonesia
patient
place
natur
ventil
ward
singapor
aircondit
ward
rel
larg
outbreak
similarli
larg
outbreak
occur
winter
nontrop
area
like
hong
kong
humid
temperatur
low
toscana
viru
tosv
arthropodborn
viru
vector
sand
fli
tosv
infect
long
recogn
central
itali
howev
emerg
caus
mening
enceph
spain
franc
howev
ecolog
epidemiolog
tosv
franc
poorli
understood
object
summer
sand
fli
captur
organ
surround
two
larg
citi
marseil
nice
vicin
dog
kennel
hors
stabl
pool
constitut
respect
trap
locat
sex
speci
identif
maximum
individu
per
pool
pcr
assay
target
three
genom
region
use
final
identif
done
via
sequenc
method
pool
constitut
respect
trap
origin
sex
speci
test
rtpcr
primer
target
either
polymeras
gene
phlebovirus
specif
tosv
nucleoprotein
gene
result
discuss
total
sand
fli
trap
identifi
morpholog
key
posit
result
obtain
tosv
specif
primer
pool
collect
marseil
sequenc
analysi
show
pool
contain
viru
close
relat
distinct
tosv
sinc
ident
nucleotid
amino
acid
level
respect
observ
tosv
strain
isol
itali
first
time
tosv
detect
sandfli
southern
franc
one
pool
includ
sergentomyia
minuta
sand
fli
constitut
first
detect
tosv
speci
minuta
readili
bite
reptil
affin
bite
human
poorli
known
sandfli
could
howev
play
role
mainten
tosv
natur
three
pool
found
posit
phleboviru
gener
primer
wherea
neg
tosv
specif
primer
sequenc
analysi
indic
high
genet
divers
recogn
phlebovirus
sequenc
data
avail
indic
viru
could
repres
new
speci
within
genu
phleboviru
howev
anoth
phleboviru
arbia
viru
repeatedli
isol
itali
though
sequenc
data
avail
arbia
viru
current
sequenc
determin
natur
phleboviru
detect
pool
studi
show
tosv
anoth
phleboviru
distribut
throughout
coastal
southeastern
franc
clinic
manifest
character
fever
arthralgia
myalgia
headach
skin
rash
total
almost
case
regist
confirm
via
serolog
test
mauritiu
island
total
number
case
estim
occur
april
late
june
object
marseil
citi
host
second
larger
commun
comorian
world
total
number
individu
sinc
oper
frequent
back
forth
travel
comoro
island
marseil
aim
studi
investig
impact
chikv
african
outbreak
onto
popul
resid
marseil
method
chikv
strain
ross
use
infect
vero
cell
produc
immunofluoresc
assay
detect
antichikv
igg
igm
sera
dilut
pb
test
total
sera
collect
patient
return
comoro
reunion
mauritiu
island
admit
one
infecti
diseas
unit
public
hospit
system
marseil
test
earli
serum
specimen
test
via
pcr
viru
isol
attempt
cell
result
sera
found
antibodi
chikv
show
either
igm
seroconvers
result
pcr
test
viru
cultur
discuss
interestingli
clinic
featur
return
patient
similar
report
reunion
island
hospit
admiss
motiv
fever
minor
complain
arthralgia
discuss
crimeancongo
haemorrhag
fever
east
black
sea
region
turkey
report
case
n
sucu
k
aydin
ksal
r
caylan
g
yilmaz
trabzon
tr
object
crimeancongo
haemorrhag
fever
viru
cchfv
belong
genu
nairoviru
bunyavirida
famili
caus
potenti
fatal
diseas
short
incub
period
crimeancongo
haemorrhag
fever
cchf
character
acut
febril
syndrom
sudden
onset
high
fever
sever
headach
dizzi
myalgia
sever
case
haemorrhag
manifest
develop
two
outbreak
cchf
occur
east
black
sea
region
turkey
spring
summer
year
studi
report
case
suspect
cchf
outbreak
method
patient
acut
febril
syndrom
admit
hospit
may
august
seventyeight
patient
analys
epidemiolog
clinic
featur
mortal
diagnosi
confirm
elisa
andor
rtpcr
result
fiftysix
patient
femal
twentytwo
male
mean
age
rang
malais
fever
muscl
ach
common
present
symptom
sixti
percent
patient
histori
tick
bite
handl
livestock
admitt
white
blood
cell
platelet
count
lower
normal
valu
gener
alanin
aminotransferas
alt
aspart
aminotransferas
ast
lactat
dehydrogenas
ldh
level
higher
normal
level
mean
valu
ul
ul
ul
respect
thirtynin
patient
treat
oral
ribavirin
thirti
patient
replac
platelet
andor
erythrocyt
suspens
fiftyfour
patient
immunoglobulin
antibodi
andor
pcr
result
posit
cchfv
serum
sampl
three
patient
die
conclus
cchf
epidem
recent
year
turkey
east
black
sea
region
also
import
region
diseas
cchf
case
lower
mortal
rate
report
could
explain
earli
defin
diseas
outbreak
support
therapi
year
infecti
diseas
medicin
year
infecti
diseas
medicin
esposito
bosi
n
principi
milan
year
signific
achiev
pediatr
infecti
diseas
includ
substanti
progress
area
respiratori
infect
vaccin
sever
acut
respiratori
syndrom
sar
defeat
world
health
organ
show
great
leadership
period
crisi
avian
influenza
viru
strain
caus
recent
local
outbreak
threaten
escal
pandem
statu
remark
progress
made
studi
epidemiolog
pathogenesi
human
metapneumoviru
sinc
discoveri
novel
coronavirus
identifi
europ
us
appear
play
import
previous
unrecogn
role
pediatr
diseas
grow
use
specialis
diagnost
techniqu
allow
consider
amount
new
inform
obtain
concern
role
mycoplasma
pneumonia
chlamydia
pneumonia
seem
play
signific
role
caus
respiratori
tract
infect
previous
thought
associ
tonsil
also
frequent
children
age
less
five
year
regard
vaccin
demonstr
increas
use
influenza
vaccin
among
children
could
reduc
ill
household
commun
contact
clinic
trial
also
highlight
pneumococc
conjug
vaccin
prevent
invas
diseas
pneumonia
acut
otiti
media
vaccin
children
reduc
nasopharyng
carriag
vaccinetyp
pneumococci
dramat
effect
adult
diseas
moreov
phase
iii
trial
human
papillomaviru
vaccin
well
rotaviru
vaccin
progress
wide
spread
optim
prospect
regulatori
approv
gener
distribut
vaccin
year
furthermor
substanti
progress
made
manag
children
adolesc
hiv
infect
well
approach
infect
pediatr
transplant
recipi
year
also
introduc
sever
new
challeng
emerg
commun
strain
methicillin
resist
staphylococcu
aureu
problem
relat
nosocomi
infect
evolut
travel
diseas
hypervirul
strain
clostridium
difficil
share
experi
europ
north
america
symposium
arrang
esgcd
spread
new
variant
clostridium
difficil
netherland
europ
new
strain
clostridium
difficil
recent
report
canada
unit
state
caus
outbreak
often
associ
increas
diseas
sever
increas
virul
consid
associ
product
binari
toxin
increas
product
toxin
b
character
strain
reveal
belong
toxinotyp
iii
pulsedfield
gel
electrophoresi
pfge
type
restrict
endonucleas
analyi
group
bi
pcr
ribotyp
period
februari
june
strain
also
recogn
uk
outbreak
involv
patient
death
stoke
mandevil
hospit
sinc
isol
type
refer
refer
laboratori
cardiff
hospit
recognit
first
outbreak
clostridium
difficileassoci
diarrhoea
cdad
juli
due
type
among
patient
st
jansdal
hospit
harderwijk
death
strain
thu
far
caus
outbreak
hospit
nurs
home
netherland
addit
hospit
strain
found
isol
case
cdad
without
outbreak
total
isol
belong
found
netherland
septemb
pcr
ribotyp
strain
isol
patient
cdad
ieper
belgium
subsequ
pattern
identifi
among
strain
three
outbreak
occur
brussel
involv
patient
respect
ostend
belgium
anoth
outbreak
found
patient
pcr
ribotyp
toxinotyp
iii
strain
characterist
antimicrobi
suscept
pattern
sinc
resist
newer
fluoroquinolon
erythromycin
suscept
clindamycin
strain
also
binari
toxin
gene
contain
delet
toxin
regul
gene
tcdc
gene
encod
tcda
tcdb
demonstr
numer
nucleotid
sequenc
chang
compar
strain
belong
toxinotyp
european
studi
group
clostridium
difficil
esgcd
undertaken
survey
collect
strain
european
countri
current
investig
preliminari
result
indic
toxinogen
isol
deriv
countri
toxinotyp
iii
found
conclud
c
difficil
ribotyp
toxinotyp
iii
alreadi
europ
sinc
rapidli
spread
clostridium
difficileassoci
diseas
grow
threat
us
public
health
sever
line
evid
suggest
chang
epidemiolog
clostridium
difficileassoci
diseas
cdad
first
increas
report
individu
hospit
outbreak
mani
instanc
associ
increas
death
colectomi
second
sharp
increas
sinc
number
rate
us
acut
care
hospit
discharg
code
cdad
final
nation
survey
conduct
past
year
half
suggest
us
infecti
diseas
physician
perceiv
increas
incid
sever
likelihood
cdad
recurr
possibl
reason
increas
incid
diseas
sever
could
involv
trend
antimicrobi
drug
ie
stomach
acid
suppress
medic
usag
chang
infect
control
practic
ie
hand
hygien
environment
surfac
disinfect
emerg
one
strain
c
difficil
increas
antimicrobi
resist
andor
virul
inde
novel
strain
emerg
appear
respons
outbreak
unit
state
canada
recent
england
strain
possess
somewhat
uniqu
toxin
gene
variat
includ
delet
put
neg
regul
tcdc
toxin
b
gene
addit
toxin
known
binari
toxin
although
strain
isol
infrequ
us
patient
past
year
recent
sinc
appear
caus
major
outbreak
one
reason
may
emerg
increas
resist
fluoroquinolon
strain
possibl
provid
select
advantag
strain
also
evid
suggest
strain
produc
much
greater
quantiti
toxin
b
strain
produc
toxin
earlier
log
phase
growth
experi
date
suggest
control
hospit
outbreak
caus
strain
difficult
achiev
like
requir
multifacet
intervent
includ
care
attent
infect
control
practic
well
form
antimicrobi
usag
restrict
final
recent
develop
chang
epidemiolog
cdad
appear
increasingli
sever
diseas
previous
low
risk
popul
includ
individu
littl
exposur
either
healthcar
set
antimicrobi
improv
surveil
necessari
fulli
understand
magnitud
communityacquir
cdad
possibl
reason
recent
increas
incid
bloodborn
virus
health
care
facilitiesth
silent
enemi
overview
transmiss
bbv
healthcar
facil
estim
million
hiv
infect
peopl
south
africa
recent
sexual
transmiss
consid
main
rout
transmiss
blood
born
virus
hiv
report
unsaf
inject
health
deliveri
practic
might
contribut
infect
particularli
children
follow
publish
report
tygerberg
hospit
stellenbosch
uni
children
found
hiv
infect
whose
biolog
mother
hiv
uninfect
larg
crosssect
nest
case
control
studi
undertaken
identifi
risk
factor
children
age
year
old
hiv
infect
uninfect
biolog
mother
evalu
infect
control
practic
dental
mother
child
healthcar
facil
undertaken
one
provinc
south
africa
fifteen
percent
children
test
age
year
found
hiv
infect
howev
children
hiv
infect
yet
biolog
mother
hiv
uninfect
infect
control
ic
studi
protocol
assess
knowledg
health
staff
provis
ic
safe
practic
ward
unit
level
actual
clinic
practic
among
dental
matern
staff
clean
steril
critic
item
test
presenc
occult
blood
surrog
marker
ic
practic
express
breast
milk
ebm
sent
viral
load
estim
find
suggest
transmiss
via
unsaf
inject
improp
clean
steril
instrument
item
found
contamin
blood
poorli
label
express
breast
milk
rna
viral
load
copi
ml
higher
found
ebm
hiv
infect
mother
could
contribut
transmiss
hiv
blood
born
virus
health
care
facil
africa
uniqu
regard
report
hepat
b
c
reus
multidos
vial
report
sweden
denmark
unit
state
clearli
risk
transmiss
blood
born
virus
high
low
incom
countri
like
due
lack
proper
care
healthcar
procedur
econom
cmv
lead
caus
congenit
viral
infect
worldwid
incid
rang
percent
live
birth
percent
case
congenit
cmv
infect
symptomat
birth
major
children
go
develop
sever
neurolog
sequela
contrast
percent
patient
clinic
inappar
infect
neonat
period
develop
sequela
sensorineur
hear
loss
signific
complic
bilater
percent
progress
percent
late
appear
percent
patient
predictor
hear
loss
includ
presenc
petechia
thrombocytopenia
hepatosplenomegali
laboratori
evid
hepat
intracrani
calcif
progress
natur
delay
onset
hear
loss
demonstr
inadequaci
mass
screen
hear
base
test
newborn
infant
prenat
diagnosi
achiev
test
amniot
fluid
pcr
cultur
obtain
week
gestat
quantit
pcr
good
predict
valu
symptomat
infect
children
congenit
cmv
infect
follow
first
trimest
matern
infect
like
cn
sequela
especi
hear
loss
whose
mother
infect
later
pregnanc
mother
known
infect
cmv
month
year
concept
risk
congenit
infect
infant
appear
matern
reinfect
differ
strain
short
durat
preconcept
immun
influenc
outcom
preconcept
matern
immun
less
perfect
prevent
foetal
infect
foetal
damag
issu
rais
concern
futur
develop
vaccin
howev
provoc
new
data
nonrandom
studi
suggest
treatment
cmvspecif
hyperimmun
globulin
ganciclovir
primari
cmv
infect
pregnanc
may
effect
prevent
treatment
congenit
cmv
infect
brucellosi
molecular
method
diagnosi
human
brucellosi
brucella
spp
endem
worldwid
infect
caus
signific
morbid
develop
countri
due
heterogen
nonspecif
clinic
symptom
brucellosi
diagnosi
alway
requir
laboratori
confirm
diagnosi
brucellosi
current
base
isol
brucella
detect
immun
respons
classic
serolog
method
presenc
characterist
clinic
find
howev
situat
criteria
unsatisfactori
new
improv
diagnost
method
need
realtim
pcr
revolution
way
clinic
microbiolog
laboratori
diagnos
mani
human
microbi
infect
last
year
three
realtim
pcr
assay
detect
quantif
brucella
spp
b
melitensi
develop
use
lightcycl
roch
overal
use
realtim
pcr
brucella
suffer
lack
sensit
lack
standard
variabl
result
depend
laboratori
perform
use
realtim
pcr
detect
quantif
brucella
dna
util
diagnosi
followup
patient
brucellosi
review
recent
quantit
realtim
pcr
qpcr
techniqu
develop
laboratori
monitor
evolut
b
melitensi
dna
load
initi
diagnosi
posttherapi
followup
brucellosi
patient
collect
peripheralblood
sampl
brucellosi
patient
sensit
qpcr
initi
infect
relaps
similar
result
obtain
et
al
despit
posit
respons
treatment
sharp
declin
bacteria
load
initi
therapi
patient
relaps
nonrelaps
subject
low
levelposit
qpcr
upon
final
treatment
conclus
followup
almost
patient
relaps
nonrelaps
case
asymptomat
continu
low
bacteria
dna
load
conclus
data
suggest
brucellosi
may
chronic
relaps
diseas
compar
caus
intracellular
pathogen
mycobacterium
tuberculosi
bacteria
persist
therapi
despit
appropri
antibiot
treatment
good
host
respons
order
better
understand
cours
brucellosi
signific
persist
b
melitensi
dna
brucellosi
patient
natur
relaps
prospect
studi
includ
larger
homogen
treat
sampl
focu
monitor
longterm
posttherapi
cours
diseas
new
treatment
human
brucellosi
brucellosi
common
zoonot
diseas
worldwid
recent
reemerg
new
foci
develop
world
enter
develop
world
evolut
intern
travel
food
traffick
treatment
principl
remain
unchang
sinc
last
issu
world
health
organ
recommend
although
variou
clinic
vitro
trial
attempt
improv
overal
outcom
current
mar
relaps
rate
overal
difficulti
treat
seriou
diseas
complic
advanc
treat
brucellosi
categor
follow
use
altern
regimen
incorpor
aminoglycosid
ii
use
altern
regimen
incorpor
classic
newer
quinolon
iii
modif
durat
treatment
iv
reapprais
tradit
altern
agent
cotrimoxazol
v
attempt
monotherapi
vi
evalu
newer
agent
tigecyclin
vii
modif
major
pathogenet
event
diseas
although
aspect
subject
debat
past
decad
definit
conclus
drawn
sinc
applic
laboratori
studi
clinic
practic
limit
brucellosi
exist
clinic
trial
often
illdesign
conflict
result
object
communityacquir
methicillinresist
staphylococcu
aureu
camrsa
isol
produc
pantonvalentin
leucocidin
pvl
worldwid
concern
europ
iv
isol
predomin
concern
unit
state
strain
appear
pulsedfield
type
iv
recent
describ
iv
better
understand
european
situat
compar
genom
content
isol
mrsa
strain
highdens
microarray
analysi
method
genom
composit
two
isol
assess
use
affymetrix
aureu
genechip
affymetrix
santa
clara
ca
purifi
chromosom
dna
isol
queri
hybrid
presenc
absenc
loci
repres
chip
includ
resist
determin
exoenzym
exoor
enterotoxin
varieti
virul
regul
cell
surfac
factor
result
compar
microarray
data
recent
obtain
aureu
isol
tenov
et
al
j
clin
microbiol
press
result
overal
isol
relat
differ
primarili
conserv
hypothet
open
read
frame
intergen
sequenc
gener
isol
similar
isol
exampl
isol
appear
share
capsular
polysaccharid
synthesi
type
agr
type
howev
import
differ
two
strain
observ
case
fibronectinbind
protein
b
fnba
fnbb
absent
present
isol
analysi
loci
suggest
presenc
gene
combin
potenti
import
facilit
persist
spread
strain
commun
environ
conclus
highdens
microarray
analysi
relat
isol
close
communityacquir
rather
hospitalacquir
mrsaconsist
clinic
experi
similar
differ
note
epidem
mrsa
strain
repres
import
resourc
identifi
gene
combin
specif
isol
data
help
strain
identif
epidemiolog
analysi
provid
greater
understand
mechan
clonal
lineag
persist
spread
commun
set
object
pantonvalentin
leucocidin
pvl
toxin
found
staphylococcu
aureu
isol
associ
seriou
invas
infect
aim
studi
determin
preval
pvl
among
erythromycinand
methicillinresist
clindamycinsuscept
communityacquir
aureu
isol
children
texa
method
erythromycin
methicillin
resist
clindamycin
suscept
strain
total
test
presenc
pvl
scc
type
strain
studi
relat
presenc
pvl
macrolid
resist
mechan
also
studi
result
mrsa
scc
ii
scc
iv
scc
type
one
strain
could
determin
method
use
scc
ii
strain
pvl
carri
erm
gene
alon
strain
msr
strain
among
scc
iv
strain
pvl
pvl
pvl
strain
carri
erm
gene
erm
c
alon
erm
c
msr
gene
four
strain
carri
msr
alon
pvl
strain
msr
alon
erm
c
strain
erm
c
strain
erm
posit
preval
pvl
communityacquir
strain
increas
progress
year
conclus
pvl
commonli
present
macrolideresist
clindamycinsuscept
scc
iv
mrsa
absent
among
scc
ii
strain
erm
isol
children
texa
ident
macrolideresist
clone
streptococcu
pyogen
portug
support
europewid
dissemin
lineag
object
although
overal
macrolid
resist
remain
stabl
portug
rapid
invers
domin
phenotyp
note
sharp
decreas
mlsb
phenotyp
parallel
increas
phenotyp
gain
insight
chang
character
macrolid
resist
isol
previous
character
emm
type
method
combin
pulsedfield
gel
electrophoresi
pfge
multilocu
sequenc
type
mlst
use
use
isoschizom
smai
digest
strain
phenotyp
refractori
smai
digest
allow
direct
comparison
mlsb
isol
bionumer
softwar
use
creat
upgma
dendrogram
smai
fragment
pattern
dice
similar
coeffici
use
optim
posit
toler
set
respect
pfge
cluster
includ
isol
related
dendrogram
mlst
analysi
perform
repres
major
lineag
bacitracin
suscept
determin
isol
disk
diffus
result
isol
includ
studi
typeabl
pfge
pfge
mlst
highli
concord
identifi
eight
major
clone
account
isol
exclus
associ
singl
macrolid
resist
phenotyp
two
major
clone
found
among
mlsb
isol
character
sequenc
type
st
wherea
among
isol
clone
domin
clone
defin
correspond
bacitracin
resist
clone
circul
europ
novel
variant
express
surfac
antigen
detect
conclus
although
larg
divers
among
macrolid
resist
genotyp
notabl
among
isol
present
phenotyp
clone
account
major
isol
frequent
lineag
repres
isol
analys
studi
period
presenc
four
major
clone
european
countri
report
previous
suggest
europewid
dissemin
macrolid
resist
lineag
kp
clinic
isol
submit
nation
esbl
refer
laboratori
hungarian
hospit
select
accord
high
resist
cefotaxim
aminoglycosid
tetracyclin
ciprofloxacin
suscept
antimicrobi
discdiffus
method
esbl
express
detect
accord
nccl
criteria
molecular
type
perform
tem
shv
ctxm
pcr
sequenc
analysi
pcr
amplicon
xbaipfg
resist
cefotaxim
transfer
conjug
rifampinr
e
coli
plasmid
extract
perform
alkalin
lysi
result
total
esblkp
isol
collect
variou
hospit
infect
sampl
hungarian
hospit
isol
collect
parallel
nosocomi
outbreak
report
icu
two
differ
hospit
first
outbreak
counti
isol
recov
inpati
mortal
median
age
year
rang
median
length
stay
day
rang
surgic
wound
lower
respiratori
tract
urin
blood
conjunctiva
bile
sputum
second
outbreak
budapest
isol
recov
inpati
median
age
year
rang
mean
length
stay
day
rang
blood
urin
trachea
sputum
vagin
secret
environment
sampl
discern
appar
sourc
outbreak
pfge
analysi
reveal
strong
clonal
link
isol
previous
describ
epidem
clone
detect
similar
larg
plasmid
select
isol
transconjug
found
conclus
till
end
shv
common
blactamas
detect
kp
nosocomi
isol
hungari
sinc
begin
esblkp
clinic
isol
predominantli
produc
evid
background
esbl
chang
countrywid
spread
mdr
kp
epidem
clone
erupt
dissemin
geograph
distinct
hospit
emphas
necess
immedi
intervent
epidemiolog
monitor
evid
low
rate
ciprofloxacin
rifampicin
resist
persist
helicobact
pylori
infect
sa
chisholm
rj
owen
london
uk
object
studi
aim
determin
rate
ciprofloxacin
cip
rifampicin
rif
resist
english
dyspept
patient
refract
h
pylori
infect
agent
propos
compon
rescu
therapi
instanc
recommend
firstlin
possibl
secondlin
therapi
fail
howev
studi
monitor
level
resist
particularli
patient
fail
erad
therapi
method
primari
antibiot
resist
determin
isolatesspecimen
refer
specialist
unit
isol
dualli
resist
metronidazol
mtz
clarithromycin
cla
recov
patient
fail
least
one
erad
attempt
n
examin
etest
suscept
cip
rif
addit
cip
rif
suscept
determin
eightfullysensit
isol
n
recov
pretreat
result
isol
refer
n
n
mtz
cla
resist
respect
n
dualli
resist
incid
dual
resist
higher
patient
previou
treatment
failur
document
treatmentfailur
group
cip
mic
rang
mgl
isol
cip
sensit
mgl
two
remain
isol
cip
resist
mic
mgl
mgl
eight
pretreat
isol
cip
sensit
rif
mic
rang
mgl
lower
propos
resist
breakpoint
mgl
rais
mic
rif
mgl
observ
treatment
failur
n
pretreat
group
n
interestingli
isol
display
highlevel
cip
resist
mgl
rif
mic
mgl
show
reduc
suscept
tetracyclin
mic
mgl
addit
mtz
cla
resist
conclus
resist
cip
rif
rare
dyspept
patient
uk
even
patient
infect
dualli
resist
strain
h
pylori
alreadi
fail
least
one
erad
therapi
identif
multiresist
strain
demonstr
import
test
suscept
refract
h
pylori
wider
rang
therapeut
agent
object
stress
hyperglycaemia
condit
relat
transient
elev
blood
glucos
level
due
variou
kind
stress
sever
sepsi
result
infect
may
sometim
lead
organ
dysfunct
death
aim
present
studi
investig
impact
stress
hyperglycaemia
surviv
nondiabet
patient
sever
sepsi
patient
method
studi
includ
non
diabet
patient
women
men
sever
sepsi
hospit
three
peripher
hospit
southwestern
greec
oneyear
period
patient
divid
two
group
accord
glycaem
profil
admiss
patient
baselin
hyperglycaemia
group
h
patient
normal
glucos
level
group
n
hyperglycaemia
defin
admiss
inhospit
fast
glucos
level
mgdl
random
blood
glucos
level
mgdl
determin
immunosuppress
patient
exclud
sever
sepsi
classifi
sepsisrel
organ
failur
assess
score
sofa
result
forti
nine
patient
stress
hyperglycaemia
patient
group
h
older
group
n
year
vs
year
mean
glucos
plasma
level
admiss
group
h
mgdl
signific
differ
sex
bmi
crp
blood
cultur
hospit
day
two
group
interestingli
hyperglycaem
patient
first
degre
rel
diabet
percentag
normoglycaem
group
h
significantli
higher
sofa
score
group
n
mean
vs
p
sourc
infect
patient
follow
respiratori
tract
urinari
tract
intraabdomin
central
nevrou
system
soft
tissu
endocard
caus
infect
similar
group
significantli
higher
percentag
septic
patient
stress
hyperglycaemia
die
compar
patient
normal
baselin
glucos
level
vs
p
conclus
stress
hyperglycaemia
common
find
nondiabet
patient
sever
sepsi
relat
genet
predisposit
diabet
mellitu
may
relat
cytokin
relat
insulin
resist
seem
signific
predictor
outcom
nondiabet
septic
patient
object
diabet
may
associ
increas
mortal
pneumonia
due
decreas
immun
impair
lung
function
hyperglycaem
derang
examin
diabet
predictor
mortal
larg
cohort
adult
patient
hospit
pneumonia
method
populationbas
cohort
studi
three
danish
counti
north
jutland
viborg
aarhu
patient
firsttim
hospit
discharg
diagnosi
pneumonia
identifi
hospit
discharg
registri
inform
diabet
comorbid
obtain
discharg
registri
prescript
databas
patient
follow
day
hospit
danish
civil
registr
system
compar
mortal
rate
patient
without
diabet
adjust
gender
age
comorbid
result
total
adult
patient
hospit
pneumonia
median
age
year
patient
diabet
overal
mortal
diabet
patient
compar
patient
pneumonia
vs
day
vs
day
adjust
mortal
rate
patient
diabet
margin
increas
mortal
rate
ratio
ci
day
ci
day
compar
nondiabet
pneumonia
patient
conclus
result
corrobor
previou
report
suggest
diabet
limit
influenc
outcom
patient
hospit
pneumonia
object
although
demonstr
type
diabet
patient
increas
risk
urinari
tract
infect
uti
much
known
predictor
complic
cours
safe
feasibl
manag
strategi
patient
high
low
risk
uti
could
improv
effici
antimicrobi
use
may
direct
prevent
measur
need
develop
predict
rule
complic
uti
patient
primari
care
method
conduct
prospect
cohort
studi
includ
patient
age
year
older
second
dutch
nation
survey
gener
practic
carri
period
primari
outcom
measur
complic
cours
composit
recurr
cystiti
acut
pyelonephr
prostat
multivari
logist
regress
analysi
perform
produc
clinic
predict
rule
area
receiveroper
curv
auc
characterist
calcul
measur
discrimin
capac
score
cutoff
point
follow
testcharacterist
calcul
posit
neg
predict
valu
sensit
specif
proport
subject
select
result
mean
age
patient
year
sd
male
overal
incid
rate
outcom
per
patient
year
n
per
femal
per
male
independ
predictor
increas
age
odd
ratio
confid
interv
ci
male
sex
number
physician
contact
per
class
incontin
urin
cerebrovascular
diseas
dementia
renal
diseas
auc
ci
subgroup
analys
gender
show
differ
discrimin
abil
use
cutoff
score
point
rang
patient
would
select
tailor
care
wherea
patient
complic
cours
uti
would
miss
conclus
abl
deriv
accur
model
predict
complic
uti
male
femal
patient
primari
care
confirm
extern
popul
model
may
use
improv
manag
uti
patient
object
among
elderli
person
diabet
dm
elev
risk
complic
lower
respiratori
tract
infect
lrti
care
risk
assess
use
accur
object
predict
rule
could
help
gener
practition
target
manag
infect
effici
howev
rule
unselect
popul
might
inaccur
highrisk
group
part
larg
retrospect
cohort
studi
among
elderli
person
age
year
conduct
subgroup
analysi
determin
applic
develop
predict
rule
probabl
complic
cours
lrti
diabet
method
origin
cohort
studi
use
computer
databas
univers
medic
center
utrecht
gener
practition
research
network
gener
practition
attend
episod
acut
bronchiti
exacerb
copd
asthma
pneumonia
includ
outcom
composit
hospit
death
follow
episod
lrti
potenti
predictor
accord
predict
rule
unselect
popul
type
lrti
diagnosi
age
presenc
heart
failur
predison
use
hospit
preced
year
antibiot
previou
month
highrisk
group
specif
interest
ad
valu
diabet
specif
variabl
presenc
cardiovascular
comorbid
use
insulin
oral
diabet
medic
calibr
test
hosmerlemeshow
good
fit
test
discrimin
capac
estim
area
receiv
oper
curv
auc
result
among
episod
lrti
among
elderli
patient
dm
endpoint
occur
attack
rate
reliabl
model
good
goodnessoffit
test
p
discrimin
properti
origin
rule
accept
auc
confid
interv
low
risk
group
point
patient
end
hospit
death
high
risk
group
point
conclus
predict
rule
probabl
hospit
death
deriv
unselect
elderli
popul
lrti
appear
accept
discrimin
properti
diabet
patient
also
may
use
target
manag
common
diseas
appli
rule
may
safe
restrict
need
treatment
help
gp
target
addit
effort
patient
need
object
foot
infect
patient
diabet
mellitu
among
common
bacteri
infect
encount
clinic
practic
aim
present
studi
evalu
aetiolog
medic
outcom
includ
risk
complic
mortal
adult
patient
hospit
sever
dfi
method
report
describ
retrospect
analysi
medic
record
hospit
patient
admit
consult
infecti
diseas
depart
sever
dfi
januari
novemb
univers
hospit
result
male
femal
averag
patient
age
year
patient
level
wagner
scale
patient
combin
osteomyel
deep
soft
tissu
infect
fortyseven
bacteria
document
microbiolog
case
staphylococcu
aureu
enterobacteriacea
common
isol
overal
patient
discharg
earli
day
patient
hospit
day
requir
earli
surgic
debrid
underw
least
one
digit
amput
amput
common
level
patient
compar
ssti
overal
mortal
factor
associ
death
male
sex
presenc
multipl
comorbid
condit
congest
hearth
failur
morbid
obes
hypoalbuminaemia
renal
insuffici
shock
conclus
dfi
seriou
bacteri
diseas
often
underestim
poorli
recognis
find
indic
deep
foot
infect
patient
diabet
heterogen
entiti
type
sever
relat
choic
treatment
strategi
outcom
pump
resist
object
blactam
bl
aminoglycosid
ag
fluoroquinolon
fq
substrat
one
sever
rnd
efflux
pump
mexaboprm
mexcdoprj
mexefoprn
mexxyoprm
pseudomona
aeruginosa
aim
studi
determin
preval
efflux
mechan
resist
clinic
strain
p
aeruginosa
method
hundr
seventi
strain
p
aeruginosa
reduc
suscept
ticarcillin
mic
mgl
collect
french
hospit
analys
overexpress
efflux
gene
mexb
mexc
mex
mexi
realtim
rtpcr
mic
antibiot
determin
use
convent
agar
dilut
method
result
n
n
n
n
select
isol
found
overproduc
mexaboprm
mexxi
mexcdoprj
orand
mexefoprn
respect
strain
resist
ticarcillin
ciprofloxacin
mic
mgl
overexpress
mexaboprm
bacteria
resist
amikacin
mic
mgl
ciprofloxacin
exhibit
upregul
mexxi
respect
interestingli
strain
non
suscept
ciprofloxacin
overproduc
mexaboprm
mexxi
preval
mexxi
mechan
correl
level
resist
ciprofloxacin
strain
mic
ciprofloxacin
mgl
mexxyoverproduc
respect
amikacin
strain
mic
amikacin
mgl
conclus
result
show
contrast
mexcdoprj
mexefoprn
system
mexaboprm
mexxi
oprm
frequent
upregul
among
clinic
p
aeruginosa
isol
show
decreas
suscept
bl
ag
andor
fq
furthermor
drug
efflux
mediat
mexxyoprm
highli
preval
isol
strong
level
resist
ag
fq
express
mexi
gene
druginduc
amikacin
resist
small
coloni
variant
p
aeruginosa
islam
vang
b
wretlind
stockholm
se
object
p
aeruginosa
mexxi
multidrug
efflux
system
contribut
intrins
induc
resist
long
array
antibiot
includ
aminoglycosid
fluoroquinolon
p
aeruginosa
abil
chang
phenotyp
special
circumst
growth
lung
cystic
fibrosi
patient
one
phenotyp
smallcoloni
variant
scv
trend
chang
scv
goe
toward
increas
mic
valu
antipseudomon
agent
especi
aminoglycosid
induc
mexxi
depend
drug
ribosom
interact
result
higher
signal
level
upregul
operon
report
operon
role
drug
induc
overexpress
mexxi
operon
studi
tri
explain
relationship
express
aminoglycosid
resist
scv
mutant
paeruginosa
method
ten
aminoglycosid
induc
scv
mic
mgl
wild
type
mgl
mutant
isol
character
wild
type
strain
express
mrna
mexi
pump
protein
determin
realtim
pcr
result
mexi
mrna
overexpress
strain
test
rang
fold
two
strain
mic
amikacin
mgl
overproduc
mrna
respect
also
express
mexi
mrna
one
strain
mic
mgl
fold
regul
produc
mexi
mrna
rest
strain
produc
mrna
similar
wild
type
strain
conclus
elev
express
mrna
suggest
role
upregul
mexxi
operon
follow
higher
mic
valu
aminoglycosid
overal
data
suggest
play
import
role
highli
elev
express
mexi
therebi
might
necessari
drug
induc
aminoglycosid
resist
p
aeruginosa
scv
similar
mechan
probabl
also
relev
p
aeruginosa
strain
cf
patient
contribut
efflux
pump
overexpress
carbapenem
heteroresist
pseudomona
aeruginosa
object
investig
carbapenem
heteroresist
phenotyp
pseudomona
aeruginosa
examin
molecular
basi
materi
method
twenti
consecut
clinic
isol
p
aeruginosa
exhibit
coloni
grown
within
appar
zone
inhibit
disk
diffus
includ
studi
isol
screen
etest
determin
imipenem
meropenem
mic
genotyp
pulsedfield
gel
electrophoresi
pfge
heteroresist
subpopul
substanti
popul
analysi
clone
rtpcr
exponenti
rang
analysi
perform
examin
level
transcript
gene
code
efflux
pump
particularli
mexi
mexb
contribut
bacterium
cell
wall
heteroresist
examin
rtpcr
lpxc
gene
multicopi
gene
code
rrna
singl
copi
gene
rpsl
use
intern
control
result
macrorestrict
analysi
isol
show
least
nine
unrel
genotyp
mic
isol
imipenem
meropenem
rang
mgl
isol
exhibit
coloni
grown
also
within
appar
inner
zone
inhibit
imipenem
meropenem
etest
strip
popul
analysi
reveal
subpopul
grown
concentr
mgl
mgl
meropenem
imipenem
respect
rtpcr
exponenti
rang
analysi
one
isol
clone
show
substanti
increas
transcript
level
mexi
mexb
carbapenem
subpopul
transcript
variat
lpxc
detect
conclus
efflux
pump
seem
contribut
heteroresist
isol
carbapenem
phenotyp
readili
observ
isol
lower
level
resist
yet
known
whether
use
carbapenem
would
lead
select
resist
subpopul
subsequ
caus
infect
resist
isol
treatment
failur
object
activ
efflux
antimicrobi
hydrophob
agent
one
import
bacteri
defenc
system
inhibitori
host
factor
two
wellcharacter
mdr
efflux
pump
mtrcde
farabmtr
exist
neisseria
gonorrhoea
mtrcde
encod
efflux
pump
neisseria
gonorrhoea
mediat
energi
depend
efflux
process
structur
divers
hydrophob
agent
gonococci
strain
neisseria
gonorrhoea
show
resist
hydrophob
agent
often
contain
mutat
code
region
promot
region
operon
product
adjac
mtrr
gene
neg
regul
express
mtrcde
operon
mtre
encod
put
lipoprotein
kda
associ
mtr
phenotyp
method
earlier
studi
report
mutat
qrdr
region
gyra
parc
gene
clinic
isol
neisseria
gonorrhoea
show
high
resist
ciprofloxacin
mic
rang
lgml
account
variat
mic
valu
sampl
show
similar
mutat
gyra
parc
gene
check
mutat
mtrr
mtre
gene
nucleotid
sequenc
pcr
amplifi
mtrr
gene
analys
compar
nucleotid
sequenc
wild
type
neisseria
gonorrhoea
result
isol
show
missens
mutat
locat
downstream
helixturnhelix
motif
mtrr
base
pair
addit
mutat
promot
region
mtrr
nucleotid
sequenc
mtre
show
distinct
mutat
differ
clinic
isol
invari
posit
viz
conclus
envisag
alter
dnamtrr
protein
interact
result
increas
express
protein
involv
efflux
hydrophob
antibiot
may
one
import
mechan
pathogen
becom
resist
ciprofloxacin
chaudhri
u
ray
k
bala
saluja
mutat
pattern
gyra
parc
gene
ciprofloxacin
resist
isol
neisseria
gonorrhoea
india
sex
transm
infect
acquir
blactam
resist
three
escherichia
coli
strain
due
overexpress
acrab
tolc
object
previou
studi
three
multidrug
resist
escherichia
coli
mutant
select
vitro
ceftazidim
lomefloxacin
two
e
coli
suscept
clinic
isol
mutant
increas
cyclohexan
toler
foldblactam
mic
without
increas
blactamas
activ
decreas
permeabl
blactam
resist
describ
interplay
acrab
system
blactamas
aim
work
studi
potenti
interplay
acrabtolc
overexpress
penicillin
bind
protein
pbp
chang
mechan
explain
blactam
resist
three
mutant
method
inner
outer
membran
protein
imp
omp
analys
sdspage
pbp
detect
bocillin
fl
imperi
protein
stain
formul
coomassi
express
acra
acrb
mara
sox
gene
studi
revers
transcript
total
rna
pcr
cdna
rtpcr
use
gapa
gene
intern
control
express
pcr
product
separ
sdspage
silver
stain
strain
induc
noninduc
mm
salicyl
control
strain
result
level
express
acra
acrb
gene
mutant
parent
strain
higher
found
noninduc
strain
omp
tolc
increas
mutant
coincid
increas
cyclohexan
toler
neither
parent
strain
mutant
show
mara
sox
gene
overexpress
nacl
induc
ompf
express
singl
ompf
defici
mutant
three
mutant
increas
express
imp
detect
conclus
increas
express
tolc
three
mutant
ad
loss
ompf
explain
increas
ceftazidim
mic
increas
aztreonam
mic
mutant
ii
detect
imp
concurr
loss
blactamas
activ
suggest
mppa
express
sensor
protein
murein
tripeptid
level
iii
osmoregul
ompf
gene
express
intact
strain
overexpress
mara
sox
gene
detect
strain
increas
express
rob
gene
might
explain
ompf
loss
epidemiolog
trend
leprosi
diseas
iranian
qazvin
provinc
year
r
qassemi
barqi
qazvin
ir
introduct
leprosi
chronic
infecti
diseas
import
along
histori
abil
establish
disabl
social
exclud
stealth
leprosi
exist
countri
still
although
leprosi
case
countri
includ
india
brazil
madagascar
mozambiqu
nepal
tanzania
elimin
leprosi
goal
countri
arriv
elimin
leprosi
phase
object
purpos
studi
determin
leprosi
trend
year
qazvin
provinc
descript
studi
leprosi
case
record
year
qazvin
provinc
studi
age
group
sex
clinic
symptom
disabl
stage
incid
rate
type
base
document
leprosi
surveil
system
result
year
patient
leprosi
treat
case
men
case
women
case
year
old
age
group
patient
case
year
old
multi
bacillari
case
puci
bacillari
case
lesion
macular
without
sensat
common
sign
patient
record
leprosi
diseas
elimin
phase
preval
popul
qazvin
provinc
discuss
conclus
qazvin
provinc
one
leprosi
endem
provinc
achiev
goal
elimin
leprosi
also
less
case
leprosi
sold
age
group
indic
success
program
leprosi
use
mdt
qazvin
provinc
object
clinic
epidemiolog
studi
diseas
caus
mycobacterium
kansasii
zaragoza
spain
method
retrospect
studi
carri
januari
decemb
miguel
servet
hospit
lozano
blesa
hospit
royo
villanova
hospit
diagnosi
diseas
perform
accord
american
thorac
societi
criteria
result
patient
chart
patient
isol
kansasii
record
review
sputum
far
common
sourc
isol
account
consid
patient
suffer
diseas
caus
kansasii
number
increas
second
half
studi
period
vs
case
pulmonari
diseas
frequent
clinic
present
seventi
nine
percent
patient
diseas
male
mean
age
year
common
risk
factor
associ
diseas
due
kansasii
smoke
infect
human
immunodefici
viru
hiv
chronic
obstruct
pulmonari
diseas
tuberculosi
mean
cell
count
hivinfect
patient
diagnosi
frequent
clinic
featur
respiratori
symptom
follow
fever
constitut
symptom
chest
radiograph
reveal
cavit
pulmonari
diseas
hivneg
case
hivposit
case
p
incid
unilater
diseas
hivneg
patient
hivposit
patient
p
common
treatment
regimen
rifampicin
isoniazid
ethambutol
averag
durat
month
twentyon
patient
initi
treat
tuberculosi
treatment
case
nonhivassoci
diseas
favour
outcom
hivassoci
pulmonari
dissemin
diseas
poor
conclus
increas
incid
diseas
caus
kansasii
surmis
due
aid
factor
may
extern
factor
caus
either
chang
distribut
virul
mycobacteria
environ
outcom
therapi
hivneg
patient
excel
hivposit
patient
poor
comparison
convent
antimicrobi
suscept
oligonucleotid
chip
system
detect
drug
resist
mycobacterium
tuberculosi
isol
object
rapid
detect
drug
resist
critic
manag
tuberculosi
patient
clinic
efficaci
oligonucleotid
chip
technolog
detect
drugresist
tubercl
bacilli
evalu
compar
standard
drug
suscept
test
method
oligonucleotid
chip
detect
specif
mutat
rpob
katg
inha
gene
tuberculosi
design
probe
detect
drugresist
follow
wildtyp
mutanttyp
probe
rifampin
wildtyp
mutanttyp
probe
isoniazid
target
dna
tuberculosi
amplifi
polymeras
chain
reaction
follow
hybrid
scan
direct
sequenc
perform
verifi
result
oligonucleotid
chip
result
mutat
compar
result
convent
antimycobacteri
suscept
test
use
lowensteinjensen
proport
method
result
sixtyeight
seventysix
rifampinresist
strain
mutat
rpob
gene
fortyseven
eightyon
isoniazidresist
strain
mutat
katg
gene
inha
gene
mutat
easili
detect
oligonucleotid
chip
system
within
day
conclus
diagnost
oligonucleotid
chip
mutationspecif
probe
reliabl
use
tool
rapid
detect
drugresist
rifampin
isoniazid
tuberculosi
isol
clinic
microbiolog
data
patient
infect
multidrugresist
mycobacterium
tuberculosi
strain
carri
gyras
mutat
n
veziri
j
robert
c
truffotpernot
v
jarlier
e
cambau
aubri
pari
fr
object
previou
studi
demonstr
mutat
tuberculosi
dna
gyras
either
associ
fluoroquinolon
resist
gyra
posit
gyrb
posit
normal
suscept
gyra
hypersuscept
gyra
fluoroquinolon
use
increas
tuberculosi
treatment
analys
clinic
characterist
tuberculosi
mtb
resist
pattern
patient
infect
strain
carri
mutat
gyra
gyrb
subunit
method
retrospect
review
characterist
patient
infect
multidrug
resist
mdr
strain
mtb
carri
mutat
gyra
andor
gyrb
patient
quinolon
resist
mtb
includ
studi
strain
mutat
gyra
n
n
n
g
n
n
n
n
strain
mutat
gyrb
b
patient
infect
strain
carri
novel
gyra
mutat
lead
quinolon
hypersuscept
case
normal
suscept
case
result
mdr
patient
major
male
vs
mean
age
year
born
outsid
europ
n
major
n
previous
treat
tuberculosi
hiv
posit
least
pulmonari
tuberculosi
afb
posit
mean
number
resist
mtb
strain
resist
includ
isoniazid
rifampin
resist
pyrazinamid
ethambutol
streptomycin
ethionamid
cycloserin
kanamycin
para
aminosalicyl
acid
prior
treatment
histori
avail
patient
infect
fluoroquinoloneresist
strain
receiv
fluoroquinolonecontain
regimen
conclus
mdrtb
patient
harbour
strain
gyras
mutat
extrem
drug
resist
strain
like
born
outsid
europ
compar
mdrtb
patient
previous
report
franc
vs
p
implement
autom
mycobacteri
interspers
repetit
unitvari
number
tandem
repeat
miruvntr
type
routin
laboratori
set
c
allix
p
suppli
fauvilledufaux
brussel
lill
fr
object
rapid
detect
adequ
therapi
contact
trace
stop
transmiss
key
factor
control
tuberculosi
tb
use
autom
miruvntr
type
techniqu
greatli
facilit
acceler
resolut
problem
typic
encount
clinic
mycobacteriolog
laboratori
public
health
facil
method
amplif
miruvntr
genom
loci
perform
heatinactiv
cultur
use
differ
multiplex
pcr
fluoresc
primer
dna
fragment
separ
use
abi
genet
analys
analysi
perform
genescan
genotyp
softwar
appli
biosystem
result
laboratori
cross
contamin
suspicion
laboratori
cross
contamin
frequent
caus
genotyp
analysi
request
hospit
laboratori
use
miruvntr
method
delay
deliveri
cultur
laboratori
reliabl
genotyp
result
reduc
one
two
day
worsen
tuberculosi
treatment
patient
diagnos
suscept
tuberculosi
receiv
adequ
therapi
meanwhil
went
africa
journey
week
came
back
tuberculosi
worsen
clinician
suspect
reinfect
multidrug
resist
tb
africa
miruvntr
analysi
rapidli
show
patient
still
infect
strain
overal
percentag
aureu
isol
express
methicillin
resist
increas
significantli
commun
past
decad
communitymrsa
cmrsa
infect
correspond
associ
mrsa
strain
emerg
recent
de
novo
commun
contain
frequent
panton
valentin
leukocidin
gene
cmrsa
infect
emerg
worldwid
associ
limit
number
clone
highli
epidem
commun
europ
preval
low
increas
gradual
strain
tend
infect
young
patient
especi
children
young
outbreak
cmrsa
infect
especi
skin
soft
tissu
infect
describ
among
member
close
popul
cmrsa
mainli
transmit
man
man
direct
skintoskin
contact
indirectli
contact
touch
object
contamin
infect
skin
person
mrsa
cmrsa
infect
repres
superfici
skin
soft
tissu
infect
infect
usual
nonsever
although
requir
frequent
incis
surgic
drainag
deepseat
infect
associ
cmrsa
eg
necrotis
pneumonia
rare
extrem
sever
lifethreaten
infect
case
osteomyel
septic
arthriti
caus
cmrsa
report
mainli
children
recent
case
pyomyos
due
cmrsa
describ
necrot
fasciiti
due
cmrsa
also
emerg
sever
infect
overal
evid
multipl
dissemin
abscess
patient
mrsa
bacteraemia
highli
specul
due
pvlposit
strain
cmrsa
isol
typic
sensit
wide
varieti
non
blactam
antibiot
includ
trimethoprimsulfamethoxazol
minocyclin
fluoroquinolon
vancomyin
linezolid
quinupristindalfopristin
daptomycin
cmrsa
easili
transmit
patient
soft
tissu
infect
counsel
import
hand
hygien
share
person
item
towel
appropri
wound
care
mrsa
transmiss
dynam
hospit
control
polici
final
succeed
success
control
communic
diseas
requir
one
thing
averag
number
secondari
case
gener
typic
primari
case
less
one
transmiss
reduc
threshold
sustain
spread
pathogen
becom
imposs
evid
form
nation
surveil
data
clinic
intervent
studi
mathemat
model
review
use
assess
possibl
reduc
transmiss
level
lead
longterm
control
mrsa
transmiss
hospit
commun
mrsa
reservoir
commun
transmiss
mislead
surveil
data
limit
infect
control
resourc
overreli
control
measur
limit
effect
repres
potenti
obstacl
success
control
mrsa
hospit
import
obstacl
consid
mean
overcom
discuss
mechan
infecti
diseas
new
scienc
novel
insight
innat
immun
streptococcu
pneumonia
r
read
sheffield
uk
streptococcu
pneumonia
major
caus
morbid
mortal
worldwid
commonli
colon
upper
respiratori
tract
colon
individu
organ
transloc
tissu
caus
lifethreaten
diseas
includ
pneumonia
bacteraemia
mening
nonimmun
host
reli
upon
innat
immun
defenc
pneumococcu
pneumonia
rel
resist
complementmedi
kill
via
termin
membran
attack
complex
phagocyt
initi
alveolar
macrophag
subsequ
recruit
neutrophil
critic
import
major
serum
mucos
fluid
opsonin
apart
immunoglobulin
complement
protein
contact
pneumococci
activ
result
stabilis
bacteri
surfac
recogn
phagocyt
receptor
potenti
opsonin
includ
collectin
eg
mbl
surfact
protein
recogn
collectin
receptor
crp
probabl
recogn
fcr
pneumococci
possess
number
element
modifi
complement
activ
consequ
mediat
opsonophagocytosi
includ
polysaccharid
capsul
pneumolysin
pspa
pspc
altern
gene
product
hic
pneumococcu
manipul
initi
innat
immun
modifi
rate
decay
phagocytosi
proce
number
cellular
mechan
includ
gener
reactiv
oxygen
speci
ro
nitric
oxid
facilit
gener
bacteri
kill
pneumococci
kill
ro
studi
suggest
pneumococci
inhibit
spontan
ro
product
addit
pneumococci
express
manganes
superoxid
dismutas
limit
rosmedi
kill
contribut
bacteri
kill
induct
apoptosi
macrophag
evid
pneumococci
detoxifi
metabol
microbicid
molecul
implic
pneumococc
kill
includ
cathepsin
b
bdefensin
alveolar
macrophag
process
overwhelm
pneumococci
must
recruit
assist
neutrophil
clear
infect
initi
chemokin
releas
alveolar
macrophag
also
alveolar
epitheli
cell
chemokin
cytokin
induct
occur
activ
tolllik
receptor
nod
protein
respons
number
pneumococc
product
includ
peptidoglycan
lipoteicho
acid
pneumolysin
alveolar
macrophag
apoptosi
featur
subclin
murin
pneumococc
infect
model
establish
pneumococc
pneumonia
inhibit
vivo
macrophag
apoptosi
caspas
inhibit
associ
decreas
bacteri
clearanc
enhanc
rate
invas
pneumococc
diseas
therefor
induct
macrophag
apoptosi
pneumococci
may
contribut
bacteri
kill
although
mechan
underli
associ
remain
defin
recent
discoveri
element
innat
immun
pneumococci
discuss
brucellosi
novel
virul
determin
cellular
organel
facult
intracellular
pathogen
brucella
caus
agent
brucellosi
worldwid
zoonosi
affect
mammal
includ
human
essenti
brucella
virul
abil
surviv
replic
insid
host
macrophag
understand
molecular
interact
brucella
replic
nich
may
lead
new
tool
use
vaccin
design
shown
model
brucella
abortu
infect
murin
bone
marrow
deriv
macrophag
fraction
bacteria
surviv
initi
host
cell
kill
proceed
replic
compart
segreg
endocyt
pathway
matur
brucellacontain
vacuol
involv
sustain
interact
fusion
endoplasm
reticulum
er
creat
replic
compart
erlik
properti
acquisit
er
membran
replic
brucella
independ
ergolgi
copi
vesicular
transport
depend
copii
molecular
system
mutant
virb
type
iv
secret
system
necessari
intracellular
surviv
unabl
sustain
interact
fuse
er
kill
via
eventu
fusion
lysosom
thu
demonstr
live
intracellular
brucella
evad
macrophag
kill
virbdepend
sustain
interact
er
lead
hypothesi
brucella
effector
molecul
secret
type
iv
secret
system
may
target
futur
vaccin
osmoregul
periplasm
glucan
opg
gener
constitu
envelop
gramneg
bacteria
glucos
sole
constitut
molecul
play
critic
biolog
role
shown
fact
mutant
unabl
synthes
avirul
plant
anim
host
opg
brucella
genu
constitut
cyclic
cg
glucos
backbon
result
suggest
import
role
cbg
brucella
virul
addit
periplasm
sugar
liposom
extract
cholesterol
caus
haemolysi
erythrocyt
perturb
lipid
raft
periton
macrophag
addit
mutant
defect
periplasm
glucan
product
partial
recov
intracellular
replic
cbg
ad
bacteri
cultur
media
prior
macrophag
infect
data
suggest
cbg
play
import
role
brucella
virul
onset
infect
drug
abl
modul
vacuolar
environ
may
lead
circumv
brucella
infect
foreign
bodi
infect
orthoped
infect
tricki
diagnos
hard
treat
orthoped
devic
increasingli
use
allevi
pain
joint
prosthes
fixat
bone
fractur
intramedullari
nail
externalfix
pin
plate
screw
infect
associ
orthoped
implant
occur
rare
produc
signific
morbid
consum
substanti
healthcar
expenditur
implantassoci
infect
typic
caus
microorgan
attach
surfac
embed
extracellular
matrix
structur
call
microbi
biofilm
organ
complex
commun
structur
function
heterogen
resembl
multicellular
organ
exist
biofilm
render
microorgan
difficult
detect
hard
erad
prosthet
joint
infect
usual
defin
presenc
one
follow
criteria
microbi
growth
synovi
fluid
intraop
tissu
least
posit
cultur
requir
lowvirul
organ
ii
visibl
purul
iii
acut
inflamm
histopatholog
examin
presenc
sinu
tract
infect
classifi
accord
onset
clinic
symptom
implant
earli
month
delay
month
late
month
infect
earli
delay
infect
usual
acquir
implant
surgeri
periop
wherea
late
infect
predominantli
acquir
haematogen
seed
combin
clinic
laboratori
histopatholog
microbiolog
imag
studi
necessari
accur
diagnosi
infect
new
techniqu
disrupt
microbi
biofilm
eg
sonic
remov
implant
molecular
method
eg
quantit
pcr
facilit
diagnost
accuraci
success
treatment
usual
requir
adequ
surgic
procedur
combin
longterm
antimicrobi
therapi
month
ideal
agent
act
adher
stationaryphas
microorgan
rifampin
excel
activ
biofilm
staphylococci
must
alway
combin
anoth
drug
eg
quinolon
blactam
glicopeptid
prevent
emerg
resist
surgic
modal
includ
debrid
retent
prosthesi
onestag
twostag
exchang
resect
arthroplasti
arthrodesi
amput
debrid
retent
reason
option
durat
clinic
sign
symptom
week
implant
stabl
soft
tissu
good
condit
agent
activ
biofilm
microorgan
avail
object
investig
efficaci
toler
two
commerci
avail
alcoholbas
antisept
solut
prepar
care
central
venou
cathet
cvc
insert
site
one
solut
contain
bispyridin
octenidin
dihydrochlorid
method
doubl
blind
random
control
trial
undertaken
haematolog
unit
univers
hospit
one
surgic
unit
adult
patient
nontunnel
cvc
enrol
prospect
inform
consent
randomli
assign
differ
skin
disinfect
regimen
insert
site
octenidin
b
ethanol
treatment
compar
respect
skin
colonis
within
first
day
cvc
insert
ii
posit
cathet
tip
cfu
iii
occurr
cvc
relat
sepsi
quantit
skin
cultur
obtain
insert
site
regular
interv
cultur
cvc
tip
remov
undertaken
roll
plate
techniqu
cvcrelat
bloodstreaminfect
bsi
defin
accord
criteria
set
centr
diseas
control
prevent
cdc
statist
analysi
perform
accord
intentiontotreat
principl
statist
test
alpha
apriori
order
hypothes
equal
treatment
group
respect
efficaci
criteria
perform
independ
biostatist
depart
use
linear
regress
criterion
logist
regress
criteria
model
includ
centr
adjust
result
four
hundr
patient
insert
cvc
enrol
group
show
differ
patient
characterist
tabl
skin
colon
cvc
insert
site
first
day
show
highli
signific
reduct
group
vs
b
p
analysi
patient
due
miss
valu
posit
cathet
tip
significantli
lower
group
vs
b
odd
ratio
p
analysi
patient
statist
differ
occurr
cvcrelat
bsi
side
effect
ie
burn
show
relev
differ
group
conclus
disinfect
alcohol
skin
antisept
contain
octenidin
lead
signific
decreas
skin
cathet
tip
colon
promis
option
prevent
cvcrelat
infect
pool
analysi
mortal
cardiac
safeti
moxifloxacin
choudhri
f
smann
c
reiter
west
us
wuppert
de
object
moxifloxacin
mxf
establish
treatment
respiratori
tract
infect
use
oral
intraven
sequenti
intraven
follow
oral
therapi
pool
analysi
control
mxf
phase
ii
iii
iv
studi
transfer
global
integr
analysi
databas
august
conduct
determin
cardiac
safeti
profil
mortal
risk
mxf
vs
rang
compar
treatment
method
pool
analysi
includ
patient
treat
oral
mxf
treat
compar
therapi
oral
studi
patient
treat
mxf
patient
treat
compar
therapi
sequenti
intravenousor
studi
patient
includ
random
receiv
least
one
dose
studi
drug
deem
valid
safeti
analysi
compar
drug
includ
cefuroxim
clarithromycin
levofloxacin
amoxicillin
clavulan
acid
ofloxacin
cephalexin
doxycyclin
azithromycin
amoxicillin
cotrimoxazol
cefixim
dosag
indic
accord
manufactur
guidelin
result
mortal
cardiac
safeti
data
treatment
oral
sequenti
mxf
vs
compar
drug
shown
tabl
clinic
signific
differ
estim
risk
mxf
compar
group
paramet
conclus
larg
patient
popul
pool
rang
clinic
trial
mxf
treatment
result
increas
risk
cardiac
morbid
mortal
overal
mortal
vs
compar
therapi
shortcours
fluoroquinolon
vs
singl
dose
fosfomycin
acut
uncompl
cystiti
systemat
review
metaanalysi
object
acut
uncompl
cystiti
auc
one
common
bacteri
infect
adult
oral
fluoroquinolon
fosfomycin
antimicrobi
often
recommend
auc
second
firstlin
therapi
aim
studi
compar
efficaci
safeti
quinolon
vs
fosfomycin
auc
method
system
review
sr
metaanalysi
random
control
trial
rct
perform
search
via
cochran
regist
control
trial
issu
medlin
septemb
embas
septemb
refer
list
articl
abstract
confer
proceed
without
languag
restrict
carri
rct
compar
shortcours
sc
fluoroquinolon
day
singl
dose
sd
fosfomycin
patient
auc
select
result
rct
boerema
de
jong
evalu
includ
fosfomycin
sd
compar
norfloxacin
two
studi
ciprofloxacin
one
studi
day
pull
analysi
three
studi
perform
tab
clinic
well
microbiolog
efficaci
fluoroquinolon
sc
signific
higher
fosfomycin
sd
odd
ratio
erad
rate
end
therapi
sustain
microbiolog
respons
day
end
therapi
reinfect
rate
document
infect
unexplain
fever
daili
dose
rang
mg
imp
mg
cef
tdm
perform
day
median
rang
treatment
initi
cmin
rang
imp
mgl
cef
assess
appropri
blood
level
shown
tabl
intervent
patient
l
imp
level
rang
mgl
prolong
perfus
time
n
increas
daili
dose
n
repetit
tdm
n
chang
antibiot
n
patient
h
cef
level
rang
mgl
impair
renal
function
creatinin
clearanc
mlmin
prevent
toxic
daili
dose
decreas
n
antibiot
chang
n
data
n
conclus
interindividu
variabl
imp
cef
blood
level
larg
low
high
drug
level
observ
high
proport
patient
suggest
tdm
may
help
ensur
dose
antibiot
therapi
appropri
prospect
studi
need
confirm
clinic
util
tdm
integr
analysi
efficaci
faropenem
medoxomil
treatment
uncompl
skin
skin
structur
infect
faropenem
medoxomil
fm
oral
penem
potent
activ
pyogen
methicillinsuscept
aureu
integr
analysi
conduct
describ
efficaci
fm
base
noninferior
design
random
clinic
trial
rct
method
noninferior
defin
lower
limit
ci
day
mg
bid
fm
compar
day
either
amoxicillinclavulan
ac
cephalexin
c
object
cephalosporin
activ
gramneg
anaerob
bacteria
nevertheless
wide
use
consid
clinic
effect
prophylaxi
obstetr
gynecolog
surgeri
perform
prospect
random
studi
compar
use
cefuroxim
vs
ampicillinsulbactam
due
activ
gram
neg
anaerob
bacteria
singl
dose
prophylaxi
obstetr
gynecolog
oper
patient
come
safe
conclus
nevertheless
worth
mention
postop
surgic
site
infect
due
gramneg
anaerob
bacteria
observ
patient
receiv
cefuroxim
prophylaxi
efficaci
safeti
cefepim
systemat
review
metaanalysi
object
assess
safeti
efficaci
cefepim
fourth
gener
cephalosporin
wide
recommend
sever
indic
method
systemat
review
metaanalysi
random
control
trial
trial
compar
cefepim
anoth
blactam
antibiot
alon
addit
nonblactam
antibiot
studi
arm
includ
enlist
specif
advers
event
report
reveal
specif
advers
event
potenti
respons
increas
mortal
conclus
studi
show
signific
increas
allcaus
mortal
among
patient
treat
cefepim
random
trial
despit
broader
vitro
spectrum
coverag
compar
assess
trial
claim
reduc
resist
induct
advantag
cefepim
observ
regard
clinic
microbiolog
failur
bacteri
superinfect
use
cefepim
reconsid
object
investig
clinic
patholog
molecular
aspect
fatal
case
influenzaassoci
encephalopathi
iae
netherland
method
two
fatal
case
iae
occur
analys
clinic
detail
review
medic
record
patholog
molecular
analysi
postmortem
fresh
paraffinembed
tissu
one
case
hospit
databas
search
medlin
literatur
search
perform
document
fatal
case
hospit
netherland
respect
result
two
unrel
nativ
dutch
patient
male
adolesc
girl
admit
hospit
shock
coma
sign
profus
bleed
gastrointestin
respiratori
tract
patient
short
prodrom
ill
consist
flulik
symptom
vomit
increas
drowsi
influenza
viru
cultur
respiratori
tract
patient
girl
respiratori
symptom
physic
examin
infiltr
chest
radiograph
neuroimag
normal
patient
patient
die
within
hour
admiss
follow
rapidli
progress
multiorgan
failur
mof
dissemin
intravascular
coagul
shock
postmortem
analysi
lung
male
reveal
extens
haemorrhag
bronchiti
earli
diffus
alveolar
damag
bronchial
epitheli
cell
posit
influenza
viru
immunohistochemistri
patholog
chang
immunohistochem
posit
cell
observ
organ
influenza
rna
detect
multipl
organ
includ
brain
blood
specimen
addit
fatal
case
uncov
hospit
knowledg
fatal
case
iae
document
netherland
asian
influenza
pandem
case
report
conclus
fatal
iae
extrem
rare
except
among
japanes
children
death
year
case
commonli
preced
rapidli
progress
coma
mof
sever
thrombocytopenia
similar
present
describ
two
previous
healthi
unvaccin
dutch
children
warrant
monitor
sever
influenza
determin
true
incid
fatal
iae
influenza
rna
detect
multipl
organ
brain
one
patient
suggest
causal
relationship
viral
dissemin
sever
neurolog
system
diseas
object
rapid
diagnosi
influenza
hospit
patient
import
prevent
transmiss
infect
hospit
prospect
studi
design
determin
relationship
clinic
diagnosi
influenza
made
physician
admiss
presenc
influenza
viru
patient
respiratori
tract
infect
studi
conduct
larg
dutch
teach
hospit
influenza
season
period
three
week
patient
year
older
admit
respiratori
tract
infect
includ
studi
clinic
laboratori
paramet
chest
radiograph
blood
sputum
cultur
nasopharyng
swab
polymeras
chain
reaction
pcr
obtain
patient
addit
physician
opinion
admiss
whether
patient
influenza
record
result
total
patient
hospit
respiratori
tract
infect
influenza
viru
detect
pcr
among
patient
pcr
proven
presenc
influenza
viru
clinic
diagnosi
made
case
fals
posit
case
ie
clinic
diagnosi
influenza
viru
detect
observ
neither
creactiv
protein
leucocyt
infiltr
chest
radiograph
could
discrimin
viral
bacteri
infect
respiratori
tract
discuss
present
find
fail
demonstr
signific
relationship
clinic
diagnosi
influenza
pcr
detect
viru
specif
viru
present
least
twice
often
influenza
clinic
diagnos
consequ
decis
take
protect
measur
control
spread
viru
reli
clinic
diagnosi
object
despit
vaccin
flu
epidem
nurs
home
happen
occasion
occur
summer
time
rare
event
describ
influenza
outbreak
assess
prophylact
measur
situat
descript
epidem
outbreak
start
june
last
day
juli
nurs
home
resid
r
mean
age
year
health
care
worker
hcw
fever
cough
wheez
report
main
symptom
among
r
hcw
duti
mention
period
day
one
patient
hospit
knowledg
sever
similar
case
clinic
featur
short
incub
fever
wheez
cough
normal
pulmonari
xray
gave
ground
perform
rapid
diagnosi
test
influenza
rhinopharyng
sampl
rp
despit
season
result
turn
posit
day
symptomat
resid
rp
rapid
diagnost
test
perform
time
posit
collabor
department
medic
author
staff
nurs
home
isol
patient
plu
wear
surgic
mask
hcw
visitor
ambulatori
resid
decid
oseltamivir
prescrib
start
patient
hcw
symptomat
hour
receiv
oseltamivir
mg
bid
day
prophylact
treatment
mg
od
day
given
resid
well
remain
hcw
epidem
stop
hour
later
viral
strain
similar
winter
epidem
strain
season
case
fatal
rate
receiv
former
one
dose
later
day
end
treatment
due
myocardi
infect
other
symptom
hour
receiv
flu
vaccin
coverag
resid
midsumm
heat
alert
resid
stay
singl
aircondit
room
explain
high
rapid
attack
rate
conclus
rapid
diagnosi
test
clue
rapidli
interven
nurs
home
confirm
flu
epidem
soon
outbreak
recogn
crisi
cell
put
place
appli
measur
control
epidem
describ
nation
instruct
particularli
prescript
rapid
control
respons
found
quit
effect
effect
statin
therapi
risk
seriou
outcom
influenza
epidem
method
effect
statin
assess
patient
age
year
older
univers
medic
center
utrecht
primari
care
network
follow
four
epidem
nonepidem
influenza
season
primari
endpoint
composit
communityacquir
pneumonia
prednisolonetr
acut
respiratori
diseas
myocardi
infarct
stroke
death
caus
control
quantifi
confound
obtain
estim
reduct
outcom
control
event
dermatomycosi
irrit
bowel
syndrom
associ
statin
therapi
adjust
demograph
health
characterist
result
studi
person
provid
personsperiod
statin
therapi
use
personperiod
primari
endpoint
occur
event
respiratori
influenza
epidem
statin
therapi
associ
reduct
primari
endpoint
rel
risk
rr
confid
interv
ci
p
reduct
respiratori
diseas
rr
ci
p
reduct
allcaus
mortal
rr
ci
p
find
consist
across
subgroup
accord
age
cardiovascular
diseas
exposur
influenza
vaccin
nonepidem
influenza
season
signific
reduct
primari
endpoint
observ
statin
therapi
associ
reduct
control
event
rate
n
either
season
conclus
statin
therapi
associ
substanti
reduct
risk
seriou
mainli
respiratori
outcom
influenza
epidem
find
direct
futur
studi
potenti
implic
pandem
n
oropeza
b
acosta
c
aragon
b
galindo
havana
cu
influenza
highli
contagi
acut
respiratori
diseas
global
import
vaccin
inactiv
influenza
viru
current
effect
measur
reduc
impact
diseas
prevent
complic
mortal
person
risk
object
determin
antibodi
respons
vacun
strain
identifi
antibodi
protector
level
one
strain
detect
seroconvert
protect
level
studi
popul
identifi
differ
respons
differ
highrisk
group
method
evalu
humor
immun
respons
influenza
vaccin
highrisk
group
conduct
prospect
longitudin
descript
studi
haemagglutin
inhibit
test
use
determin
antibodi
level
three
strain
includ
vaccin
result
conclus
studi
popul
antibodi
vaccin
strain
vaccin
circul
similar
strain
season
concord
intern
report
prevaccin
gmt
agre
result
detect
high
percent
protect
three
strain
respons
vaccin
gmt
increas
valu
higher
three
group
includ
studi
asthmat
diabet
hypersthen
good
respons
vaccin
diabet
better
respond
two
group
protect
two
strain
vaccin
b
object
cirrhosi
major
chronic
diseas
mani
asian
countri
estim
preval
cirrhosi
case
korea
around
case
constitut
among
major
chronic
diseas
korea
though
includ
cirrhot
patient
among
influenza
vaccinetarget
group
consid
one
prioriti
group
korea
howev
avail
data
impact
influenza
liver
cirrhosi
extrem
limit
therefor
decid
evalu
efficaci
influenza
vaccin
chronic
liver
diseas
intend
studi
clinic
outcom
influenza
patient
liver
cirrhosi
method
two
hundr
sixtyf
patient
liver
cirrhosi
octob
persuad
vaccin
influenza
among
patient
vaccin
trival
influenza
vaccin
other
vaccin
vaccin
unvaccin
group
observ
may
self
report
system
oper
influenzalik
ill
ili
suspect
patient
diagnost
test
perform
rapid
diagnosi
kit
quick
view
tm
viral
cultur
compar
incid
ili
posit
rate
diagnost
test
vaccin
nonvaccin
group
result
demograph
data
indistinguish
vaccin
unvaccin
group
howev
proport
patient
sever
hepat
dysfunct
somewhat
larger
vaccin
group
compar
unvaccin
childpugh
b
c
vaccine
vs
nonvaccine
overal
incid
ili
p
cultur
confirm
influenza
p
significantli
higher
unvaccin
group
vaccin
group
patient
influenza
complain
febril
sens
myalgia
typic
manifest
cough
sore
throat
frequent
note
patient
influenza
accompani
aggrav
underli
hepat
dysfunct
hepat
encephalopathi
uncontrol
ascit
oliguria
one
influenza
patient
complic
secondari
bacteri
pneumonia
conclus
influenza
vaccin
cirrhot
patient
effect
prevent
diseas
occurr
influenza
cirrhot
patient
show
atyp
clinic
present
caus
aggrav
underli
hepat
dysfunct
though
direct
caus
mortal
clinic
effect
influenza
vaccin
adult
diabet
mellitu
looijmansvan
den
akker
verheij
e
busken
g
rutten
e
hak
utrecht
nl
object
evid
conflict
regard
potenti
benefit
influenza
vaccin
patient
diabet
part
prisma
studi
hak
e
et
al
arch
intern
med
assess
clinic
effect
influenza
vaccin
adult
diabet
specif
examin
potenti
modif
effect
age
prior
influenza
vaccin
method
conduct
casecontrol
studi
nest
larg
cohort
patient
recommend
influenza
vaccin
influenza
epidem
n
select
case
control
diagnosi
diabet
origin
studi
popul
n
vaccin
statu
record
gener
practition
primari
endpoint
composit
allcaus
mortal
hospit
diabet
event
acut
respiratori
cardiovascular
diseas
epidem
separ
compon
secondari
endpoint
evalu
effect
vaccin
influenc
prior
vaccin
mean
logist
regress
analysi
control
age
gender
health
insur
coverag
prior
health
care
use
medic
use
comorbid
condit
result
observ
hospit
death
combin
endpoint
reduc
confid
interv
hospit
ci
death
ci
among
person
diabet
age
year
observ
somewhat
higher
reduct
primari
endpoint
elderli
person
diabet
year
age
versu
vaccin
first
time
primari
endpoint
reduc
ci
receiv
prior
vaccin
reduct
ci
conclus
adult
diabet
alik
recommend
risk
group
healthi
elderli
person
patient
cardiovascular
pulmonari
diseas
benefit
consider
influenza
vaccin
differ
vaccin
effect
observ
first
time
repeat
vaccin
immunogen
baculovirusexpress
trival
influenza
ha
vaccin
randomis
doubleblind
doseescal
singl
institut
studi
adult
patient
bcell
lymphoma
background
immunogen
respons
convent
influenza
vaccin
markedli
impair
patient
hematolog
malign
sought
evalu
possibl
benefici
effect
increas
vaccin
dose
specif
neutral
immunoglobulin
respons
among
patient
nonhodgkin
lymphoma
method
prospect
studi
perform
later
half
sponsor
nation
institut
health
nih
random
undertaken
independ
nih
design
agenc
preand
week
postvaccin
antibodi
titer
measur
code
bcm
test
virus
neutral
assay
antigen
similar
viru
use
influenza
test
anew
bhong
result
pleas
refer
tabl
attachedal
patient
visit
outpati
lymphoma
clinic
screen
receiv
antineoplast
therapi
within
month
andor
rituximab
past
month
consid
studi
splenctom
patient
receiv
system
corticosteroid
includ
serou
advers
reaction
note
enrolle
month
postvaccin
follow
among
influenza
higher
dose
associ
increas
strainspecif
protect
neutral
antibodi
titer
wherea
benefici
effect
seen
patient
receiv
higher
dose
influenza
b
vaccin
conclus
recombin
baculovirusexpress
influenza
vaccin
safe
compromis
patient
nonhodgkin
bcell
lymphoma
preliminari
result
indic
potenti
immunogen
benefit
associ
influenza
recombin
vaccin
doseescal
rapid
method
identif
bacteri
clone
pathogen
object
previous
identifi
genotyp
distinct
subset
epidem
enterococcu
faecium
efm
design
use
multilocu
sequenc
type
mlst
investig
whether
whole
genom
microarray
approach
would
type
strain
similarli
epidem
specif
marker
could
identifi
method
shotgun
librari
construct
efm
strain
kb
dna
fragment
spot
slide
label
dna
mlst
type
efm
isol
differ
sourc
outbreak
infect
survey
anim
contin
vancomycin
resist
suscept
hybrid
array
togeth
label
dna
librari
strain
spot
met
qualiti
criteria
includ
normal
epp
data
transform
kim
et
al
transvers
hierarch
cluster
hc
perform
base
strain
spot
insert
insert
differenti
identifi
visual
data
matrix
pcr
amplifi
sequenc
sequenc
blast
genebank
ncbi
result
hc
result
differ
cluster
small
cluster
strain
resembl
mlst
genogroup
four
cluster
consist
mainli
strain
includ
two
epidem
strain
approxim
insert
conserv
insert
associ
epidem
cluster
select
sequenc
reveal
differenti
insert
gene
fragment
encod
potenti
virul
factor
resist
determin
transposon
element
protein
involv
replic
regul
well
hypothet
protein
hit
show
signific
homolog
conclus
compar
genom
efm
base
mix
whole
genom
microarray
discern
epidem
mlst
subpopul
analysi
insert
identifi
differenti
includ
regulatori
potenti
virul
gene
technolog
may
provid
new
target
diagnost
develop
select
drug
hospitaladapt
efm
genet
relationship
streptococcu
pneumonia
isol
respons
case
mening
asymptomat
carriag
children
attend
daycar
centr
lisbon
object
colonis
nasopharyngx
streptococcu
pneumonia
although
asymptomat
prerequisit
develop
clinic
infect
howev
underli
mechan
turn
benign
state
colon
clinic
diseas
poorli
understood
thu
order
understand
molecular
mechan
defin
virul
pneumonia
clear
pictur
genet
relationship
invas
carri
pneumococci
need
method
characteris
pneumococc
strain
recov
blood
cerebrospin
fluid
csf
child
mening
nasopharyng
isol
asymptomat
carrier
attend
room
day
care
centr
dcc
use
antimicrobi
suscept
profil
serotyp
pfge
mlst
also
investig
presenc
lysogen
phage
sinc
shown
associ
virul
determin
streptococci
result
strain
recov
sick
child
seven
carriag
isol
fulli
suscept
express
serotyp
belong
new
clone
pfge
mlst
howev
band
differ
pfge
pattern
isol
csf
carriag
vivo
loss
lysogen
phage
csf
isol
account
differ
suggest
involv
phage
transit
colon
diseas
howev
local
attb
intergen
region
put
function
adjac
gene
support
hypothesi
remain
isol
recov
asymptomat
carrier
belong
clone
includ
intern
clone
previous
found
associ
invas
diseas
eg
conclus
pneumococc
clone
simultan
respons
carriag
invas
diseas
differ
host
vivo
loss
lysogen
prophag
isol
recov
blood
one
csf
suggest
involv
bacteriophag
transit
local
attb
site
intergen
region
suggest
function
adjac
gene
support
hypothesi
object
bacteri
vaginosi
bv
illdefin
disord
vagin
microflora
associ
impair
health
condit
women
possibl
fetus
newborn
cultiv
limit
valu
diagnosi
bv
current
base
microscop
techniqu
eg
nugent
gram
stain
criteria
molecular
identif
method
suppos
provid
detail
insight
bacteri
composit
disturb
vagin
flora
howev
techniqu
describ
far
sequenc
rdna
clone
librari
timeconsum
suitabl
routin
purpos
therefor
adapt
cultureindepend
method
bacteri
commun
analysi
call
termin
restrict
fragment
length
polymorph
trflp
need
routin
microbiolog
laboratori
method
vagin
swab
collect
patient
bv
control
healthi
subject
diseas
statu
assess
use
nugent
criteria
analys
bacteri
commun
directli
swab
specimen
mean
trflp
method
trflp
analysi
base
restrict
endonucleas
digest
fluoresc
endlabel
pcr
amplif
deriv
rrna
gene
identif
bacteria
trflp
raw
data
develop
inhous
comput
softwar
result
use
trflp
analysi
vagin
microflora
could
accomplish
within
hour
bv
sampl
found
averag
typic
fingerprint
correspond
definit
bacteri
speci
atopobium
vagina
bv
sampl
gardnerella
vaginali
prove
predomin
speci
follow
lactobacillu
iner
prevotella
sp
peptoniphilu
sp
least
differ
far
uncharacter
bacteria
clostridial
order
could
regularli
detect
one
presum
megasphaera
sp
frequenc
healthi
control
lactobacilli
detect
conclus
molecular
tool
current
favour
analysi
vagin
microflora
tool
trflp
prove
promis
rapid
detail
analysi
bacteri
commun
inhabit
vagina
techniqu
may
especi
help
context
clinic
studi
collect
reliabl
extens
microbiolog
data
may
crucial
interpret
studi
result
develop
valid
realtim
pcr
assay
multicentr
studi
assess
preval
epidemiolog
shigatoxin
produc
escherichia
coli
netherland
object
tradit
laboratori
surveil
shigatoxin
produc
escherichia
coli
stec
focus
detect
e
coli
stool
cultur
sorbitolmacconkey
agar
smac
infect
e
coli
rang
mild
selflimit
diarrhea
hemorrhag
coliti
hemolyticurem
syndrom
hu
recent
strain
increasingli
associ
diarrhea
hu
sever
european
countri
therefor
nationwid
screen
program
take
place
netherland
novemb
novemb
screen
realtim
pcrbase
rtpcr
subsequ
stec
isol
posit
stool
prior
start
program
rtpcr
assay
develop
valid
method
assay
target
gene
develop
lightcycl
lc
taqman
tm
lc
assay
describ
bellin
et
al
j
clin
microbiol
tm
assay
adapt
jinneman
et
al
appl
environ
microbiol
wherea
assay
new
design
stool
process
minimag
stool
protocol
phocin
herp
use
intern
control
ic
assay
valid
panel
well
character
e
coli
strain
n
none
coli
strain
n
intra
interassay
variat
analyt
sensit
assess
dilut
seri
n
spike
faecal
matric
analys
day
daili
subsequ
day
result
assay
prove
specif
gene
crossreact
observ
tm
assay
capabl
detect
approxim
cfug
stool
hit
rate
semisolid
liquid
stool
lower
hit
rate
observ
approxim
cfug
lc
assay
prove
log
less
sensit
hit
rate
compar
tm
assay
semisolid
stool
furthermor
lc
assay
detect
approxim
cfug
coeffici
variat
cv
tm
lc
assay
conclus
tm
lc
assay
prove
reproduc
although
sensit
equal
lower
sensit
lc
assay
compar
tm
howev
still
line
publish
fecal
rtpcr
assay
probabl
detriment
screen
sinc
still
log
sensit
compar
report
sensit
smac
screen
rtpcr
assay
current
use
dutch
stec
screen
program
base
upon
repeat
pattern
variabl
number
tandem
repeat
pattern
analysi
infer
clonal
group
staphylococcu
aureu
strain
spa
type
data
object
molecular
type
staphylococcu
aureu
particular
mrsa
dna
sequenc
polymorph
x
region
protein
spa
gene
well
establish
highli
discriminatori
method
spa
region
consist
variabl
number
bp
long
repeat
vari
composit
result
differ
spa
type
hypothes
region
reflect
shortbut
also
longterm
epidemiolog
due
two
differ
mechan
evolut
ie
repeatduplicationdelet
point
mutat
howev
today
algorithm
exist
infer
clonal
related
differ
spa
type
therefor
base
upon
repeat
pattern
burp
algorithm
develop
evalu
studi
method
evalu
burp
aureu
strain
previous
character
whole
genom
microarray
spa
multi
locu
enzym
electrophoresi
mlee
pulsedfield
gel
electrophoresi
pfge
coagulas
coa
gene
type
use
koreen
et
al
j
clin
microbiol
burp
cluster
spacc
strain
determin
use
ridom
staphtyp
version
ridom
gmbh
rzburg
germani
softwar
algorithm
take
repeatduplicationdelet
point
mutat
event
account
calcul
related
differ
spa
type
spa
type
shorter
repeat
exclud
analysi
reliabl
evolutionari
signal
could
extract
subsequ
spacc
compar
cluster
variou
type
method
use
concord
analysi
result
maximum
achiev
concord
variou
paramet
exclud
spa
type
shorter
x
cluster
spa
type
spacc
cost
distanc
less
burp
spacc
method
wholegenom
microarray
lineag
pearson
correl
coeffici
mlee
lineag
mlee
type
pfge
type
coa
lineag
coa
type
short
spa
type
exclud
analysi
maximum
concord
spacc
manual
koreen
et
al
group
spa
lineag
obtain
conclus
burp
abl
extract
automat
evolutionari
signal
spa
repeat
pattern
rather
congruent
signal
found
type
approach
therefor
use
singl
variabl
number
tandem
repeat
sequenc
aureu
first
time
meaning
cluster
could
realiz
multipl
locu
variabl
number
tandem
repeat
assay
differenti
communityassoci
healthcareassoci
lineag
methicillinresist
staphylococcu
aureu
object
abil
type
methicillinresist
staphylococcu
aureu
mrsa
strain
rapidli
clinic
laboratori
differenti
multiresist
healthcareassoci
ha
mrsa
strain
suscept
virul
communityassoci
ca
mrsa
strain
could
improv
public
health
infect
control
effort
reduc
mrsa
spread
hospit
commun
guid
empir
therapi
publish
report
suggest
multipl
locu
variabl
number
tandem
repeat
assay
mlva
aureu
parallel
result
pulsedfield
gel
electrophoresi
pfge
object
determin
simpl
mlva
protocol
suitabl
clinic
laboratori
could
differenti
known
haand
camrsa
type
replac
tediou
costli
pfge
type
method
eighti
wellcharacter
isol
repres
major
lineag
aureu
us
select
strain
collect
center
diseas
control
prevent
cdc
project
icar
mlva
perform
use
rapid
dna
extract
method
multiplex
polymeras
chain
reaction
assay
primer
sdrcde
clfa
clfb
sspa
spa
gener
band
follow
agaros
gel
electrophoresi
pfge
perform
use
smai
per
cdc
protocol
band
pattern
analys
visual
would
done
clinic
laboratori
use
bionumer
softwar
bionumer
dice
coeffici
use
upgma
cluster
algorithm
gener
dendrogram
result
isol
typeabl
mlva
appear
initi
differenti
among
pfge
lineag
howev
addit
isol
type
mlva
result
place
isol
pfge
type
commonli
isol
camrsa
us
sever
unrel
cluster
similar
mlva
pattern
isol
also
cluster
pattern
isol
mlva
consist
differenti
camrsa
lineag
hamrsa
lineag
conclus
although
mlva
feasibl
clinic
laboratori
use
result
parallel
pfge
major
lineag
camrsa
hamrsa
us
mlva
may
use
rapid
analysi
isol
potenti
outbreak
replac
pfge
sinc
strain
cluster
differ
epidemiolog
clinic
util
differ
mlva
pfge
result
requir
studi
object
portugues
health
author
report
tuberculosi
tb
incid
popul
nationwid
tuberculosi
case
multidrug
resist
mdrtb
despit
signific
declin
tb
incid
past
decad
portug
remain
countri
highest
rate
notifi
case
due
mycobacterium
tuberculosi
central
eastern
eu
correspond
incid
three
half
time
eu
averag
lisbon
portugues
district
highest
incid
case
per
inhabit
compar
standard
method
restrict
fragment
length
polymorph
rflp
type
method
base
mycobacteri
interspers
repetit
unit
variablenumb
tandem
repeat
miruvntr
analysi
offer
altern
accur
method
identifi
epidemiolog
link
patient
tuberculosi
aim
present
studi
determin
genet
divers
tuberculosi
strain
circul
lisbon
evalu
possibl
continu
preval
previou
detect
famili
lisboa
strain
evalu
proport
recent
transmit
diseas
patient
method
fourhundr
clinic
tuberculosi
isol
collect
sever
hospit
public
health
laboratori
lisbon
area
characteris
molecular
level
use
miruvntr
type
includ
mdrtb
strain
resist
strain
mdrtb
result
among
tuberculosi
isol
lisbon
found
differ
miruvntr
pattern
fiftythre
miruvntr
cluster
found
analys
strain
rang
size
two
patient
largest
cluster
cluster
lisboa
includ
mdrtb
strain
found
anoth
three
signific
cluster
isol
first
one
cluster
lisboa
also
major
mdrtb
conclus
famili
lisboa
strain
still
respons
main
tuberculosi
lisbon
area
particularli
mdrtb
case
although
epidemiolog
investig
still
go
abl
establish
epidemiolog
relationship
cluster
patient
carri
famili
lisboa
strain
find
support
conclus
case
result
recent
transmiss
nevertheless
detect
signific
outbreak
cluster
strain
mostli
collect
sever
hospit
unit
clinic
impact
rapid
pcrbase
identif
staphylococci
directli
posit
blood
cultur
p
agmon
oren
r
finkelstein
h
sprecher
haifa
il
object
staphylococc
bacteremia
common
among
hospit
patient
associ
signific
morbid
mortal
staphylococci
major
gram
posit
isol
blood
cultur
medic
center
caus
coagulas
neg
staphylococci
con
isol
con
unlik
bacteremia
coagulas
posit
staphylococci
cop
often
result
contamin
blood
cultur
rapid
accur
identif
cop
vs
con
determin
suscept
methicillin
crucial
institut
time
appropri
therapi
howev
standard
identif
suscept
test
requir
averag
three
day
aim
present
studi
evalu
rapid
method
identif
staphylococci
directli
blood
cultur
use
multiplex
pcr
assay
method
threemonth
prospect
surveil
patient
staphylococc
bacteremia
conduct
standard
microbiolog
approach
pcrbase
assay
compar
studi
dna
extract
posit
blood
cultur
bottl
use
benzyl
alcoholguanidin
hydrochlorid
method
four
set
oligonucleotid
primer
use
univers
bacteri
rrna
staphylococc
specif
sequenc
rrna
gene
cop
specif
nuc
gene
meca
gene
encod
resist
methicillin
result
studi
staphylococci
isol
patient
con
isol
patient
cop
methicillinresist
staphylococcu
aureu
mrsa
sensit
pcr
assay
compar
convent
microbiolog
test
pcr
assay
shorten
turnaround
time
identif
suscept
result
hour
translat
practic
term
one
calendar
day
cost
pcr
assay
found
lower
cost
convent
approach
applic
pcr
assay
found
prevent
unnecessari
therapi
patient
con
isol
p
correctli
direct
treatment
choic
cop
p
conclus
pcrbase
detect
staphylococci
directli
blood
cultur
bottl
rapid
h
highli
sensit
implement
assay
shown
significantli
improv
qualiti
patient
manag
consid
result
recommend
applic
molecular
assay
standard
assay
identif
staphylococc
bacteremia
method
purpos
studi
evalu
idimrsa
tm
prototyp
mrsasa
assay
geneohm
scienc
inc
san
diego
ca
direct
detect
mrsa
methicillinsensit
sa
mssa
posit
blood
cultur
use
realtim
pcr
technolog
idimrsa
assay
provid
posit
result
mrsa
present
sampl
mrsasa
combin
target
specif
mrsa
sccmecorfx
junction
saspecif
target
provid
separ
result
mrsa
mssa
thu
allow
direct
detect
mrsa
mssa
assay
also
includ
intern
control
aliquot
posit
blood
cultur
directli
process
idi
lysi
compon
test
assay
use
cepheid
instrument
result
blood
cultur
test
date
known
posit
mrsa
posit
pathogen
mrsa
includ
coagulas
neg
staphylococci
mssa
known
neg
blood
cultur
idimrsa
tm
mrsasa
assay
show
complet
agreement
convent
identif
suscept
result
idimrsa
tm
prototyp
mrsasa
assay
excel
altern
detect
mrsa
mssa
combin
assay
directli
posit
blood
cultur
assay
rapid
hour
posit
blood
cultur
accur
sensit
specif
flexibl
singl
sampl
batch
test
adapt
easili
exist
laboratori
workflow
pro
con
combin
antimicrobi
treatment
combin
therapi
communityacquir
pneumonia
sever
communityacquir
pneumonia
scap
refer
patient
communityacquir
pneumonia
admit
intens
care
unit
frequenc
scap
rang
indic
lack
uniform
use
criteria
icu
admissionth
definit
scap
matter
interest
accur
criteria
describ
ewig
et
al
presenc
one
two
major
criteria
mechan
ventil
septic
shock
two
three
minor
criteria
systol
blood
pressur
multilobar
involv
ratio
result
sensit
specif
criteria
compar
favour
score
psi
bt
rule
summari
probabl
best
rule
patient
cap
benefit
icu
admiss
mortal
scap
rang
prognost
factor
associ
death
cap
divid
basic
admiss
baselin
admiss
diseas
progress
factor
import
potenti
reduc
treatment
failur
mortal
inadequaci
antimicrobi
therapi
delay
appropri
therapi
two
studi
show
increas
mortal
antibiot
treatment
start
hour
emerg
depart
arriv
respect
adequaci
initi
antimicrobi
treatment
refer
right
antimicrobi
coverag
includ
resist
causal
microorgan
use
correct
dosag
case
etiolog
scap
unknown
expert
given
recommend
empir
treatment
base
case
definit
microbi
etiolog
foundmicrobi
etiolog
scap
differ
accord
age
presenc
pulmonari
commorbid
hiv
geograph
season
variabl
differ
taken
account
presenc
atyp
microorgan
legionella
virus
resist
antibiot
factor
consid
prescrib
initi
antibiot
scap
nursinghom
patient
treat
nosocomi
pneumonia
recent
recommend
guidelin
recent
publish
recommend
antibiot
combin
empir
treatment
scap
betalactam
plu
macrolid
mainli
clarithromycin
azithromycin
respiratori
quinolon
mainli
levofloxacin
moxifloxacin
two
option
pseudomona
isa
consider
betalactam
antipseudomon
activ
plu
ciprofloxacin
best
therapeut
option
find
suggest
respiratori
quinolon
could
better
option
macrolid
use
combin
therapi
moxifloxacin
slightli
better
clinic
efficaci
compar
combin
third
gener
cephalosporin
plu
minu
macrolid
one
studi
larg
seri
hospit
cap
treatment
failur
investig
respiratori
quinolon
prove
protect
none
guidelin
mention
recommend
monotherapi
initi
treatment
scap
one
main
reason
avoid
monotherapi
lack
extens
experi
scap
anoth
reason
bodi
evid
suggest
combin
antibiot
may
improv
mortal
bacterem
pneumococc
pneumonia
two
retrospect
studi
found
combin
least
two
antibiot
show
better
outcom
compar
monotherapi
find
difficult
explain
could
due
potenti
hidden
presenc
atyp
pneumonia
legionella
associ
streptococcu
pneumonia
secondli
antiinflammatori
effect
type
antibiot
macrolid
potenti
pitfal
two
studi
lack
control
confound
retrospect
design
recent
observ
prospect
multin
studi
baddour
et
al
prove
benefici
effect
combin
therapi
compar
monotherapi
bacterem
pneumococc
pneumonia
septic
shock
present
open
random
clinic
trial
compar
levofloxacin
monotherapi
combin
cefotaxim
plu
ofloxacin
publish
studi
clinic
success
similar
two
arm
bacteriolog
respons
also
similar
group
importantli
patient
septic
shock
prior
inclus
exclud
patient
treatment
failur
could
includ
unless
one
antibiot
studi
previous
given
conclus
author
levofloxacin
least
effect
combin
scap
unless
patient
requir
vasopressor
mechan
ventil
howev
antibiot
combin
chosen
author
probabl
best
current
treat
scap
consequ
say
monotherapi
levofloxacin
effect
standard
recommend
combin
hand
patient
septic
shock
exclud
septic
shock
may
present
patient
scap
third
specif
criteria
sever
prospect
use
fact
inclus
criteria
trial
icu
admiss
criteria
subject
depend
icu
hospit
avail
necess
new
trial
use
specif
criteria
scap
describ
literatur
ensur
inclus
f
heterogen
popul
final
monotherapi
treat
group
failur
toc
visit
similar
rate
report
combin
howev
case
insuffici
respons
treatment
monotherapi
group
vs
combin
group
find
need
evalu
fogarti
et
al
investig
safeti
efficaci
levofloxacin
compar
ceftriaxon
plu
erythromycin
follow
amoxiclavulan
plu
clarythromycin
treatment
seriou
cap
adult
studi
term
seriou
equival
icuadmit
patient
overal
clinic
efficaci
similar
arm
close
key
issu
topic
whether
antibiot
monotherapi
use
confid
treatment
scap
imposs
answer
current
momentit
import
avoid
combin
small
sever
group
cap
patient
answer
use
combin
antibiot
scap
may
improv
treatment
failur
mortal
without
import
impact
resist
addit
cost
issu
consid
patient
opinion
continu
recommend
combin
antibiot
treat
scap
avoid
monotherapi
least
first
day
treatment
new
rc
trail
address
find
safeti
clinic
efficaci
deescal
therapi
determin
best
antibiot
combin
combin
antifung
dubio
agit
akova
ankara
tr
year
ago
combin
amphotericin
b
amb
shown
effect
amb
alon
treatment
cryptococc
mening
sinc
accumul
evid
use
antifung
combin
invas
fungal
infect
slow
initi
due
controversi
relat
vitro
antagon
azol
polyen
lesser
frequenc
invas
fungal
infect
treatabl
earli
azol
fluconazol
case
candidiasi
amphotericin
b
suffici
provid
coverag
mold
infect
howev
clinic
pictur
significantli
chang
last
two
decad
first
incid
invas
fungal
infect
sharpli
increas
epidemiolog
chang
secondli
newer
broaderspectrum
antifung
previous
nonexist
mechan
effect
becom
commerci
avail
dissemin
infect
caus
noncandid
yeast
aspergillu
spp
also
previous
rare
seen
nonaspergillu
mold
infect
emerg
signific
caus
morbid
mortal
among
immunosuppress
patient
sinc
infect
usual
difficulttotreat
relat
mortal
infect
patient
remain
high
especi
persist
immunosuppress
clinician
tempt
use
variou
newer
antifung
novel
mechan
action
combin
differ
clinic
set
especi
invas
aspergillosi
rational
behind
rekindl
interest
achiev
synergi
lesser
extend
reduc
antifung
resist
although
control
clinic
trial
compar
antifung
combin
monotherapi
far
evid
gather
small
seri
anectod
experi
clearli
indic
antifung
combin
therapi
becom
clinic
realiti
particularli
patient
sever
immunosuppress
dissemin
mould
infect
avail
data
mention
observ
also
point
combin
newli
approv
imidazol
eg
voriconazol
echinocandin
e
ubiqu
multidrug
mdr
pump
support
idea
origin
function
antibiot
resist
ar
fact
mdr
pump
find
p
aeruginosa
isol
clinic
nonclin
environ
shown
mdr
pump
besid
contribut
antibiot
resist
play
role
modul
bacteri
virul
p
aeruginosa
mdr
pump
contribut
intrins
acquir
ar
sinc
p
aeruginosa
mdr
pump
extrud
quorum
sens
qs
autoinduc
qs
respons
promin
role
p
aeruginosa
virul
mdr
pumpsoverexpress
multiresist
bacteria
might
less
virul
wildtyp
one
establish
p
aeruginosa
mutant
overproduc
mexaboprm
mexcdoprj
produc
less
amount
qsregul
virul
factor
reduc
virul
scenario
complex
overexpress
either
mexcdoprj
mexefoprn
reduc
p
aeruginosa
cytotox
challeng
type
iii
secret
via
qsindepend
way
mdr
bacteria
less
virul
wildtyp
one
select
infect
two
possibl
possibl
antibiot
treatment
resist
consid
colon
factor
antibiot
resist
might
make
bacteria
profici
produc
specif
type
infect
found
neither
mexaboprm
mexcdoprj
express
reduc
biofilm
format
p
aeruginosa
major
caus
chronic
infect
cystic
fibrosi
patient
biofilm
import
persist
infect
epidemiolog
data
shown
chronic
infect
p
aeruginosa
evolv
produc
less
amount
qsregul
virul
factor
tend
defect
maintain
biofilm
product
thu
virul
factor
requir
either
acut
chronic
infect
might
differ
sinc
overproduct
p
aeruginosa
mdr
pump
associ
phenotyp
chronic
infect
isol
mdr
pumpsoverproduc
p
aeruginosa
strain
might
impair
develop
acut
infect
mainten
chronic
escherichia
coli
common
microorgan
caus
urinari
tract
infect
uropathogen
e
coli
upec
strain
possess
sever
virul
determin
allow
colon
urinari
tract
avoid
host
defens
caus
damag
uroepithelium
biofilm
format
also
consid
virul
determin
quinoloneresist
e
coli
strain
fewer
virul
factor
quinolonesuscept
strain
sever
urovirul
gene
locat
pathogen
island
pai
investig
capac
quinolon
induc
loss
virul
factor
hemolysin
cytotox
necrot
pfimbria
autotransport
sat
includ
pai
three
uropathogen
ecoli
strain
well
relationship
quinoloneresist
acquisit
biofilm
format
three
quinolonesuscept
uropathogen
ecoli
clinic
isol
belong
phylotyp
chosen
multistep
select
three
strain
lost
hemolyt
capac
passag
incub
subinhibitori
concentr
ciprofloxacin
show
partial
total
loss
pai
contain
hli
hemolysin
cytotox
necrot
gene
recamut
obtain
two
e
coli
strain
partial
total
loss
pai
inactiv
reca
protein
affect
partial
loss
pai
induc
quinolon
spontan
loss
pai
observ
incub
absenc
quinolon
either
wildtyp
mutant
ecoli
strain
growth
biofilmproduc
e
coli
presenc
salycil
inhibit
product
biofilm
quinoloneresist
upec
mutant
obtain
biofilmproduc
upec
strain
resist
mutant
produc
biofilm
mutat
amino
acid
codon
gyra
gene
express
efflux
pump
complement
mutant
strain
wildtyp
gyra
revert
product
biofilm
suggest
mechan
quinolon
resist
rather
mutat
gyra
gene
could
involv
decreas
format
biofilm
fact
quinoloneresist
nonproduc
biofilm
upec
mutant
show
decreas
express
fima
papa
gene
conclus
quinolon
induc
partial
total
loss
pai
vitro
uropathogen
e
coli
so
depend
independ
pathway
respect
moroev
acquisit
quinolon
resist
may
decreas
product
biofilm
upec
efflux
pump
express
bacteri
surviv
neisseria
gonorrhoea
wm
shafer
atlanta
us
neisseria
gonorrhoea
strict
human
pathogen
caus
sexual
transmit
diseas
gonorrhea
million
case
gonorrhea
occur
year
worldwid
gonorrhea
remain
treatabl
antibiot
recommend
treatment
regimen
expens
compar
rel
cheap
cost
penicillin
previous
prior
drug
choic
efflux
pump
possess
n
gonorrhoea
contribut
develop
resist
certain
antibiot
penicillin
efflux
pump
express
bacteria
includ
n
gonorrhoea
long
antibiot
use
treat
bacteri
infect
bacteria
capabl
exist
outsid
host
extend
period
time
efflux
pump
like
provid
abil
resist
antimicrobi
soil
water
would
bacteria
typic
must
exist
within
anoth
live
system
possess
efflux
pump
answer
bacteria
must
rapid
mean
deal
hostderiv
antimicrobi
either
natur
present
surfac
becom
avail
bodili
fluid
perish
efflux
pump
abil
recogn
structur
divers
antimicrobi
serv
host
antibiot
frontlin
innat
immun
respons
specif
exampl
action
efflux
pump
recogn
export
antimicrobi
mtrcmtrdmtre
efflux
pump
n
gonorrhoea
recogn
antibiot
macrolid
certain
betalactam
host
antimicrobi
antibacteri
peptid
produc
phagocyt
epitheli
cell
pump
shown
essenti
gonococc
surviv
vagin
mucos
surfac
experiment
murin
infect
model
express
gene
encod
efflux
pump
regul
transcript
level
repressor
activ
n
gonorrhoea
dnabind
protein
also
regul
bacteri
gene
involv
virul
bacteri
physiolog
thu
like
efflux
pump
integr
overal
process
bacteri
surviv
object
rapid
correct
identif
suscept
test
bacteria
valuabl
good
patient
care
rapid
identif
suscept
result
shown
costeffect
reduc
mortal
unit
state
studi
examin
whether
acceler
bacteri
diagnost
costeffect
result
signific
differ
mortal
dutch
set
method
inpati
erasmu
mc
rotterdam
netherland
randomli
assign
either
intervent
arm
control
arm
posit
cultur
normal
steril
bodi
fluid
exclud
urin
sampl
intervent
use
fast
autom
method
bacteri
identif
antimicrobi
suscept
test
vitek
system
marcyl
toil
franc
combin
direct
inocul
blood
cultur
control
arm
standard
method
use
vitek
marcyl
toil
franc
system
inocul
subcultur
plate
patient
prospect
follow
week
inclus
mortal
data
cost
health
care
total
cost
hospit
calcul
take
true
cost
possibl
otherwis
charg
use
defin
nation
health
tariff
author
ctg
result
patient
includ
random
intervent
arm
control
arm
arm
patient
includ
base
posit
blood
cultur
result
remain
includ
base
posit
cultur
bodi
fluid
cultur
contain
gramneg
rod
case
coagulaseneg
staphylococci
saureu
organ
differ
time
two
arm
random
result
laboratori
avail
averag
hour
suscept
result
averag
hour
identif
p
treatmentcost
patient
intervent
arm
averag
cost
control
arm
averag
differ
signific
number
death
intervent
arm
patient
control
arm
patient
differ
signific
conclus
hospit
rapid
bacteri
identif
antimicrobi
suscept
test
lead
signific
differ
mortal
cost
comparison
nuclisen
easymag
nuclisen
minimag
qiagen
nucleic
acid
extract
system
use
throat
swab
detect
pneumonia
c
pneumonia
object
evalu
perform
nuclisen
easymag
na
extract
system
throat
swab
qiagen
extract
minimag
refer
subsequ
dna
rna
amplif
respect
materi
method
throat
swab
patient
communityacquir
pneumonia
includ
studi
arriv
lab
sampl
aliquot
nucleic
acid
na
extract
use
qiagen
blood
mini
kit
na
extract
analys
realtim
pcr
detect
pneumonia
dna
c
pneumonia
dna
na
retrospect
extract
aliquot
specimen
use
nuclisen
minimag
nuclisen
easymag
offboard
protocol
subsequ
subject
realtim
pcr
realtim
nasba
detect
dna
rna
organ
respect
result
realtim
pcr
detect
pneumonia
c
pneumonia
throat
swab
qiagen
extract
swab
easymag
extract
realtim
nasba
detect
pneumonia
c
pneumonia
throat
swab
minimag
easymag
extract
detect
pneumonia
posit
specimen
differ
lightcycl
ct
valu
obtain
nuclisen
easymag
extract
qiagen
extract
respect
detect
c
pneumonia
posit
specimen
ct
valu
obtain
nuclisen
easymag
respect
compar
result
obtain
qiagen
extract
similar
result
obtain
realtim
nasba
amplif
organ
number
invalid
result
neg
specimen
due
inhibit
obtain
realtim
nasba
decreas
use
minimag
easymag
respect
furthermor
na
extract
could
use
rna
dna
amplif
conclus
studi
nuclisen
easymag
extract
effici
rna
dna
clinic
sampl
higher
recoveri
andor
less
inhibitor
show
averag
lower
ct
valu
lightcycl
realtim
pcr
assay
less
invalid
result
realtim
nasba
assay
instrument
featur
userfriendli
softwar
intuit
softwar
deliv
high
throughput
capabl
minut
turnaroundtim
intellig
sampl
prepar
improv
nucleic
acidbas
pathogen
detect
object
cultur
independ
pathogen
detect
method
becom
increasingli
interest
due
limit
blood
cultur
techniqu
eg
neg
result
antibiot
pretreat
noncultiv
micro
organ
timetoresult
delay
day
howev
exist
nucleic
acidbas
detect
na
method
eg
pcr
seriou
drawback
appli
clinic
sampl
like
whole
blood
howev
sensit
adequ
compar
gold
standard
blood
cultur
techniqu
reduc
sensit
na
method
bacteri
detect
due
low
amount
bacteri
dna
compar
human
dna
background
therefor
improv
na
method
achiev
innov
sampl
prepar
procedur
reduc
human
dna
background
significantli
enrich
bacteri
dna
simultan
sampl
prepar
method
shown
overcom
limit
cultur
independ
na
system
method
recombin
protein
specif
bind
affin
prokaryot
dna
keyston
innov
easytous
sampl
prepar
method
valid
properti
protein
perform
classic
gel
retard
radioact
experi
classic
well
real
time
pcr
experi
use
artifici
dna
mixtur
contain
proand
eukaryot
dna
well
spike
blood
sampl
result
experi
show
prokaryot
dna
specif
retain
describ
protein
protein
immobilis
matric
transfer
spin
column
enrich
experi
dna
prepar
procedur
use
column
enabl
enrich
prokaryot
dna
mixtur
contain
proand
eukaryot
dna
furthermor
mean
radioact
real
time
pcr
experi
could
shown
applic
procedur
decreas
background
human
dna
significantli
lead
increas
sensit
pcr
method
bacteri
detect
blood
sampl
conclus
propos
uniqu
preanalyt
method
improv
sensit
pcr
na
method
detect
small
amount
bacteri
dna
complex
sampl
eg
human
whole
blood
signific
reduct
eukaryot
dna
background
enrich
bacteri
dna
simultan
might
mileston
allow
day
diagnosi
sepsi
sir
well
object
gb
main
caus
seriou
earlyonset
neonat
sepsi
industrialis
countri
intrapartum
antibiot
prophylaxi
iap
prevent
infect
current
decis
women
receiv
iap
base
either
risk
factor
present
labour
cultur
vagin
rectal
swab
week
gestat
neither
approach
allow
optim
target
iap
aim
project
determin
accuraci
realtim
pcr
smartcycl
cepheid
optic
immunoassay
oia
thermobiostar
feasibl
point
care
test
poct
labour
women
method
healthcar
assist
laboratori
background
train
undertak
test
within
compet
assess
framework
test
accuraci
determin
use
enrich
cultur
gold
standard
neonat
ear
swab
cultur
gb
investig
relationship
matern
result
neonat
colonis
result
staff
achiev
compet
undertak
test
howev
high
turnov
staff
level
creat
ongo
train
need
train
time
oia
pcr
hour
minimum
handson
test
time
result
turnaround
time
oia
min
min
pcr
greater
train
need
longer
handson
test
time
pcr
significantli
increas
resourc
requir
provid
reliabl
test
result
test
vagin
rectal
swab
women
follow
babi
colonis
gb
born
mother
rectal
colonis
conclus
earli
data
indic
pcr
accur
detect
gb
carrier
labour
pcr
feasibl
poct
consider
staff
time
would
requir
maintain
robust
clinic
servic
smartcycl
platform
drawback
overcom
new
gener
fulli
integr
pcr
system
eg
genexpert
almost
elimin
manual
specimen
prepar
reduc
train
handson
test
time
evid
vertic
transmiss
occur
without
detect
vagin
colonis
suggest
intrapartum
screen
programm
might
requir
test
rectal
well
vagin
swab
although
whether
rectal
colonis
alon
risk
factor
gb
diseas
rather
colonis
remain
determin
work
fund
nh
hta
programm
introduct
tradit
blood
cultur
bc
well
known
limit
time
first
result
hour
sensit
new
method
need
molecular
biolog
seem
offer
interest
opportun
evalu
part
european
multicent
studi
object
aim
studi
evalu
new
pcr
base
molecular
assay
pathogen
detect
six
hour
clinic
impact
comparison
bc
result
method
bc
perform
bactalert
system
biomerieux
incub
day
septifast
test
perform
lightcycl
roch
diagnost
principl
method
explain
pcr
sampl
collect
bc
patient
fulfil
sir
criteria
patient
data
set
collect
clinic
laboratori
data
microbiolog
result
specimen
result
final
discuss
group
clinician
result
total
sampl
collect
patient
sampl
bc
pcr
neg
posit
rate
bc
pcr
sampl
bc
pcr
posit
bc
posit
coagulaseneg
staphylococci
cn
pcr
neg
bc
neg
pcr
posit
detect
cn
clinic
import
pcr
abl
detect
streptococcu
viridan
group
patient
endocard
b
staphylococcu
aureu
patient
pancreat
c
aureu
patient
spondylodiscitisth
pcr
result
avail
hour
biopsi
valv
cultur
result
report
day
sampl
pcr
detect
pathogen
aspergillu
fumigatu
stenotrophomona
maltophilia
escherichia
coli
aureu
enterococcu
faecali
addit
data
confirm
result
conclus
studi
pcr
detect
bc
posit
sampl
best
test
abl
help
right
diagnosi
patient
pcr
requir
dnafre
workflow
welltrain
worker
otherwis
result
could
mislead
detect
environment
dnapcr
faster
sensit
bc
studi
show
best
use
interest
new
method
method
consecut
swab
wound
rectal
nasal
pool
nasalaxillagroinperineum
patient
facil
inocul
onto
medium
mrsa
yield
rel
workload
cost
determin
h
h
incub
c
mrsa
confirm
use
pastorex
staph
plu
biorad
tube
coagulas
agglutin
denka
seiken
clsi
oxacillin
screen
plate
perform
directli
primari
media
possibl
result
specimen
grew
mrsa
least
one
medium
use
gold
standard
medium
compar
term
h
sensit
specif
posit
neg
predict
valu
report
materi
labour
cost
express
increas
decreas
compar
msf
protocol
standardsubcultur
protocol
h
h
read
h
read
direct
test
primari
medium
conclus
br
read
h
perform
significantli
better
p
media
ad
cost
direct
test
reduc
time
report
posit
cultur
howev
incub
exceed
h
br
specif
highli
compromis
mod
read
h
perform
second
best
overal
significantli
p
specif
msf
bd
read
h
compar
mod
limit
mix
growth
prevent
direct
test
thu
increas
turnaroundtim
diagnost
valu
procalcitonin
distinguish
monomicrobi
blood
stream
infect
coagulaseneg
staphylococci
contamin
pilot
studi
p
schuetz
b
mueller
trampuz
basel
ch
object
growth
coagulaseneg
staphylococci
cn
blood
cultur
alway
indic
bloodstream
infect
bsi
serum
procalcitonin
proct
shown
use
marker
bacteri
infect
antimicrobi
guidanc
therefor
evalu
diagnost
valu
proct
distinguish
bsi
contamin
cn
method
april
august
prospect
evalu
patient
growth
cn
blood
cultur
patient
bacteremia
caus
addit
microorgan
polymicrobi
infect
exclud
infecti
diseas
specialist
classifi
patient
bsi
contamin
accord
standard
clinic
laboratori
criteria
blind
proct
result
serum
proct
measur
one
day
day
day
blood
cultur
collect
day
follow
day
day
use
ultrasensit
immunoluminometr
function
assay
sensit
ngml
valu
compar
use
mann
whitney
u
test
receiv
oper
characterist
roc
curv
analysi
perform
result
patient
exclud
due
polymicrobi
infect
remain
patient
monomicrobi
bsi
contamin
cn
tabl
median
rang
serum
proct
concentr
ngdl
significantli
higher
patient
bsi
compar
contamin
three
time
point
contrast
crp
valu
leukocyt
count
significantli
discrimin
day
proct
cutoff
ngdl
show
sensit
specif
day
day
day
respect
conclus
pilot
studi
proct
earli
accur
biomark
distinguish
bsi
contamin
cn
confirm
larger
trial
proct
may
prevent
unnecessari
treatment
cours
suspect
cn
bsi
guid
rapid
treatment
yet
meet
criteria
cn
bsi
introduct
current
screen
b
burgdorferiinfect
reli
twotier
strategi
combin
sensit
eia
screen
specif
immunoblot
confirm
object
compar
perform
singl
step
beadbas
system
convent
twotier
approach
materi
method
unselect
sera
sent
privat
commerci
laboratori
primari
serolog
screen
test
igg
igm
recombin
antigen
eia
reactiv
sampl
confirm
recombin
immunoblot
recomwel
recomblot
borrelia
mikrogen
dneuri
sera
consid
posit
reactiv
least
one
specif
plu
one
nonspecif
band
indetermin
reactiv
one
specif
band
follow
storag
sampl
batchanalys
luminexbeadbas
assay
recombead
microbionixmikrogen
igg
seven
antigen
vlse
ospc
three
strain
test
igm
three
ospcantigen
three
strain
test
intern
standard
curv
allow
normal
individu
immunoglobulin
concentr
igg
sampl
consid
posit
posit
least
two
beadregion
indetermin
posit
one
beadregionfor
system
posit
interpret
base
presenc
igg
igm
neg
interpret
base
absenc
igg
igm
situat
consid
indetermin
result
sera
analys
agre
interpret
convent
luminex
test
found
sampl
posit
indetermin
sera
posit
convent
neg
luminex
test
neg
convent
posit
luminex
indetermin
convent
neg
luminex
test
neg
convent
indetermin
luminex
test
posit
vs
indetermin
discrep
consid
minor
found
sera
conclus
overal
good
qualit
agreement
observ
seriou
discrep
ie
lead
potenti
fals
neg
report
found
falseneg
convent
test
may
due
introduct
vlse
luminex
assay
potenti
falseposit
convent
test
may
attribut
improv
igmspecif
luminex
assay
conclud
singlestep
luminex
test
may
suitabl
replac
convent
twotier
strategi
object
develop
evalu
panfung
realtim
pcr
earli
detect
presumpt
identif
pathogen
fungi
directli
clinic
specimen
method
base
comprehens
sequenc
align
design
panfung
pcr
target
variabl
region
smallsubunit
ribosom
gene
assay
consist
forward
primer
revers
primer
fluorescencelabel
probe
ensur
effici
detect
ascomycet
basidiomycet
zygomycet
sensit
assess
comparison
quantit
aspergillu
fumigatusspecif
pcr
specif
test
use
refer
dna
fungal
bacteri
human
origin
retrospect
clinic
evalu
conduct
use
dna
extract
clinic
specimen
patient
proven
invas
fungal
infect
n
neg
control
n
ident
amplicon
determin
compar
sequenc
analysi
result
analyt
sensit
panfung
pcr
found
compar
fumigatusspecif
approach
ie
one
target
copi
per
reaction
howev
order
avoid
fals
posit
reaction
due
minut
fungal
contamin
introduc
occasion
sampl
process
specimen
diagnost
detect
limit
consid
target
copi
per
reaction
specif
fungal
dna
confirm
amplif
fungal
refer
dna
investig
absenc
posit
reaction
refer
dna
bacteri
human
origin
clinic
sensit
specif
respect
consid
particular
specimen
pcr
posit
exhibit
least
posit
reaction
per
triplic
test
pneumocysti
n
least
speci
group
level
instanc
usual
suscept
candida
speci
eg
c
albican
c
parapsilosi
c
tropicali
clearli
distinguish
usual
less
suscept
speci
c
glabrata
c
krusei
conclus
present
panfung
realtim
pcr
repres
promis
tool
improv
diagnosi
empir
treatment
invas
fungal
infect
thu
warrant
clinic
valid
result
total
case
laboratoryconfirm
ipd
report
ak
n
gn
ic
n
sweden
fin
casefat
ratio
vari
pneumonia
septicemia
mening
common
clinic
present
rate
ipd
aborigin
ak
n
case
per
person
respect
rate
ipd
children
year
age
person
year
age
rang
case
per
person
respect
ak
rate
ipd
children
serotyp
declin
routin
vaccin
p
rate
serotyp
ak
increas
children
year
age
p
overal
isol
person
year
age
serotyp
contain
polysaccharid
vaccin
proport
isol
fullyresist
penicillin
vari
countri
fin
ak
conclus
rate
ipd
high
aborigin
children
year
age
resid
arctic
countri
introduct
ak
rate
diseas
children
year
age
serotyp
rapidli
declin
howev
increas
rate
non
serotyp
concern
merit
surveil
continu
surveil
need
determin
impact
ak
area
n
high
ipd
rate
children
warrant
consider
use
circumpolar
countri
object
main
aim
studi
describ
patient
invas
pneumococc
diseas
ipd
era
hiv
infect
determin
factor
associ
increas
mortal
method
retrospect
record
review
case
ipd
admit
johannesburg
hospit
decemb
novemb
demograph
clinic
laboratori
microbiolog
outcom
data
record
risk
factor
possibl
associ
poor
outcom
compar
survivor
nonsurvivor
result
case
enrol
male
femal
mean
age
yr
rang
yr
hivseroposit
eleven
patient
underli
comorbid
condit
malign
diabet
mellitu
chronic
renal
failur
renal
transplant
sourc
bacteraemia
lower
respiratori
tract
multilobar
pneumonia
mening
unknown
acut
otiti
media
septic
arthriti
skin
soft
tissu
infect
complic
infect
record
case
sometim
multipl
pleural
effus
signific
haemoptysi
renal
failur
pericardi
effus
suppur
jaundic
empyema
gastroenter
ard
case
haematemesi
cva
case
case
die
patient
pneumonia
acut
exacerb
copd
associ
gastroenter
associ
empyema
mening
hiv
statu
underli
comorbid
ill
age
complic
impact
outcom
patient
mening
significantli
higher
mortal
case
pneumonia
mortal
versu
p
overal
isol
show
decreas
suscept
penicillin
intermedi
fulli
resist
resist
erythromycin
conclus
pneumococc
bacteraemia
common
infecti
complic
hivseroposit
patient
clinic
cours
outcom
patient
pneumonia
similar
hivseroneg
case
howev
outcom
case
primari
diagnosi
mening
particularli
poor
pneumonia
sever
index
use
predict
mortal
communityacquir
pneumonia
object
two
differ
index
develop
predict
mortal
communityacquir
pneumonia
cap
pneumonia
sever
index
psi
score
calcul
paramet
divid
patient
sever
risk
class
iv
score
base
paramet
confus
urea
valu
respir
rate
blood
pressur
age
yield
score
aim
compar
two
score
identif
cap
patient
low
high
risk
death
method
record
patient
hospit
clinic
discharg
code
cap
period
retrospect
screen
patient
chest
xray
infiltr
two
symptom
indic
cap
includ
studi
psi
score
calcul
data
surviv
day
admiss
collect
popul
regist
clinic
featur
specifi
consid
normal
result
among
identifi
episod
cap
initi
serumurea
valu
avail
thirtyfour
episod
follow
death
within
day
tabl
show
distribut
psi
risk
class
score
correl
mortal
conclus
psi
score
identifi
cap
patient
lowrisk
highrisk
mortal
support
clinic
judgment
decis
regard
outpati
treatment
level
hospit
supervis
easili
handl
prefer
psi
clinic
practic
tigecyclin
safe
effect
levofloxacin
treat
patient
communityacquir
pneumonia
object
tigecyclin
tgc
firstinclass
glycylcyclin
approv
treat
complic
skin
skin
structur
infect
complic
intraabdomin
infect
expand
spectrum
activ
gramposit
gramneg
anaerob
atyp
bacteria
includ
resist
strain
primari
object
compar
tgc
efficaci
safeti
levofloxacin
lev
patient
communityacquir
pneumonia
cap
method
phase
multicentr
randomis
doubleblind
studi
hospit
patient
cap
receiv
day
iv
tgc
mg
load
dose
follow
mg
everi
hour
iv
lev
mg
twice
daili
coprimari
efficaci
endpoint
clinic
respons
clinic
evalu
ce
clinic
modifi
intenttotreat
cmitt
popul
testofcur
toc
secondari
endpoint
microbiolog
efficaci
suscept
data
tgc
rang
bacteria
caus
cap
safeti
evalu
includ
vital
sign
laboratori
test
chest
radiograph
electrocardiogram
record
advers
event
ae
background
presenc
pseudomona
aeruginosa
pa
sputum
associ
sever
diseas
ambulatori
copd
patient
clinic
signific
hospit
patient
remain
unclear
better
knowledg
clinic
mean
presenc
pa
sputum
patient
import
choos
appropri
antimicrobi
treatment
emerg
room
method
prospect
studi
exacerb
copd
patient
hospit
june
septemb
follow
readmiss
one
year
sputum
collect
admiss
spirometri
perform
one
month
discharg
thorac
scan
done
random
manner
determin
presenc
bronchiectasi
quantifi
follow
valid
scale
express
data
analys
ttest
mannwhitney
test
v
qualit
data
result
patient
includ
mean
age
year
patient
hospit
admiss
previou
year
previou
month
expos
antimicrobi
previou
month
bronchiectasi
document
patient
mean
bronchiectasi
score
patient
requir
readmiss
anoth
episod
acut
exacerb
studi
total
episod
analys
valid
sputum
collect
episod
two
microorgan
present
episod
three
microorgan
isol
episod
pa
present
h
influenza
pneumonia
enterobacteriacea
normal
flora
patient
bacteri
infect
lower
neg
sputum
cultur
p
presenc
pa
sputum
strongli
associ
low
p
worst
walk
test
p
number
packsyear
p
conclus
presenc
pa
sputum
entri
patient
hospit
exacerb
copd
higher
previous
report
associ
smoke
histori
function
impair
relationship
presenc
bronchiectasi
pa
sputum
could
demonstr
object
chronic
obstruct
pulmonari
diseas
copd
frequent
caus
hospit
admiss
antibiot
use
recogn
main
factor
develop
resist
danish
outpati
antibiot
consumpt
low
inhday
compar
countri
europ
ddd
inhday
object
describ
epidemiolog
microbiolog
find
copd
patient
admit
exacerb
copdptt
relat
efficaci
empir
firstlin
treatment
method
retrospect
studi
copdptt
admit
three
intern
medicin
ward
icu
identifi
hospit
databas
sputum
sampl
spontan
expector
suck
standard
microbiolog
analysi
data
analys
spss
softwar
surviv
assess
kaplanmei
test
pvalu
consid
signific
result
copdptt
admiss
includ
popul
app
inhabit
sputum
sampl
ptt
obtain
three
monthsmort
ptt
find
sputum
ptt
neg
sampl
p
potenti
pathogen
microorgan
ppm
grew
sampl
ptt
sampl
ppm
growth
sampl
suitabl
analysi
find
copdptt
pneumonia
h
influenza
p
aureuginosa
candida
spp
other
ppm
penicillinresist
ptt
similar
find
report
rest
europ
administr
iv
penicillin
suffici
admiss
posit
find
conclus
low
antibiot
consumpt
influenc
microbiolog
find
copdptt
compar
highconsumpt
set
penicillin
suffici
firstlin
treatment
recommend
manag
sever
communityacquir
pneumonia
background
sever
communityacquir
pneumonia
scap
major
sourc
infect
sepsi
icu
earli
therapi
associ
improv
outcom
patient
retrospect
studi
object
identifi
characterist
manag
patient
scap
admit
icu
analys
antibiot
therapi
rx
influenc
outcom
patient
method
patient
scap
admit
icu
period
prospect
followedup
clinic
featur
comorbid
sever
score
incl
pneumonia
sever
score
psi
hospit
present
sap
ii
lod
icu
admiss
aetiolog
time
select
rx
record
variabl
associ
mortal
identifi
result
includ
pt
age
yr
ultim
rapidli
fatal
underli
diseas
mean
psi
score
class
iiii
class
ivv
mean
median
sap
ii
hypotens
requir
vasopressor
admiss
receiv
mechan
ventil
mv
icu
admiss
survivor
icu
hospit
discharg
respect
infect
microbiolog
document
thirtynin
receiv
antibiot
rx
h
admiss
other
n
median
lag
hospit
admiss
antibiot
rx
hour
rx
delay
h
h
hosp
admiss
pt
respect
pt
start
rx
icu
n
within
h
therapi
delay
h
h
icu
admiss
pt
respect
initi
empir
therapi
includ
mostli
coamoxiclav
gener
cephalosporin
combin
macrolid
quinolon
respect
adjust
psi
score
gener
sever
score
bacteremia
gnb
infect
time
antibiot
therapi
use
combin
influenc
outcom
although
inappropri
rx
document
scap
conclus
antibiot
rx
hospit
icu
delay
h
pt
respect
although
earli
antibiot
rx
desir
sever
infect
appropri
like
import
outcom
patient
treatment
mortal
bacteraem
pneumococcc
diseas
toronto
canada
background
sever
prospect
studi
suggest
choic
antibiot
regimen
influenc
mortal
patient
sever
pneumococc
infect
examin
impact
treatment
choic
mortal
pneumococc
bacteremia
pb
torontopeel
canada
method
popul
base
surveil
pb
resid
torontopeel
region
ontario
canada
pop
ongo
sinc
demograph
medic
data
collect
patient
physician
sinc
data
includ
antibiot
therapi
result
episod
pb
identifi
median
age
patient
rang
day
life
patient
male
patient
chronic
underli
ill
includ
cardiac
diseas
lung
diseas
diabet
mellitu
cancer
liver
diseas
kidney
diseas
hiv
infect
aspleniasickl
cell
diseas
episod
isol
avail
serotyp
includ
vaccin
isol
resist
penicillin
erythromycin
ceftriaxon
levofloxacin
moxifloxacin
overal
patient
admit
icu
requir
mechan
ventil
patient
die
includ
children
adult
children
adult
receiv
discord
antibiot
therapi
children
adult
receiv
discord
therapi
die
p
vs
adult
factor
associ
day
mortal
multivari
mv
analysi
older
age
mv
odd
ratio
decad
ci
chronic
organ
system
diseas
mv
ci
nurs
home
acquisit
mv
ci
hospit
acquisit
mv
ci
requir
mechan
ventil
mv
ci
patient
treat
respiratori
fluoroquinolon
monotherapi
mv
ci
macrolid
combin
antibiot
mv
ci
less
like
die
result
differ
patient
adult
includ
analysi
conclus
bp
diseas
adult
associ
high
mortal
therapi
respiratori
fluoroquinolon
alon
combin
therapi
macrolid
antibiot
associ
signific
reduct
mortal
antimicrobi
suscept
pneumococc
isol
caus
bacteraem
communityacquir
pneumonia
public
privat
sector
gauteng
south
africa
object
contradictori
high
rate
pneumococc
resist
report
previous
differ
surveil
studi
conduct
south
africa
aim
studi
review
suscept
data
isol
adult
patient
present
bacterem
pneumococc
communityacquir
pneumonia
cap
compar
case
public
privat
sector
gauteng
south
africa
method
wish
recruit
consecut
adult
patient
pneumococc
bacteraemia
cap
patient
without
radiograph
evid
pneumonia
clinic
diagnos
eg
mening
exclud
repeat
isol
exclud
antimicrobi
suscept
test
done
accord
clsi
guidelin
use
disc
screen
mic
determin
agar
dilut
etest
result
case
recruit
public
privat
sector
public
sector
patient
younger
median
age
year
vs
year
p
hiv
infect
less
comorbid
ill
case
privat
sector
like
receiv
antibiot
past
month
overal
rate
antimicrobi
resist
consider
lower
report
previous
south
africa
resist
penicillin
public
privat
sector
significantli
differ
also
signific
differ
suscept
isol
ceftriaxon
chloramphenicol
tetracyclin
rifampicin
ofloxacin
howev
significantli
resist
seen
privat
sector
isol
erythromycin
vs
p
clindamycin
vs
p
conclus
number
clinic
differ
seen
public
vs
privat
sector
patient
bacteraem
pneumococc
pneumonia
gauteng
south
africa
rate
antibiot
resist
much
lower
previous
report
south
africa
differ
note
higher
rate
resist
erythromycin
clindamycin
privat
sector
possibl
erm
gene
mutat
mechan
macrolid
resist
outcom
adult
penicillin
highresist
suscept
invas
streptococcu
pneumonia
communityacquir
pneumonia
introduct
emerg
streptococcu
pneumonia
exhibit
high
resist
penicillin
prsp
mic
lgml
evok
concern
infect
would
respond
poorli
antibiot
usual
use
treatment
communityacquir
pneumonia
pneumonia
due
penicillin
intermedi
pisp
mic
lgml
isol
investig
adult
invas
pneumonia
pneumonia
infect
prsp
pisp
match
control
suscept
infect
pssp
mic
lgml
determin
whether
resist
penicillin
key
factor
clinic
outcom
method
identifi
adult
invas
pneumonia
pneumonia
due
pnsp
prsp
pisp
admit
hospit
huntington
wv
match
age
admiss
time
period
group
patient
pssp
pneumonia
isol
capsular
type
death
count
occur
seventh
hospit
day
mic
determin
etest
capsular
type
quellung
procedur
result
signific
differ
pnsp
pssp
group
mean
age
sever
admiss
vital
sign
day
fever
mean
total
leukocyt
count
number
lobe
involv
preexist
underli
diseas
antibiot
treatment
regimen
group
tachypnea
modest
tachycardia
moder
leukocytosi
case
one
lobe
lung
involv
casefat
rate
cfr
first
seven
day
hospit
differ
significantli
invas
prsp
pssp
pneumonia
case
respect
p
fisher
exact
test
twotail
similarli
cfr
significantli
differ
invas
pisp
pssp
pneumonia
case
respect
p
fisher
exact
test
twotail
prsp
pisp
pssp
group
often
receiv
antibiot
regimen
compris
cephalosporin
macrolid
occasion
fluoroquinolon
signific
differ
cfr
compar
antibiot
regimen
conclus
find
suggest
antibiot
regimen
effect
treatment
invas
pssp
pneumonia
less
effect
treatment
prsp
mic
lgml
pisp
obviat
need
complex
antibiot
regimen
treatment
microorgan
easili
form
biofilm
medic
devic
develop
similar
microfilm
mucos
surfac
may
hamper
presenc
sever
line
defenc
oper
epitheli
cell
exampl
biolog
interfac
electr
charg
secret
antibiot
compound
modul
hydrophob
mainli
product
surfact
materi
addit
recent
data
demonstr
diffus
chemosensori
system
continu
monitor
presenc
microorgan
mucos
surfac
bacteria
commun
one
anoth
via
signal
molecul
process
gener
call
quorum
sens
quorum
sens
signal
act
differ
bacteria
speci
also
influenc
behaviour
metabol
plant
anim
suggest
involv
interspeci
interkingdom
commun
eukaryot
suscept
infect
bacteria
use
quorum
sens
evolv
natur
therapi
design
imped
bacteri
colon
inhibit
quorum
sens
mediat
process
detect
quorum
sens
signal
would
permit
host
organ
mount
earli
local
respons
bacteri
invas
new
data
demonstr
express
chemosensori
receptor
g
protein
molecul
chemoreceptori
cascad
secretori
element
direct
contact
bacteria
express
suggest
secretori
process
could
control
chemoreceptor
mechan
method
function
magnet
reson
imag
allow
vivo
evalu
secretori
respons
expand
knowledg
obtain
vitro
approach
work
review
studi
suggest
eukaryot
cell
sens
qs
signal
bacteria
describ
respons
signal
work
also
propos
model
mammalian
perceiv
bacteri
signal
base
idea
chemoreceptor
may
involv
percept
signal
initi
respons
addit
respons
mediat
immun
system
clean
care
safer
care
initi
improv
patient
safeti
worldwid
health
careassoci
infect
affect
hundr
million
peopl
worldwid
develop
transit
develop
countri
major
global
issu
patient
safeti
world
health
organ
support
creation
intern
allianc
improv
patient
safeti
global
initi
world
allianc
patient
safeti
embrac
exist
strategi
reduc
health
careassoci
infect
also
creat
momentum
new
action
improv
hand
hygien
patient
care
major
object
clean
care
safer
care
rais
awar
impact
health
careassoci
infect
patient
safeti
promot
prevent
strategi
within
countri
build
commit
countri
prioritis
reduc
health
careassoci
infect
test
implement
new
guidelin
hand
hygien
health
care
specif
district
worldwid
part
integr
packag
action
deriv
exist
strategi
field
blood
safeti
inject
immunis
safeti
clinic
procedur
safeti
water
basic
sanit
wast
manag
human
papillomavirus
impact
diseas
vaccin
intervent
papillomavirus
remark
heterogen
group
dna
virus
causal
involv
etiolog
differ
benign
malign
neoplast
lesion
anogenit
oropharyng
cutan
epithelium
classifi
genera
five
alpha
beta
gamma
mu
nu
compos
exclus
human
papillomavirus
hpv
current
distinct
hpv
genotyp
fulli
character
substanti
number
put
novel
hpv
genotyp
predict
amplifi
subgenom
dna
fragment
clinic
import
alphahpv
compris
hpv
genotyp
origin
refer
genit
mucos
hpv
subdivid
lowrisk
highrisk
genotyp
accord
risk
malign
progress
thu
lowrisk
genotyp
etiolog
associ
develop
virtual
genit
wart
laryng
squamou
cell
papilloma
contrast
persist
infect
subgroup
least
high
risk
hpv
genotyp
consid
necessari
although
insuffici
etiolog
factor
develop
cervic
carcinoma
consequ
hpv
test
recent
becom
import
part
cervic
carcinoma
screen
detect
algorithm
thu
sever
consensu
guidelin
recommend
hpv
test
appropri
triag
women
borderlin
cytolog
result
ii
test
cure
treatment
highgrad
cervic
lesion
iii
primari
screen
test
cervic
carcinoma
conjunct
cytolog
women
age
year
prevent
hpv
infect
achiev
induct
genotypespecif
neutral
antibodi
trigger
recombin
virallik
particl
vlp
vaccin
vlp
attract
candid
prophylact
vaccin
empti
noninfecti
dnafre
viral
capsid
morpholog
indistinguish
nativ
virus
sever
multival
vlpbase
vaccin
clinic
develop
phase
ii
trial
shown
vlpbase
hpv
vaccin
well
toler
induc
high
titer
neutral
antibodi
fold
greater
natur
infect
protect
high
efficaci
persist
hpv
infect
hpvrelat
clinic
diseas
phase
iii
trial
hpv
vaccin
current
underway
public
health
benefit
associ
vaccin
may
soon
realiz
emerg
transfer
quinolon
resist
symposium
jointli
arrang
icaac
programm
committe
world
emerg
qnr
novel
famili
quinolon
resist
gene
transfer
plasmidmedi
quinolon
resist
first
found
strain
klebsiella
pneumonia
one
region
unit
state
shown
due
qnr
encod
member
pentapeptid
repeat
ppr
famili
protein
qnr
protein
caus
lowlevel
quinolon
resist
bind
protect
gyras
topoisomeras
iv
quinolon
action
anoth
ppr
protein
mfpa
mycobacterium
tuberculosi
structur
mimic
dna
may
bind
gyras
dnabind
domain
although
qnr
identifi
earli
followup
survey
identifi
ciprofloxacinand
ceftazidimeresist
clinic
isol
escherichia
coli
shanghai
china
subsequ
similar
isol
k
pneumonia
enterobact
spp
throughout
us
qnr
also
found
sever
differ
speci
enterobacteriacea
europ
thailand
qnr
locat
class
integron
plasmid
also
found
chromosom
environment
water
bacterium
shewanella
alga
suggest
organ
may
sourc
qnr
gene
two
member
qnr
famili
qnr
qnrb
found
origin
qnr
term
qnra
qnr
homolog
found
genom
sequenc
sever
vibrio
spp
photobacterium
profundum
qnr
identifi
plasmid
shigella
salmonella
spp
qnrb
found
varieti
enter
bacteria
us
india
notabl
three
qnr
gene
found
ciprofloxacinsuscept
isol
well
quinoloneresist
isol
suggest
presenc
promot
higher
level
resist
due
chromosom
mutat
shown
laboratori
us
ceftazidimeresist
isol
enterobact
spp
notabl
high
preval
qnr
gene
qnra
anoth
qnrb
preval
increas
time
unexpectedli
studi
evalu
fourfold
differ
mic
ciprofloxacin
qnra
transconjug
anoth
plasmidencod
quinolon
resist
determin
identifi
variant
aac
ib
gene
encod
aminoglycosid
acetyltransferas
acquir
abil
acetyl
ciprofloxacin
reduc
activ
fourfold
aac
ib
variant
occur
independ
higher
preval
qnra
strain
set
togeth
qnra
plasmid
caus
addit
transfer
resist
approach
clinic
breakpoint
ciprofloxacin
suscept
like
qnr
variant
possibl
variant
modifi
enzym
may
identifi
quinolon
select
pressur
continu
toxinantitoxin
system
function
distribut
bacteri
world
toxinantitoxin
system
ta
small
genet
element
compos
two
gene
organis
operon
encod
stabl
toxin
unstabl
cognat
antitoxin
atpdepend
proteas
respons
antitoxin
degrad
antitoxin
antagon
toxin
form
tight
proteinprotein
complex
complex
also
respons
autoregul
operon
ta
origin
discov
low
copynumb
plasmid
genet
context
ta
contribut
plasmid
stabil
grow
bacteri
popul
kill
select
bacteria
lost
plasmiddatabas
search
reveal
plasmid
ta
mani
homologu
bacteri
chromosom
although
shown
chromosom
ta
activ
starvat
type
stress
biolog
role
well
select
advantag
confer
bacteria
still
investig
current
hypothes
ta
serv
growth
modul
program
cell
death
system
respons
stress
compar
wellstudi
plasmid
ta
ccdf
e
coli
f
plasmid
one
homologu
locat
chromosom
pathogen
e
coli
despit
low
level
ident
ccdf
protein
protein
conserv
essenti
motif
function
ta
ie
toxin
target
dnagyras
antitoxin
degrad
lon
proteas
howev
toxinantitoxin
interact
domain
two
homologu
diverg
indic
plasmid
ccdf
system
function
despit
presenc
chromosom
homologu
propos
chromosom
ta
might
serv
exclus
system
protect
bacteria
exogen
dna
carri
ident
ta
therefor
plasmid
ta
abl
evad
crossinteract
might
coexist
homolog
chromosom
ta
although
show
chromosom
system
express
host
unabl
mediat
plasmid
stabil
clone
unstabl
plasmid
support
idea
plasmid
chromosom
ta
play
differ
role
propos
homolog
ta
deriv
common
ancestor
reach
differ
bacteri
speci
andor
locat
horizont
transfer
function
evolv
accord
new
locat
overal
mortal
remain
high
despit
import
advanc
earli
diagnosi
transesophag
echocardiogram
earli
cardiac
surgeri
etiolog
chang
staphylococc
ie
frequent
streptococc
ie
nosocomi
ie
caus
highli
aminoglycosid
resist
enterococcu
spp
methicillinresist
staphylococcu
aureu
epidermidi
increas
last
decad
therapeut
point
view
antibiot
therapi
viridan
group
streptococci
ie
aureu
rightsid
ie
drug
abus
shorten
simplifi
type
ie
treat
ceftriaxon
plu
gentamicin
cloxacillin
plu
gentamicin
two
week
respect
furthemor
introduct
ceftriaxon
teicoplanin
allow
administr
singl
daili
dose
drug
iv
im
rout
make
possibl
outpati
antibiot
therapi
ie
special
homecar
unit
hand
multiresist
staphylococci
mrsa
gisa
enterococci
ie
high
mortal
ratio
antibiot
altern
way
preliminari
vitro
vivo
clinic
data
new
antibiot
combin
eg
ampicillin
plu
third
gener
cephalosporin
fosfomycin
plu
betalactam
antibiot
new
antibiot
class
eg
linezolid
quinupristindalfopristin
daptomycin
telavancin
open
new
therapeut
altern
treat
ie
caus
multirresist
bacteria
object
aim
studi
evalu
potenti
pathogen
differ
probiot
strain
lactobacillu
rhamnosu
l
paracasei
rat
model
experiment
endocard
method
total
l
rhamnosu
probiot
endocard
l
paracasei
probiot
faecal
endocard
test
rat
catheterinduc
aortic
veget
inocul
iv
increas
number
organ
cfuml
h
sacrif
lowest
inoculum
size
infect
veget
coloni
count
determin
bacteri
densiti
infect
veget
analys
use
mannwhitney
u
test
adhes
properti
lactobacilli
reveal
use
crystal
violet
measur
elisa
reader
nm
collagen
type
ix
fibrinogen
fibronectin
laminin
use
substrat
twofold
dilut
microtit
plate
strain
classifi
adher
nm
weakli
adher
nm
nonadher
nm
plateletinduc
kill
assess
fibrinopeptid
fpa
result
four
six
probiot
l
rhamnosu
strain
show
least
time
higher
cfuml
clinic
isol
two
probiot
l
rhamnosu
demonstr
line
higher
rang
cfuml
clinic
isol
importantli
two
strain
share
genotyp
type
clinic
isol
show
lowest
cfuml
l
paracasei
tend
lower
infect
l
rhamnosu
cfuml
endocard
well
probiot
faecal
isol
strain
compar
bacteri
count
veget
p
except
one
strain
adher
fibronectin
nm
laminin
nm
test
lactobacilli
adher
weakli
nm
platelet
peptid
fpa
show
microbicid
activ
lactobacilli
conclus
overal
result
indic
probiot
lactobacilli
gener
less
abl
caus
experiment
endocard
isol
human
endocard
although
differ
infect
l
rhamnosu
endocard
probiot
isol
seen
could
explain
differ
adher
plateletmicrobicid
protein
suscept
diseasepromot
factor
might
exist
organ
warrant
investig
object
studi
influenc
borrelia
b
speci
primari
human
isol
site
bacteria
dissemin
strain
b
burgdorferi
group
murin
model
lyme
borreliosi
method
seventeen
human
european
north
american
isol
b
burgdorferi
group
b
burgdorferi
sensu
stricto
b
garinii
b
afzelii
use
strain
isol
erythema
migran
em
n
borreli
lymphocytoma
bl
n
acrodermat
chronicum
atrophican
aca
n
neuroborreliosi
nb
n
lyme
arthriti
la
n
spirochet
strain
inocul
intraderm
rout
five
mice
develop
arthriti
sought
measur
tibiotars
joint
four
week
later
mice
euthanas
murin
infect
check
seroconvers
spirochet
dissemin
investig
cultur
pcr
murin
target
organ
skin
heart
joint
result
mice
seroposit
b
burgdorferi
day
post
infect
clinic
murin
arthriti
red
swell
significantli
correl
joint
diamet
mm
p
low
rate
discrep
b
burgdorferi
cultur
pcr
result
observ
skin
heart
wherea
addit
joint
found
posit
pcr
p
regard
borrelia
speci
use
murin
infect
b
burgdorferi
sensu
stricto
b
garinii
strain
dissemin
frequent
mous
skin
b
afzelii
strain
b
afzelii
strain
dissemin
frequent
joint
b
burgdorferi
sensu
stricto
b
garinii
strain
p
regard
primari
human
isol
site
strain
secondari
late
cutan
lesion
bl
aca
significantli
often
detect
skin
p
strain
involv
human
nb
la
frequent
detect
murin
joint
p
strain
em
dissemin
murin
organ
conclus
dissemin
b
burgdorferi
sensu
lato
mous
model
lyme
borreliosi
vari
accord
borrelia
speci
primari
human
isol
site
human
strain
isol
secondari
late
cutan
manifest
preferenti
detect
murin
skin
wherea
strain
abl
dissemin
human
preferenti
detect
murin
joint
em
strain
human
dissemin
capabl
unknown
wide
dissemin
mice
introduct
discoveri
commun
system
quorum
sens
system
regul
bacteri
virul
afford
novel
opportun
control
infecti
bacteria
without
interf
growth
compound
overrid
commun
signal
found
cellfre
lactobacillu
probiot
strain
cultur
previou
vitro
screen
antimicrobi
activ
solubl
product
lactobacillu
cultur
phenyl
lactic
acid
pla
found
exhibit
qs
inhibitori
qsi
activ
purpos
studi
tri
demonstr
role
pla
bacteri
virul
attenu
use
vivo
mous
infect
model
studi
design
overnight
cultur
ps
aeruginosa
aureu
grown
without
subinhibitori
concentr
pla
bacteri
suspens
ufcml
prepar
pb
use
mice
inocul
one
singl
dose
given
intraven
iv
intranas
intraperiton
ip
rout
mice
follow
one
week
infect
bodi
weight
mortal
morbid
rate
measur
everi
day
microbi
charg
studi
viabl
cell
count
lung
spleen
intestin
mucosa
blood
mice
lot
infect
wild
ps
aeruginosa
bacteri
cultur
exhibit
mortal
rate
iv
ip
rout
exhibit
high
cell
count
ufcg
ml
blood
lung
intestin
spleen
exchang
lot
infect
pla
treat
bacteri
cultur
exhibit
good
surviv
rate
mortal
even
though
euthanis
high
viabl
cell
count
found
intestin
blood
cfuml
g
concern
aureu
infect
experiment
lot
exhibit
compar
surviv
rate
signific
differ
notic
concern
clearanc
bacteri
cell
infect
mice
total
experiment
lot
infect
pla
treat
bacteri
cell
compar
infect
untreat
cultur
show
high
microbi
charg
intestin
conclus
studi
use
mous
infect
model
show
pla
act
potent
antagonist
bacteri
quorum
sens
regul
virul
factor
p
aeruginosa
aureu
improv
surviv
rate
well
clearanc
bacteri
strain
bodi
specif
manner
depend
infect
rout
microbi
strain
object
aim
present
studi
determin
frequenc
resist
rifampin
rif
multiresist
acinetobact
baumannii
ab
expos
rif
vitro
vivo
prevent
develop
resist
rif
use
associ
antimicrobi
method
vitro
studi
vitro
select
rifresist
variant
use
timekil
curv
concentr
time
mic
rif
possibl
combin
rif
imipenem
imp
sulbactam
sb
concentr
time
mic
respect
b
control
experi
imp
sb
alon
perform
c
mic
rif
singl
coloni
growth
h
incub
determin
stabil
rifresist
variant
stabil
variant
ab
resist
rif
test
six
daili
passag
riffre
agar
plate
vivo
studi
pneumonia
experiment
model
mice
use
b
treatment
group
h
con
without
treatment
rif
mgkgipd
imp
mgkgimd
sb
mgkgimd
imp
sb
imp
rif
sb
rif
c
mic
rif
isol
obtain
mice
perform
frequenc
rifresist
variant
experiment
pneumonia
model
use
two
treatment
group
con
without
treatment
rif
mgkgipd
result
vitro
result
mic
rif
increas
mgl
mgl
variant
select
h
incub
ab
presenc
rif
alon
b
suscept
rif
chang
experi
imp
sb
alon
c
differ
combin
rif
plu
imp
sb
mic
rif
chang
rifresist
variant
maintain
resist
mic
mgl
six
daili
passag
fresh
riffre
agar
plate
vivo
result
mice
treat
rif
alon
mic
rif
chang
mgl
mice
treat
rif
imp
sb
mic
rif
remain
mgl
b
frequenc
rif
variant
obtain
conclus
result
suggest
rifampin
must
use
alon
treatment
infect
caus
multiresist
baumannii
due
induct
rifresist
high
frequenc
case
rifampin
may
use
combin
imipenem
sulbactam
prevent
develop
resist
clinic
resist
lnz
associ
mutat
rrna
domain
v
region
aim
studi
develop
experiment
model
emerg
lnzresist
strain
digest
tract
method
studi
rate
emerg
lnzr
e
faecali
mutant
digest
tract
gnotobiot
mice
monoassoci
lnzsuscept
e
faecali
fed
water
contain
gl
li
micegroup
fecal
r
e
faecali
count
daili
day
agar
contain
mgl
lnz
rrna
mutat
character
sequenc
individu
copi
rrna
operon
lnz
concentr
mous
pellet
measur
hplc
result
gl
group
lnzr
mutant
mic
mgl
isol
one
mous
day
one
treatment
r
mutant
mic
mgl
isol
two
mice
day
treatment
gl
treatment
group
r
mutant
mic
mgl
isol
mice
day
treatment
persist
ufcg
fece
gl
treatment
group
r
mutant
mic
mgl
appear
day
treatment
persist
ufcg
fecal
concentr
lnz
lgg
fece
regimen
respect
r
mutant
select
gl
group
mutat
contrast
gl
treatment
group
observ
correl
number
rrna
copi
mutat
level
resist
lnz
express
mutant
obtain
vivo
conclus
intestin
emerg
lnzr
mutant
could
readili
obtain
vivo
use
wide
rang
treatment
dose
howev
strike
differ
observ
dose
regimen
term
rate
emerg
intestin
concentr
mutant
type
associ
mutat
object
evalu
epidemiolog
outcom
invas
fungal
infect
ifi
patient
pt
underw
autolog
auto
allogen
allo
hemopoiet
stem
cell
transplant
hsct
method
cohortretrospect
studi
conduct
hsct
patient
admit
hematolog
divis
tertiari
care
univers
hospit
develop
ifi
proven
probabl
result
evalu
pt
underw
hsct
allo
hsct
auto
hsct
ifi
occur
pt
overal
incid
regist
episod
sustain
mould
incid
yeast
incid
incid
rate
depend
upon
type
transplant
episod
occur
allo
hsct
incid
auto
hsct
incid
tabl
among
mould
detect
etiolog
agent
aspergillu
spp
episod
incid
candida
spp
respons
yeast
infect
regist
incid
aspergillosi
intraspeci
character
possibl
case
total
aspergillosi
afumigatu
identifi
case
flavu
terreu
anig
diagnosi
proven
case
case
aspergillosi
probabl
overal
mortal
rate
allo
auto
hsct
case
fatal
rate
cfr
regist
popul
death
differ
allo
hsct
auto
hsct
etiolog
influenc
pt
outcom
aspergillosi
cfr
allo
hsct
auto
hsct
one
due
candida
spp
allo
hsct
auto
hsct
interestingli
aspergillosi
cfr
vari
studi
period
decreas
rr
pvalu
conclus
ifi
repres
frequent
complic
particularli
pt
undergo
allohsct
aspergillu
spp
frequent
detect
agent
pt
character
high
mortal
rate
rare
auto
hsct
pt
develop
aspergillosi
convers
observ
differ
candidemia
incid
crf
two
group
diagnosi
confirm
direct
microscopi
pcr
dihydroptero
synthas
dhp
gene
bronchial
alveolar
lavag
fluid
data
concern
underli
diseas
medic
comorbid
outpati
depart
visit
demograph
data
obtain
file
transmiss
card
construct
detect
contact
patient
genotyp
pneumocysti
strain
perform
sequenc
analysi
intern
transcrib
spacer
number
gene
region
result
suspect
case
identifi
confirm
pcp
case
microscopi
pcr
pcr
patient
clinic
symptom
radiolog
sign
compat
pcp
none
die
background
rate
approxim
pcp
case
per
year
risk
factor
develop
pcp
eg
activ
cytomegaloviru
replic
treatment
reject
present
patient
alter
immunesuppress
regimen
implement
transmiss
card
show
patienttopati
transmiss
pneumocysti
possibl
multipl
occas
sequenc
analysi
gene
region
show
type
ne
sampl
type
bi
sampl
sampl
genotyp
could
determin
type
e
twice
g
determin
genotyp
fail
sampl
conclus
cluster
pcp
clinic
data
well
molecular
type
compat
patienttopati
transmiss
common
sourc
infect
howev
definit
proof
transmiss
given
data
nosocomi
legionellosi
outbreak
occur
immunosuppress
patient
cancer
centr
object
scarc
inform
regard
impact
earli
diagnosi
nosocomi
legionellosi
urin
antigen
test
levofloxacin
therapi
outcom
immunosuppress
patient
infect
report
legionellosi
outbreak
due
legionella
pneumophila
serogroup
occur
cancer
center
modal
rapid
diagnosi
treatment
use
method
outbreak
involv
patient
diseas
detect
first
patient
feb
outbreak
last
week
two
case
diagnos
within
h
univers
urin
antigen
test
n
patient
indic
pulsedfield
gel
electrophoresi
pfge
type
perform
isol
sputum
water
system
sampl
superh
flush
water
system
undertaken
control
outbreak
result
male
femal
age
yr
seven
patient
underli
hematolog
disord
lymphoma
acut
leukemia
aplast
anemia
patient
solid
tumor
lung
cancer
dissemin
cancer
pancrea
cancer
one
patient
receiv
steroid
patient
immunosuppress
drug
time
day
infect
three
patient
profound
neutropenia
one
also
invas
aspergillosi
requir
icu
admiss
ten
patient
present
pneumonia
multilobar
cavit
two
patient
asymptomat
time
urin
antigen
test
perform
urin
antigen
test
posit
case
l
pneumophila
serogroup
isol
sputum
patient
water
system
sampl
first
patient
treat
clarithromycin
die
wherea
remain
patient
receiv
levofloxacin
surviv
overal
mortal
day
pfge
type
demonstr
ident
clonal
pattern
among
isol
recov
sputum
water
sampl
superh
flush
water
system
success
termin
outbreak
conclus
earli
diagnosi
case
univers
urin
antigen
test
earli
levofloxacin
therapi
associ
outcom
much
better
classic
report
sever
immunosupress
patient
legionellosi
object
defin
group
neutropen
patient
like
benefit
antibiot
prophylaxi
updat
previou
metaanalysi
assess
antibiot
prophylaxi
afebril
neutropenia
assess
outcom
patient
solid
tumor
lymphoma
soli
patient
acut
leukemia
bonemarrow
transplant
al
bmt
method
systemat
review
metaanalysi
includ
random
control
trial
compar
antibiot
treatment
vs
placebo
treatment
control
afebril
cancer
patient
follow
chemotherapi
last
search
conduct
septemb
primari
outcom
assess
allcaus
mortal
rel
risk
rr
confid
interv
calcul
use
fix
effect
model
number
need
treat
nnt
calcul
use
mortal
rate
observ
placebo
group
new
trial
result
two
larg
trial
includ
patient
albmt
patient
soli
ad
metaanalysi
altogeth
compris
trial
quinolon
assess
trial
compar
control
antibiot
prophylaxi
significantli
reduc
allcaus
mortal
rr
reduct
greater
limit
studi
assess
quinolon
rr
among
albmt
patient
signific
reduct
caus
mortal
observ
prophylaxi
rr
quinolon
prophylaxi
rr
nnt
prevent
one
death
patient
signific
reduct
mortal
observ
also
studi
assess
soli
patient
first
chemotherapi
cours
rr
prophylaxi
rr
quinolon
nnt
patient
secondari
outcom
reduc
al
bmt
soli
patient
includ
febril
neutropenia
bacteremia
clinic
document
infect
infectionrel
mortal
tabl
gramneg
gramposit
infect
rate
reduc
fungal
infect
increas
prophylaxi
associ
seriou
advers
event
signific
differ
quinoloneresist
infect
studi
arm
observ
studi
compar
quinolon
control
conclus
given
low
nnt
allcaus
mortal
antibiot
prophylaxi
use
quinolon
consid
patient
albmt
among
soli
patient
prophylaxi
may
warrant
first
chemotherapi
cours
object
examin
coverag
empir
antibiot
treatment
first
episod
bacteraemia
patient
haematolog
malign
determin
impact
inappropri
treatment
mortal
method
conduct
populationbas
cohort
studi
north
jutland
counti
denmark
includ
patient
year
new
haematolog
malign
regist
hospit
discharg
registri
danish
cancer
registri
success
episod
bacteraemia
regist
counti
bacteraemia
registri
empir
antibiot
therapi
classifi
inappropri
isol
found
resist
administ
antibiot
dose
rout
administr
insuffici
mortal
within
day
determin
civil
registr
system
cox
regress
analysi
use
compar
mortal
rate
adjust
age
gender
comorbid
analysi
stratifi
accord
neutropenia
neutrophil
count
l
result
total
patient
includ
first
notif
posit
blood
cultur
patient
alreadi
die
decis
withhold
therapi
made
patient
termin
ill
patient
exclud
due
miss
inform
remain
patient
empir
antibiot
treatment
found
appropri
patient
inappropri
patient
cumul
mortal
patient
given
inappropri
empir
antibiot
treatment
vs
appropri
group
yield
adjust
mortal
rate
ratio
mrr
ci
correspond
cumul
mortal
vs
yield
adjust
mrr
ci
neutropen
patient
adjust
mrr
day
day
follow
ci
ci
respect
correspond
mrr
nonneutropen
patient
ci
ci
conclus
one
third
haematolog
patient
bacteraemia
given
inappropri
empir
antibiot
treatment
associ
increas
mortal
data
support
neutropen
patient
bacteraemia
particular
sensit
inappropri
empir
antibiot
treatment
object
commun
acquir
infect
caus
esblproduc
bacteria
emerg
problem
digest
tract
colon
prerequisit
infect
esblproduc
microorgan
aim
studi
determin
preval
risk
factor
fecal
carriag
esblproduc
escherichia
coli
klebsiella
spp
commun
method
total
stool
sampl
admit
laboratori
period
includ
studi
sampl
dilut
salin
cultur
two
emb
agar
plate
supplement
mgml
cefotaxim
mgml
ceftazidim
respect
isol
grew
identifi
speci
level
ecoli
klebsiella
spp
strain
test
esbl
product
ceftazidim
ceftazidimeclavulon
disc
acccord
clinic
laboratori
standard
institut
clsi
guidelin
result
stool
sampl
includ
isol
inpati
isol
outpati
sixtythre
hospit
outpati
harbor
esblproduc
e
coli
klebsiella
spp
p
chronic
hepat
failur
p
recent
antibiot
use
p
found
associ
esbl
posit
hospit
patient
recent
antibiot
use
p
found
independ
variabl
associ
esbl
posit
outpati
conclus
high
preval
fecal
carriag
esblproduc
bacteria
commun
warrant
studi
field
includ
consequ
colon
hospit
set
differ
epidemiolog
extendedspectrum
betalactamas
produc
escherichia
coli
accord
type
enzym
object
extendedspectrum
betalactamaseproduc
escherichia
coli
esblec
emerg
caus
commun
nosocomi
infect
analys
epidemiolog
esblec
area
accord
type
esbl
produc
method
patient
esblec
isol
area
popul
januari
may
includ
follow
data
collect
age
sex
chronic
underli
diseas
previou
healthcar
relat
hcr
invas
procedur
previou
antimicrobi
use
type
infect
esbl
product
antimicrobi
suscept
studi
microdilut
nccl
guidelin
esbl
character
isoelectr
focus
pcr
sequenc
clonal
relationship
among
isol
determin
reppcr
result
ninetysix
case
includ
previou
hcr
fortynin
outpati
among
attend
primari
care
emerg
servic
outpati
clinic
patient
hospit
seventyfour
consid
infect
uti
skin
soft
tissu
primari
bacteraemia
respiratori
tract
seventytwo
percent
isol
produc
one
esbl
produc
produc
isol
produc
ctxm
enzym
mainli
produc
shv
mainli
tem
two
homogen
group
identifi
comparison
patient
isol
produc
ctxm
n
produc
tem
shv
ctxm
n
signific
differ
found
nosocomi
acquisit
vs
p
nonfat
diseas
vs
p
diabet
vs
p
urinari
cathet
vs
p
fluoroquinolon
use
vs
p
isol
produc
ctxm
enzym
frequent
suscept
gentamicin
vs
p
ciprofloxacin
vs
p
clonal
relationship
among
ctxmproduc
isol
produc
tem
shv
belong
clonal
group
conclus
signific
differ
epidemiolog
esblec
accord
type
enzym
produc
isol
produc
ctxm
enzym
commonli
communityacquir
less
frequent
resist
nonbetalactam
clonal
relat
produc
tem
shv
caus
nosocomi
outbreak
differ
taken
account
design
control
measur
object
aim
examin
frequenc
predictor
colon
respiratori
tract
gramneg
bacteri
blavim
gene
patient
admit
newli
establish
intens
care
unit
icu
tertiari
care
hospit
method
specimen
tracheobronchi
aspir
obtain
everi
day
first
three
day
icu
stay
subsequ
everi
third
day
rest
icu
stay
microbiolog
studi
also
cultur
specimen
axillari
inguin
area
patient
taken
fifth
day
icu
stay
addit
cultur
specimen
sever
environment
site
well
oropharynx
hand
staff
taken
molecular
studi
perform
identifi
bacteria
blavim
gene
also
analysi
potenti
risk
factor
colon
gramneg
bacteria
blavim
gene
done
result
thirtyf
patient
male
femal
hospit
initi
threemonth
period
function
icu
colon
lower
respiratori
tract
gramneg
bacteria
found
patient
first
day
median
day
follow
admiss
icu
acinetobact
baumannii
patient
pseudomona
aeruginosa
enterobact
aerogen
klebsiella
pneumonia
stenotrophomona
maltophilia
baumannii
p
aeruginosa
isol
cultur
specimen
patient
bed
bar
respect
six
patient
colon
gramneg
bacteria
microorgan
blavim
gene
previou
use
carbapenem
p
blactam
p
well
stay
icu
day
p
associ
colon
bacterium
blavim
gene
conclus
colon
gramneg
bacteria
respiratori
tract
patient
newli
establish
icu
common
use
blactam
includ
carbapenem
associ
subsequ
colon
respiratori
tract
gramneg
bacteria
blavim
gene
epidemiolog
investig
quinolon
resist
infect
due
extendedspectrum
betalactamaseproduc
enterobacteriacea
tertiari
hospit
katsandri
vasilakopoul
v
mela
gl
petrikko
c
kosmidi
j
papaparaskeva
avlami
athen
gr
object
incid
infect
due
extendedspectrum
blactamas
esbl
produc
enterobacteriacea
increas
markedli
recent
year
although
treatment
difficult
frequent
multidrug
resist
quinolon
offer
effect
altern
therapi
aim
studi
identif
risk
factor
quinolon
resist
esbl
infect
materi
method
prospect
studi
consecut
esbl
hospit
infect
tertiari
care
hospit
one
year
period
conduct
data
collect
includ
gender
age
ward
type
durat
hospit
number
hospit
day
infect
infect
site
invas
procedur
underli
diseas
outcom
antimicrobi
profil
infect
organ
well
antimicrobi
therapi
prior
recoveri
isol
document
infect
quinolon
resist
esbl
produc
bacteria
qresbl
use
case
quinolon
sensit
esbl
qsesbl
produc
isol
use
control
result
esbl
isol
identifi
clinic
specimen
patient
preval
qresbl
bacteria
median
age
patient
year
percentag
femal
distribut
esbl
isol
e
coli
klebsiella
spp
enterobact
spp
proteu
spp
serratia
spp
other
site
infect
vari
frequent
site
urinari
tract
wound
surgic
site
bacteraemia
respiratori
tract
overal
mortal
isol
kidney
transplant
patient
significantli
like
quinolon
resist
p
ci
infect
qresbl
bacteria
associ
increas
hospit
stay
mean
day
vs
p
averag
qresbl
bacteria
isol
cultur
later
hospit
qsesbl
bacteria
mean
day
vs
p
factor
associ
quinolon
resist
previou
use
carbapenem
p
quinolon
p
qresbl
bacteria
significantli
like
resist
cotrimoxazol
p
gentamicin
p
tobramycin
p
conclus
quinolon
resist
widespread
among
esbl
produc
bacteria
risk
factor
associ
increas
hospit
stay
previou
use
carbapenem
quinolon
chang
epidemiolog
sequenti
outbreak
multiresist
acinetobact
baumannii
bacteraemia
tenyear
studi
intens
care
unit
jj
camarena
r
gonzalez
r
zaragoza
jc
navarro
sancho
artero
jm
nogueira
valencia
es
object
last
ten
year
multiresist
acinetobact
baumannii
mrab
bacteremia
remain
like
import
problem
icunosocomi
acquir
infect
teach
hospit
goal
studi
describ
phenogenotyp
characterist
mrab
bloodstream
infect
tempor
evolut
clone
associ
outbreak
endem
infect
influenc
adequ
empir
treatment
aet
control
measur
method
prospect
studi
strain
baumannii
isol
bacterem
patient
icu
last
year
genotyp
analysi
dna
pfge
reppcr
suscept
studi
isol
perform
diskdiffus
etestr
cluster
phenolgenotyp
pattern
analysi
tempor
evolut
analysi
aet
prevent
control
measur
result
total
isol
signific
ab
bacteremia
case
icu
analys
impact
ab
bacteremia
icuacquir
infect
differ
two
studi
period
first
one
conclus
sinc
detect
mrab
bacterem
case
endemoepidem
situat
nine
sequenti
outbreak
phenogenotip
character
describ
icu
teach
hospit
ten
year
mrab
bacteremia
icu
continu
despit
aet
guidelin
prevent
measur
control
endemoepidem
situat
seriou
icuproblem
although
mean
ensur
hh
promot
guidelin
recommend
alcoholbas
hand
rub
ahr
point
care
gold
standard
hh
provid
instruct
inhous
local
product
suitabl
effect
lowcost
formul
method
group
intern
expert
microbiolog
infect
control
consult
identifi
ingredi
relat
proport
alcoholbas
formul
handrub
issu
relat
procur
raw
materi
safeti
distribut
storag
finish
product
also
discuss
solut
propos
result
two
propos
formul
differ
alcohol
content
ethanol
vv
isopropyl
alcohol
vv
includ
h
final
concentr
preserv
spore
humectantlik
substanc
increas
user
accept
whodesign
independ
laboratori
test
formul
efficaci
accord
astm
intern
european
committe
standard
method
base
expert
opinion
formul
prefer
liquid
form
rather
gel
suitabl
hygien
hand
antisepsi
surgic
hand
prepar
latter
substanc
sustain
antimicrobi
activ
could
ad
consid
necessari
routin
hand
antisepsi
alcoholbas
handrub
equival
safeti
efficaci
profil
may
also
consid
issu
alcohol
content
consid
set
use
prohibit
religi
cultur
reason
case
reus
contain
clean
decontamin
autoclav
boil
chemic
disinfect
chlorin
reusabl
bottl
refil
empti
clean
tropic
climat
particular
addit
care
need
storag
alcoholcontain
materi
conclus
government
author
healthcar
administr
make
everi
possibl
effort
provid
healthcar
worker
ahr
point
care
achiev
maximum
benefit
optim
complianc
hh
propos
formul
design
suitabl
worldwid
use
base
cost
efficaci
procur
cultur
factor
within
pilot
phase
guidelin
implement
strategi
propos
formul
evalu
feasibl
accept
intervent
multidisciplinari
team
neurosurgeri
clinic
microbiolog
hospit
hygien
design
strategi
base
pillar
implement
drain
manag
protocol
medic
nurs
staff
base
notouch
concept
optim
hygien
strict
criteria
placement
remov
drain
implement
algorithm
diagnost
therapeut
manag
patient
suspect
drainrel
mening
implement
new
protocol
preoper
prophylaxi
introduct
close
drain
system
result
depict
tabl
decreas
infect
rate
period
iii
versu
pronounc
eld
evd
rr
acquir
infect
per
day
risk
decreas
eld
ci
evd
ci
period
iii
sharp
shift
observ
kind
microorgan
isol
csf
period
iii
typic
nosocomi
pathogen
disappear
conclus
incid
drainrel
mening
decreas
less
awar
problem
intervent
perform
probabl
import
caus
factor
reduct
adequ
prophylaxi
remain
point
concern
new
strategi
seem
need
improv
preval
mrsa
vari
wide
among
countri
netherland
mrsa
preval
clinic
isol
due
nation
search
destroy
polici
efficaci
polici
endem
situat
debat
studi
describ
larg
mrsa
outbreak
highli
transmiss
strain
dutch
hospit
measur
taken
control
epidem
method
mrsa
isol
use
convent
cultur
includ
select
broth
mrsaisol
type
use
puls
field
gel
electrophoresi
measur
use
control
epidem
includ
screen
contact
patient
hospit
staff
screen
readmiss
depart
regular
interv
discharg
addit
strict
isol
colon
infect
patient
decolonis
patient
hospit
staff
mrsa
carrier
use
topic
agent
also
electron
patient
signal
personnel
cultureinform
system
develop
result
epidem
start
around
novemb
involv
strain
low
oxacillin
mic
immedi
recogn
mrsa
januari
gradual
contact
screen
appear
mrsa
spread
mani
depart
member
staff
also
colon
nov
dec
new
isol
detect
among
patient
staff
member
respect
person
infect
isol
belong
four
epidem
clone
remaind
sporad
type
sinc
mayjun
last
upsurg
one
clone
occur
sporad
case
detect
conclus
studi
show
applic
strict
search
destroy
polici
even
endem
mrsa
control
result
rate
mrsa
infect
patient
case
per
admiss
respect
signific
reduct
infect
rate
observ
compar
p
rr
p
rr
signific
reduct
infect
rate
observ
p
rr
signific
reduct
methicillin
resist
rate
staphylococcu
aureu
isol
observ
respect
p
trend
conclus
search
destroy
strategi
base
upon
combin
activ
surveil
contact
precaut
topic
treatment
might
effect
significantli
reduc
mrsa
acquisit
rate
even
icu
high
rate
mrsa
colon
infect
patient
isol
cohort
improv
result
obtain
search
destroy
strategi
comparison
bacteri
efficaci
accept
alcoholbas
hand
rins
alcoholbas
hand
gel
routin
patient
care
alcoholbas
gel
use
handrub
report
less
efficaci
alcohol
base
rins
use
standard
method
usual
better
accept
health
care
worker
hcw
compar
bacteri
efficaci
handrub
alcohol
rins
two
differ
alcohol
gel
reduc
hand
contamin
practic
use
materi
method
prospect
crossov
clinic
trial
perform
medic
intens
care
unit
french
universityaffili
hospit
consecut
period
period
one
product
avail
handrub
hcw
use
either
sterillium
rins
mecetronium
ethylsulf
sterillium
gel
ethanol
manugel
plu
ethanol
isopropanol
immedi
direct
contact
patient
preand
posthandrub
hand
contamin
measur
use
glove
juic
techniqu
bacteri
count
evalu
blindli
trypticas
soy
agar
plate
end
period
selfadminist
questionnair
complet
hcw
skin
toler
accept
assess
use
visual
analog
scale
va
data
enter
analys
use
epiinfo
softwar
cdc
atlanta
result
studi
handrub
opportun
median
durat
handrub
sec
sterillium
rins
sterillium
gel
manugel
plu
respect
mean
reduct
factor
express
cfuml
sterillium
rins
sterillium
gel
manugel
plu
respect
sterillium
rins
sterillium
gel
significantli
effect
reduc
bacteri
count
hand
manugel
plu
p
sterillium
rins
sterillium
gel
also
significantli
better
toler
va
dryness
versu
p
better
accept
va
versu
p
manugel
plu
conclus
test
practic
use
condit
sterillium
gel
found
similar
sterillium
rins
efficaci
better
toler
manugel
plu
galactomannan
antigen
detect
invas
aspergillosi
test
optimis
impact
patient
manag
symposium
organis
bio
rad
object
platelia
aspergillu
pa
elisa
biorad
franc
routin
use
mani
institut
earli
diagnosi
invas
aspergillosi
ia
consider
variabl
cutoff
valu
use
although
cutoff
recommend
manufactur
institut
use
lower
cutoff
valu
vari
usa
kit
use
approv
cutoff
valu
aim
current
studi
reevalu
cutoff
level
paelisa
method
retrospect
studi
perform
use
prospect
collect
analys
serum
sampl
adult
patient
hematolog
disord
high
risk
develop
ia
data
collect
differ
site
site
univers
hospit
gasthuisberg
leuven
belgium
site
radboud
univers
nijmegen
medic
center
nijmegen
netherland
patient
classifi
accord
eortcmsg
consensu
definit
roc
analysi
perform
order
determin
optim
cutoff
valu
result
treatment
episod
patient
enrol
site
serum
sampl
episod
patient
site
serum
sampl
among
patient
diagnos
proven
ia
probabl
ia
analysi
cumul
data
proven
probabl
case
show
decreas
posit
index
correspond
increas
sensit
decreas
specif
perform
cutoff
valu
similar
site
sensitv
specif
respect
site
respecitv
site
combin
cutoff
highest
sensit
achiev
well
accept
specif
posit
neg
predict
valu
respect
conclus
cutoff
valu
favour
perform
characterist
found
paelisa
cutoff
valu
ident
approv
usa
galactomannan
comput
tomographybas
preemptiv
antifung
therapi
neutropen
patient
high
risk
invas
fungal
infect
time
reliabl
diagnosi
invas
aspergillosi
patient
underli
hematolog
disord
remain
frustratingli
difficult
seldomachiev
ant
mortem
convent
laboratori
diagnost
method
insensit
time
consum
result
late
diagnosi
treatment
contribut
unaccept
high
mortal
respons
diagnost
obstacl
prophylact
empir
strategi
recommend
especi
prolong
neutropen
patient
hematopoiet
stem
cell
transplant
recipi
howev
treatment
associ
strategi
result
increas
toxic
cost
use
sensit
rapid
noncultur
base
diagnost
assay
detect
aspergillu
antigen
galactomannan
betadglucan
detect
genom
dna
sequenc
may
allow
shift
emphasi
empir
preemptiv
therapi
especi
substanti
suggest
radiolog
find
tool
may
use
confirm
presum
diagnosi
invas
aspergillosi
use
screen
highrisk
patient
may
identifi
infect
earli
stage
diseas
excel
neg
predict
valu
new
tool
may
convinc
clinician
withhold
antifung
therapi
persist
febril
neutropen
patient
sign
fungal
infect
hand
consecut
posit
result
highrisk
popul
least
trigger
complet
diagnost
workupwheth
preemptiv
strategi
final
improv
patient
outcom
whether
prove
costeffect
remain
investig
care
design
random
clinic
trial
detect
next
emerg
pathogen
predict
emerg
viral
pathogen
intrins
difficult
highli
pretenti
howev
assess
current
knowledg
present
time
organis
diagnosi
research
laboratori
allow
propos
modest
practic
possibl
elabor
specif
sheet
good
candid
viral
emerg
meet
definit
emerg
pathogen
respons
sever
million
death
year
associ
specif
clinic
present
hepat
immunosuppress
haemorrhag
fever
enceph
respiratori
syndrom
etc
observ
transmit
variou
rout
aerosol
oralfec
bite
arthropod
sexual
relat
etc
howev
strikingli
virus
rna
genom
zoonot
possibl
identifi
common
featur
previous
observ
scenarii
emerg
case
step
report
transmiss
anim
viru
human
step
poorli
understood
human
activ
plastic
viru
genom
seem
crucial
determin
ii
interhuman
transmiss
select
viru
mutant
key
factor
allow
emerg
humanis
viru
iii
massiv
spread
diseas
human
primarili
link
human
behavioursinc
paramet
relat
viral
genet
chang
futur
risk
relat
human
behaviour
travel
deforest
overpopul
etc
increas
constantli
expect
viral
emerg
decreas
futur
appropri
laboratori
capac
diagnosi
previou
bioterrorist
alert
shown
centralis
diagnost
structur
would
poorli
adapt
diagnosi
emerg
pathogen
case
outbreak
elabor
standard
diagnost
kit
especi
realtim
pcr
assay
avail
larg
number
hospit
necessari
requir
larg
effort
organis
appropri
laboratori
capac
research
effort
necessari
bring
togeth
medic
veterinari
research
within
common
research
survey
programm
ii
presenc
european
research
institut
develop
countri
import
studi
emerg
pathogen
date
poorli
organis
expens
merit
reassess
iii
studi
anim
virus
relat
human
pathogen
promot
iv
tremend
effort
need
identifi
antivir
effect
rna
virusesth
role
ec
potenti
major
import
ec
support
larg
research
programm
aim
promot
diagnosi
emerg
virus
studi
viru
group
like
includ
emerg
virus
identifi
new
antivir
link
asthma
viral
respiratori
infect
n
papadopoulo
athen
gr
viral
respiratori
infect
relat
asthma
sever
way
sever
bronchiol
earli
life
relat
subsequ
wheez
therefor
may
repres
marker
suscept
asthma
altern
could
involv
initi
diseas
also
propos
infect
may
protect
develop
asthma
allergi
promot
host
respons
howev
whether
respiratori
virus
could
mediat
protect
effect
debat
nevertheless
well
establish
viral
common
cold
major
precipit
asthma
exacerb
use
sensit
diagnost
methodolog
epidemiolog
studi
last
decad
allow
identif
human
rhinovirus
rv
gener
recogn
common
cold
virus
major
asthma
precipit
associ
establish
evalu
impact
rv
infect
airway
obstruct
inflamm
natur
acquir
experiment
induc
rv
cold
strong
evid
rv
abl
infect
propag
upper
also
lower
airway
bronchial
pulmonari
epithelia
infect
rv
rich
sourc
inflammatori
mediat
may
initi
andor
augment
airway
inflamm
obstruct
furthermor
atop
environ
respons
viru
skew
toward
atop
like
balanc
may
enhanc
inflamm
exacerb
asthma
recent
evid
indic
immun
environ
may
also
affect
epitheli
inflammatori
respons
viru
reduc
product
proinflammatori
mediat
observ
correl
increas
viral
prolifer
increas
virusinduc
cytotox
also
associ
increas
product
growth
factor
tgfb
vegf
affect
fibrosi
angiogenesi
respect
suggest
viral
infect
may
also
implic
airway
remodel
asthma
paediatr
influenza
sever
need
protect
lind
solna
se
children
engin
influenza
epidem
interpandem
year
limit
immun
circul
viru
strain
therefor
agespecif
attack
rate
highest
among
children
twenti
twentyf
per
cent
young
children
may
contract
diseas
yearli
main
complic
otiti
media
children
prescrib
antibiot
yearli
indirectli
due
influenza
risk
hospitalis
highest
children
year
age
estim
person
month
main
reason
hospitalis
suspect
septicaemia
lower
respiratori
tract
infect
asthmabronch
febril
seizur
influenza
infect
normal
selflimit
children
fatal
occur
children
sever
heart
andor
lung
diseas
sever
debilit
diseas
belong
risk
group
sever
influenza
like
adult
influenza
season
children
report
dead
due
influenza
us
japan
sever
case
lethal
encphalopathia
influenzainfect
children
recent
year
dead
children
belong
known
risk
group
influenza
may
thu
sever
diseas
among
children
children
three
year
age
vulner
ordinari
influenza
vaccin
reactogen
children
adult
vaccin
children
demand
two
dose
good
strain
match
vaccin
protect
efficaci
may
reduc
incid
otiti
media
around
us
vaccin
children
month
recommend
sinc
measur
regard
costeffect
may
also
diminish
spread
influenza
elderli
despit
european
countri
recommend
gener
influenza
vaccin
children
even
rate
vaccin
vulner
children
risk
complic
diseas
low
one
reason
may
unproven
fear
vaccin
may
prevent
develop
basic
immun
influenza
intranas
vaccin
live
coldadapt
viru
proven
induc
similar
heterolg
immun
drift
influenza
strain
wildtyp
infect
children
larg
studi
vaccin
recent
conduct
europ
outcom
publish
jan
success
may
attract
option
prevent
consequ
influenza
children
human
metapneumoviru
infect
children
approach
prevent
b
van
den
hoogen
rotterdam
nl
acut
respiratori
tract
infect
rti
major
caus
morbid
mortal
worldwid
detect
previous
unknown
viru
sampl
hospitalis
children
suffer
rti
classic
virolog
genet
analys
reveal
novel
viru
first
human
member
genu
metapneumoviru
pneumovirina
subfamili
paramyxovirida
famili
human
metapneumoviru
hmpv
relat
rsv
belong
pneumoviru
genu
within
subfamili
identif
hmpv
research
around
world
begun
analys
epidemiolog
clinic
present
hmpv
relat
diseas
demonstr
viru
circul
world
wide
primarili
winter
month
hmpv
infect
account
approxim
report
rti
hospitalis
children
primarili
month
rsv
often
found
children
slightli
younger
hmpv
infect
patient
older
year
occur
mani
patient
impair
immun
underli
diseas
gener
commun
hmpv
account
rtirel
visit
physician
wide
spectrum
clinic
symptom
associ
hmpv
infect
report
patient
age
rang
mild
rti
sever
diseas
requir
hospitalis
compar
studi
hmpv
infect
tend
slightli
milder
rsv
infect
although
mani
studi
differ
statist
signific
recombin
hmpv
produc
use
revers
genet
techniqu
techniqu
use
develop
live
attenu
vaccin
base
delet
gene
insert
heterolog
gene
anim
studi
virus
shown
attenu
abl
produc
viru
neutralis
antibodi
protect
infect
therefor
could
futur
vaccin
candid
rsv
prophylact
therapeut
use
viru
neutralis
monoclon
antibodi
direct
fusion
protein
report
decreas
sever
ill
similar
reagent
current
develop
hmpv
limit
antibiot
usag
commun
benefit
collater
effect
impact
reduct
antibiot
use
antibiot
resist
commun
goal
ration
use
antimicrobi
agent
effect
treatment
minim
amount
harm
sideeffect
deal
bacteri
infect
use
antimicrobi
agent
also
know
substanti
overus
drug
part
world
sideeffect
includ
allerg
reaction
antibiot
diarrhoea
cost
develop
bacteri
resist
also
disturb
normal
human
microbiota
normal
flora
may
import
previous
thought
bacteri
resist
link
consumpt
antimicrobi
agent
hospit
commun
countri
level
less
antimicrobi
agent
link
less
bacteri
resist
resist
bacteria
may
spread
despit
low
level
antibiot
use
sever
articl
show
use
certain
antibiot
lead
increas
resist
drug
howev
studi
show
effect
reduct
antibiot
use
high
level
resist
due
multiresist
reduct
antibiot
use
may
best
way
decreas
antibiot
resist
ration
way
tackl
antibiot
resist
tri
prevent
develop
spread
resist
bacteria
includ
optim
antimicrobi
prescrib
also
improv
hygien
measur
especi
child
day
care
centr
optim
antimicrobi
prescrib
need
nation
current
care
guidelin
uniformli
wide
accept
term
optim
ration
use
includ
care
clinic
laboratori
diagnost
automat
comput
notif
may
best
way
guid
prudent
antimicrobi
prescrib
current
care
guidelin
also
flexibl
react
bacteri
resist
situat
chang
econom
approach
price
especi
reimburs
polici
may
also
reason
approach
need
increas
public
awar
antibiot
use
harm
effect
link
improp
use
purpos
sever
interest
public
recent
publish
report
show
healthi
human
microbiota
seem
protect
use
allergi
obes
cancer
antibiot
use
may
greatli
disturb
balanc
paradox
antibiot
use
may
also
increas
risk
bacteri
infect
data
accumul
may
better
understand
valu
microbiota
hope
patient
may
anymor
eager
ask
antimicrobi
prescript
bacteri
resist
emerg
protect
normal
microbiota
therefor
new
therapeut
option
develop
treat
prevent
bacteri
infect
alreadi
interest
new
studi
field
like
bacteriotherapi
therapi
bacteriophag
enzym
futur
show
import
approach
final
also
put
hope
unexpect
discoveri
total
new
solut
medic
technolog
may
creat
need
creativ
innov
reduct
antibiot
use
gener
practic
led
reemerg
infect
tool
avail
reduc
impact
antimicrobi
resist
limit
consist
infect
control
new
agent
includ
vaccin
becom
avail
prudent
main
part
less
antimicrobi
prescrib
well
known
agent
come
stream
near
futur
infect
control
commun
set
extrem
difficult
therefor
main
approach
countri
control
antibiot
use
howev
risk
associ
approach
evid
much
weak
countri
either
low
prescrib
pattern
recent
reduc
prescrib
increas
incid
advers
effect
breakthrough
infect
problem
studi
examin
critic
advic
event
could
approach
seek
prudent
approach
antimicrobi
prescribingin
counti
amount
antibiot
prescrib
high
risk
low
howev
suggest
low
prescrib
countri
may
see
effect
must
state
risk
outweigh
potenti
benefit
limit
abil
reduc
antibiot
prescrib
strategi
preserv
antibiot
efficaci
howev
develop
countri
yet
approach
limit
clinic
public
health
impact
antibiot
resist
b
dunai
nice
fr
clinic
antibiot
resist
respons
delay
diagnosi
prolong
diseas
eventu
disabl
chronic
infect
exposur
success
antimicrobi
agent
potenti
seriou
advers
event
hospitalis
doubl
risk
dissemin
patient
resist
microb
acquisit
new
resist
nosocomi
pathogen
may
introduc
communityfrom
angl
public
health
resist
pathogen
circul
commun
repres
threat
suscept
popul
ie
children
elderli
individu
chronic
diseas
andor
depress
immun
respons
exchang
genet
inform
commens
flora
result
dissemin
resist
trait
thu
widen
reservoir
patient
hospitalis
due
ineffect
first
line
treatment
entail
high
cost
commun
loss
revenu
patient
escal
antimicrobi
use
draw
effect
compound
previous
kept
last
resort
lead
vanish
resourc
antibiot
therapi
increasingli
rapid
resist
new
antibiot
discourag
industri
conduct
new
research
reinforc
surveil
attempt
revers
situat
becom
necessari
consider
cost
specif
exampl
briefli
examin
antibacteri
suscept
studi
activ
mechan
drug
interact
object
faropenem
medoxomil
novel
prodrug
antibiot
current
develop
oral
administ
drug
treatment
commun
infect
faropenem
medoxomil
rapidli
convert
faropenem
activ
drug
follow
oral
absorpt
plasma
esteras
high
degre
bioavailabl
faropenem
clear
plasma
glomerular
filtrat
activ
renal
secret
sever
clinic
drugdrug
interact
studi
perform
one
studi
faropenem
probenicid
result
modest
increas
c
max
auc
valu
faropenem
object
studi
evalu
abil
faropenem
inhibit
enzym
vitro
evalu
correspond
potenti
clinic
relev
drugdrug
interact
method
faropenem
evalu
potenti
inhibit
human
enzym
pool
human
liver
microsom
isoform
test
addit
stabil
faropenem
pool
human
liver
microsom
evalu
result
stabil
analysi
faropenem
lm
human
liver
microsom
show
substanti
degrad
time
cours
requir
inhibit
analysi
human
inhibit
studi
none
enzym
evalu
inhibit
faropenem
concentr
lm
mgl
conclus
absenc
inhibit
observ
faropenem
eight
enzym
evalu
indic
low
potenti
drugdrug
interact
faropenem
previou
drugdrug
interact
studi
faropenem
medoxomil
follow
drug
theophyllin
warfarin
digoxin
furosemid
probenicid
ranitidin
maalox
cholestyramin
microgynon
oral
contracept
shown
minim
effect
except
probenicid
faropenem
c
max
auc
increas
respect
increas
total
exposur
faropenem
expect
due
effect
probenicid
block
activ
renal
secret
overal
observ
nine
drugdrug
interact
studi
vitro
inhibit
studi
indic
low
potenti
interact
faropenem
medoxomil
drug
may
coadminist
clinic
background
staphylococcu
aureu
import
pathogen
hospit
commun
glycopeptid
consid
drug
choic
treat
methicillin
resist
aureu
mrsa
infect
howev
emerg
hvisa
isol
caus
concern
prospect
new
treatment
mrsa
especi
visahvisa
includ
daptomycin
acid
cyclic
lipopeptid
cidal
activ
gramposit
bacteria
studi
aim
determin
bactericid
activ
compar
vancomycin
v
use
timekil
curv
analysi
method
timekil
curv
use
v
mic
perform
vancomycinsuscept
aureu
vssa
heterovancomycin
intermedi
aureu
hvisa
strain
viabl
count
taken
h
plot
antimicrobi
concentr
log
reduct
viabl
count
lrvc
area
bacteri
kill
curv
aubkc
area
curvem
calcul
result
h
bactericid
reduct
vssa
hvisa
strain
mic
v
bactericid
averag
potent
v
vssa
strain
h
addit
bactericid
h
hvisa
strain
mic
v
bactericid
either
vssa
hvisa
strain
h
howev
v
bactericid
h
mic
hvisa
strain
conclus
consider
greater
bactericid
activ
vssa
especi
hvisa
v
new
agent
promis
altern
treatment
infect
caus
hvisa
high
activ
meropenem
gramneg
bacteria
paediatr
intens
care
unit
poland
poland
among
enterobacteriacea
found
three
isol
two
e
cloaca
one
e
amnigenu
resist
carbapenem
among
ipmresist
p
aeruginosa
isol
metallobetalactamas
produc
strain
found
overal
order
suscept
test
isol
betalactam
fep
taz
caz
ctx
suscept
aminoglycosid
gm
tm
character
gramneg
isol
respect
incid
ampc
betalactamas
extend
spectrum
betalactamas
produc
among
enterobacteriacea
decreas
conclus
mem
ipm
cip
activ
antibiot
suscept
test
strain
observ
reduct
activ
year
carbapenem
mem
use
option
first
line
therapi
nosocomi
infect
icu
morpholog
bactericid
effect
amoxicillin
clarithromycin
helicobact
pylori
f
demirbilek
g
karabay
h
arslan
ankara
tr
background
coccoid
form
helicobact
pylori
suspect
play
import
role
transmiss
relaps
infect
amoxicillin
clarithromycin
use
h
pylori
erad
therapi
studi
focus
growth
kinet
h
pylori
expos
amoxicillin
clarithromycin
differ
amoxicillinclarithromycin
combin
conjunct
cell
morpholog
method
h
pylori
nctc
inocul
brucella
broth
fetal
calf
serum
expos
concentr
antibiot
either
alon
combin
growth
characterist
determin
time
kill
assay
tem
use
ultra
structur
morpholog
result
amoxicillin
clarithromycin
alon
decreas
viabl
count
h
pylori
depend
antibiot
concentr
exposur
antimicrobi
result
morpholog
chang
cell
shape
cellwal
disintegr
cell
lyse
amoxycillin
show
potent
effect
viabil
morpholog
h
pylori
accompani
increas
coccoid
form
concentr
fold
higher
mic
rapidli
hour
inocul
effect
clarithromycin
observ
hour
inocul
amoxicillin
plu
clarithromycin
combin
show
addit
effect
viabl
count
caus
decreas
morpholog
chang
conclus
result
show
amoxicillinclarithromycin
combin
caus
decreas
frequenc
transform
coccoid
form
higher
growth
inhibit
amoxicillin
exposur
alon
although
clinic
import
coccoid
form
unknown
form
take
consider
antihelicobact
pylori
agent
test
vitro
comparison
suscept
antibiot
nosocomi
nonnosocomi
infect
hospit
israel
object
purpos
studi
compar
suscept
antibiot
nosocomi
nonnosocomi
infect
microbiolog
data
collect
rabin
medic
center
israel
method
retrospect
studi
base
bacteraemia
databas
clinic
signific
blood
isol
bacteraem
patient
collect
databas
includ
name
pathogen
whether
infect
nosocomi
vitro
suscept
set
antibiot
pathogen
databas
probabl
suscept
antibiot
determin
nosocomi
nonnosocomi
case
exact
twosid
confid
interv
base
binomi
distribut
odd
ratio
confid
interv
ci
calcul
pathogen
repres
case
databas
mantelhaenszel
method
per
pathogen
per
antibiot
b
per
antibiot
c
per
pathogen
across
pathogen
antibiot
result
nosocomi
nonnosocomi
infect
repres
case
databas
respect
preval
pathogen
escherichia
coli
probabl
suscept
ampicillin
nonnosocomi
infect
ci
ci
nosocomi
give
ci
nonnosocomi
escherichia
coli
suscept
nosocomi
across
pathogen
antibiot
or
could
calcul
rang
ci
ofloxacin
ci
ceftazidim
escherichia
coli
across
antibiot
ci
among
microorgan
lowest
or
observ
proteu
enterococcu
spp
ci
highest
or
klebsiella
pneumonia
ci
acinetobact
sp
averag
obtain
across
antibiot
pathogen
ci
conclus
low
or
proteu
sp
enterococcu
sp
show
antibiot
pressur
two
pathogen
equal
hospit
commun
highest
acinetobact
sp
bacterium
turn
pathogen
hospit
high
ceftazidim
surpris
sinc
cephalosporin
use
hospit
or
fluoroquinolon
small
indic
antibiot
pressur
similar
two
compart
compar
minimum
inhibitori
mutant
prevent
concentr
contemporari
urinari
tract
pathogen
test
ciprofloxacin
levofloxacin
j
blondeau
borso
c
hesj
saskatoon
ca
object
urinari
tract
infect
remain
amongst
common
clinic
complaint
femal
patient
fluoroquinolon
import
agent
treatment
compar
minimum
inhibitori
mic
approach
determin
drug
concentr
threshold
requir
block
growth
firststep
mutant
billion
cfu
expos
drug
interest
compar
mic
mutant
prevent
concentr
mpc
valu
contemporari
e
coli
ec
k
pneumonia
kp
enterococcu
en
pathogen
recov
urinari
tract
specimen
order
determin
urinari
drug
concentr
ciprofloxacin
cpx
levofloxacin
lfx
exceed
valu
recommend
dosag
dose
interv
method
mic
test
perform
accord
recommend
procedur
clinic
laboratori
standard
institut
util
cfuml
expos
doubl
dilut
drug
ambient
atmospher
temperatur
mpc
test
billionaecfu
appli
agar
plate
contain
concentr
increment
drug
follow
incub
ambient
atmospher
temperatur
lowest
drug
concentr
prevent
growth
record
either
mic
mpc
result
total
ec
kp
en
speci
cpx
lfx
suscept
test
determin
mic
mpc
valu
ec
cpx
lfx
valu
ugml
respect
versu
mpc
valu
versu
nine
strain
cpx
mpc
ugml
compar
strain
test
lfx
kp
cpx
lfx
valu
ugml
respect
versu
mpc
valu
versu
strain
mpc
ugml
en
cpx
mic
mpc
valu
ugml
versu
respect
lfx
one
isol
mpc
lfx
ugml
ec
kp
strain
mpc
valu
suscept
breakpoint
cpx
lfx
conclus
mpc
valu
cpx
lfx
recent
collect
uropathogen
ugml
well
within
achiev
sustain
urin
drug
concentr
base
convent
dose
dose
ensur
drug
concentr
excess
mpc
minim
resist
select
repres
ration
approach
treat
uti
minim
resist
select
prolong
clinic
util
compound
object
currentgener
quinolon
potenti
drug
therapi
lower
respiratori
tract
infect
lrti
skin
soft
tissu
infect
ssti
infect
mrsa
isol
suscept
quinolon
observ
increas
frequenc
present
studi
investig
activ
moxifloxacin
mox
isol
method
mrsa
isol
classifi
ciprofloxacin
cip
suscept
disc
diffus
collect
consecut
hamburg
area
time
period
februari
april
clonal
relationship
isol
determin
use
puls
field
electrophoresi
pfge
mic
valu
oxacillin
oxa
cip
mox
determin
isol
use
etest
method
result
isol
could
character
pfge
wherea
isol
pfgepattern
could
determin
even
repeat
assay
isol
identifi
communityacquir
ca
mrsa
homolog
pfgepattern
compar
camrsa
preval
franc
quinolonesresist
camrsa
isol
detect
studi
period
four
year
pantonvalentineleucocidin
gene
could
detect
camrsa
pcr
addit
four
clonal
group
observ
pfge
analysi
compris
isol
remain
isol
distribut
sporad
pfgepattern
isol
includ
camrsa
display
mic
oxa
mgl
lower
wherea
isol
display
mic
valu
oxa
greater
mgl
valu
cip
mox
determin
mgl
mgl
respect
valu
determin
mgl
mgl
cip
mox
respect
contrast
initi
result
disc
diffus
test
two
isol
display
mic
cip
mgl
isol
display
mic
valu
mox
mgl
mgl
observ
mic
data
indic
four
eightfold
higher
activ
mox
compar
cip
investig
mrsa
isol
conclus
camrsa
isol
hamburg
area
sinc
suscept
quinolon
modern
quinolon
mox
four
eightfold
higher
activ
observ
compar
cip
data
indic
modern
quinolon
highli
activ
drug
therapi
lrti
ssti
even
area
camrsa
endem
antimicrobi
suscept
pattern
correl
staphylococc
cassett
chromosom
mec
type
hospitaland
communityacquir
methicillinresist
staphylococcu
aureu
kilic
hj
li
se
sefer
cw
stratton
yw
tang
nashvil
us
object
mrsa
becom
commonli
isol
gramposit
pathogen
caus
commun
acquir
ca
hospit
acquir
ha
infect
differ
antimicrobi
suscept
pattern
aim
studi
compar
antimicrobi
suscept
pattern
staphylococc
cassett
chromosom
mec
sccmec
type
method
invas
noninvas
mrsa
isol
recov
vanderbilt
univers
medic
center
vumc
collect
octob
septemb
realtim
pcr
assay
taqman
develop
detect
differenti
four
sccmec
type
associ
hamrsa
sccmeci
ii
iii
camrsa
sccmeciv
antibiot
suscept
amoxicillinclavulan
cefazolin
clindamycin
erythromycin
gentamicin
levofloxacin
minocyclin
penicillin
rifampin
trimethoprim
sulfamethoxazol
sxt
vancomycin
determin
disc
diffus
method
induc
clindamycin
resist
determin
zone
test
result
among
total
mrsa
isol
collect
sccmecii
sccmeciv
mix
sccmeciiiv
untyp
sccmecii
detect
invas
isol
sccmeciv
vs
p
vice
versa
noninvas
one
vs
p
camrsa
strain
carri
sccmeciv
show
greater
suscept
sccmeciicarri
hamrsa
strain
clindamycin
vs
p
erythromycin
vs
p
levofloxacin
vs
p
gentamicin
vs
p
rifampin
vs
p
minocyclin
vs
p
sxt
vs
p
within
clindamycinresist
isol
hamrsa
strain
erythromycin
induc
comparison
camrsa
strain
p
noninvas
strain
show
signific
greater
suscept
invas
one
clindamycin
vs
p
levofloxacin
vs
p
isol
resist
methicillin
amoxicillinclavulan
cefazolin
penicillin
isol
resist
vancomycin
conclus
data
indic
mrsa
isol
predominantli
recov
vumc
carri
either
sccmeciv
camrsa
sccmecii
hamrsa
sccmec
type
correl
major
antimicrobi
suscept
pattern
camrsa
strain
possess
significantli
greater
suscept
sever
commonli
use
antibiot
compar
mic
mpc
result
five
quinolon
compound
repeatedli
test
american
type
cultur
collect
control
strain
suggest
mpc
qualiti
control
valu
rang
j
blondeau
c
hesj
borso
l
blondeau
b
blondeau
saskatoon
ca
object
minimum
inhibitori
concentr
mic
determin
minimum
drug
concentr
inhibit
cfuml
bacteria
vitro
wherea
mutant
prevent
concentr
mpc
determin
minimum
drug
concentr
requir
block
growth
firststep
mutant
billion
cfu
appli
drug
contain
agar
plate
mic
test
standard
control
use
american
type
cultur
collect
atcc
strain
similar
standard
protocol
yet
avail
mpc
test
compar
mic
mpc
result
atcc
strain
repeatedli
test
quinolon
document
mic
mpc
qc
rang
method
mic
test
base
current
clinic
laboratori
standard
institut
procedur
use
cfuml
inoculum
mpc
test
billion
cfu
inocul
drug
contain
mediaeach
concentr
increment
optim
media
incub
establish
atmospher
temperatur
use
organ
type
lowest
drug
concentr
prevent
growth
record
either
mic
mpc
atcc
strain
includ
aureu
sa
pneumonia
sp
test
garenoxacin
gar
gatifloxacin
gat
gemifloxacin
gem
levofloxacin
lfx
moxifloxacin
mfx
result
follow
repeat
mic
assay
mic
within
accept
qc
limit
major
mic
middl
qc
rang
organismscompound
test
mpc
test
follow
qc
organ
mpc
result
ugml
note
atcc
strain
gar
gat
gem
lfx
mfx
mic
result
qc
strain
mpc
valu
fell
within
middl
mpc
rang
major
compound
strain
test
conclus
mic
test
mpc
test
provid
reproduc
qc
organ
result
consist
narrow
drug
concentr
rang
major
mpc
middl
rang
mpc
drug
concentr
rang
present
may
serv
use
guid
insur
mpc
assay
accuraci
clinic
isol
sp
sa
test
quinolon
investig
toler
triclosan
five
intern
mrsa
clone
z
aldoori
morrison
gf
edward
cg
gemmel
glasgow
uk
triclosan
broad
spectrum
biocid
use
year
use
hospit
decolonis
patient
mrsa
abil
bacteria
especi
mrsa
develop
resist
antimicrobi
biocid
well
report
import
product
test
resist
aris
repeat
continu
exposur
two
hundr
thirti
two
mrsa
isol
scottish
hospit
test
mic
triclosan
nccl
method
adaptationtoler
studi
perform
repres
five
major
intern
mrsa
clone
grow
bhi
broth
presenc
increas
concentr
triclosan
day
triclosan
toler
isol
check
stabil
fifteen
serial
passag
triclosan
free
broth
investig
suscept
triclosan
mic
parent
triclosan
toler
isol
passag
isol
determin
triclosan
mic
mrsa
lgml
lgml
rang
lgml
triclosan
mic
parent
isol
use
adapt
lgml
lgml
lgml
lgml
lgml
adapt
studi
mrsa
small
coloni
variant
scv
emerg
differ
clone
differ
time
exposur
triclosan
day
triclosan
exposur
triclosan
mic
five
adaptedtoler
deriv
lgml
follow
serial
passag
mic
remain
lgml
bactericid
assay
triclosan
less
effect
toler
isol
reduct
min
parent
reduct
min
conclus
mrsa
clone
respond
differ
increas
concentr
triclosan
three
five
clone
test
produc
toler
deriv
high
increas
triclosan
mic
compar
parent
object
resist
proport
use
european
antimicrobi
resist
surveil
system
earss
often
present
indic
magnitud
antimicrobi
resist
differ
countri
nevertheless
compar
bias
variabl
sampl
ascertain
procedur
incid
rate
superior
provid
patient
base
risk
mostli
avail
due
lack
denomin
data
earss
collect
resist
data
well
denomin
inform
studi
incid
antimicrobi
resist
calcul
relat
resist
proport
possibl
effect
differenti
sampl
blood
cultur
examin
well
method
sinc
earss
collect
routin
antimicrobi
suscept
test
data
amongst
other
invas
aureu
isol
test
accord
standard
protocol
questionnair
sent
collect
denomin
inform
number
patient
day
blood
cultur
rate
etc
calcul
mrsa
incid
per
patient
day
link
inform
patient
day
resist
result
databas
spearman
correl
coeffici
wilcoxon
ranksum
test
linear
regress
use
statist
analysi
result
year
hospit
laboratori
earss
countri
respond
questionnair
report
overal
aureu
isol
differ
countri
mrsa
proport
rang
incid
rate
vari
overal
resist
proport
incid
rate
highli
correl
spearman
coeffici
p
subgroup
analysi
separ
eastern
western
european
countri
correl
coeffici
even
higher
highest
latter
western
european
countri
significantli
higher
cultur
rate
eastern
european
countri
regress
analysi
becam
clear
blood
cultur
rate
influenc
relationship
mrsa
resist
proport
incid
rate
eastern
european
countri
wherea
western
conclus
resist
proport
seem
similar
resist
incid
rate
case
mrsa
nevertheless
relationship
appear
depend
precondit
exampl
level
blood
cultur
paper
summaris
year
local
region
nation
statist
analys
depart
health
mandatori
staphylococcu
aureu
bacteraemia
surveil
scheme
requir
done
throughout
acut
healthcar
system
nh
england
method
number
mrsa
bacteraemia
trust
quarter
use
depend
variabl
neg
binomi
regress
analysi
denomin
data
calcul
multipli
report
averag
bed
occup
particular
financi
year
within
quarter
fall
actual
number
day
within
quarter
natur
logarithm
denomin
use
offset
within
regress
model
allow
direct
estim
incid
rate
ratio
semest
type
trust
region
use
independ
factor
requir
assess
linear
trend
semest
fit
covari
rather
factor
within
regress
model
result
nation
first
four
year
april
march
mandatori
surveil
scheme
total
mrsa
bacteraemia
report
nh
trust
within
england
estim
occupi
bedday
give
estim
incid
densiti
mrsa
bacteraemia
per
beddaysther
evid
suggest
rate
differ
quarter
signific
test
heterogen
rate
use
neg
binomi
regress
model
give
likelihood
ratio
test
statist
degre
freedom
p
region
evid
increas
trend
time
one
region
eight
region
neg
binomi
regress
model
show
littl
evid
tempor
trend
trust
strong
evid
trend
differ
trust
categori
district
gener
hospit
three
time
number
hospit
increas
trend
mrsa
bacteraemia
rate
compar
decreas
trend
rate
specialist
hospit
twice
mani
decreas
trend
rate
compar
increas
trend
conclus
mandatori
surveil
reveal
strong
evid
trend
local
level
relat
type
hospit
yet
evid
reduc
rate
mrsa
bacteraemia
nation
region
acut
sector
nh
hospit
practic
england
massiv
spread
new
yorkjapan
mrsa
clone
ii
european
countri
object
earlier
report
preval
methicillinresist
staphylococcu
aureu
mrsa
hungari
show
major
epidem
mrsa
clone
design
hungarian
clone
iii
spa
type
ridom
spa
type
b
kreiswirth
id
relat
wide
dispers
hungarian
hospit
present
work
provid
updat
mrsa
clonal
type
circul
hungari
method
mrsa
isol
includ
studi
compris
isol
previous
character
antibiogram
pulsedfield
gel
electrophoresi
pfge
select
repres
differ
pfge
type
circul
hungarian
hospit
ii
repres
total
invas
isol
recov
sever
hospit
locat
hungarian
counti
isol
recov
analyz
antibiogram
phage
type
pfge
repres
pfge
profil
also
character
spa
type
multilocu
sequenc
type
mlst
sccmec
type
result
although
mrsa
recov
distribut
pfge
pattern
almost
half
isol
show
singl
pfge
profil
associ
spa
type
correspond
new
yorkjapan
clone
addit
belong
southern
german
clone
pfge
b
spa
type
brazilian
clone
pfge
c
spa
type
hannov
clone
pfge
f
spa
type
isol
show
genet
background
hungarian
clone
pfge
similar
brazilian
clone
earlier
predomin
clone
hungari
character
isol
spa
type
sccmec
type
mlst
group
clone
evidenc
absenc
low
preval
new
yorkjapan
southern
german
clone
respect
conclus
studi
document
complet
replac
hungarian
clone
new
yorkjapan
southern
german
epidem
clone
among
hospit
set
hungari
moreov
describ
first
time
domin
massiv
spread
new
yorkjapan
clone
european
countri
ae
fossum
k
almkristiansen
g
bukholm
object
incid
methicillinresist
staphylococcu
aureu
mrsa
isol
discov
southeastern
part
norway
increas
year
studi
characteris
mrsa
isol
time
period
compar
isol
group
health
care
institut
primari
health
care
method
isol
analyz
use
multilocu
sequenc
type
mlst
staphylococcu
cassett
chromosom
mec
type
sccmec
polymeras
chain
reaction
verifi
presenc
pantonvalentin
leukocidin
pvl
gene
loci
result
mrsa
isol
person
incid
mrsa
increas
less
isol
per
year
period
estim
number
trend
observ
group
twentyseven
differ
sequenc
type
st
discov
among
domin
repres
isol
st
repres
group
evenli
distribut
group
differ
sccmec
type
discov
mrsa
type
iv
domin
type
studi
type
iv
increas
repres
less
isol
increas
approxim
equal
isol
group
sccmeciv
isol
studi
contain
pvl
gene
loci
percentag
mrsa
contain
sccmeciv
pvl
gene
loci
differ
group
among
primari
health
care
isol
sccmec
type
iv
contain
pvl
gene
loci
higher
health
care
institut
isol
conclus
southeastern
part
norway
incid
mrsa
isol
increas
health
care
institut
primari
health
care
incid
mrsa
isol
contain
sccmec
type
iv
increas
today
type
repres
isol
pvl
gene
loci
found
almost
exclus
mrsa
sccmec
type
iv
markedli
preval
isol
primari
health
care
health
care
institut
object
denmark
year
low
preval
countri
mrsa
howev
last
year
signific
rise
mrsa
infect
especi
commun
onset
comrsa
observ
order
characteris
patient
staphylococc
infect
identifi
possibl
risk
factor
comrsa
infect
conduct
nationwid
casecontrol
studi
method
patient
commun
onset
mrsa
denmark
identifi
control
select
random
sampl
patient
commun
onset
methicillin
sensit
aureu
mssa
inform
consent
patient
interview
telephon
regard
type
infect
previou
antibiot
treatment
chronic
ill
household
infect
hospitalis
contact
health
care
institut
travel
abroad
sport
occup
gener
practition
patient
receiv
questionnair
regard
clinic
sign
localis
infect
chronic
ill
result
comrsa
patient
identifi
gp
patient
questionnair
complet
mssa
control
identifi
laboratori
questionnair
complet
skin
soft
tissu
infect
predomin
manifest
case
control
larg
proport
case
control
underli
skin
diseas
skin
lesion
prior
infect
associ
reduc
risk
mrsa
ci
case
control
receiv
antibiot
within
last
month
resp
hospit
within
last
year
mrsa
patient
hospitalis
day
foreign
ethnic
associ
increas
risk
mrsa
conclus
prior
hospit
within
last
year
day
ethnic
danish
found
signific
risk
factor
comrsa
infect
comrsa
infect
domin
skin
soft
tissu
infect
major
mrsa
patient
receiv
antibiot
within
last
month
appar
protect
effect
skin
lesion
yet
fulli
understood
object
hospit
infect
caus
methicillinresist
aureu
mrsa
particularli
critic
due
limit
therapeut
option
last
year
rate
mrsa
increas
germani
contrast
netherland
mrsa
preval
remain
due
consequ
search
destroy
polici
differ
becom
problem
border
region
furthermor
camrsa
also
note
germani
netherland
method
order
control
problem
establish
euregio
mrsanet
euinterreg
iiia
fund
network
crossbord
cooper
nsterland
region
main
goal
network
understand
epidemiolog
mrsa
coordin
action
health
care
provid
ie
hospit
laboratori
public
health
servic
gp
fight
mrsa
local
level
order
lower
preval
mrsa
camrsa
side
border
outsid
hospit
mrsaguidelin
region
must
synchronis
usercent
epidemiolog
backbon
project
spatyp
network
provid
common
nomenclatur
type
mrsa
result
sequenc
base
type
perform
major
laboratori
isol
patient
hospit
nurs
home
region
alreadi
type
result
could
compar
within
whole
region
across
border
spatyp
frequent
clone
region
result
questionnair
german
hospit
screen
patient
type
erad
polici
show
although
hospit
say
screen
patient
risk
group
admiss
screen
eg
patient
chronic
ulcer
german
hospit
type
everi
first
mrsa
isol
patient
type
outbreak
associ
mrsa
indic
isol
patient
mrsa
perform
erad
therapi
case
erad
therapi
continu
dismiss
patient
hospit
conclus
crossbord
transfer
patient
healthcar
provid
becom
import
euregio
mrsanet
set
network
two
border
region
low
medium
size
endem
mrsa
project
want
elucid
euregion
epidemiolog
mrsa
provid
backbon
diminish
mrsabarri
exist
high
qualiti
crossbord
health
care
conclus
pvlmrsa
highli
preval
resid
staff
three
nurs
home
carrier
rate
could
lower
significantli
systemat
screen
decontamin
effort
hygien
train
staff
conclud
outbreak
pvlmrsa
nurs
home
may
happen
possibl
could
sens
screen
nurs
home
resid
hospit
admiss
detect
pvlmrsa
nurs
home
resid
prompt
systemat
screen
resid
staff
approv
method
screen
decolonis
train
staff
control
mrsa
may
appli
control
pvlmrsa
nurs
home
tabl
resid
staff
three
nurs
home
posit
pvlmrsa
mrsa
screen
person
nn
first
nation
methicillinresist
staphylococcu
aureu
preval
studi
belgian
nurs
home
indic
high
carriag
rate
among
resid
b
jan
c
sueten
deni
struelen
brussel
increas
incid
import
methicillin
resist
staphylococcu
aureu
mrsa
case
acutecar
facil
belgium
led
us
investig
preval
mrsa
carrier
among
nurs
home
nh
resid
object
studi
nation
preval
mrsa
colonis
belgian
nhresid
identifi
risk
factor
mrsa
carriag
method
preval
survey
perform
random
stratifi
sampl
nh
repres
geograph
region
countri
patient
care
profil
nh
maximum
resid
randomli
select
screen
nose
throat
skin
wound
urinari
meatu
singl
day
survey
risk
factor
mrsa
carriag
collect
questionnair
resid
nh
level
result
mean
size
nh
bed
highcar
bed
facil
privat
locat
flander
region
walloon
region
brussel
region
screen
resid
aureu
carrier
ci
mrsa
carrier
statist
signific
differ
mrsa
preval
region
proport
highcar
bed
nh
nh
size
mrsa
carriership
frequent
privat
public
nh
p
nh
infect
control
protocol
mrsa
preval
lower
nh
without
protocol
p
among
aureu
carrier
mean
resist
proport
ci
linear
relat
observ
resist
proport
preval
mrsa
carriership
pearson
p
conclus
first
nation
preval
survey
belgian
nh
reveal
colonis
mrsa
affect
one
five
resid
region
countri
bad
infect
control
practic
associ
higher
mrsa
preval
rate
analysi
risk
factor
residentand
nh
level
clarifi
determin
high
preval
mrsa
carriag
episa
studi
characteris
fusid
acid
methicillinresist
staphylococcu
aureu
caus
skin
soft
tissu
infect
outpati
franc
object
two
staphylococcu
aureu
aureu
clone
recent
associ
skin
soft
tissu
infect
ssti
differ
european
countri
european
commun
acquir
mrsa
pantonvalentin
leukocidin
pvl
posit
clone
european
epidem
impetigo
clone
clone
resist
fusid
acid
caus
fusb
gene
part
episa
studi
aureu
caus
ssti
french
commun
character
respect
resist
methicillin
mrsa
fusid
acid
farsa
mrsa
farsa
isol
found
type
order
see
two
mention
paneuropean
clone
also
dissemin
french
commun
method
total
patient
ssti
enrol
episa
studi
aureu
isol
grown
lesion
swab
patient
mrsa
farsa
isol
subject
pfge
spa
type
repres
isol
type
mlst
toxin
gene
profil
obtain
pcr
pvl
toxic
shock
syndrom
toxin
exfoli
toxina
eta
b
etb
sccmec
type
iiv
analys
mrsa
fusid
acid
resist
mechan
fusb
analys
pcr
use
fusb
specif
primer
result
total
twelv
mrsa
nine
farsa
found
one
isol
resist
antibiot
sequenc
type
st
domin
genet
lineag
howev
isol
display
differ
pfge
pattern
remain
isol
belong
mrsa
carri
sccmeciv
isol
harbour
toxin
gene
except
pvl
posit
resist
fusid
acid
caus
fusb
one
isol
none
fusb
posit
european
epidem
impetigo
clone
found
conclus
mrsa
isol
compris
total
aureu
isol
caus
ssti
patient
franc
isol
domin
among
mrsafarsa
isol
surprisingli
isol
harbour
pvl
toxin
gene
studi
identifi
one
isol
european
commun
acquir
mrsa
pvl
posit
clone
known
caus
ssti
commun
none
fusb
posit
european
epidem
impetigo
clone
found
result
indic
epidemiolog
aureu
caus
ssti
differ
franc
european
countri
uk
ireland
germani
scandinavian
countri
object
staphylococcu
aureu
sa
enterotoxin
suggest
impact
specif
local
ige
product
nasal
polyp
patient
allergi
hypothet
high
level
local
ige
long
period
mayb
associ
methicillinresist
staphylococcu
aureu
mrsa
format
upper
respiratori
tract
enlarg
group
children
allergi
aim
present
investig
detect
amount
mrsa
carrier
among
children
allergi
nasal
polyposi
np
allerg
rhiniti
ar
method
nasopharyng
swab
sa
mrsa
nasal
tissu
sampl
taken
children
age
np
person
ar
person
healthi
children
age
enrol
longterm
studi
patient
age
gender
diagnosi
allergi
therapi
ige
level
use
antibiot
record
antibiot
resist
strain
determin
disc
diffus
method
nasal
tissu
sampl
analyz
total
specif
ige
sa
result
rate
nasal
carriag
sa
found
control
group
patient
np
ar
mrsa
found
control
patient
np
ar
patient
mrsa
strain
predomin
children
age
year
p
glucocorticoid
use
np
p
rate
hospit
p
specif
local
ige
level
p
significantli
associ
mrsa
colon
nasal
carriag
mrsa
patient
nasal
polyposi
high
undetect
grow
possibl
allergi
mayb
caus
nasal
carriag
mrsa
children
np
ar
unidentifi
less
well
studi
group
high
risk
spread
mrsa
children
hospit
daycar
center
school
pathogenesi
therapi
sepsi
symposium
jointli
arrang
isf
pathophysiolog
role
blood
monocyt
releas
solubl
trigger
receptor
express
myeloid
cell
patient
sepsi
object
solubl
counterpart
surfac
receptor
highli
express
neutrophil
matur
monocyt
bacteri
fungal
trigger
exact
site
product
remain
unclarifi
present
studi
aim
investig
role
monocyt
releas
patient
sepsi
correl
monocyt
apoptosi
method
peripher
blood
monocyt
isol
patient
septic
syndrom
due
ventilatorassoci
pneumonia
seven
consecut
day
present
sepsi
densiti
gradient
centrifug
whole
blood
incub
rpmi
remov
nonadher
cell
apoptot
rate
first
day
measur
flow
cytometri
incub
fitcconjug
monoclon
antibodi
annexinv
propidium
iodid
monocyt
cultur
absenc
presenc
lp
concentr
supernat
estim
enzym
immunoassay
result
concentr
supernat
isol
monocyt
higher
first
day
compar
next
six
day
p
see
figur
increas
observ
trigger
monocyt
lp
median
supernat
monocyt
isol
first
day
patient
sepsi
sever
sepsi
septic
shock
cell
pn
sepsi
sever
sepsi
p
sever
sepsi
septic
shock
neg
correl
observ
monocyt
supernat
apoptot
rate
rs
p
median
supernat
monocyt
day
patient
eventu
surviv
cell
compar
cell
nonsurvivor
p
conclus
releas
monocyt
isol
form
patient
septic
syndrom
releas
invers
correl
monocyt
apoptosi
lower
event
septic
shock
data
signifi
antiinflammatori
mediat
sepsi
host
defenc
pneumococc
pneumonia
van
der
poll
amsterdam
nl
introduct
lung
repeatedli
expos
respiratori
pathogen
either
inhal
micro
aspir
microorgan
colon
oropharynx
infecti
agent
pass
structur
defenc
enter
termin
airway
may
caus
pneumonia
one
common
infecti
diseas
streptococcu
pneumonia
pneumococcu
frequent
isol
pathogen
patient
communityacquir
pneumonia
cap
unit
state
alon
half
million
case
pneumococc
pneumonia
report
year
fatal
rate
bacteremia
pneumonia
almost
case
consequ
pneumococc
pneumonia
addit
recent
sepsi
trial
pneumonia
import
caus
pathogen
especi
context
pneumonia
mortal
rate
per
year
caus
pneumonia
unit
state
larger
mortal
rate
caus
bacteri
pathogen
infect
caus
pneumonia
increasingli
difficult
treat
due
emerg
antibiot
resist
strain
altogeth
clear
respiratori
tract
infect
pneumonia
repres
major
health
care
problem
innat
immun
three
cell
type
present
lung
primarili
respons
host
defenc
pneumonia
ie
respiratori
epitheli
cell
macrophag
granulocyt
respiratori
epithelium
play
import
role
prevent
colon
infect
inhal
bacteria
physic
remov
microorgan
ciliari
clearanc
presenc
broadspectrum
antimicrobi
agent
mucu
line
epithelium
alveolar
macrophag
primari
phagocyt
cell
airway
ideal
posit
orchestr
initi
respons
infecti
challeng
reach
lower
airway
like
bacteri
challeng
small
andor
low
virul
macrophag
elimin
invad
bacteria
without
recruit
granulocyt
airspac
howev
challeng
extens
larg
number
granulocyt
recruit
alveolar
space
margin
pool
granulocyt
pulmonari
vasculatur
process
regul
varieti
solubl
mediat
cytokin
chemokin
leukotrien
aspect
innat
immun
respons
discuss
tolllik
receptor
innat
immun
system
discrimin
potenti
pathogen
self
seri
receptor
recogn
conserv
motif
pathogen
found
higher
eukaryot
motif
term
pathogenassoci
molecular
pattern
pamp
wherea
cognat
bind
partner
host
cell
involv
innat
immun
respons
name
patternrecognit
receptor
prr
exampl
pamp
includ
lipopolysaccharid
lp
outer
membran
gramneg
bacteria
peptidoglycan
present
bacteria
lipoteicho
acid
mani
gramposit
bacteria
mannan
yeast
cell
wall
toll
famili
receptor
conserv
throughout
evolut
fli
human
implic
play
central
role
prr
initi
cellular
innat
immun
respons
consid
promin
prr
recognit
pamp
express
gramposit
bacteria
nonetheless
play
limit
role
pneumococc
pneumonia
mice
lack
lower
chemokin
concentr
lung
tissu
togeth
reduc
pulmonari
pmn
influx
cytokin
level
bacteri
outgrowth
surviv
differ
compar
wildtyp
anim
find
explain
anoth
report
reveal
pneumolysin
one
crucial
virul
factor
pneumonia
ligand
recognit
pneumolysin
demonstr
correl
invas
pneumococc
diseas
vivo
addit
moder
impair
surviv
increas
bacteri
outgrowth
found
mice
invas
pneumococc
pneumonia
cytokin
ampl
evid
underlin
import
tnf
host
defenc
bacteri
pneumonia
murin
pneumonia
pneumonia
model
treatment
neutral
antitnf
moab
strongli
impair
antibacteri
defenc
antitnftreat
result
enhanc
outgrowth
pneumonia
lung
antitnftr
mice
die
significantli
earlier
pneumococc
pneumonia
control
mice
compar
result
obtain
receptor
type
defici
mice
infect
pneumonia
display
increas
bacteri
outgrowth
togeth
reduc
capac
form
inflammatori
infiltr
consider
interest
treat
receptor
defici
mice
neutral
antitnf
antibodi
made
extrem
suscept
pneumococc
pneumoniamor
receptor
knockout
mice
treat
control
antibodi
wild
type
mice
treat
antitnf
thu
wherea
excess
product
proinflammatori
cytokin
system
level
caus
organ
failur
death
anim
model
fulmin
sepsi
local
product
proinflammatori
cytokin
importantli
contribut
host
defenc
pulmonari
infect
coagul
fibrinolysi
recent
year
interact
coagul
inflamm
receiv
much
attent
demonstr
local
activ
coagul
fibrinolysi
within
bronchoalveolar
compart
patient
pneumococc
pneumonia
inhibit
coagul
recombin
inhibitor
tissu
factor
influenc
outcom
murin
pneumococc
pneumonia
moreov
mice
defici
plasminogen
activ
inhibitor
type
show
unremark
host
defenc
pneumonia
pneumonia
thu
role
coagul
fibrinolysi
seem
limit
pneumococc
pneumonia
conclus
pneumoccoc
pneumonia
remain
major
challeng
clinician
knowledg
host
defenc
mechan
spneumonia
rapidli
increas
abstract
repres
select
recent
acquir
inform
immun
respons
pneumococcu
airway
hope
knowledg
enlarg
therapeut
arsen
near
futur
nonpneumococc
communityacquir
rti
current
state
art
chang
drug
suscept
h
influenza
special
refer
macrolid
azalid
ketolid
quinolon
pc
appelbaum
hershey
us
untyp
haemophilu
influenza
strain
import
pathogen
communityacquir
respiratori
tract
infect
pneumonia
otiti
media
sinus
particularli
acut
exacerb
chronic
bronchiti
countri
without
hib
vaccin
system
bacteremia
mening
also
import
main
mechan
resist
h
influenza
product
rare
ampicillinresist
resist
blnar
strain
mutat
also
occur
recent
describ
increas
frequenc
europ
especi
franc
spain
portug
uk
ireland
poland
incid
blnar
strain
japan
approach
produc
strain
mutat
report
franc
japan
intrafamili
spread
h
influenza
differ
genotyp
pediatr
carrier
describ
although
quinolon
activ
h
influenza
strain
resist
organ
mutat
qrdr
describ
clinic
outbreak
quinolon
resist
strain
longtermcar
facil
associ
levofloxacin
use
describ
new
york
citi
recent
fatal
case
pneumonia
caus
quinolon
resist
h
influenza
strain
patient
treat
levofloxacin
emphas
need
suscept
test
strain
test
quinolon
suscept
prior
levofloxacin
therapi
macrolid
azalid
ketolid
recommend
treatment
communityacquir
respiratori
tract
infect
includ
caus
h
influenza
drug
yield
unimod
mic
distribut
howev
macrolid
azalid
ketolid
efflux
mechan
detect
strain
baselin
mic
suscept
clsi
strain
without
efflux
significantli
lower
macrolid
azalid
ketolid
mic
occur
clinic
incid
approxim
strain
also
clindamycin
suscept
approxim
strain
highli
resist
macrolid
efflux
plu
one
ribosom
protein
mutat
rrna
light
find
efflux
mechan
suscept
strain
suggest
macrolid
azalid
ketolid
h
influenza
breakpoint
high
reevalu
strain
also
regular
monitor
blnar
develop
quinolon
resist
risk
assess
primari
care
clairvoy
evidencebas
medicin
symposium
arrang
esprit
cystiti
mostli
simpl
alway
want
discuss
problem
gener
practition
face
manag
simpl
issu
potenti
uncompl
upper
urinari
tract
infect
qualit
high
standard
field
cystiti
least
three
major
diagnost
two
therapeut
problem
interest
concern
clinic
microbiologist
gener
practition
first
diagnost
problem
deal
gold
standard
threshold
consid
signific
infect
word
year
old
discuss
kass
stamm
secondli
basic
diagnost
problem
test
substanti
improv
diagnost
accuraci
given
prior
probabl
clinic
sign
thirdli
even
without
test
need
rule
frequent
seriou
problem
mislead
ie
chlamydia
trachomati
infect
result
potenti
pid
fertil
problem
choic
therapeut
strategi
still
complic
multitud
possibl
treatment
regim
recent
cochran
review
compar
treatment
regim
day
offer
interest
point
discuss
cours
day
effect
longer
one
regard
symptomat
cure
relaps
less
effect
bacteriolog
erad
final
problem
empir
treatment
remain
alreadi
decad
find
pathogen
primari
care
world
eschericia
coli
nearli
case
although
uropathogen
antimicrobi
resist
profil
differ
period
alarm
resist
data
releas
region
bacteriolog
laboratori
appar
bacteriologist
convinc
worri
data
make
clinician
use
less
broadspectrum
antimicrobi
agent
often
effect
opposit
grow
resist
rather
encourag
gener
practition
use
newer
broadspectrum
agent
sinc
fear
patient
cure
carri
resist
bacteria
one
key
issu
debat
reliabl
resist
data
even
limit
ambulatori
patient
data
strongli
overestim
real
situat
sinc
gener
practition
send
urin
investig
suspect
complic
infect
investig
issu
two
countri
differ
use
antimicrobi
drug
belgium
norway
differ
use
reflect
resist
uropathogen
found
microbiolog
laboratori
popul
typic
patient
consult
gp
cystiti
healthi
adult
women
kind
surveil
convinc
clinician
continu
use
antimicrobi
drug
trimethoprim
nitrofurantoin
empir
perhap
simpl
criteria
could
make
easili
access
laboratori
data
reliabl
applic
primari
care
shall
discuss
issu
one
major
goal
gener
practic
treat
simpl
thing
high
standard
care
clinic
microbiologist
help
us
greatli
task
collabor
research
bacteri
mening
lifethreaten
diseas
estim
incid
per
peopl
per
year
develop
countri
tentim
higher
less
develop
countri
bacteri
mening
often
consid
adult
difficult
recogn
optim
use
clinic
examin
aid
physician
identifi
patient
suffici
risk
mening
requir
definit
diagnost
test
lumbar
punctur
patient
mening
suspect
requir
invas
procedur
effect
establish
refut
diagnosi
studi
show
physic
examin
lack
adequ
sensit
accur
identifi
mening
adult
present
communityacquir
acut
bacteri
mening
sensit
classic
triad
fever
neck
stiff
alter
mental
statu
low
almost
patient
present
least
two
four
symptomsheadach
fever
neck
stiff
alter
mental
statu
defin
score
glasgow
coma
scale
textbook
provid
tabl
classic
describ
lumbar
punctur
result
viral
bacteri
diseas
avail
literatur
suggest
find
reliabl
predict
risk
bacteri
mening
individu
patient
fact
sever
publish
studi
report
signific
number
patient
bacteri
mening
find
initi
lumbar
punctur
would
tradit
predict
bacteri
mening
delay
initi
antimicrobi
therapi
result
poor
outcom
diseas
countri
famili
doctor
advis
give
parenter
antibiot
transfer
patient
hospit
meningococc
mening
suspect
first
difficulti
set
identifi
patient
meningococc
mening
second
dilemma
whether
patient
benefit
prehospit
treatment
gener
practition
decid
treat
patient
suspect
bacteri
mening
parenter
antibiot
dexamethason
given
first
dose
new
approach
treatment
bacteri
mening
establish
recommend
antimicrobi
therapi
chang
result
emerg
antimicrobi
resist
furthermor
manag
critic
ill
neurolog
patient
bacteri
mening
pose
import
dilemma
import
controversi
area
review
relev
literatur
discuss
framework
current
treatment
guidelin
updat
influenza
pandem
threat
pandem
threat
r
fouchier
rotterdam
nl
outbreak
caus
highli
pathogen
influenza
viru
occur
live
bird
market
hong
kong
also
result
first
report
case
human
infect
fatal
attribut
directli
avian
influenza
viru
viru
resurfac
devast
poultri
industri
larg
part
se
asia
subsequ
viru
appear
mongolia
kazakhstan
russia
turkey
romania
croatia
outbreak
viru
transmit
human
lead
death
januari
isol
pig
cat
tiger
leopard
addit
poultri
wild
bird
far
human
case
result
birdtohuman
transmiss
still
larg
unknown
viru
fatal
human
recent
studi
suggest
viru
may
replic
beyond
respiratori
tract
mammal
gener
case
highli
pathogen
virus
bird
whether
viru
could
becom
transmiss
human
start
new
pandem
still
one
key
question
prepar
potenti
pandem
candid
vaccin
prepar
use
revers
genet
technolog
current
test
human
howev
sever
problem
relat
vaccin
make
unlik
could
becom
avail
human
use
short
term
drug
neuraminidas
inhibitor
anoth
tool
protect
diseas
infect
howev
possibl
resist
drug
could
becom
problem
use
larg
scale
mathemat
epidemiolog
model
suggest
neuraminidas
inhibitor
could
use
control
outbreak
human
use
earli
intervent
realtim
diagnost
method
avail
surveil
human
anim
facilit
intensifi
surveil
studi
around
globerec
develop
outbreak
discuss
key
observ
outbreak
discuss
context
outbreak
dutch
influenza
viru
outbreak
netherland
context
pandem
last
centuri
antimicrobi
pkpd
object
stochast
forecast
method
mont
carlo
simul
mc
increasingli
use
predict
pharmacokinet
pk
variabl
antimicrobi
popul
base
wellcharacter
data
rel
subject
previous
shown
multiplemodel
mm
approach
stochast
pk
simul
associ
higher
precis
convent
mc
wellcharacter
cohort
tam
icaac
howev
abil
extrapol
cohort
depend
size
sampl
popul
investig
sampl
size
necessari
provid
robust
pk
predict
use
mm
simul
method
univers
popul
consist
subject
linear
model
construct
use
known
model
paramet
valu
kel
h
kcp
h
kpc
h
v
l
dispers
cv
paramet
serial
concentr
h
central
compart
simul
mg
bolu
dose
normal
distribut
paramet
valu
correl
among
paramet
assum
system
nois
incorpor
fix
proport
drug
concentr
bestfit
paramet
estim
determin
use
nonparametr
adapt
grid
program
use
variou
sampl
size
pk
profil
randomli
pick
quadrupl
base
estim
mean
sd
sampl
popul
simul
use
mm
approach
weight
averag
simul
discret
vector
support
point
compar
deriv
known
valu
univers
popul
result
increas
size
sampl
popul
trend
toward
accur
consist
estim
univers
popul
observ
sampl
popul
size
found
necessari
achiev
error
mean
sd
estim
respect
conclus
result
suggest
infer
capabl
mm
pk
simul
depend
sampl
popul
size
order
obtain
reason
robust
pk
predict
nonparametr
model
deriv
sampl
popul
size
may
necessari
input
inform
method
data
systemat
review
identifi
pub
med
current
content
cochran
central
regist
control
trial
refer
relev
articl
review
random
clinic
trial
compar
continu
intermitt
intraven
administr
antibiot
regimen
examin
pharmacokinet
pharmacodynam
properti
includ
systemat
review
two
review
extract
independ
data
regard
clinic
set
number
particip
antimicrobi
agent
dosag
use
well
maximum
serum
concentr
c
max
trough
serum
concentr
c
min
steadi
state
plateau
serum
concentr
c
ss
area
concentrationtim
curv
auc
time
mic
mic
aucmic
elimin
rate
constant
elimin
halflif
volum
distribut
systemat
clearanc
result
total
random
clinic
trial
compar
pharmacokinet
pharmacodynam
data
antibiot
administ
continu
intermitt
intraven
mode
includ
analysi
mean
cmax
intermitt
administ
antibiot
higher
compar
c
ss
achiev
continu
infus
antibiot
elig
studi
c
max
averag
time
higher
c
ss
rang
c
ss
averag
time
higher
c
min
intermitt
administ
antibiot
rang
studi
length
time
drug
concentr
mic
respons
pathogen
longer
patient
receiv
antibiot
continu
conclus
mode
intraven
antibiot
administr
seem
greater
import
least
confront
bacteria
high
mic
continu
infus
antibiot
timedepend
bacteri
kill
seem
superior
mode
administr
pharmacodynam
point
view
compar
intermitt
case
multiresist
bacteri
infect
test
mutant
select
window
hypothesi
vitro
dynam
model
pro
con
firsov
lubenko
zinner
moscow
ru
cambridg
us
object
contradictori
report
enrich
resist
mutant
vitro
model
studi
simul
antibiot
pharmacokinet
probabl
relat
inappropri
experiment
design
data
analysi
mutant
select
window
msw
hypothesi
provid
better
understand
phenomenon
might
also
use
properli
relat
resist
simul
ratio
area
curv
auc
mic
test
hypothesi
select
resist
staphylococcu
aureu
studi
lypopeptid
glycopeptid
fluoroquinolon
simul
concentr
within
msw
method
three
fiveday
treatment
mimick
oncedaili
daptomycin
gatifloxacin
levofloxacin
moxifloxacin
twicedaili
vancomycin
ciprofloxacin
rang
h
aucmic
peak
antibiot
concentr
simul
close
mic
mic
mutant
prevent
concentr
mpc
mpc
chang
suscept
aureu
examin
daili
mic
determin
result
term
suscept
test
popul
analysi
select
resist
mutant
occur
antibiot
concentr
fell
msw
concentr
msw
similar
bellshap
aucmic
relationship
resist
establish
daptomycin
vancomycin
four
fluoroquinolon
base
find
aucmic
ratio
protect
select
resist
mutant
predict
h
lypopeptid
glycopeptid
h
fluoroquinolon
estim
concord
report
data
ciprofloxacinand
garenoxacinexpos
aureu
although
relationship
resist
time
antibiot
concentr
within
msw
tmsw
controversi
conclus
overal
avail
data
support
msw
hypothesi
addit
test
group
antibiot
need
also
examin
tmsw
relationship
resist
suggest
object
telavancin
tlv
lipoglycopeptid
multipl
mechan
action
exhibit
rapid
concentrationdepend
bactericid
activ
gram
posit
bacteria
includ
mrsa
demonstr
previous
tlv
bactericid
intracellular
mssa
icaac
compar
activ
tlv
extracellular
intracellular
form
mssa
mrsa
use
pharmacodynam
model
analys
timeand
doserespons
bacteria
drug
wide
rang
clinic
achiev
concentr
method
mssa
atcc
mrsa
atcc
use
infect
mous
human
macrophag
cell
expos
h
tlv
x
mic
activ
assess
examin
chang
cfu
recov
infect
cell
compar
initi
postinfect
inoculum
extracellular
activ
measur
parallel
use
whole
cultur
medium
cfu
count
result
tlv
mic
lgml
strain
extracellular
bactericid
activ
develop
bimod
fashion
concentr
h
zone
concentrationdepend
around
mic
ii
concentr
higher
x
mic
h
log
limit
detect
reach
strain
c
max
lg
ml
intracellular
activ
develop
slowli
lesser
extent
also
show
bimod
respons
respect
extracellular
concentr
tabl
describ
bimod
concentrationeffect
relationship
h
extracellular
h
intracellular
effect
observ
c
max
concentr
rang
express
x
mic
effect
chang
log
cfu
initi
inoculum
conclus
tlv
display
concentrationand
timedepend
bactericid
activ
extracellular
intracellular
mssa
mrsa
bimod
doserespons
observ
may
relat
multipl
mechan
action
tlv
data
support
use
tlv
infect
intracellular
aureu
present
compar
pharmacodynam
pd
moxifloxacin
levofloxacin
pneumonia
follow
exposur
bioequival
pdsurrog
paramet
dalhoff
schubert
h
stass
kiel
wuppert
de
object
usual
vitro
pharmacodynam
pd
studi
simul
pharmacokinet
pk
monitor
serum
human
follow
administr
standard
dose
drug
consequ
mechanist
comparison
drug
difficult
perform
sinc
pkpd
paramet
e
g
aucmic
c
max
mic
ratio
differ
aim
studi
investig
kill
kinet
lfx
mfx
pneumonia
spn
wild
type
first
step
mutant
exposur
drug
concentr
lead
equal
aucmic
c
max
mic
ratio
order
draw
conclus
mechan
action
method
onecompart
model
use
simul
fluctuat
serum
concentr
vitro
moxifloxacin
mxf
serum
concentr
declin
h
levofloxacin
lfx
h
simul
aucmic
mxf
lfx
rang
h
h
viabl
count
determin
everi
hour
h
h
parallel
actual
drug
concentr
quantit
time
need
reduc
inoculum
titr
time
erad
area
bactericid
kill
curv
aubkc
normal
initi
inoculum
calcul
wild
type
one
gyras
topoivmut
spn
serv
test
strain
result
gener
increas
mxfaucmic
ratio
translat
rapid
reduct
viabl
count
thu
earlier
erad
test
system
mxf
exert
concentrationdepend
antibacteri
effect
strain
aubkc
valu
decreas
continu
throughout
entir
rang
drug
exposur
lfx
exhibit
bimod
antispn
effect
activ
lfx
spn
strain
increas
aucmic
h
gain
antibacteri
activ
achiev
increas
lfx
exposur
phenomenon
pronounc
expos
step
mutant
increas
lfx
auc
conclus
exposur
spn
wild
type
step
mutant
equival
aucmic
cmaxmic
ratio
either
mxf
lfx
result
differ
antispn
effect
bioequival
drug
exposur
either
mxf
lfx
translat
equal
bactericid
efficaci
spn
indic
mxf
lfx
share
pdtarget
maxim
antibacteri
effect
thu
one
pkpd
surrog
paramet
fit
fluoroquinolon
pharmacokinet
moxifloxacin
tissu
femal
urogenit
tract
h
stass
h
delesen
kubitza
halabi
ch
gleiter
wuppert
kiel
tubingen
de
object
studi
pharmacokinet
pk
moxifloxacin
urogenit
tract
femal
patient
undergo
surgeri
due
gynecolog
indic
openlabel
prospect
singlecentr
studi
method
pk
moxifloxacin
plasma
tissu
sampl
predominantli
uteru
biopsi
determin
patient
singl
intraven
h
infus
moxifloxacin
mg
biopsi
collect
h
group
b
c
e
respect
start
infus
plasma
sampl
collect
h
moxifloxacin
concentr
analys
use
valid
hplc
fluoresc
assay
pk
analysi
use
noncompartment
method
statist
analysi
pk
use
anova
result
plasma
pk
compar
result
obtain
studi
healthi
volunt
patient
undergo
abdomin
surgeri
moxifloxacin
concentr
plasma
genit
tract
tissu
shown
tabl
geometr
mean
cv
moxifloxacin
penetr
well
tissu
femal
urogenit
tract
moxifloxacin
concentr
exceed
mic
suscept
pathogen
encount
gynecolog
infect
entir
studi
period
concentr
significantli
higher
found
plasma
see
tabl
incl
ci
conclus
pk
data
suggest
moxifloxacin
suitabl
option
treat
femal
patient
suffer
infect
urogenit
tract
object
determin
pharmacokinet
pk
moxifloxacin
gastrointestin
gi
tissu
patient
elig
elect
surgeri
random
openlabel
prospect
multicentr
studi
method
pk
moxifloxacin
plasma
gi
tissu
determin
male
femal
patient
singl
intraven
h
infus
moxifloxacin
mg
immedi
prior
surgeri
surgeri
time
allow
gi
tissu
sampl
collect
gut
wall
specimen
h
group
b
c
e
respect
start
infus
plasma
sampl
collect
h
moxifloxacin
concentr
analys
use
valid
hplc
fluoresc
assay
pk
analysi
use
noncompartment
method
statist
analysi
pk
use
anova
result
plasma
pk
compar
result
previous
obtain
healthi
volunt
moxifloxacin
concentr
plasma
gitissu
shown
tabl
geometr
mean
cv
moxifloxacin
penetr
well
tissu
gitract
moxifloxacin
concentr
exceed
mic
suscept
pathogen
encount
intraabdomin
infect
eg
e
coli
entir
studi
period
concentr
significantli
higher
found
plasma
see
tabl
incl
ci
pk
data
suggest
moxifloxacin
suitabl
option
treat
patient
suffer
abdomin
infect
object
assess
penetr
tigecyclin
colon
wall
tissu
epitheli
line
fluid
elf
method
analys
includ
data
patient
without
infect
phase
intraabdomin
infect
phase
patient
receiv
mg
load
dose
follow
mg
everi
hour
intraven
tigecyclin
elf
phase
patient
steadyst
serum
sampl
collect
patient
n
colon
wall
elf
specimen
obtain
patient
without
infect
n
n
respect
separ
model
creat
elf
colon
wall
tissu
model
tissu
serum
data
simultan
comodel
use
bignpag
distinct
threecompart
open
model
zeroord
iv
input
firstord
elimin
employ
examin
full
rang
tissu
penetr
associ
probabl
two
subject
mont
carlo
simul
perform
one
elf
one
colon
wall
result
data
well
fit
use
model
describ
valu
result
mont
carlo
simul
tigecyclin
exposur
penetr
serum
colon
wall
tissu
elf
stratifi
infect
statu
present
tabl
patient
without
infect
median
colon
wall
elf
penetr
ratio
respect
see
tabl
estim
colon
wall
penetr
higher
patient
intraabdomin
infect
like
due
tissu
inflamm
conclus
simul
result
indic
tissu
penetr
vari
consider
patient
like
explain
unexpect
clinic
outcom
patient
infect
strain
margin
minimum
inhibitori
concentr
mic
distribut
pharmacokineticpharmacodynam
analys
efficaci
use
estim
serum
effect
site
tigecyclin
exposur
patient
complic
intraabdomin
infect
introduct
tigecyclin
demonstr
efficaci
treatment
complic
intraabdomin
infect
ciai
analys
design
examin
relationship
tigecyclin
exposur
measur
ratio
area
concentrationtim
curv
minimum
inhibitori
concentr
drug
organ
auc
mic
two
matric
serum
colon
wall
outcom
method
pk
analys
use
drug
concentr
phase
serum
colon
wall
concentr
noninfect
patient
phase
ciai
serum
studi
n
drug
concentr
data
comodel
use
npag
pkpd
analys
util
clinic
outcom
patient
covari
serumand
colon
wallbas
auc
mic
estim
base
infect
organ
highest
mic
valu
univari
multivari
logist
regress
backward
step
perform
covari
p
valu
univari
analys
consid
inclus
multivari
model
treebas
model
use
identifi
pkpd
breakpoint
predict
clinic
cure
pkpd
breakpoint
use
evalu
potenti
suscept
breakpoint
use
mont
carlo
simul
result
median
tissu
penetr
auccolon
wall
aucserum
ratio
phase
phase
patient
respect
patient
includ
pkpd
analys
mic
valu
drive
auc
mic
estim
primarili
base
enterobacteriacea
follow
anaerob
gram
posit
organ
object
emerg
resist
suggest
depend
dose
regimen
pharmacodynam
indic
pdi
numer
vitro
studi
studi
effect
ceftazidim
caz
dose
increment
frequenc
dose
select
cazresist
e
cloaca
intestin
treatment
pulmonari
infect
caus
k
pneumonia
rat
method
rat
pulmonari
infect
n
per
group
receiv
dose
mgkgday
caz
frequenc
h
day
start
h
bacteri
inocul
emerg
resist
e
cloaca
monitor
cultur
fresh
stool
specimen
day
agar
plate
lgml
without
caz
caz
pharmacokinet
assess
infect
rat
determin
pdi
well
time
insid
mutat
select
window
regimen
cazresist
mutant
e
cloaca
isol
characteris
variou
way
among
determin
activ
cefoxitininduc
noninduc
condit
result
reduct
suscept
e
cloaca
isol
faec
observ
day
show
signific
correl
fauc
significantli
cazresist
e
cloaca
isol
day
anim
expos
dose
mgkgday
administ
h
inject
frequenc
compar
h
inject
frequenc
number
cazresist
e
cloaca
day
correl
time
caz
plasma
concentr
insid
mutat
select
window
cazresist
mutant
mic
lgml
characteris
stabl
derepress
mutant
conclus
reduct
e
cloaca
depend
total
daili
dose
caz
emerg
resist
correl
time
within
select
window
significantli
stabli
derepress
caz
resist
e
cloaca
mutant
select
dose
mgkgday
caz
administ
frequenc
h
instead
h
object
aim
present
studi
assess
whether
express
trigger
receptor
express
myeloid
surfac
blood
neutrophil
monocyt
concentr
solubl
form
correl
progress
septic
syndrom
method
patient
enrol
studi
present
septic
syndrom
ascpsccm
criteria
induc
ventil
associ
pneumonia
peripher
blood
collect
upon
onset
sepsi
day
thereaft
estim
surfac
neutrophil
monocyt
solubl
serum
red
blood
cell
lyze
ammonium
chlorid
leukocyt
wash
three
time
pb
stain
phycoerythrinconjug
monoclon
antibodi
r
system
analys
flow
cytometri
solubl
serum
estim
immunoassay
result
enrol
patient
present
sepsi
sever
sepsi
septic
shock
median
valu
surfac
given
tabl
p
compar
sepsi
sever
sepsi
p
compar
sepsi
septic
shock
posit
correl
express
surfac
neutrophil
monocyt
detect
day
examin
p
correl
observ
express
surfac
myeloid
cell
concentr
solubl
form
conclus
increas
express
surfac
neutrophil
monocyt
cours
septic
syndrom
may
reflect
pivot
role
surfac
transit
sepsissever
sepsi
septic
shock
decreas
patient
septic
shock
may
design
antiinflammatori
role
solubl
counterpart
caenorhabd
elegan
kill
model
new
tool
studi
uropathogen
escherichia
coli
virul
object
sever
studi
suggest
correl
resist
quinolon
low
level
virul
factor
vf
relationship
resist
virul
base
presenceabs
vf
anim
studi
conduct
monitor
virul
vivo
examin
collect
extend
spectrum
betalactamas
esbl
produc
uropathogen
e
coli
strain
level
virul
use
nematod
c
elegan
test
uropathogen
e
coli
strain
isol
surveil
program
univers
hospit
strain
includ
esblproduc
e
coli
sensit
e
coli
strain
suscept
antimicrobi
test
isol
test
pcr
presenc
gene
encod
known
vf
c
elegan
infect
assay
use
worm
compar
entir
surviv
curv
nematod
kill
assay
use
cox
regress
spss
result
sensit
strain
possess
vf
respect
mean
surviv
time
c
elegan
infect
stage
day
sensit
strain
tem
strain
ctxm
strain
mean
surviv
time
worm
fed
control
strain
day
worm
infect
sensit
e
coli
kill
day
time
longer
worm
infect
temproduc
e
coli
produc
e
coli
cox
regress
show
infect
sensit
e
coli
strain
reduc
larval
surviv
factor
p
compar
nematod
infect
ctxmproduc
e
coli
strain
result
highli
repeat
sinc
differ
three
repetit
conclus
develop
novel
vivo
assay
assess
virul
properti
numer
e
coli
strain
effect
uropathogen
e
coli
strain
c
elegan
demonstr
signific
parallel
molecular
data
abil
kill
worm
significantli
correl
presenc
vf
antibiot
sensit
strain
kill
faster
tem
ctxm
strain
molecular
virul
profil
vivo
behaviour
suggest
ctxmgroup
genotyp
although
adapt
surviv
antibioticrich
environ
hospit
milieu
littl
intrins
virul
potenti
clump
factor
b
essenti
human
staphylococcu
aureu
nasal
colonis
object
staphylococcu
aureu
persist
colon
vestibulum
nasi
signific
fraction
human
risk
factor
subsequ
infect
mechan
nasal
colonis
unknown
studi
vitro
studi
small
rodent
present
studi
first
result
human
nasal
colon
model
aureu
adhesin
studi
method
defin
role
staphylocc
cytokeratinbind
proteinclump
factor
b
clfb
colon
process
artifici
inocul
human
volunt
wild
type
strain
singl
locu
clfb
knock
mutant
persist
follow
quantit
nasal
cultur
bacteri
genotyp
day
result
result
show
mutant
strain
elimin
vestibulum
nasi
volunt
significantli
faster
wild
type
median
day
versu
day
p
number
aureu
cfu
inocul
alway
higher
wild
type
strain
figur
load
statist
significantli
higher
day
week
averag
number
cfu
log
cfu
per
cultur
higher
wild
type
strain
cfu
versu
cfu
p
conclus
present
first
homo
data
show
clfb
protein
alreadi
prime
determin
nasal
aureu
carriag
alanin
ester
enterococc
lipoteicho
acid
role
biofilm
format
resist
antimicrobi
peptid
f
fabretti
c
theilack
kropec
koch
j
huebner
freiburg
de
boston
us
object
e
faecali
one
lead
caus
nosocomi
infect
increas
occurr
enterococc
strain
resist
multipl
antibiot
underscor
necess
better
understand
pathogen
microrgan
aim
present
studi
evalu
effect
dalanin
ester
teichoic
acid
biofilm
product
autolysi
antimicrobi
peptid
sensit
neutrophil
kill
opsonis
method
nonpolar
delet
dlta
gene
creat
clinic
e
faecali
strain
result
dltamut
compar
wildtyp
strain
microtit
biofilm
assay
triton
induc
autolysi
opsonophagocyt
assay
suscept
antimicrobi
cation
peptid
result
lta
purifi
wt
strain
dlta
delet
mutant
absenc
dalanin
lta
isol
mutant
confirm
nmr
wildtyp
strain
delet
mutant
show
signific
differ
autolysi
neutrophil
kill
opsonophagocytosi
mutant
strain
produc
significantli
less
biofilm
grown
presenc
glucos
compar
wild
type
mutant
strain
sensit
polymixin
b
consider
increas
mic
vs
ugml
colistin
vs
ugml
nisin
vs
um
conclus
data
confirm
main
effect
absenc
dalanin
lta
wta
increas
sensit
cation
antimicrobi
peptid
probabl
due
increas
net
neg
charg
surfac
alanin
residu
also
seem
enhanc
biofilm
product
shown
multifactori
process
probabl
involv
also
electrostat
interact
mediat
zwitterion
molecul
teichoic
acid
quinolon
induc
partial
total
loss
uropathogen
escherichia
coli
pathogen
island
two
differ
pathway
soto
mt
jimenez
de
anta
j
vila
barcelona
es
object
previou
studi
demonstr
quinolon
induc
loss
pathogen
island
pai
uropathogen
escherichia
coli
upec
object
present
studi
analys
pathway
use
quinolon
induc
loss
method
two
haemolyt
clinic
upec
nonhaemolyt
deriv
obtain
wild
type
strain
submit
sub
inhibitori
concentr
ciprofloxacin
select
knockout
mutant
reca
gene
gener
wildtyp
strain
interrupt
reca
gene
cassett
present
tetracyclin
resist
origin
strain
knockout
mutant
submit
subinhibitori
concentr
ciprofloxacin
determin
reca
involv
loss
pai
presenc
hli
hra
gene
test
pcr
use
genespecif
primer
result
recadid
show
loss
haemolysin
capac
strain
submit
subinhibitori
concentr
ciprofloxacin
indic
involv
reca
procedur
presenc
hra
gene
locat
extrem
pai
nonhaemolyt
deriv
indic
partial
loss
pai
hand
recashow
loss
haemolysin
capac
similar
wildtyp
strain
indic
case
reca
involv
procedur
moreov
nonhaemolyt
deriv
present
hra
gene
indic
total
loss
pai
conclus
quinolon
induc
loss
pai
two
differ
pathway
partial
loss
pai
contain
hli
gene
so
system
ii
total
loss
so
system
implic
recombin
express
characteris
put
streptococc
pyrogen
exotoxin
spegdi
speldi
spemdi
streptococcu
dysgalactia
subsp
equisimili
object
besid
human
pathogen
streptococcu
pyogen
ga
group
c
gc
g
gg
streptococci
pathogen
differ
mammalian
human
pathogen
gc
gg
hpgcsgg
streptococcu
dysgalactia
subsp
equisimili
caus
like
ga
wound
infect
otiti
media
pharyng
streptococc
toxic
shock
syndrom
recent
found
superantigen
sag
like
gene
spegdi
hpgg
later
gene
encod
speldi
spemdi
also
detect
hpgg
sequenc
encod
protein
spe
highli
homolog
fulli
ident
correspond
gene
group
streptococci
method
result
clone
three
gene
deriv
hpgg
e
coli
construct
put
signal
peptid
omit
three
recombin
protein
express
inclus
bodi
remain
solubl
urea
buffer
minimum
concentr
renatur
succeed
stabilis
mgml
albumin
follow
stepwis
reduct
urea
concentr
dialysi
tri
nacl
buffer
ph
prepar
test
lymphocyt
transform
test
ltt
cultur
filtrat
origin
hpgg
strain
show
human
cell
stimul
activ
manner
e
coli
express
recombin
protein
rspegdi
well
rspeldi
stimul
human
lymphocyt
rspemdi
still
investig
absenc
biolog
activ
surpris
recombin
put
spe
hpgg
contain
zinc
bind
region
hfd
bind
site
like
speg
spea
ga
recombin
protein
clone
ga
stimul
cell
seem
differ
aa
sequenc
hpgg
put
sag
ga
sag
respons
decreas
biolog
activ
protein
deriv
hpgg
conclus
activ
mitogen
human
cell
isol
hpgc
hpgg
activ
mitogen
far
came
group
c
group
g
streptococci
isol
hors
anim
instanc
spegdi
case
found
gene
transfer
hpgg
ga
suggest
gene
transfer
spe
gg
ga
gene
receiv
strain
alter
ga
may
chang
result
product
activ
sag
use
put
spe
hpgg
ltt
experi
cell
blood
anim
suscept
gcsgg
infect
progress
ebert
r
nau
u
michel
gottingen
de
object
activin
member
transform
growth
factorbeta
tgfbeta
famili
growth
differenti
factor
multifunct
cytokin
one
role
immun
system
inflammatori
process
follistatin
fs
high
affin
bind
protein
activin
antagonis
action
previous
demonstr
concentr
activin
fs
elev
serum
patient
septicemia
cerebrospin
fluid
csf
patient
mening
sourc
elev
concentr
protein
csf
yet
discov
method
primari
mous
microgli
cell
cultur
expos
tlr
agonist
tripalmitoylsglycerylcystein
tlr
endotoxin
lp
tlr
oligonucleotid
contain
unmethyl
cytosinguanosin
motif
cpg
tlr
hour
presenc
interferongamma
ifngamma
uml
concentr
activin
fs
cell
cultur
supernat
measur
elisa
r
system
gmbh
mannwhitneyutest
perform
analys
differ
activin
concentr
group
n
respect
pvalu
consid
statist
signific
data
express
median
minimummaximum
result
treatment
microgli
cultur
ifngamma
alon
control
group
activin
concentr
cell
cultur
supernat
detect
limit
elisa
combin
treatment
ifngamma
one
tlragonist
activin
concentr
cell
cultur
supernat
significantli
elev
pgml
treatment
ugml
lp
p
pgml
treatment
ugml
p
pgml
treatment
ugml
cpg
p
fs
concentr
group
detect
limit
elisa
discuss
result
show
first
time
microgli
cell
releas
activin
upon
activ
bacteri
tlragonist
find
provid
evid
role
activin
innat
immun
respons
suggest
microgli
cell
sourc
elev
activin
concentr
observ
csf
bacteri
mening
object
despit
regul
pia
synthesi
sigmab
regulon
epidermidi
still
almost
uncharacter
investig
influenc
sigmab
activ
secret
protein
investig
cultur
supernat
sigmab
mutant
gener
clinic
isol
epidermidi
method
protein
cultur
supernat
compar
use
sdspage
wild
type
mutant
strain
protein
identifi
differenti
express
characteris
use
malditof
mass
spectroscopi
transcript
gene
identifi
differenti
express
analys
use
quantit
rtpcr
result
two
protein
identifi
serin
proteas
cystein
proteas
significantli
upregul
sigmab
mutant
compar
respect
wild
type
transcript
analysi
reveal
respect
gene
repress
sigmab
depend
manner
phenotyp
analysi
reveal
significantli
increas
proteas
activ
investig
sigmab
mutant
therebi
strain
display
highest
proteolyt
activ
induc
mutant
inactiv
antisigmafactor
rsbw
still
intact
sigb
gene
display
reduc
proteas
activ
compar
respect
wild
type
strain
corrobor
neg
regul
extra
cellular
proteas
sigmab
one
protein
identifi
pre
proenzym
lipas
gehd
upregul
wherea
protein
significantli
reduc
howev
transcript
analysi
gehd
gene
reveal
increas
transcript
sigmab
mutant
zymograph
quantit
enzymat
analys
reveal
also
differenti
behaviour
investig
wild
type
mutant
display
increas
lipolyt
activ
seem
caus
increas
process
proenzym
fulli
activ
lipas
reduc
lipolyt
activ
detect
result
rapid
proteolyt
degrad
proenzym
activ
enzym
conclus
present
data
indic
sigmab
neg
transcript
regul
proteas
lead
increas
proteolyt
activ
sigmab
mutant
addit
sigmab
act
neg
regul
lipas
gehd
howev
lipolyt
activ
individu
strain
also
determin
proteolyt
activ
ak
szkaradkiewicz
b
tukiendorf
j
stopa
poznan
pl
object
etiopathogenesi
periodont
still
remain
unclear
diagnosi
requir
complex
procedur
therefor
studi
aim
examin
role
lactobacillu
spp
present
whole
saliva
adult
patient
moder
sever
periodont
method
materi
studi
involv
sampl
full
saliva
obtain
patient
year
age
clinic
criteria
permit
diagnos
moder
patient
sever
periodont
patient
sampl
full
saliva
healthi
individu
stationari
cari
year
age
serv
control
sampl
saliva
quantit
plate
rogosa
agar
cultur
isol
obtain
anaerob
condit
identifi
use
api
chl
biomerieux
parallel
detect
hydrogen
peroxid
product
isol
lactobacillu
spp
tmbplu
agar
appli
moreov
use
tmb
method
salivari
peroxidas
activ
estim
saliva
supernat
result
patient
moder
periodont
group
presenc
hydrogen
peroxideproduc
lactobacillu
spp
disclos
mean
content
lactobacilli
millionml
saliva
patient
sever
periodont
group
presenc
lactobacillu
spp
unabl
produc
hydrogen
peroxid
observ
mean
content
lactobacilli
millionml
saliva
control
group
saliva
patient
found
contain
hydrogen
peroxideproduc
lactobacillu
spp
remain
two
patient
saliva
contain
lactobacillu
spp
unabl
produc
hydrogen
peroxid
mean
content
lactobacilli
amount
millionml
saliva
parallel
activ
saliva
peroxidas
patient
sever
periodont
amount
uml
differ
activ
remain
group
p
conclus
hydrogen
peroxid
produc
lactobacillu
spp
exert
antimicrobi
effect
seem
protect
progress
periodont
detect
hydrogen
peroxid
produc
lactobacillu
spp
saliva
may
diagnost
import
evalu
risk
periodont
progress
mitochondria
newli
discov
target
gramposit
neg
bacteri
toxin
p
boquet
nice
fr
mitochondria
potenti
intracellular
target
bacteri
toxin
bacteri
virul
factor
ignor
long
time
although
mani
virus
alreadi
well
known
interfer
organel
past
year
follow
descript
group
vacuol
toxin
vaca
helicobact
pylori
target
mitochondria
mani
report
appear
literatur
show
mitochondria
classic
power
plant
cell
well
central
execution
death
sentenc
target
bacteri
toxin
virul
factor
particular
appear
pore
form
toxin
might
exert
patholog
effect
host
cell
direct
activ
mitochondria
induc
necrosi
apoptosi
recent
report
staphylococcu
aureu
pantonvalentin
leukocidin
howev
addit
poreform
toxin
nonpor
form
virul
factor
secret
bacteria
via
type
iii
secret
system
may
impact
mitochondria
provok
necrosi
apoptosi
may
alter
normal
host
physiolog
instanc
barrier
function
epithelium
present
show
mitochondria
may
consid
pathogen
bacteria
good
target
virul
event
lead
pathogen
implic
chemotherapyrel
mucos
barrier
injuri
n
blijleven
nijmegen
nl
mucos
alimentari
tract
clinic
manifest
mucos
barrier
injuri
induc
receiv
chemotherapi
without
irradi
affect
mouth
throughout
intestin
also
associ
advers
clinic
econom
outcom
recent
year
begun
unravel
pathogenesi
mucos
reveal
complex
dynam
pathobiolog
process
provid
biolog
basi
target
molecularbas
intervent
mucos
thought
occur
five
phase
initi
upregul
messag
gener
amplif
signal
ulcer
heal
risk
factor
systemat
evalu
charact
onset
progress
mucos
markedli
influenc
natur
intens
cytotox
insult
anticanc
therapi
activ
nuclear
transcript
factor
nfkb
result
product
releas
proinflammatori
cytokin
tnfa
lpsbind
protein
epitheli
cell
system
inflammatori
respons
seen
hsct
recipi
follow
myeloabl
therapi
mirror
pattern
mucos
barrier
injuri
measur
gut
integr
lr
ratio
daili
mucos
score
serum
citrullin
concentr
concentr
lbp
crp
alreadi
significantli
elev
first
week
transplant
profound
neutropenia
even
onset
fever
bacteraemia
inflammatori
respons
marker
reach
peak
serum
citrullin
concentr
reach
nadir
maximum
dm
attain
significantli
decreas
gut
integr
suggest
mucos
barrier
injuri
rather
system
infect
eg
bacteraemia
determin
onset
intens
inflammatori
responseepitheli
cell
integr
compon
anatom
immunolog
mucos
barrier
function
front
line
host
defenc
microorgan
gramposit
bacteraemia
tend
occur
far
often
among
stem
cell
transplant
recipi
gramneg
bacillari
infect
simpli
result
use
antimicrobi
prophylaxi
fluoroquinolon
bacteraemia
due
oral
viridan
streptococci
ov
miti
group
streptococcu
miti
streptococcu
orali
relat
mucos
damag
associ
seriou
complic
sepsi
adult
respiratori
distress
syndrom
carri
high
mortal
though
mucos
barrier
injuri
predictor
viridan
streptococc
shock
syndrom
coagulaseneg
staphylococci
con
frequent
caus
bacteraemia
though
frequent
relat
use
central
venou
cathet
also
relat
mucos
mucos
site
also
import
sourc
staphylococci
notwithstand
role
bacteria
augment
inflammatori
respons
mucos
barrier
injuri
remain
intrigu
anticanc
therapi
block
clonogen
epitheli
stem
cell
renew
result
apoptosi
necrosi
manifest
epitheli
atrophi
ulcer
lesion
ov
univers
commens
resid
oral
caviti
henc
lesion
might
offer
portal
entri
bacteria
could
either
pathogen
passeng
word
ov
bacteraemia
use
marker
markedli
disturb
mucos
barrier
rather
harbing
system
infect
ov
bacteraemia
indic
hsct
recipi
risk
develop
seriou
infecti
complic
even
signifi
increas
risk
mortal
mucos
report
risk
factor
bacteraemia
due
acinetobact
speci
stenotrophomona
maltophilia
capnocytophaga
speci
fusobacterium
nucleatum
addit
bacteraemia
due
staphylococcu
aureu
pseudomona
aeruginosa
certain
clostridium
speci
candida
speci
associ
neutropen
enterocol
typhliti
extrem
manifest
treatmentinduc
mucos
barrier
injuri
appear
result
disturb
delic
balanc
host
microbi
flora
set
prolong
exposur
antibiot
given
complex
relationship
fever
neutropenia
infect
context
mucos
barrier
injuri
seem
exercis
futil
attempt
circumv
bacteraemia
tackl
one
facet
process
inde
antimicrobi
therapi
alon
without
use
haematopoiet
growth
factor
success
prevent
febril
neutropenia
rather
may
fruit
aim
either
downregul
inflammatori
respons
restor
mucos
barrier
jelinek
berlin
de
accord
million
peopl
suffer
malaria
episod
annual
million
letal
outcom
around
transmiss
occur
subsaharan
africa
falciparum
malaria
pose
increasingli
common
problem
endem
region
treatment
failur
increas
due
drug
resist
sever
endem
area
suffer
multiresist
falciparum
malaria
approxim
case
import
malaria
regist
annual
germani
conserv
estim
put
risk
infect
plasmodium
falciparum
east
west
africa
per
month
recent
studi
show
rate
high
depend
behaviour
travel
mortal
rate
reach
nonimmun
untreat
patient
fast
diagnosi
effect
treatment
mandatori
treatment
malaria
depend
sever
factor
speci
malaria
caus
infect
sever
infect
age
infect
individu
pattern
drug
resist
malaria
treatment
area
individu
acquir
infect
identifi
earli
treat
appropri
almost
malaria
complet
cure
howev
even
short
delay
diagnosi
malaria
make
treatment
difficult
less
success
current
recommend
offer
varieti
highli
effect
antimalari
treatment
chosen
accord
specif
need
individu
patient
data
european
network
import
infecti
diseas
surveil
tropneteurop
show
wide
disparag
use
treatment
regimen
malaria
throughout
europ
translat
signific
differ
treatment
cost
inpati
time
variou
european
countri
public
expert
statement
european
treatment
standard
seem
highli
desir
view
futur
streamlin
strategi
tropneteurop
done
first
step
direct
public
statement
treatment
sever
falciparum
malaria
europ
malaria
chemoprophylaxi
wwwtropnetnet
method
rectal
swab
collect
msm
seen
proctiti
medic
clinic
san
francisco
attempt
isol
chlamydia
trachomati
made
cycloheximid
treat
l
cell
lgv
strain
differenti
trachoma
biovar
growth
characterist
requir
centrifug
lgv
isol
still
avail
sent
amsterdam
test
pcr
sequenc
ompa
gene
type
result
isol
type
result
shown
tabl
earli
chlamydia
commonli
recov
proctiti
case
isol
rate
drop
case
throughout
time
lgv
strain
isol
modern
molecular
method
confirm
earlier
biolog
identif
lgv
biovar
san
francisco
isol
posit
lgv
variant
realtim
pcr
sequenc
variabl
segment
ompa
gene
identifi
prototyp
genovari
spaargaren
et
al
emerg
infect
di
conclus
chlamydia
commonli
recov
rectal
swab
msm
proctiti
earli
isol
rate
drop
earli
throughout
time
isol
lgv
thought
new
strain
first
identifi
netherland
major
caus
recent
outbreak
actual
isol
obtain
san
francisco
year
ago
result
suggest
chlamydia
becam
less
common
caus
proctiti
gay
commun
modifi
behaviour
respons
aid
lgv
proctiti
common
like
maintain
core
group
continu
riski
behaviour
may
expand
recent
year
relax
safesex
behaviour
concomit
increas
std
role
chlamydia
trachomati
chronic
prostatitischron
pelvic
pain
syndrom
object
aim
studi
determin
role
chlamydia
trachomati
patient
differ
form
chronic
prostatitischron
pelvic
pain
syndrom
cpcpp
method
patient
least
month
clinic
evid
cpcpp
well
healthi
volunt
includ
studi
patient
healthi
individu
antibiot
treatment
preced
month
evalu
mear
stamey
local
techniqu
categor
cpcpp
perform
accord
nation
institut
health
nih
classif
commerci
pcr
amplisen
russia
primer
specif
c
trachomati
urethr
swab
us
express
prostat
secret
ep
perform
patient
chronic
bacteri
prostat
cbp
nih
categori
ii
patient
inflammatori
cpp
nih
categori
iiia
patient
noninflammatori
cpp
nih
categori
iiib
healthi
volunt
result
accord
pcr
data
among
patient
cbp
c
trachomati
found
case
us
ep
among
patient
inflammatori
cpp
case
us
well
ep
among
patient
noninflammatori
cpp
case
us
ep
correspondingli
among
healthi
volunt
c
trachomati
found
case
patient
noninflammatori
cpp
ep
sampl
pcrposit
wherea
us
sampl
pcrneg
c
trachomati
statist
signific
differ
among
frequenc
detect
c
trachomati
patient
cbp
inflammatori
cpp
noninflammatori
cpp
healthi
individu
us
ep
sampl
conclus
rate
pcrposit
result
c
trachomati
patient
clinic
prostat
syndrom
healthi
individu
demonstr
doubt
etiolog
role
infect
cpcpp
howev
take
account
high
virul
c
trachomati
reproduct
system
routin
evalu
patient
prostat
syndrom
pathogen
might
use
c
trachomati
may
assess
caus
agent
cpcpp
men
pcrposit
ep
sampl
pcrneg
us
sampl
organ
object
common
sexual
transmit
bacteri
pathogen
chlamydia
trachomati
ct
neisseria
gonorrhoea
ng
purpos
studi
evalu
accept
feasibl
selftaken
vagin
swab
sv
firstcatch
urin
sampl
fcu
sampl
detect
ct
gc
young
women
attend
public
health
std
clinic
method
young
women
age
visit
public
health
std
clinic
august
august
particip
patient
instruct
take
sv
fcu
educ
stdnurs
patient
fill
questionnair
concern
demograph
data
reason
std
examin
accept
method
prefer
examin
method
sampl
test
presenc
ct
gc
naat
intern
inhibit
control
strand
displac
amplif
assay
sda
becton
dickinson
probetec
et
system
compar
test
result
sv
fcu
specimen
focus
analysi
percent
agreement
result
method
result
ct
ng
diagnos
patient
respect
femal
particip
never
previous
std
examin
test
std
posit
mention
undergo
intimit
vagin
examin
one
reason
go
public
health
std
clinic
self
collect
vagin
swab
almost
uniformli
report
easi
perform
self
collect
urin
sampl
vagin
swab
prefer
gynaecolog
examin
percent
agreement
test
ct
gc
conclus
ct
ng
preval
among
young
women
yet
willing
undergo
tradit
gynaecolog
std
test
limit
effort
enhanc
complianc
test
among
atrisk
women
need
sv
fcu
appropri
specimen
highli
sensit
std
diagnosi
sv
fcu
highli
accept
feasibl
among
risk
group
therefor
easi
sampl
method
would
good
use
clinic
nonclin
set
test
provid
new
opportun
std
control
increas
std
test
coverag
among
young
women
enabl
noninvas
detect
mani
std
would
otherwis
remain
undiagnos
untreat
asymptomat
bacteriuria
last
fluctuat
condit
among
elderli
live
commun
n
rodh
l
englund
lstad
falun
se
background
asymptomat
bacteriuria
abu
common
among
elderli
institut
care
less
known
preval
among
elderli
live
commun
set
even
less
known
turnov
abu
popul
better
knowledg
area
brick
import
work
reduc
unnecessari
use
antibiot
object
studi
preval
turnov
abu
popul
elderli
peopl
age
live
noninstitut
commun
set
method
design
longitudin
cohort
studi
set
catchment
area
primari
health
care
center
swedish
middles
town
particip
everi
resid
area
age
invit
women
men
particip
measur
baselin
month
urin
specimen
cultur
posit
cultur
repeat
within
two
week
confirm
abu
presenc
leukocyt
esteras
urinari
nitrit
record
result
percentag
bacteriuria
women
men
correspond
figur
abu
women
men
test
three
time
abu
found
least
women
men
abu
occur
time
follow
consecut
sampl
posit
convers
rate
go
abu
neg
abu
posit
result
neg
convers
rate
e
coli
found
almost
subject
abu
conclus
bacteriuria
common
rate
turnov
consider
among
elderli
live
noninstitut
commun
set
whether
persist
abu
caus
differ
strain
e
coli
analys
recurr
urinari
tract
infect
caus
escherichia
coli
gualandri
endimiani
g
brigant
f
luzzaro
toniolo
vares
introduct
escherichia
coli
common
pathogen
isol
urinari
tract
infect
uti
infect
occur
frequent
healthi
women
reinfect
within
six
month
first
uti
episod
fluoroquinolon
fq
trimethoprimsulfamethoxazol
sxt
frequent
empir
treatment
use
uti
notabl
underestim
uti
progress
seriou
ill
bloodstream
infect
bsi
method
urinari
sampl
collect
institut
studi
retrospect
identif
antimicrobi
suscept
test
ast
achiev
use
phoenix
system
becton
dickinson
diagnost
system
spark
md
epicent
becton
dickinson
powerlab
unitech
milano
system
use
obtain
clinic
microbiolog
data
reinfect
defin
new
uti
occur
least
two
week
first
infecti
episod
result
studi
period
patient
diagnos
uti
due
e
coli
observ
reinfect
found
patient
major
women
communityacquir
uti
averag
utiyear
patient
detect
major
patient
episodesyear
respect
preval
age
group
year
year
respect
regard
first
isol
respons
recurr
uti
ast
result
show
follow
resist
incid
fq
sxt
ampicillin
amoxicillinclavulan
ceftriaxon
isol
caus
subsequ
infect
character
increas
resist
fq
sxt
ampicillin
amoxicillinclavulan
ceftriaxon
patient
recurr
uti
liabl
develop
bsi
patient
one
infecti
episod
respect
conclus
e
coli
recurr
uti
episod
occur
commonli
age
woman
communityacquir
infect
recurr
infect
may
evolv
bsi
frequent
patient
show
singl
uti
episod
high
incid
isol
resist
antimicrobi
eg
fq
sxt
underlin
ineffect
plan
adequ
empir
therapi
therefor
recurr
uti
opportun
use
suitabl
therapi
base
etiolog
ast
result
g
likataviciu
devaux
j
alix
nardon
behalf
eurohiv
introduct
incid
aid
westerneurop
stabilis
sinc
peak
easterneurop
continu
increas
aid
report
sinc
late
first
time
aid
incid
rate
greater
westerneurop
method
eurohiv
collat
inform
hivaid
countri
european
region
individu
data
compil
european
non
aggreg
aid
data
set
four
aid
indic
diseas
aid
id
report
one
case
present
data
countri
aid
indic
diseas
adult
adolesc
data
analys
geograph
region
west
centr
east
sex
data
aid
case
unavail
eight
countri
eight
exclud
aid
id
miss
aid
case
result
aid
case
report
countri
west
centr
east
frequent
aid
id
west
tuberculosi
tb
among
aid
id
pneumocysti
carinii
pneumonia
pcp
oesophag
candidiasi
hiv
wast
syndrom
toxoplasmosi
kaposi
sarcoma
centr
hiv
wast
syndrom
pcp
tb
oesophag
candidiasi
hiv
encephalopathi
toxoplasmosi
east
tb
hiv
wast
syndrom
oesophag
candidiasi
hiv
encephalopathi
recurr
pneumonia
candidiasi
bronchi
trachea
lung
among
women
tb
frequent
report
aid
id
west
centr
east
among
men
frequent
report
aid
id
pcp
west
hiv
wast
syndrom
centr
tb
east
conclus
west
two
common
aid
id
tb
pcp
whilst
centr
hiv
wast
syndrom
pcp
common
aid
epidem
east
close
relat
tb
epidem
nevertheless
higher
proport
certain
indic
diseas
hiv
wast
syndrom
encephalopathi
recurr
pneumonia
rais
question
access
treatment
diagnosi
aid
polymorph
tolllik
receptor
influenc
suscept
hiv
infect
clinic
cours
object
tolllik
receptor
tlr
key
role
innat
immun
particip
antivir
defenc
mechan
examin
whether
singl
nucleotid
polymorph
snp
tlr
influenc
suscept
cours
hiv
infect
swiss
hiv
cohort
method
snp
tlr
analys
haart
naiv
hiv
patient
case
blood
donor
control
use
sequenom
technolog
distribut
snp
frequenc
compar
case
control
hiv
patient
tcell
declin
calcul
use
least
squar
regress
line
model
use
latent
variabl
impact
tlr
snp
cell
declin
hiv
rna
evalu
use
linear
regress
model
logist
regress
model
use
estim
risk
associ
snp
compar
rapid
progressor
slope
percentil
slow
progressor
slope
percentil
other
patient
result
snp
linkag
disequilibrium
frequent
hiv
patient
control
carrier
statu
frequenc
versu
ci
p
frequenc
versu
ci
p
frequenc
versu
ci
p
among
hiv
case
two
snp
linkag
disequilibrium
untransl
independ
associ
faster
declin
snp
show
addit
effect
declin
mean
slope
aa
ag
p
gg
p
stratifi
hiv
patient
progress
group
observ
carrier
frequent
among
rapid
progressor
other
ci
p
ga
versu
aa
ci
p
gg
versu
aa
similar
result
found
calcul
slope
individu
regress
latent
variabl
conclus
first
demonstr
associ
tlr
snp
progress
hiv
infect
addit
found
differ
distribut
snp
hiv
individu
healthi
blood
donor
genet
studi
cohort
help
assess
role
snp
prognost
marker
hiv
infect
vitro
studi
allow
understand
function
role
tlr
mutat
hiv
infect
chronic
immun
activ
major
determin
aid
pathogenesi
role
type
interferon
respons
stapran
kluck
barri
r
chavan
k
dalbey
g
silvestri
feinberg
atlanta
us
object
pathogen
simian
immunodefici
viru
siv
infect
nonhuman
primat
eg
rhesu
macaqu
hiv
infect
human
character
cell
deplet
associ
high
viremia
gener
immun
activ
contrast
siv
infect
primat
natur
host
reservoir
siv
sooti
mangabey
character
cell
preserv
absenc
aberr
immun
activ
despit
highlevel
viremia
suggest
chronic
gener
immun
activ
associ
immunopatholog
import
determin
aid
direct
cytopath
effect
viru
replic
current
studi
aim
elucid
cellular
molecular
basi
whether
chronic
immun
activ
attend
immunopatholog
follow
cell
tropic
lentiviru
infect
method
develop
compar
infect
model
studi
host
innat
adapt
immun
respons
diverg
follow
siv
infect
mangabey
macaqu
compar
result
obtain
studi
hivinfect
human
result
differ
innat
immun
respons
eg
dendrit
cell
dc
activ
migrat
siv
infect
evid
first
day
infect
differ
vivo
behaviour
dc
recapitul
follow
ex
vivo
exposur
plasmacytoid
dc
pdc
specif
tolllik
receptor
tlr
ligand
inactiv
siv
contrast
pdc
macaqu
human
mangabey
pdc
produc
significantli
lower
level
interferon
alpha
respons
ligand
sivappar
result
diverg
propag
activ
signal
along
postreceptor
pathway
organism
level
gene
express
profil
studi
indic
major
featur
distinguish
pathogen
nonpathogen
hivsiv
infect
extent
type
ifn
product
respons
profil
manifest
conclus
mangabey
avoid
aid
genet
program
failur
innat
immun
system
respond
siv
type
ifn
respons
enabl
antiinflammatori
immun
respons
protect
natur
host
bystand
damag
seen
pathogen
hiv
infect
elev
circul
hlag
level
hivinfect
patient
without
viscer
leishmaniasi
l
donaghi
f
gro
l
amiot
c
mari
maillard
c
guiguen
jp
gangneux
renn
marseil
fr
object
hlag
non
classic
class
histocompat
complex
molecul
capabl
inhibit
cell
prolifer
cytotox
cell
nk
mediat
lysi
hlag
molecul
seem
involv
viral
persist
surfac
express
markedli
increas
peripher
blood
mononuclear
cell
hivinfect
patient
compar
data
avail
express
level
plasma
solubl
hlag
shlag
isoform
hivinfect
patient
without
opportunist
infect
measur
full
length
shlag
isoform
hivseroposit
seroneg
patient
without
viscer
leishmaniasi
vl
healthi
control
method
shlag
level
measur
elisa
sandwich
method
serum
subject
hivseroneg
vl
vl
infect
result
shlag
concentr
statist
differ
among
group
subject
p
frequenc
shlag
posit
group
statist
differ
group
p
shlag
elisa
posit
hivinfect
patient
hivvl
coinfect
patient
shlag
elisa
posit
hivseroneg
patient
vl
healthi
control
conclus
result
confirm
strong
cell
surfac
express
hlag
molecul
hiv
infect
demonstr
level
plasma
solubl
form
also
elev
hivleishmania
coinfect
patient
shlag
secret
could
contribut
tolerogen
environ
might
help
leishmania
parasit
evad
cellmedi
immun
respons
patient
object
studi
pattern
resist
peripher
blood
mononuclear
cell
pbmc
plasma
treat
infect
individu
determin
whether
drugresist
variant
persist
blood
treatment
interrupt
method
plasma
pbmc
collect
heavili
treat
hiv
infect
individu
genotyp
revers
transcriptas
rt
proteas
gene
pro
perform
use
fluoresc
dideoxytermin
method
trugen
hiv
drug
resist
defin
accord
genotip
resist
interpret
algorithm
guid
linestm
rule
result
comparison
amino
acid
sequenc
rt
pro
gene
cellassoci
variant
plasma
reveal
patient
test
exhibit
differ
genotyp
resist
pattern
discord
sampl
ds
consequ
differ
resist
report
sampl
show
concord
resist
report
resist
pattern
detect
cellassoci
compart
differ
plasma
viru
presenc
andor
absenc
one
mutat
sampl
studi
pattern
resist
detect
concord
two
compart
ds
expect
plasma
compart
higher
number
mutat
howev
remain
case
ds
higher
number
mutat
found
provir
dna
analysi
genotyp
resist
pbmc
plasma
treatment
interrupt
perform
far
patient
reveal
rebound
wild
type
viru
plasma
strictli
depend
viral
popul
archiv
pbmc
conclus
hiv
mutat
pattern
detect
plasma
necessarili
reflect
mutat
pattern
detect
cellassoci
compart
observ
provir
dna
may
contain
archiv
differ
resist
variant
make
provir
reservoir
interest
substrat
analysi
resistancepotenti
given
patient
molecular
epidemiolog
tool
public
health
symposium
jointli
arrang
eupha
reconstruct
hcv
transmiss
histori
use
phylogenet
popul
genet
method
hepat
c
viru
hcv
genet
divers
rna
viru
infect
least
million
peopl
worldwid
hcvassoci
mortal
expect
increas
substanti
futur
estim
cost
billion
per
year
usa
alon
success
hcv
treatment
prevent
strategi
must
ground
clear
understand
hcv
transmiss
dynam
howev
standard
longitudin
survey
particularli
inform
hcv
epidem
began
viru
discov
ii
insuffici
archiv
strain
reliabl
measur
seropreval
retrospect
iii
absenc
specif
symptom
hinder
estim
past
preval
medic
record
result
analys
partial
genom
sequenc
particularli
gene
proven
crucial
investig
hcv
epidemiolog
recent
develop
method
base
phylogenet
popul
genet
model
use
date
origin
hcv
outbreak
estim
past
rate
transmiss
track
migrat
differ
strain
among
locat
risk
group
genotyp
measl
virus
monitor
elimin
process
diseas
santibanez
wolbert
mankertz
siedler
burki
tischer
berlin
de
basel
ch
set
goal
elimin
measl
european
region
year
low
incid
measl
case
per
mio
popul
year
absenc
endem
transmiss
achiev
impli
transmiss
indigen
measl
viru
mv
interrupt
import
mv
establish
longterm
circul
therefor
level
measl
suscept
popul
kept
low
possibl
maintain
high
immun
coverag
two
dose
measl
vaccin
genet
data
detect
mv
essenti
trace
pathway
viru
transmiss
inform
requir
discrimin
whether
local
appear
measl
due
viru
import
reflect
still
ongo
circul
indigen
viru
standard
nomenclatur
genotyp
mv
introduc
enabl
descript
mv
circul
global
context
present
distinct
mv
genotyp
recogn
experi
show
countri
areawid
continu
monitor
measl
level
incid
correl
pattern
mv
genotyp
demonstr
germani
laboratori
support
nationwid
measl
sentinel
establish
genotyp
data
period
year
reveal
sporad
case
observ
recent
eastern
part
mainli
caus
import
mv
genotyp
contrast
western
part
endem
transmiss
observ
associ
mv
genotyp
newli
emerg
endem
transmiss
taper
measl
occur
sporad
nationwid
incid
measl
decreas
howev
local
outbreak
occur
feder
state
hess
bavaria
hess
outbreak
due
import
mv
romania
epidem
observ
sinc
last
quarter
origin
mv
caus
bavarian
outbreak
howev
remain
unknown
observ
two
independ
outbreak
demonstr
despit
declin
measl
incid
recent
year
potenti
limit
circul
mv
still
present
germani
studi
perform
switzerland
onward
also
indic
absenc
endem
transmiss
import
mv
genotyp
predominantli
detect
could
even
establish
limit
circul
correspond
incid
measl
remark
increas
year
decreas
studi
demonstr
assess
level
achiev
process
measl
elimin
essenti
combin
mv
genotyp
inform
epidemiolog
data
even
european
region
circul
former
widespread
mv
genotyp
may
interrupt
mani
countri
nonetheless
continu
countri
molecular
biolog
diagnosi
identif
mycobacteria
e
tortoli
florenc
avail
new
tool
molecular
biolog
deepli
affect
diagnost
microbiolog
particular
concern
organ
character
problemat
growth
cultur
even
cultiv
sinc
earli
develop
nucleic
acid
amplif
techniqu
mycobacterium
tuberculosi
consid
one
attract
target
dream
rapid
diagnosi
tuberculosi
appear
within
reach
immedi
pioneer
period
character
develop
variou
homemad
techniqu
readytous
commerci
kit
spread
worldwid
evid
routin
practic
standard
conveni
robust
offer
commerci
system
advantag
counter
balanc
higher
sensit
ant
lower
cost
home
made
method
three
commerci
method
monopol
present
market
amplifi
mycobacterium
tuberculosi
direct
genprob
usa
base
transcriptasemedi
amplif
tuberculosisspecif
trait
rrna
amplicor
roch
usa
amplifi
use
classic
pcr
procedur
genusmycobacteriumspecif
segment
rdna
bdprobetec
et
reli
strand
displac
amplif
aim
portion
hundr
paper
evalu
compar
kit
without
find
substanti
differ
among
easi
perform
suitabl
routin
highli
specif
poorli
sensit
possibl
detect
inhibitor
present
two
method
sole
realli
import
distinct
featur
although
commerci
amplif
kit
licens
respiratori
specimen
commonli
use
extra
pulmonari
specimen
use
consid
improp
moder
lower
sensit
emerg
sampl
imput
lower
bacteri
charg
character
univers
agre
reliabl
amplif
method
direct
detect
tuberculosi
satisfactori
microorgan
unsatisfactori
sensit
among
possibl
reason
limit
problemat
extract
dna
imput
extrem
simplifi
procedur
may
problem
uniqu
structur
mycobacteri
cell
wall
uneven
textur
mucou
matrix
respiratori
sampl
far
commonli
investig
specimen
stand
limit
unquestion
exclud
possibl
use
amplif
techniqu
substitut
microscopi
cultur
therefor
remain
backbon
diagnost
mycobacteriolog
new
gener
nucleic
acid
amplif
system
base
real
time
pcr
round
corner
although
seem
potenti
replac
present
method
littl
inform
far
avail
less
import
field
applic
molecular
method
mycobacteriolog
concern
speci
identif
taxonomi
genu
mycobacterium
reveal
complex
unsuspect
year
ago
number
offici
recogn
speci
exce
nowaday
like
still
substanti
increas
undoubt
rapid
differenti
non
tubercul
mycobacteria
member
tuberculosi
complex
crucial
identif
everi
strain
specieslevel
howev
also
import
assess
clinic
signific
find
case
set
proper
treatment
popular
method
identif
mycobacteria
includ
pcrrestrict
analysi
pra
genet
probe
hybrid
dnaprob
pra
first
develop
telenti
year
ago
base
enzymat
digest
fragment
gene
separ
use
two
differ
restrict
enzym
bsteii
haeiii
proper
algorithm
drive
microbiologist
final
identif
size
restrict
fragment
care
determin
mean
electrophoresi
method
inexpens
easi
perform
increas
number
speci
show
overlap
profil
major
limit
presenc
multipl
pattern
within
singl
speci
although
confus
counterbalanc
opportun
recogn
differ
biotyp
pra
essenti
homemad
method
dnaprob
almost
sole
reli
commerci
kit
sever
approach
commerci
three
differ
firm
present
avail
aim
differ
region
within
ribosom
dna
operon
target
method
base
liquid
phase
hybrid
accuprob
genprob
usa
rrna
amplif
requir
posit
result
reveal
product
chemioluminesc
signal
hybridizationprotect
assay
method
highli
specif
rapid
handi
howev
suitabl
identifi
littl
number
speci
may
result
costli
test
one
probe
requir
altern
methodolog
solid
phase
revers
hybrid
reli
multipl
probe
immobil
differ
posit
cellulos
strip
amplifi
biotinyl
genet
target
hybrid
specif
probe
colour
band
develop
follow
addit
avidinenzym
conjug
chromogen
substrat
known
posit
strip
differ
speciesspecif
probe
lead
identif
basi
locat
colour
hybrid
band
becom
therefor
possibl
identifi
singl
test
multipl
speci
inno
lipa
mycobacteria
innogenet
belgium
aim
intern
transcrib
spacer
identifi
differ
speci
two
differ
strip
becam
recent
avail
rival
system
genotyp
mycobacterium
hein
germani
direct
rdna
combin
two
strip
allow
identifi
mani
speci
specif
sensit
revers
hybridizationbas
test
excel
even
minor
cross
reaction
rare
encount
speci
report
sequencingbas
identif
reli
insight
dna
probe
technolog
ie
investig
highli
conserv
genet
region
harbour
speciesspecif
variabl
sever
region
detect
mycobacteria
rdna
rdna
soda
reca
rpob
rdna
far
frequent
investig
character
presenc
two
hyper
variabl
region
within
first
bp
trait
allow
identif
almost
offici
speci
within
intraspeci
variabl
extrem
limit
correspond
databas
avail
internet
rich
much
larger
variabl
present
mani
speci
character
sever
sequevar
region
thank
characterist
use
differenti
speci
present
overlap
rdna
despit
import
databas
yet
report
sequenc
frequent
detect
rdna
contrast
poorli
variabl
sever
speci
identifi
region
rpob
gene
recent
propos
particularli
suitabl
identif
rapid
grower
high
variabl
character
region
seem
fact
particularli
suit
organ
includ
speci
sometim
undistinguish
level
rdna
genet
sequenc
refer
method
identifi
mycobacteria
differ
dna
probe
limit
exist
number
speci
identifi
repres
furthermor
power
research
tool
thank
number
speci
variant
enorm
increas
last
year
handili
searchabl
publicli
avail
databas
mainli
genbank
embl
repres
core
genet
sequenc
open
access
everyon
depos
new
sequenc
repres
time
major
valu
limit
one
hand
new
deposit
keep
databas
date
hand
lack
control
may
result
mislead
queri
sequenc
present
time
best
resembl
short
unreli
sequenc
hinder
signific
one
although
disregard
differenti
speci
belong
tuberculosi
complex
import
differ
suscept
pyrazinamid
character
tuberculosi
bovi
epidemiolog
reason
revers
hybrid
system
genotyp
mtbc
hein
target
differ
genom
region
rdna
gyrb
allow
easi
accur
differenti
frequent
encount
member
complex
concern
tuberculosi
molecular
biolog
made
avail
number
techniqu
provid
use
inform
branch
known
fingerprint
allow
differenti
tuberculosi
famili
even
singl
strain
epidemiolog
field
benefit
investig
less
import
util
recogn
mix
infect
distinguish
new
diseas
relaps
great
practic
import
final
monitor
laboratori
contamin
spoligotyp
base
polymorph
spacer
present
dr
region
suitabl
fine
differenti
optim
group
strain
larg
group
like
beij
famili
mani
other
restrict
fragment
length
polymorph
target
insert
element
present
variabl
number
copi
differ
posit
within
tuberculosi
genom
present
consid
gold
standard
suitabl
differenti
practic
almost
everi
tuberculosi
strain
recent
develop
method
investig
polymorph
tandem
repeat
sequenc
known
mycobacteri
interspers
repetit
unit
system
character
high
discriminatori
power
fulli
automat
potenti
provid
real
time
result
candid
becom
futur
refer
method
microarray
essenti
miniatur
multiprob
system
consid
last
develop
solid
phase
hybrid
techniqu
seem
like
pay
major
role
futur
mycobacteriolog
sever
prototyp
alreadi
develop
commit
commerci
compani
field
yet
import
microarray
becom
possibl
inquir
larg
number
genet
target
suitabl
provid
import
inform
identif
antimicrobi
suscept
fingerprint
mycobacteria
risk
underr
spread
techniqu
refer
laboratori
reliabl
sophist
technolog
reli
fact
high
special
user
infect
due
mycobacteria
tuberculosi
mott
nonhiv
patient
nontubercul
mycobacteria
ntm
also
known
mycobacteria
tuberculosi
mott
increasingli
divers
group
organ
speci
current
recogn
clinic
diseas
observ
multipl
speci
includ
man
mycobacterium
avium
intracellular
kansasii
major
caus
chronic
pulmonari
diseas
fortuitum
abscessu
marinum
ulceran
major
caus
chronic
skinsoft
tissu
diseas
emerg
ntm
diseas
includ
follicul
follow
use
foot
spa
abscessu
diseas
cystic
fibrosi
diseas
due
previou
anim
pathogen
includ
porcinum
senegalens
treatment
chronic
pulmonari
infect
due
avium
complex
abscessu
xenopi
remain
difficult
diseas
control
microbiolog
cure
endpoint
therapi
mani
patient
cutan
soft
tissu
diseas
develop
countri
usual
readili
treatabl
drug
resist
due
target
site
mutat
presenc
erm
gene
fortuitum
group
complic
drug
therapi
slowli
grow
rapidli
grow
speci
approv
clsi
clinic
lab
standard
institut
formerli
nccl
standard
suscept
test
ntm
approv
us
recommend
test
method
involv
broth
macrodilut
microdilut
laboratori
identif
increasingli
involv
molecular
method
older
methodolog
often
fail
recogn
newer
speci
current
identif
involv
number
gene
sequenc
includ
rrna
gene
initi
bp
intern
transcrib
spacer
region
gene
rpob
gene
use
rflp
pattern
sequenc
housekeep
gene
open
door
molecularbas
popul
studi
individu
speci
kansasii
studi
greatest
detail
use
gene
type
strain
recogn
major
human
pathogen
studi
ongo
involv
avium
simia
lentiflavum
studi
suggest
individu
clone
subspeci
associ
differ
host
differ
geograph
site
complet
genom
sequenc
multipl
strain
mani
ntm
major
need
better
understand
ntm
divers
pathogen
studi
slowli
take
place
environment
reservoir
ntm
remain
import
anim
bird
human
pathogen
increas
clinic
signific
object
assess
qualiti
manag
sore
throat
among
finnish
gener
practition
determin
good
manag
sore
throat
focus
microbiolog
test
possibl
group
streptococc
ga
tonsil
prescript
antibiot
posit
test
result
ga
prescript
analges
patient
sore
throat
method
oneweek
survey
mid
novemb
finnish
health
centr
popul
symptom
report
patient
parent
physician
report
diagnosi
diagnost
test
treatment
result
patient
sore
throat
one
symptom
complaint
patient
also
coryza
cough
among
patient
diagnos
tonsil
pharyng
urti
respiratori
infect
correspond
figur
among
patient
patient
tonsil
pharyng
urti
microbiolog
test
done
antibiot
prescrib
analges
correspond
figur
patient
sore
throat
coryza
cough
conclus
microbiolog
test
use
quit
frequent
test
done
coryza
cough
low
preval
ga
good
likelihood
ratio
test
result
guid
treatment
decis
correctli
even
pretest
probabl
ga
low
howev
excess
use
test
without
care
clinic
consider
increas
cost
manag
frequenc
prescript
antibiot
lower
microbiolog
test
howev
analysi
show
mani
prescript
given
without
test
diverg
routin
manag
good
clinic
practic
widest
use
analges
point
emphasis
inform
deliv
finnish
gener
practition
import
clinic
diagnosi
preced
use
microbiolog
test
treatment
use
analges
preval
streptococcu
viridan
isol
nasopharyng
sampl
children
attend
daycar
centr
alp
maritim
franc
oral
standard
azol
therapi
flu
mg
daili
itz
solut
mg
twice
daili
complet
remiss
week
patient
follow
least
day
randomis
overal
investigatordetermin
ifirel
mortal
secondari
endpoint
studi
evalu
use
kaplanmei
km
analysi
time
death
surviv
comparison
base
logrank
test
result
studi
although
fewer
patient
die
po
group
statist
signific
differ
overal
surviv
treatment
group
use
logrank
test
tabl
studi
significantli
fewer
overal
death
occur
po
group
probabl
surviv
day
randomis
significantli
higher
po
significantli
fewer
ifirel
death
observ
po
studi
conclus
prophylaxi
po
provid
signific
overal
surviv
benefit
among
aml
md
patient
undergo
chemotherapi
compar
azol
addit
po
prophylaxi
significantli
reduc
ifirel
mortal
hsct
recipi
gvhd
well
aml
md
patient
neutropenia
result
suggest
futur
prophylaxi
trial
design
adequ
power
detect
differ
overal
ifirel
mortal
differ
micalamb
adjust
neutropenia
correspond
ci
treatment
success
rate
similar
c
albican
infect
mica
vs
lamb
nonalbican
c
infect
mica
vs
lamb
modifi
intent
treat
popul
confirm
ic
least
one
dose
studi
drug
overal
treatment
success
mica
group
lamb
group
posttreat
period
differ
recurr
invas
fungal
infect
group
predefin
safeti
paramet
show
mica
advantag
lamb
renal
function
assess
estim
glomerular
filtrat
rate
lower
incid
infusionrel
reaction
p
conclus
studi
demonstr
noninferior
micafungin
versu
first
line
treatment
ic
advantag
micafungin
predefin
safeti
paramet
object
echinocandin
drug
mycamin
micafungin
show
superior
vitro
antifung
drug
efficaci
rel
cancida
caspofungin
yet
echinocandinclass
drug
show
high
level
bound
serum
protein
suggest
differenti
bind
differ
drug
could
alter
rel
antifung
efficaci
explor
possibl
differenti
effect
serum
micafungin
direct
comparison
caspofungin
examin
assay
vitro
antifung
suscept
epidemiolog
distinct
collect
clinic
isol
candida
spp
aspergillu
spp
method
determin
mic
mec
valu
caspofungin
micafungin
wide
rang
clinic
isol
candida
spp
aspergillu
spp
presenc
human
serum
assess
effect
human
serum
inhibit
glucan
synthas
activ
highli
enrich
prepar
glucan
synthas
obtain
productentrap
techniqu
use
determin
valu
inhibit
enzym
candida
albican
aspergillu
fumigatu
presenc
absenc
human
serum
result
human
serum
decreas
antifung
properti
caspofungin
micafungin
howev
human
serum
shift
vitro
antifung
potenc
micafungin
much
greater
extent
caspofungin
divers
candida
spp
aspergillu
spp
shift
reflect
potent
vitro
antifung
properti
micafungin
absenc
serum
yet
presenc
serum
yield
nearli
equival
mic
mec
valu
effect
negat
appar
vitro
superior
micafungin
rel
caspofungin
reduc
potenc
drug
presenc
serum
also
manifest
increas
less
potent
level
inhibit
glucan
synthas
gs
activ
gs
slightli
sensit
caspofungin
micafungin
absenc
serum
suggest
vitro
superior
micafungin
unrel
action
target
conclus
overal
data
suggest
presenc
serum
significantli
reduc
efficaci
micafungin
rel
caspofungin
clinic
import
candida
aspergillu
spp
impact
serum
effect
neutral
vitro
antifung
superior
micafungin
rel
caspofungin
vivo
signific
find
present
assess
vitro
resist
amphotericin
b
caspofungin
clinic
isol
c
glabrata
confirm
mous
model
object
candida
glabrata
isol
icu
patient
found
resist
amphotericin
b
andor
caspofungin
invitro
three
clinic
c
glabrata
isol
studi
mous
model
method
mic
determin
four
c
glabrata
strain
two
microdilut
method
clsi
eucast
use
rpmi
etest
timekil
curv
done
drug
media
outbre
nmri
mice
challeng
iv
treat
ip
group
six
daili
day
amphotericin
b
mgkgday
caspofungin
mgkgday
salin
mice
sacrif
day
five
kidney
remov
homogen
salin
cfu
determin
differ
cfu
control
versu
treat
mice
use
effect
paramet
pvalu
consid
signific
result
amphotericin
b
etest
four
strain
result
higher
micvalu
lgml
compar
broth
microdilut
method
lgml
respect
microdilut
method
differ
media
separ
amphotericin
b
suscept
amphotericin
b
resist
isol
poorli
caspofungin
suscept
resist
isol
separ
quit
clearli
mous
model
strain
amphotericin
b
etest
lgml
found
resist
intermedi
suscept
suscept
respect
mous
model
susceptibilityresist
caspofungin
confirm
conclus
amphotericin
b
resist
isol
c
glabrata
possibl
clinic
signific
determin
use
etest
easili
overlook
microdilut
method
resist
amphotericin
b
determin
etest
confirm
mous
model
suscept
determin
invitro
caspofungin
isol
c
glabrata
confirm
mous
model
effect
amphotericin
b
formul
antifung
activ
human
monocyt
neutrophil
medic
import
filament
fungi
j
doti
simitsopoul
dalakiourid
konstantin
walsh
e
roilid
thessaloniki
gr
bethesda
us
object
amphotericin
b
formul
ambf
deoxychol
damb
lipid
associ
liposom
lamb
lipid
complex
ablc
colloid
dispers
abcd
variou
immunomodulatori
activ
compar
effect
oxid
antifung
activ
human
monocyt
mnc
neutrophil
pmn
hypha
aspergillu
fumigatu
fusarium
solani
method
isol
healthi
blood
donor
mnc
pmn
incub
mgl
damb
mgl
lamb
ablc
abcd
co
hr
respect
super
oxid
anion
product
assess
reduct
cytochrom
c
respons
hypha
hyphal
damag
assess
xtt
assay
effector
cell
hypha
ratio
anova
dunn
test
use
analysi
n
mnc
n
pmn
result
produc
mnc
pmn
upon
hyphal
challeng
gener
affect
drug
except
mgl
damb
mgl
abcd
reduc
product
pmn
respons
fumigatu
p
comparison
ambf
result
signific
increas
damag
induc
mnc
pmn
fumigatu
f
solani
hypha
p
ratio
compar
untreat
mnc
pmn
especi
high
drug
concentr
ablc
induc
highest
increas
hyphal
damag
achiev
type
phagocyt
compar
ambf
effect
ambf
hyphal
damag
induc
mnc
pmn
concentrationdepend
effect
drug
pmn
hyphal
damag
much
higher
mnc
conclus
lack
enhanc
product
gener
increas
hyphal
damag
induc
mnc
pmn
two
filament
fungi
indic
nonoxid
destruct
mechan
respons
increas
hyphal
damag
immunomodulatori
differ
ambf
may
clinic
signific
manag
invas
aspergillosi
fusariosi
determin
effect
aminocandin
aspergillu
fumigatu
candida
albican
morpholog
ultrastructur
use
confoc
scan
laser
microscopi
scan
electron
microscopi
ghannoum
dutta
j
chandra
cleveland
us
object
aminocandin
ac
new
member
echinocandin
class
antifung
undergo
develop
aim
studi
assess
effect
ac
morpholog
aspergillu
fumigatu
candida
albican
use
confoc
scan
laser
microscopi
cslm
scan
electron
microscopi
sem
method
cslm
fumigatu
c
albican
grown
presenc
differ
concentr
ac
stain
two
specif
fluoresc
stain
tm
lm
concanavalin
aalexa
fluor
conjug
cona
lgml
convert
orang
cylindr
intravacuolar
structur
metabol
activ
cell
cona
bind
green
fluoresc
glucos
mannos
residu
fungal
cell
hyphal
wall
polysaccharid
differenti
intact
damag
structur
determin
structur
cell
seri
horizont
xy
optic
section
taken
throughout
full
length
cell
hyphal
form
imag
red
green
cona
conceiv
simultan
use
multitrack
mode
isol
prepar
sem
seri
fix
dehydr
step
sputter
coat
au
pd
view
amray
scan
electron
microscop
result
unlik
untreat
control
fumigatu
hyphal
form
treat
ac
lgml
lyse
bulg
end
stunt
growth
treatment
c
albican
ac
lgml
result
swell
yeast
cell
thin
cell
wall
increas
concentr
lgml
result
complet
cell
inhibit
remnant
cell
wall
seen
sem
confirm
result
obtain
cslm
isol
conclus
data
show
ac
treatment
alter
morpholog
fumigatu
c
albican
consist
mode
action
echinocandin
inhibit
betadglucan
synthas
lead
cell
wall
inhibit
collaps
eventu
death
object
indic
measur
qualiti
health
care
increasingli
develop
use
health
care
profession
polici
maker
context
increas
antimicrobi
resist
aim
develop
valid
antibiot
prescrib
qualiti
indic
ambulatori
care
produc
basi
present
esac
http
wwwuaacbeesac
data
method
twentyseven
expert
countri
particip
european
scienc
foundat
workshop
plenari
session
smaller
work
group
build
interdisciplinari
expertis
within
esprit
escmid
studi
group
primari
care
topic
eurodurg
european
drug
utilis
research
group
world
health
organis
esac
expert
field
develop
antibiot
prescrib
qualiti
indic
discuss
perspect
profession
polici
maker
set
propos
indic
produc
workshop
use
gener
format
number
list
shown
tabl
particip
ask
score
relev
propos
indic
reduc
antimicrobi
resist
patient
health
benefit
costeffect
public
health
polici
maker
use
scale
rang
complet
disagre
uncertain
complet
agre
score
process
accord
uclarand
appropri
method
take
account
particip
comment
propos
indic
judg
valid
median
score
higher
number
score
within
interv
less
one
third
panel
result
twentytwo
particip
score
nine
indic
rate
valid
antibiot
prescrib
indic
four
dimens
three
addit
indic
rate
valid
relev
reduc
antimicrobi
resist
public
health
polici
maker
taken
account
indic
valu
allow
individu
countri
posit
defin
benchmark
relat
epidemiolog
infecti
diseas
nation
guidelin
conclus
set
propos
esac
base
antibiot
prescrib
qualiti
indic
least
nine
indic
seem
valid
line
main
object
antimicrobi
surveil
european
level
subset
use
describ
antibiot
use
ambulatori
care
order
assess
qualiti
antibiot
prescrib
object
report
experi
gain
four
year
work
german
sari
project
surveil
antimicrobi
use
antimicrobi
resist
intens
less
one
day
differ
averag
length
treatment
countri
vs
amoxicillin
vs
amoxiclav
averag
number
ddd
prescrib
per
day
doubl
vs
antibiot
clarithromycin
differ
averag
number
ddd
prescrib
per
day
ddd
wherea
length
treatment
vari
three
day
day
franc
vs
england
conclus
differ
antibiot
use
europ
might
explain
substanti
part
variat
number
ddd
per
prescript
could
determin
avail
differ
present
strength
particular
antibiot
individu
countri
turn
driven
reduc
suscept
betalactam
antibiot
antimicrobi
prescrib
practic
physician
specialti
unit
state
object
littl
data
avail
trend
antibiot
prescrib
physician
specialti
object
studi
examin
prescrib
pattern
pp
oral
antibiot
physician
specialti
year
unit
state
us
method
outpati
antibiot
prescript
dispens
evalu
nine
health
care
plan
antibiot
stratifi
class
defin
american
hospit
formulari
servic
ahf
chisquar
use
statist
analys
p
valu
consid
signific
result
physician
prescrib
ab
rx
patient
physician
specialti
includ
medicin
famili
practic
internist
generalist
paediatr
specialist
emerg
medicin
dermatologist
obgyn
surgeon
dermatologist
prescrib
tetracyclin
often
emerg
medicinemacrolid
obgynsnitrofuran
pediatricianspenicillin
surgeonsfluoroquinolon
tabl
compar
medicin
physician
famili
practition
prescrib
penicillin
often
internist
prescrib
fluoroquinolon
p
conclus
interest
antibiot
pp
observ
physician
specialti
obgyn
pediatrician
prescrib
agent
classifi
safe
patient
popul
specialist
group
internist
prescrib
broaderspectrum
agent
interestingli
surgeon
prescrib
fluoroquinolon
frequent
group
impact
french
local
communityori
antibioticreduc
programm
incid
invas
diseas
malicki
v
blanc
p
bruno
p
touboul
f
berthier
p
hoflig
foss
b
dunai
p
dellamonica
c
pradier
behalf
gepi
object
peer
conduct
academ
detail
visit
pcadv
organ
improv
antibiot
prescrib
paediatr
outpati
care
alp
maritim
franc
part
local
public
health
campaign
conduct
multidisciplinari
group
group
detud
et
de
de
infect
de
lenfant
gepi
aim
present
studi
survey
evolut
invas
diseas
relat
bacteri
respiratori
pathogen
inde
practition
often
declar
prescrib
antibiot
due
fear
complic
express
focu
group
studi
well
visitor
academ
detail
visit
within
gepi
project
method
retrospect
survey
conduct
alp
maritim
among
children
age
month
year
age
studi
incid
invas
infect
due
pneumonia
h
influenza
pyogen
n
meningitidi
local
laboratori
contact
bacteri
sampl
origin
normal
steril
site
among
select
popul
bacteri
resist
data
main
antibiot
record
investig
clinic
complic
follow
ent
bacteri
infect
mastoid
rheumat
fever
also
conduct
local
hospit
databas
result
case
invas
infect
due
pneumonia
clinic
complic
record
studi
period
signific
statist
differ
annual
averag
incid
rate
campaign
pneumococc
resist
rate
penicillin
erythromycin
show
signific
chang
although
percentag
pneumonia
diminish
suscept
penicillin
lowest
drop
region
paediatr
antibiot
prescript
observ
conclus
stabil
invas
infect
clinic
complic
rate
well
bacteri
resist
campaign
reassur
result
encourag
continu
promot
ration
antibiot
prescrib
could
allay
practition
fear
concern
consequ
reduc
antibiot
prescript
messag
relay
local
practition
evolut
antibiot
consumpt
geriatr
ward
univers
hospit
result
fiveyear
polici
involv
multidisciplinari
collabor
team
b
delaer
schoevaerdt
c
swine
glupczynski
yvoir
object
infect
repres
frequent
caus
hospit
intercurr
complic
elderli
peopl
hospitalis
geriatr
unit
sinc
multidisciplinari
ambulatori
team
mat
involv
infecti
diseas
specialist
clinic
microbiologist
pharmacist
infect
control
practition
initi
institut
gener
specif
diagnosi
treatment
issu
discuss
regularli
weekli
basi
team
clinician
staff
meet
geriatr
unit
bed
order
optim
diagnosi
commonli
encount
infecti
diseas
improv
qualiti
antibiot
prescript
studi
aim
assess
impact
multidisciplinari
approach
antibiot
consumpt
pattern
geriatr
unit
compar
data
gather
whole
hospit
period
method
antibiot
consumpt
data
avail
gener
pharmaci
servic
monitor
abccalc
softwar
accord
atcwho
methodolog
data
express
defin
daili
dose
ddd
prescrib
daili
dose
pdd
bed
suscept
test
bacteri
isol
clsi
method
interpret
criteria
well
surveil
nosocomi
bacteraemia
geriatr
unit
regist
analys
result
global
consumpt
antibiot
whole
hospit
decreas
gradual
ddd
pdd
total
save
cost
acquisit
antiinfect
drug
atc
amount
period
consumpt
decreas
geriatr
unit
pdd
concern
class
antibiot
greatest
decreas
usag
record
fluoroquinolon
pdd
amoxicillin
clavulan
also
gener
decreas
parenter
antibiot
usag
quinolon
amoxicillinclavulan
reflect
mark
increas
frequenc
parenteralor
switch
antibiot
therapi
conclus
implement
close
collabor
geritrician
infecti
diseas
specialist
microbiologist
infect
control
practition
led
signific
reduct
antibiot
consumpt
bed
year
parallel
improv
qualiti
antiinfect
therapi
without
neg
impact
patient
outcom
determin
antibiot
prescrib
lower
respiratori
tract
infect
primari
care
kuyvenhoven
akkerman
j
van
der
wouden
verheij
utrecht
rotterdam
nl
object
assess
determin
antibiot
prescrib
dutch
primari
care
patient
acut
bronchiti
exacerb
copd
method
gp
n
middl
region
netherland
includ
patient
acut
bronchiti
exacerb
copd
period
winter
registr
patient
characterist
clinic
present
manag
prescrib
antibiot
assess
use
recommend
nation
guidelin
benchmark
result
lower
respiratori
tract
infect
lrti
consult
antibiot
prescrib
decis
accord
recommend
guidelin
prescrib
higher
bronchiti
exacerb
copd
consult
respect
prescrib
seen
respect
patient
get
antibiot
prescript
accord
guidelin
inflamm
sign
like
fever
sputum
or
respect
compar
get
antibiot
prescript
purul
sputum
auscult
abnorm
leftright
differ
strong
determin
inappropri
prescrib
patient
exacerb
copd
addit
bronchiti
well
exacerb
copd
inappropri
prescrib
occur
patient
sever
ill
accord
gp
or
respect
gp
assum
patient
expect
antibiot
or
respect
conclus
gp
overestim
symptom
probabl
patient
expect
appli
recommend
lrti
case
daili
practic
correct
interpret
combin
symptom
antibiot
treatment
emphasis
combin
adopt
patientcentr
consult
skill
rationalis
prescrib
antibiot
object
evalu
antibiot
use
densiti
two
cohort
intens
care
unit
icu
germani
differ
overal
antibiot
use
densiti
one
cohort
includ
icu
particip
sari
programm
sariicu
n
programm
start
collect
antibiot
use
bacteri
resist
data
quarterli
feedback
data
includ
refer
data
deriv
cohort
provid
second
icu
cohort
particip
mabus
network
mabuseicu
n
repres
conveni
sampl
hospit
southwestern
part
countri
analys
data
made
avail
provid
studi
period
method
two
dose
definit
use
whoatc
definit
defin
daili
dose
ddd
definit
prescrib
daili
dose
pdd
use
previous
subgroup
sariicu
mabuseicu
n
perform
point
preval
survey
pp
evalu
truli
prescrib
dose
compar
ddd
pdd
data
express
ddd
pdd
per
patient
day
hospit
size
affili
year
studi
icu
type
examin
variabl
potenti
influenc
overal
use
result
overal
antibiot
use
densiti
similar
year
studi
differ
two
icu
cohort
irrespect
dose
definit
use
regress
analys
show
antibiot
use
densiti
primarili
associ
hospit
affili
univers
vs
nonunivers
hospit
size
icu
type
cohort
type
independ
factor
mean
overal
antibiot
use
densiti
nonunivers
hospit
icu
differ
hospit
bed
size
categori
rang
compar
univers
hospit
icu
daili
dose
prescrib
patient
day
pp
correspond
pdd
definit
employ
us
correspond
whoatc
ddd
definit
dose
correspond
either
definit
higher
defin
ddd
pdd
thu
pdd
fact
better
reflect
current
high
dosag
parenter
drug
hospit
patient
conclus
compar
antibiot
use
densiti
icu
cohort
assess
trend
time
need
adjust
data
least
hospit
affili
size
use
atc
dose
definit
lead
substanti
overestim
true
treatment
day
intens
care
area
object
evalu
effect
inappropri
antibiot
treatment
mortal
durat
hospit
stay
rel
lowrisk
studi
popul
medic
inpati
bacteri
infect
method
two
cohort
febril
patient
hospit
medic
center
israel
itali
germani
includ
patient
data
collect
prospect
initi
empir
treatment
defin
appropri
antibiot
prescrib
within
hour
first
encount
patient
match
invitro
suscept
pathogen
deem
like
caus
infect
result
cultur
serolog
direct
test
well
data
outcom
collect
day
initi
empir
treatment
multipl
logist
regress
model
construct
assess
impact
inappropri
antibiot
treatment
mortal
adjust
medic
center
variabl
gener
linear
model
glm
use
examin
associ
inappropri
antibiot
treatment
durat
hospit
control
medic
center
variabl
result
nine
hundr
twenti
patient
includ
patient
microbiolog
document
infect
mortal
data
avail
patient
inappropri
initi
antibiot
treatment
prescrib
patient
n
similar
proport
particip
center
p
allcaus
mortal
rate
n
n
patient
receiv
inappropri
appropri
treatment
respect
ci
p
adjust
medic
center
clinic
variabl
associ
inappropri
antibiot
treatment
mortal
ci
p
tabl
medic
center
mean
durat
hospit
stay
least
day
longer
patient
prescrib
inappropri
antibiot
treatment
overal
p
associ
consist
adjust
clinic
variabl
p
conclus
appropri
empir
antibiot
treatment
associ
better
surviv
shorten
durat
hospit
stay
medic
patient
